
<html lang="en"     class="pb-page"  data-request-id="f6f99481-88b8-47fc-83d8-56bba19ac683"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm400813y;website:website:acspubs;issue:issue:10.1021/jmcmar.2013.56.issue-21;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Experimental Confirmation of New Drug–Target Interactions Predicted by Drug Profile Matching" /></meta><meta name="dc.Creator" content="László  Végner" /></meta><meta name="dc.Creator" content="Ágnes  Peragovics" /></meta><meta name="dc.Creator" content="László  Tombor" /></meta><meta name="dc.Creator" content="Balázs  Jelinek" /></meta><meta name="dc.Creator" content="Pál  Czobor" /></meta><meta name="dc.Creator" content="Andreas  Bender" /></meta><meta name="dc.Creator" content="Zoltán  Simon" /></meta><meta name="dc.Creator" content="András  Málnási-Csizmadia" /></meta><meta name="dc.Description" content="We recently introduced Drug Profile Matching (DPM), a novel affinity fingerprinting-based in silico drug repositioning approach. DPM is able to quantitatively predict the complete effect profiles o..." /></meta><meta name="Description" content="We recently introduced Drug Profile Matching (DPM), a novel affinity fingerprinting-based in silico drug repositioning approach. DPM is able to quantitatively predict the complete effect profiles o..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 23, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm400813y" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm400813y" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm400813y" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm400813y" /></link>
        
    
    

<title>Experimental Confirmation of New Drug–Target Interactions Predicted by Drug Profile Matching | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm400813y" /></meta><meta property="og:title" content="Experimental Confirmation of New Drug–Target Interactions Predicted by Drug Profile Matching" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/large/jm-2013-00813y_0004.jpeg" /></meta><meta property="og:description" content="We recently introduced Drug Profile Matching (DPM), a novel affinity fingerprinting-based in silico drug repositioning approach. DPM is able to quantitatively predict the complete effect profiles of compounds via probability scores. In the present work, in order to investigate the predictive power of DPM, three effect categories, namely, angiotensin-converting enzyme inhibitor, cyclooxygenase inhibitor, and dopamine agent, were selected and predictions were verified by literature analysis as well as experimentally. A total of 72% of the newly predicted and tested dopaminergic compounds were confirmed by tests on D1 and D2 expressing cell cultures. 33% and 23% of the ACE and COX inhibitory predictions were confirmed by in vitro tests, respectively. Dose-dependent inhibition curves were measured for seven drugs, and their inhibitory constants (Ki) were determined. Our study overall demonstrates that DPM is an effective approach to reveal novel drug–target pairs that may result in repositioning these drugs." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm400813y"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm400813y">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm400813y&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm400813y&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm400813y&amp;href=/doi/10.1021/jm400813y" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 8377-8388</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm400771k" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm400828u" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Experimental Confirmation of New Drug–Target Interactions Predicted by Drug Profile Matching</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=L%C3%A1szl%C3%B3++V%C3%A9gner">László Végner</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=%C3%81gnes++Peragovics">Ágnes Peragovics</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=L%C3%A1szl%C3%B3++Tombor">László Tombor</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bal%C3%A1zs++Jelinek">Balázs Jelinek</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=P%C3%A1l++Czobor">Pál Czobor</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Bender">Andreas Bender</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zolt%C3%A1n++Simon">Zoltán Simon</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>¶</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andr%C3%A1s++M%C3%A1ln%C3%A1si-Csizmadia">András Málnási-Csizmadia</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Biochemistry, Institute of Biology, Eötvös Loránd University, Pázmány Péter sétány 1/C, H-1117 Budapest, Hungary</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Psychiatry and Psychotherapy, Semmelweis University, Balassa Utca 6, H-1083 Budapest, Hungary</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">§</span> <span class="aff-text">Molecular Biophysics Research Group, Hungarian Academy of Sciences and Eötvös Loránd University, Pázmány Péter sétány 1/C, H-1117 Budapest, Hungary</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">∥</span> <span class="aff-text">Drugmotif Ltd., Szent Erzsébet krt 11, H-2112 Veresegyház, Hungary</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">⊥</span> <span class="aff-text">Unilever Centre for Molecular Science Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom</span></div><div class="aff-info" id="aff6"><span class="aff-symbol">¶</span> <span class="aff-text">Delta Informatika Inc., Szentendrei út 39-53, H-1033, Budapest, Hungary</span></div><div class="corresp-info"><strong>*</strong>Mailing address: Department of Biochemistry, Eötvös Loránd University, Pázmány Péter Stny 1/C, H-1117, Budapest, Hungary. Phone: +36 1 372 2500, extension 8780. Fax: +36 1 381 2172. E-mail: <a href="/cdn-cgi/l/email-protection#ef828e83818eaf8a839b8ac1879a"><span class="__cf_email__" data-cfemail="8de0ece1e3eccde8e1f9e8a3e5f8">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm400813y&amp;href=/doi/10.1021%2Fjm400813y" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 8377–8388</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 2, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 May 2013</li><li><span class="item_label"><b>Published</b> online</span>23 October 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 November 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm400813y" title="DOI URL">https://doi.org/10.1021/jm400813y</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8377%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DL%25C3%25A1szl%25C3%25B3%2BV%25C3%25A9gner%252C%2B%25C3%2581gnes%2BPeragovics%252C%2BL%25C3%25A1szl%25C3%25B3%2BTombor%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D21%26contentID%3Djm400813y%26title%3DExperimental%2BConfirmation%2Bof%2BNew%2BDrug%25E2%2580%2593Target%2BInteractions%2BPredicted%2Bby%2BDrug%2BProfile%2BMatching%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8388%26publicationDate%3DNovember%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm400813y"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1737</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">12</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm400813y" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Experimental Confirmation of New Drug–Target Interactions Predicted by Drug Profile Matching&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;László&quot;,&quot;last_name&quot;:&quot;Végner&quot;},{&quot;first_name&quot;:&quot;Ágnes&quot;,&quot;last_name&quot;:&quot;Peragovics&quot;},{&quot;first_name&quot;:&quot;László&quot;,&quot;last_name&quot;:&quot;Tombor&quot;},{&quot;first_name&quot;:&quot;Balázs&quot;,&quot;last_name&quot;:&quot;Jelinek&quot;},{&quot;first_name&quot;:&quot;Pál&quot;,&quot;last_name&quot;:&quot;Czobor&quot;},{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Bender&quot;},{&quot;first_name&quot;:&quot;Zoltán&quot;,&quot;last_name&quot;:&quot;Simon&quot;},{&quot;first_name&quot;:&quot;András&quot;,&quot;last_name&quot;:&quot;Málnási-Csizmadia&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;23&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;8377-8388&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm400813y&quot;},&quot;abstract&quot;:&quot;We recently introduced Drug Profile Matching (DPM), a novel affinity fingerprinting-based in silico drug repositioning approach. DPM is able to quantitatively predict the complete effect profiles of compounds via probability scores. In the present work, in order to investigate the predictive power of DPM, three effect categories, namely, angiotensin-converting enzyme inhibitor, cyclooxygenase inhibitor, and dopamine agent, were selected and predictions were verified by literature analysis as well as experimentally. A total of 72% of the newly predicted and tested dopaminergic compounds were confirmed by tests on D1 and D2 expressing cell cultures. 33% and 23% of the ACE and COX inhibitory predictions were confirmed by in vitro tests, respectively. Dose-dependent inhibition curves were measured for seven drugs, and their inhibitory constants (Ki) were determined. Our study overall demonstrates that DPM is an effective approach to reveal novel drug–target pairs that may result in repositioning these drugs.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400813y&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400813y" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400813y&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400813y" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400813y&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400813y" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm400813y&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400813y&amp;href=/doi/10.1021/jm400813y" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm400813y" /></input><a href="/doi/pdf/10.1021/jm400813y" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm400813y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm400813y%26sid%3Dliteratum%253Aachs%26pmid%3D24088053%26genre%3Darticle%26aulast%3DV%25C3%25A9gner%26date%3D2013%26atitle%3DExperimental%2BConfirmation%2Bof%2BNew%2BDrug%25E2%2580%2593Target%2BInteractions%2BPredicted%2Bby%2BDrug%2BProfile%2BMatching%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D21%26spage%3D8377%26epage%3D8388%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=291583" title="Mathematical methods">Mathematical methods</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jmcmar.2013.56.issue-21/production/jmcmar.2013.56.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/medium/jm-2013-00813y_0004.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/large/jm-2013-00813y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400813y&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We recently introduced Drug Profile Matching (DPM), a novel affinity fingerprinting-based in silico drug repositioning approach. DPM is able to quantitatively predict the complete effect profiles of compounds via probability scores. In the present work, in order to investigate the predictive power of DPM, three effect categories, namely, angiotensin-converting enzyme inhibitor, cyclooxygenase inhibitor, and dopamine agent, were selected and predictions were verified by literature analysis as well as experimentally. A total of 72% of the newly predicted and tested dopaminergic compounds were confirmed by tests on D1 and D2 expressing cell cultures. 33% and 23% of the ACE and COX inhibitory predictions were confirmed by in vitro tests, respectively. Dose-dependent inhibition curves were measured for seven drugs, and their inhibitory constants (<i>K</i><sub>i</sub>) were determined. Our study overall demonstrates that DPM is an effective approach to reveal novel drug–target pairs that may result in repositioning these drugs.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52301" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52301" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The high failure rate of drug candidates due to unexpected adverse reactions and lack of expected clinical efficacy have become fundamental problems of drug development. Despite the increasing efforts and resources spent on biomedical research, the number of new molecular entities stagnates.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">One result of this trend was the development of alternative strategies in pharmaceutical research, such as a turn from the discovery of new chemical entities toward drug repositioning or repurposing. Drug repositioning seeks new therapeutic applications of existing drugs and requires on average approximately 5–8 years from discovery to the market.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> While intellectually less novel, this process can also be considered a safer, cheaper, and faster way of drug development, given that compounds successfully passed clinical trials previously. However, drug repurposing also should not be oversimplified, since several aspects need to be considered before making decisions such as patent status, market characteristics, and whether the new indication represents an unmet medical need.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Nevertheless, the developmental risk can be said to be smaller,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> compared to the discovery of new chemical entities. One of the well-known examples of drug repositioning is imatinib (Gleevec) that was first approved for chronic myeloid leukemia<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> but that was subsequently approved for gastrointestinal stromal tumors.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> As another example, zidovudine was developed in the 1960s as a potential anticancer agent but failed to show efficacy. However, in 1985 it was found to be effective against AIDS as a reverse transcriptase inhibitor and became the first approved anti-HIV drug.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Finasteride was repositioned from the treatment of prostate enlargement to an antibaldness agent after the discovery that its target, 5α-reductase, is involved in these biologically distinct (though both hormonally driven) processes.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Thalidomide, which once caused severe fetal defects in pregnant women when used as an antiemetic agent, was successfully reintroduced as an antileprosy drug (with certain limitations on its usage).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">Aspirin was repositioned as a platelet aggregation inhibitor approximately 90 years after its introduction in 1899,<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> illustrating that the complete effect profiles, i.e., the whole therapeutic effect spectrum a compound exerts when administered to a human body, are often unknown even for the oldest drugs. Besides similarity in the molecular biology of diseases, drug repositioning is often driven by serendipity or SAR considerations. Therefore, there is a clear need for a systematic screening method that is able to predict the complete effect profiles of compounds, quantitatively describing their probability of exhibiting a given effect.</div><div class="NLM_p">Experimental pharmacological data can be a rich source of drug repositioning. For example, the BioPrint database by Cerep contains screening results of 2500 FDA drugs and reference molecules against 159 enzymes, receptors, ion channels, and transporters.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Part of this database was used to develop “biospectra analysis” that applies a series of in vitro percent inhibition values handled as a compound descriptor<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10-12)</a> that can then be used, for example, to retrieve compounds with a similar profile (and hence similar expected effects) from the database. Kauvar et al. developed affinity fingerprinting, a method for the characterization of compounds by their binding affinities to a set of proteins.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The vector of the binding affinity values is considered as a descriptor and is used to predict the activity of a given compound against a target not included in the protein set. Affinity fingerprinting was successfully applied to find new cyclooxygenase (COX) inhibitors among a set of druglike compounds.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Only 62 library compounds were tested, and three structurally novel active compounds were discovered.</div><div class="NLM_p">On the computational side, Koutsoukas et al. summarize several recently developed in silico pharmacology approaches that might offer candidates for off-target based drug repositioning.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> These techniques are in line with current thinking of polypharmacology that states that drugs more often than not act on multiple targets.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19">(16-19)</a> In particular, each drug hits on average six known targets according to a recent analysis on interaction data.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">One of the first approaches in the field of in silico pharmacology was PASS (Prediction of Activity Spectra for Substances), which applies a set of 2D descriptors to compounds that are then correlated with a set of bioactivities.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Bender et al. developed a similarity approach called Bayes Affinity Fingerprint in which binding affinity information against a set of target proteins is used for virtual screening with retrieval rates higher than those of conventional fingerprints.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> Keiser et al. used ligand chemical similarity to obtain biologically relevant clusters of 246 enzymes and receptors.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> This method was used for biological activity prediction by calculating the chemical similarity values of the query set (one molecule or a set of compounds) to the 246 representative ligand sets for the studied activity classes.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p">In order to expand on the previously published approaches, our group recently developed Drug Profile Matching (DPM), a pattern-based in silico drug repositioning method.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> This method enables the prediction of the effect profiles of small molecules on the basis of their docking scores against a panel of proteins and is therefore applicable in searching for drug repositioning candidates as well as in de novo drug development. Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a> represents the DPM method in graphical form. In DPM, each FDA-approved small molecule drug is docked to the ligand binding sites of 149 nontarget proteins that were selected by suitability for docking. On the basis of the docking results, Interaction Patterns (IPs), i.e., vectors containing the calculated best docking scores of the compounds on the 149 members of the protein set, were formed. Additionally, the effect profiles (EPs) of the drugs were also generated that are binary presence/absence indicators of 177 physiological effects. The effect database used in our study was extracted from DrugBank and was revised manually. Each effect entry contained at least 10 registered drugs (known actives) to provide sufficient amount of information for classification. Canonical correlation analysis (CCA) was applied between the IP matrix and a given effect to produce highly correlating factor pairs that were the inputs for linear discriminant analysis (LDA) that was used for separating the two classes (active and inactive molecules of a given effect). Using this two-step multidimensional analysis, classification functions were created for each effect and probability values were assigned for each drug–effect pair in our data set, which is hence both reclassifying known drug–effect pairs and indicating novel hypothetic associations between both domains. The prediction accuracy of the DPM method was examined by Receiver Operating Characteristics (ROC) analysis. Area under the curve (AUC) values were calculated for each effect to demonstrate the reclassification performance (which is also a measure of consistency within the effect class) of the method. To check the validity of the DPM predictions, the commonly used 10-fold cross-validation was performed and repeated 100 times.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/medium/jm-2013-00813y_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/large/jm-2013-00813y_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Graphical summary of the Drug Profile Matching method. The Interaction Pattern (IP) matrix consists of the calculated binding free energies for the 1177 drugs studied on the reference panel of 149 nontarget proteins (i.e., proteins that are not known to be involved in the mechanism of action of the drugs). The Effect Profile (EP) matrix contains pharmacological effect information on the drug set in a binary form (blue and white cells represent the presence and the absence of a given effect from the 177 categories, respectively). A two-step multidimensional analysis (canonical correlation analysis, CCA, and linear discriminant analysis, LDA) was performed using the IP and EP matrices as inputs to calculate the Effect Probability matrix. This matrix displays the probability values for each drug–effect pair. The darker is a given cell, the higher is the predicted probability. Comparison of the same effect (i.e., same column) in both effect matrices reveals those predictions that are already known (marked as valid) and highlights the predictions that need to be validated via literature search or experimental testing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/large/jm-2013-00813y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400813y&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The probabilities that were assigned for each drug–effect pair predicted several unregistered effects with high probability for many drugs. Besides the possibility that these “false positive” hits can refer to incorrect classification functions, they can also be considered as drug repositioning predictions (“putative true positives”). In order to test these findings, in the current work predictions by DPM were now verified by literature analysis as well as experimentally for three selected effect categories, namely, the in vitro inhibition of ACE (angiotensin-converting enzyme) and COX enzymes as well as cell-based activity tests on dopaminergic D1 and D2 receptors. For ACE and D1/D2 receptors, control sets containing compounds with low predicted probability for the given effect were also tested.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11155" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11155" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The detailed description of DPM has been presented recently.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Our previous analysis showed that 84% of the 171 studied effects resulted in a reclassification AUC larger than 0.95, indicating sufficient performance on the data set used. Robustness was determined by 10-fold cross-validation producing the mean of the mean probability values (mean MPV) for each effect (see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). Mean MPVs larger than 0.5 were calculated for 48.6% of the studied effects, while a random data set would result in a mean MPV of 0.027. Hence, we showed that significant differentiation of effects can be obtained by DPM, compared to random sampling.</div><div class="NLM_p">The following criteria were considered in the selection of the experimentally tested effect categories: (1) robustness (mean MPV calculated from 10-fold cross-validation) of classification functions, (2) accuracy (reclassification AUC) of classification functions, (3) the potential importance of therapeutic effects, (4) availability of in vitro test kits or cell-based assays. The dopamine agent, ACE, and COX inhibitory effect categories are good representatives of the middle and the upper region of classification robustness (mean MPVs of 0.548, 0.420, and 0.693, respectively). All show high reclassification AUCs (0.922, 0.999, and 0.989, respectively), and hence, they were chosen in this study.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> In Vitro Tests of ACE Inhibition</h3><div class="NLM_p">ACE inhibitors are widespread antihypertensive agents also used for the treatment of congestive heart failure and diabetic nephropathy.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> Their blood pressure lowering effect is due to the inhibition of angiotensin-converting enzyme, which has a dual result. First, the conversion of angiotensin I to the vasoconstrictor angiotensin II is not performed, and second, the degradation of the vasodilator bradykinin by ACE is inhibited.</div><div class="NLM_p">For ACE inhibitors, the DPM prediction acceptance threshold was set according to the level above which 14 out of the 15 originally registered ACE drugs were classified as positives. This threshold was exceeded by 15 drugs that are not registered as ACE inhibitors (“false positives” or predicted ACE inhibitors) (see Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> and <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information Tables 1 and 4">Supporting Information Tables 1 and 4</a> for details on molecular structure and plasma concentrations). A retrospective literature analysis revealed that for three of the predicted compounds, i.e., candoxatril, carvedilol, and nebivolol, an effect on ACE inhibition was indeed described earlier and just not annotated in the data set because they are not FDA registered ACE inhibitors.<a onclick="showRef(event, 'ref30 ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref33">(30-33)</a> The remaining 12 compounds were tested for ACE inhibition experimentally, and for L-proline, tipranavir, dasatinib, novobiocin, nelfinavir, and telmisartan activity was confirmed. These compounds exerted 46–97% inhibition of ACE at 500 μM inhibitor concentrations except for tipranavir which was measured at 128 μM because of low solubility and produced 31% inhibition. In order to select reasonably active molecules, hit criterion was set to 90% inhibition at 500 μM. Screening at high concentration certainly carries the risk of detecting false positives because some molecules can aggregate and act promiscuously.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> However, most drugs are not promiscuous, even at high screening concentrations.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> 33% of the predictions were confirmed experimentally or by the literature, as two active molecules were discovered in the assay and three active molecules were confirmed by the literature out of the 15 predictions.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Predicted ACE Inhibitors in Decreasing Order of Prediction Probability<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/medium/jm-2013-00813y_0007.gif" alt="" id="GRAPHIC-d58e423-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>Table a</sup><p class="last">Active compounds in the assay (inhibition of >90%) are highlighted with dark gray color along with predictions confirmed by the literature (references are included). Light gray color marks those molecules that produced significant inhibition in the assay but failed to reach the limit of 90%. Tipranavir marked with # was measured at 128 μM because of low solubility.</p></div></div><div></div></div><div class="NLM_p">Dose–response ACE inhibition curves were determined for four molecules, namely, telmisartan, L-proline, novobiocin, and dasatinib (see Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). The most pronounced ACE inhibition (with a <i>K</i><sub>i</sub> of 6 μM) was observed for telmisartan, which is registered as an angiotensin II receptor antagonist, while its ACE inhibitory activity has not been previously reported. Interestingly, telmisartan is well tolerated in patients where ACE inhibitors are contraindicated.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Nevertheless, telmisartan could not substitute angiotensin-converting enzyme inhibitors in patients intolerant to ACE inhibitor therapy.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> This finding clearly highlights the difficulty of transferring in vitro results to in vivo effects.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/medium/jm-2013-00813y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/large/jm-2013-00813y_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. In vitro ACE inhibition curves for telmisartan (a) , L-proline (b) , novobiocin (c), and dasatinib (d). All compounds show dose dependent response with resulting <i>K</i><sub>i</sub> values ranging from 6 to 715 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/large/jm-2013-00813y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400813y&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">L-proline also showed an inhibitory activity of ACE with a <i>K</i><sub>i</sub> of 86 μM. Visual inspection of the chemical structures of the common ACE inhibitors such as captopril reveals that they contain a proline moiety; however, there is no published evidence that would support the importance of this particular moiety in their pharmacologic actions (except for contributing to binding via nonspecific interactions achieved by being positioned in a lipophilic pocket). According to the measured ACE inhibitory activity of L-proline itself, we suspect that it is a key moiety in the mode of action of ACE inhibitors. Nevertheless, as expected, we measured a much stronger affinity for captopril (<i>K</i><sub>i</sub> = 2 nM), which was used as a positive control in our tests.</div><div class="NLM_p">Novobiocin, an aminocoumarin antibiotic, possessed a moderate ACE inhibitory activity (with a <i>K</i><sub>i</sub> of 167 μM) that is commensurable to the plasma concentration of the drug reported in the literature.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div class="NLM_p">Low ACE inhibitory activity (with a <i>K</i><sub>i</sub> of 715 μM) was measured for dasatinib, an anticancer agent, which however does not appear to be relevant at the therapeutic plasma concentration of the drug.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p last">A random set of eight compounds that has very low predicted probabilities for ACE inhibition (below 0.003; see <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information Table 8">Supporting Information Table 8</a>) was also selected for testing under the same conditions. The aim was to establish whether the percentage values calculated for the false positive compounds are meaningful. Although 15–67% inhibition effect was detected for them, the estimated <i>K</i><sub>i</sub> values for these compounds are considerably weaker than those of the false positives (<a class="ref internalNav" href="#notes-2" aria-label="Supporting Information Table 8">Supporting Information Table 8</a>). Known drugs do not typically possess <i>K</i><sub>i</sub> values above 50–100 μM, but higher <i>K</i><sub>i</sub> data may also be biologically relevant as indicated by the previously presented case of novobiocin. Thus, a limit of <i>K</i><sub>i</sub> = 200 μM was applied in the comparison studies of the low and high probability compounds throughout our work. If we apply this limit, three molecules remain that were all predicted with high probability (telmisartan, L-proline, novobiocin). On the basis of this analysis, we conclude that a definite enrichment can be observed on the top of the DPM prediction list regarding <i>K</i><sub>i</sub> data in the case of the ACE inhibitory effect.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> In Vitro Tests of COX Inhibition</h3><div class="NLM_p">COX inhibitors are nonsteroidal anti-inflammatory drugs (NSAIDs) and are used worldwide.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Their mechanism of action is based on the inhibition of two COX isoforms (termed COX-1 and COX-2), thereby inhibiting the conversion of arachidonic acid into prostaglandin H2, which is part of an inflammation pathway relevant in a variety of diseases.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> COX-1 is a constitutively expressed isoform in most cells, and its inhibition leads to positive anti-inflammatory effects; however, a number of side effects are also coupled with this action that include diarrhea, gastric ulcer, interstitial nephritis, and acute renal failure due to the high level of COX-1 expression in the gastric mucosa and the kidneys.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> COX-2 is an inducible enzyme, expressed only in case of inflammation. Therefore, selective COX-2 inhibitors such as celecoxib, rofecoxib, and valdecoxib have reduced gastrointestinal and renal adverse effects. On the other hand, an increased probability of cardiovascular side effects including thrombosis and myocardial infarction was reported in connection with the administration of some COX-2 inhibitors, leading to the withdrawal of rofecoxib and valdecoxib.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41, 42)</a></div><div class="NLM_p">The DPM method was also applied for predicting COX inhibitors. The prediction threshold was set to a level above which 90% of the registered COX inhibitors appeared as positives (33 out of 37), giving rise to 54 putative “false positive” predictions. Eleven drugs were excluded from the analysis because of limited practical importance or lack of commercial availability (see <a class="ref internalNav" href="#sec4_5" aria-label="Materials">Materials</a>), resulting in 43 compounds that were studied further (see Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> and <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information Tables 2 and 5">Supporting Information Tables 2 and 5</a> for details on molecular structure and plasma concentrations). Among the compounds investigated the COX inhibitory properties for valproic acid, α-linolenic acid, oxybenzone, and ciclopirox were confirmed by the literature.<a onclick="showRef(event, 'ref43 ref44 ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref43 ref44 ref45 ref46 ref47">(43-47)</a> Two other compounds, ticlopidine and azathioprine, were tested for COX inhibition earlier, but activity could not be detected for them.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48, 49)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Predicted COX Inhibitors in Decreasing Order of Prediction Probability<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/medium/jm-2013-00813y_0008.gif" alt="" id="GRAPHIC-d58e561-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup>Table a</sup><p class="last">Compounds possessing >90% inhibition and predictions confirmed by the literature (references are provided) are highlighted with dark gray color. These molecules are considered active in the evaluation. Light gray color indicates molecules which produced significant inhibition in the assay but failed to achieve the limit of 90% inhibition.</p></div></div><div></div></div><div class="NLM_p">The remaining 37 drugs, as well as α-linolenic acid, were tested experimentally for COX inhibition activity of COX-1 and COX-2, and COX-1 or COX-2 inhibitions were found in 17 cases. Seven compounds reached the applied criterion of 90% inhibitior concentration, resulting in a confirmation rate of 23% (10 actives including literature hits out of 43 compounds, Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). In this experiment, nitroxoline, α-linolenic acid, nitrofurazone, flutamide, and nilutamide were found to be the strongest inhibitors of COX.</div><div class="NLM_p">Dose–response COX inhibition curves of captopril (COX-1 and COX-2), nitroxoline (COX-2), and α-linolenic acid (COX-1) were also determined, shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>. The inhibitory effect of captopril for COX-1 increased gradually with increasing concentrations as expected; however, reduced effect was measured at 300 μM. Its <i>K</i><sub>i</sub> values were 17 and 12 μM for the COX-1 and COX-2 isoenzymes, respectively. These inhibitory constants are moderately stronger than that of acetylsalicylic acid, which is one of the most common COX inhibitors (<i>K</i><sub>i,COX-1</sub> = 62 μM and <i>K</i><sub>i,COX-2</sub> = 52 μM). However, the reported plasma level of captopril does not indicate the biological relevance of this finding.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/medium/jm-2013-00813y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/large/jm-2013-00813y_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. COX-1 and COX-2 inhibition curves for captopril (panels a and b, respectively), COX-1 inhibition curve for α-linolenic acid (c), and COX-2 inhibition curve for nitroxoline (d). All compounds show dose dependent response, and the determined <i>K</i><sub>i</sub> values range from 1 to 17 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/large/jm-2013-00813y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400813y&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">α-Linolenic acid showed a <i>K</i><sub>i</sub> of 4 μM for COX-1, and taking into account the inhibition results measured at 500 μM for COX-2, this compound appears to show a strong, nonselective COX inhibition that is in accordance with the results obtained by Ren and Chung.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46, 47)</a> Here, the authors demonstrated that this compound has an anti-inflammatory effect through different mechanisms, including COX-2 inhibition, while effects on COX-1 were not mentioned. Our results therefore extend the knowledge about the multitarget anti-inflammatory properties of α-linolenic acid.</div><div class="NLM_p last">The antibiotic nitroxoline showed a <i>K</i><sub>i</sub> of 1 μM for COX-2, and according to our results measured at 500 μM for COX-1 (97% inhibition), it also seems to be a reasonably potent nonselective COX inhibitor. This newly discovered COX inhibitory property of nitroxoline might have significance in its original antibiotic and recently described anticancer effects.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51, 52)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Cell-Based Tests of Dopaminergic Activity</h3><div class="NLM_p">We also investigated the prediction power of DPM on the dopamine agent effect category. The experimental confirmations of the predictions were performed in an independent laboratory that has large experience in receptor tests. Dopamine receptors are G-protein-coupled receptors that have five subtypes. The D1-like family contains subtypes D1 and D5, while the D2-like family consists of three members: D2, D3, and D4. Dopamine receptors, associated with cognitive processes, learning, memory, motor control, and motivation, are important targets of a series of psychiatric drugs, e.g., antipsychotic agents.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Since the investigated category did not specify which receptor subtypes will be affected by the drugs and in order to gain insights for both families, the D1 and D2 receptors were selected for testing as representatives of both groups. Predicted compounds were analyzed by a team of medical doctors, and the most promising 18 compounds were selected for a comprehensive literature survey and experimental testing for agonist and antagonist effects on these receptor subtypes, based on their prediction probabilities, clinical importance, and commercial availability. Thus, in contrast to the ACE and COX measurements, compounds were subjected to an additional prescreening process. Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> shows the measured activity values and standard deviations, applying 100 μM compound concentration except for the measurements of D2 antagonism where 50 μM was used. Celecoxib was measured at 8 μM in all tests because of solubility issues. For details on molecular structure, plasma concentrations, and known activity of true positives, see <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information Tables 3, 6, and 7">Supporting Information Tables 3, 6, and 7</a>. Measurements were not performed for three compounds because their dopaminergic effect was confirmed by the literature.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Examined Dopaminergic Candidates in Decreasing Order of Predicted Probability<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/medium/jm-2013-00813y_0009.gif" alt="" id="GRAPHIC-d58e647-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup>Table a</sup><p class="last">Dark gray color represents an activity value over 80%, while light gray cells refer to activity between 40% and 80%. Celexocib, desogestrel, mefloquine, and clomipramine showed activation during preincubation for D2<sub>long</sub> antagonist tests; therefore, their respective values are overestimated (marked with †). Flavoxate, imipramine, and desipramine were not tested, but their dopaminergic effects were confirmed by the literature (see <a class="ref internalNav" href="#sec2" aria-label="Results and Discussion">Results and Discussion</a> for details). Celecoxib marked with # was measured at 8 μM because of its low solubility.</p></div></div><div></div></div><div class="NLM_p">Celecoxib, a selective COX-2 inhibitor, was predicted to have dopaminergic effects with the highest probability (0.995), which has been confirmed experimentally for D1 receptor antagonism (95% activity at the concentration studied; note that agonist activity values are expressed as the percentage of the activity of the reference agonist at EC<sub>100</sub> concentration while antagonist activity level is expressed as the percentage of decrease of the reference agonist activity at EC<sub>80</sub> concentration). In the case of the D2 receptor, 96% antagonist activity was measured for celecoxib but the compound possessed activation during the preincubation, leading to the overestimation of antagonist activity. Interestingly, for the D2 receptor, very high agonist activity was measured: 175% of the activity of the reference agonist quinpirol. Considering the applied concentration of celecoxib (8 μM), we can conclude that the drug possesses a definite D1/D2 dopaminergic effect at a submicromolar <i>K</i><sub>i</sub>. The literature survey revealed that celecoxib was found to reduce the lipopolysaccharide induced dopamine transporter (DAT) expression.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Nevertheless, to our knowledge, exact interaction between DAT and celecoxib was not reported for this drug. However, it has been suggested for the treatment of psychiatric disorders, e.g., schizophrenia and major depression, in which the dysfunction of the dopaminergic system might be a key factor.<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55, 56)</a> Based on our literature search, the reason for its effectiveness is the inhibition of COX-2, based on numerous observations that support an inflammation theory of schizophrenia.<a onclick="showRef(event, 'ref57 ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref57 ref58 ref59 ref60">(57-60)</a> Celecoxib proved to be efficient as an adjunctive therapy for schizophrenia in randomized controlled clinical trials when coadministered with risperidone<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61, 62)</a> or amisulpride,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> while other randomized controlled clinical trials confirmed the therapeutic efficacy of celecoxib as an add-on therapy in major depressive disorder.<a onclick="showRef(event, 'ref55 ref63'); return false;" href="javascript:void(0);" class="ref ref55 ref63">(55, 63)</a> In our study, we show that celecoxib might have a direct effect on the dopaminergic system, which could be at least partially responsible for its efficacy observed in the aforementioned clinical trials. However, the connection between the observed dopamine receptor agonist activity and the presence of the psychiatric benefits remains unclear.</div><div class="NLM_p">We measured strong antagonistic effects of mefloquine on D1 and D2 (82% and 90%, respectively), while only a moderate agonistic effect was observed on the D2 receptor (45%) and no agonist effect was detected on the D1 receptor. Antimalarial drugs like mefloquine are known to induce psychosis.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64, 65)</a> The underlying mechanism is unknown; however, it is hypothesized that several neurotransmitter systems might be involved, including the dopaminergic system which would be in agreement with our findings.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><div class="NLM_p">The selective estrogen receptor modulator raloxifene produced strong antagonistic effect on both dopamine receptor subtypes (of 97% and 88% on the D1 and D2 receptors, respectively), and the effect of steroids possessing estrogen-like activity on the dopamine system has been widely discussed in the literature. Gender differences in the epidemiology and course of schizophrenia (e.g., illness onset, symptom severity during the reproductive versus postmenopausal age, etc.) are hypothesized to be at least partially attributed to the influence of estrogens on the dopaminergic system. Randomized controlled clinical trials using estrogen as an add-on therapy to antipsychotics resulted in a significantly rapid reduction of symptom severity in patients receiving combined therapy compared to the reference group in both male and female persons with schizophrenia,<a onclick="showRef(event, 'ref67 ref68 ref69 ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref67 ref68 ref69 ref70 ref71">(67-71)</a> an observation not directly linked to the dopamine receptorial effect. Recent data also show that raloxifene had a good therapeutic effect as an adjunctive therapy to antipsychotics in postmenopausal women.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> According to our in vitro measurements and the presented literature data, we may rationalize these effects by a direct dopaminergic effect of raloxifene.</div><div class="NLM_p">The antispasmatic agent cyclobenzaprine possessed high antagonist activities on D1 and D2 receptors (over 90%). Literature data supported the interaction of cyclobenzaprine with the D2 receptor in vitro.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> However, no indication was found that this effect might be relevant for efficacy or side effects.</div><div class="NLM_p">The antihistamine epinastine proved to be a selective D1 antagonist (96% and 5.5% activities on D1 and D2, respectively). Roeder et al. found that epinastine has a strong antagonist effect on insect neuronal octopamine receptors with high affinity and specificity, thus influencing insect behavior<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> and visual learning.<a onclick="showRef(event, 'ref75 ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref75 ref76 ref77">(75-77)</a> We found that the α adrenergic antagonist doxazosin is even more selective for the D1 receptor than epinastine (with 102% and 0% inhibition on D1 and D2, respectively). On the other hand, desogestrel, an estrogen-type contraceptive, has a slightly higher affinity for D2 than D1 (88% and 79% on D2 and D1, respectively). Relevant literature was not found for these drugs that would support a phenotypically relevant effect on the dopaminergic system.</div><div class="NLM_p">Other compounds were found to have lower activities on the dopamine receptors, of likely insignificant effect in physiological systems. Olopatadine, an antihistamine agent, and the antiviral rimantadine produced moderate antagonistic effect on D2 (52% and 41%, respectively) while not affecting D1. Similarly, the NSAID etodolac, the antimicrobial fosfomycin, and the antimetabolite thioguanine produced low antagonistic activity on D2 (13%, 29%, and 21%, respectively). Etodolac was proposed as an anti-inflammatory adjuvant to investigate its neuroprotective effect in a model of Parkinson’s disease, but no effect was observed.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div><div class="NLM_p">Only three compounds possessed dopamine agonist activity in the assays, namely, mitoxantrone, celecoxib, and mefloquine. The last two compounds were mentioned before; they act selectively on D2 receptor (175% and 45%, respectively), while mitoxantrone acts on the D1 receptor (with an activity of 66%). Moreover, mitoxantrone produced antagonistic effect on the D2 receptor as well (81% inhibition).</div><div class="NLM_p">The predictions for three tricyclic antidepressants, i.e., imipramine, desipramine, and the experimentally tested clomipramine, were confirmed by the literature. Imipramine and desipramine have very similar receptor profiles; they produce dopamine supersensitivity, a phenomenon related to strong D2 antagonism.<a onclick="showRef(event, 'ref79 ref80 ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref79 ref80 ref81 ref82">(79-82)</a> In our study, high dopamine antagonist activities were measured on both subtypes (over 90%) for clomipramine. A similar effect was determined for the first-generation antihistamine promethazine and confirmed by the literature.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div><div class="NLM_p">From a different structural class, flavoxate is a spasmolytic agent with a suggested anticholinergic mechanism of action. Oka et al. demonstrated the D2 affinity of this compound at micromolar concentrations, determined by radioligand assay.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Flavoxate obtained high prediction probability by DPM in accordance with the literature.</div><div class="NLM_p">In summary, 67% of the tested dopaminergic predictions proved to be highly active (10 out of 15; activity of >80%) while 81% showed at least 40% activity (12 out of 15). 72% of the 18 predictions were confirmed experimentally on the receptor level (10 compounds) or by the literature (3 compounds).</div><div class="NLM_p last">Similarly as it was presented for ACE inhibition, a random set of 10 compounds was also selected for testing that has very low predicted probabilities for dopaminergic effect (below 0.015; see <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information Tables 9 and 10">Supporting Information Tables 9 and 10</a>). Molecules were tested for D1 and D2 antagonism, applying 100 and 50 μM concentrations, respectively. From the results obtained on the single concentrations, <i>K</i><sub>i</sub> values were estimated (<a class="ref internalNav" href="#notes-2" aria-label="Supporting Information Table 9 and 10">Supporting Information Table 9 and 10</a>.). In the case of D1 antagonism, applying the previously introduced limit of <i>K</i><sub>i</sub> < 200 μM resulted in nine molecules that were predicted with high probability while only one compound, natamycin, could fulfill this criterion from the low-probability molecules. Thus, we conclude that the results presented for the top of the list are valid here. In the case of D2 antagonism, there are 18 molecules below the limit of <i>K</i><sub>i</sub> = 200 μM, from which 12 molecules possess high probability value while 6 compounds have low probability. Among the strongest 9 molecules (<i>K</i><sub>i</sub> < 10 μM), only 2 have low probability; therefore, an enrichment can be observed here as well, but the experimental results point to the weakness of the classification function applied to calculate probability values for dopaminergic effects.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26230" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26230" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this study, we prospectively validated the Drug Profile Matching algorithm for three selected effect categories by systematically testing the highest-ranked predictions, i.e., those compounds that gained highest probability for exerting the studied effect. In the case of the inhibition of ACE and COX enzymes, 33% and 23% confirmation rates were obtained, respectively. DPM predictions for dopaminergic effect were confirmed by cell-based tests, and 67% of the tested compounds proved to be active. Several interesting bioactivities were discovered such as the ACE inhibition property of the angiotensin II receptor antagonist telmisartan and the interaction of the selective COX-2 inhibitor celecoxib with the dopaminergic system. The latter could be linked to clinical observations. On the basis of the presented tests, the performance of DPM is comparable to that of other state-of-the-art ligand–target prediction methods.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Our results demonstrate the applicability of DPM in identifying unknown bioactivities of already approved drugs and hence its possible use in drug repositioning.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24331" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24331" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Drug repositioning predictions were created using Drug Profile Matching as outlined in detail in previous work.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Three effect categories were prospectively validated in the current study, namely, angiotensin-converting enzyme inhibition, cyclooxygenase inhibition, and dopaminergic agonistic and antagonistic activity. In vitro ACE and COX tests were carried out at Eötvös Loránd University (Hungary) using a laboratory robotic system and commercially available test kits. Dopaminergic predictions were performed at EuroScreen SA (Belgium) using recombinant cell lines expressing human recombinant dopaminergic receptors D1 and D2<sub>long</sub>.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Drug Profile Matching</h3><div class="NLM_p">The Drug Profile Matching (DPM) method was used as described earlier.<a onclick="showRef(event, 'ref26 ref85'); return false;" href="javascript:void(0);" class="ref ref26 ref85">(26, 85)</a> A total of 1226 FDA-approved drug molecules were extracted from DrugBank database<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> as of June 2009. The DOVIS 2.0 software (DOcking-based Virtual Screening),<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> AutoDock4 docking engine,<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Lamarckian genetic algorithm, and X-SCORE<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> scoring function were applied for docking preparations and calculations. The docking box was centered at the geometrical center of the original ligand of the protein. Twenty-five docking runs were performed for each job. Each drug was docked to each protein (1226 × 149 = 182 674 dockings, repeated 25 times). The calculated best docking scores were imported to the IP data matrix.</div><div class="NLM_p">Physiological effect information on the 1226 FDA-approved small-molecule drug set was extracted from the DrugBank database.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Effects containing at least 10 registered drugs were considered in this study. The presence or absence of the studied 177 effects for each drug is then stored in a binary matrix, i.e., the Effect Profile (EP) matrix.</div><div class="NLM_p">Canonical correlation analyses were performed in order to match the IP and EP matrices and find highly correlated factor pairs that are the linear combinations of the variables of the starting data sets. Subsequently, linear discriminant analysis was applied to determine a classification function that calculates the probability value for each drug–effect pair. The prediction accuracy of the DPM method was examined by Receiver Operating Characteristics (ROC) analysis, i.e., determining the true positive rate (TPR) and the false positive rate (FPR) for every effect using a sliding cutoff parameter for the predicted probabilities. TPR and FPR values for each possible cutoff are plotted on a two-dimensional graph called the ROC curve. The area under the ROC curve, i.e., the AUC value, can be used to characterize the reclassification accuracy. In order to check the validity of the DPM predictions, the commonly used 10-fold cross-validation was performed and repeated 100 times. Robustness was determined for each effect by a measure called “mean of the mean probability values (mean MPVs)”, which is related to the robustness of the method against the information loss occurring when a portion of the input information is removed. The closer the mean MPV is to 1, the more cohesive the group of active molecules is based on their interaction patterns.</div><div class="NLM_p last">The Statistical Analysis System for Windows (version 9.2; SAS Institute, Cary, NC) was used for the implementation of all statistical analyses.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> ACE Inhibition Assay</h3><div class="NLM_p">In vitro tests were performed on a Hamilton Starlet liquid handling workstation (Hamilton Robotics, Bonaduz, Switzerland). Spectroscopic measurements were carried out on BMG FluoStar Optima (Offenburg, Germany). The robot was programmed according to the manufacturer’s instructions. The selected drugs were initially tested at 500 μM, and certain drugs were further tested to determine <i>K</i><sub>i</sub> values. Each data point is an average of two independent measurements.</div><div class="NLM_p">ACE inhibition was tested using the ACE Kit-WST from Dojindo Molecular Technologies, Inc. (Kumamoto, Japan, catalog no. A502-10). The ACE kit of Dojindo was presented in research papers.<a onclick="showRef(event, 'ref90 ref91'); return false;" href="javascript:void(0);" class="ref ref90 ref91">(90, 91)</a></div><div class="NLM_p last">3-Hydroxybutyril-glycil-glycil-glycine is utilized as a substrate in this kit, and under the actions of ACE and aminoacylase it is converted into 3-hydroxybutyric acid. In the development step it is further oxidized into acetoacetate by the action of 3-hydroxybutyrate dehydrogenase. At the same time, the cofactor NAD<sup>+</sup> is converted into the reduced form NADH. During the oxidation of NADH to NAD<sup>+</sup> a water-soluble tetrazolium salt is reduced coupled with an electron mediator and generates a yellow formazan. Tested drugs were incubated at the given concentrations with enzyme working solution and the substrate for 60 min at 37 °C. In the next step indicator working solution was added to the reactions and the plate was incubated at room temperature for 10 min and read at 450 nm. Captopril was used as a positive control in this assay.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> COX Inhibition Assay</h3><div class="NLM_p">Experiments were carried out using the same equipment described in the previous section. Screening was performed in duplicate at a final compound concentration of 500 μM. For certain compounds, <i>K</i><sub>i</sub> values were determined by applying decreasing concentrations.</div><div class="NLM_p">COX inhibition was investigated using the COX inhibitor screening assay kit from Cayman Chemical Co. (Cayman Europe, Tallinn, Estonia; catalog no. 560131). The COX kit of Cayman Chemicals was used in several reserch projects published in scientific journals.<a onclick="showRef(event, 'ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref92 ref93">(92, 93)</a></div><div class="NLM_p last">This enzyme immunoassay kit quantifies the inhibition of COX-1 and COX-2 activities by measuring the formation of prostanoid products from the substrate arachidonic acid. Tested drugs were preincubated at the given concentrations with enzymes COX-1 and COX-2 for 10 min at 37 °C. Reactions were started by adding the substrate and then incubating the mixture for 2 min at 37 °C and were stopped by 1 M HCl. Prostaglandin screening was performed on a 96-well microplate coated with mouse anti-rabbit IgG. COX reaction samples were mixed with an AChE-linked tracer, and the antiserum was then incubated for 18 h at room temperature. The washed plate was developed by Ellman’s reagent for 60 min and read at 400 nm. Acetylsalicylic acid was used as a positive control in the assay.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Dopaminergic Agonist and Antagonist Assays</h3><div class="NLM_p">Dopamine receptor D1 and D2<sub>long</sub> tests were carried out at Euroscreen SA, Brussels, Belgium. For more information on the company, see <a href="http://www.euroscreen.com/" class="extLink">http://www.euroscreen.com/</a>.</div><div class="NLM_p">Compounds were dissolved at 20 mM in 90% DMSO and sent to EuroScreen SA where they were stored at room temperature prior to the test. In the cases of celecoxib, desogestrel, mitoxantrone, raloxifene, and doxazosin precipitation occurred. 400 μM stock solutions were prepared for testing.</div><div class="NLM_p">For D1 agonist and antagonist tests, cAMP-HTRF functional assays were used (CHO-K1 recombinant cell line, human recombinant dopamine receptor D1, catalog no. FAST-0100C). Reference compounds were SKF81297 and SCH23390 in agonist and antagonist modes, respectively. Compounds were screened in triplicate at a final concentration of 100 μM. CHO-K1 cells expressing human D1 recombinant receptor grown in antibiotic-free media were detached by gentle flushing with PBS-EDTA (5 mM EDTA), centrifugated, and resuspended in assay buffer containing 5 mM KCl, 1.25 mM MgSO<sub>4</sub>, 1.24 mM NaCl, 25 mM HEPES, 13.3 mM glucose, 1.25 mM KH<sub>2</sub>PO<sub>4</sub>, 1.45 mM CaCl<sub>2</sub>, and 0.5 g/L BSA. In agonist tests, 12 μL of cells was mixed with 6 μL of assay buffer and 6 μL of test compound solution, respectively. After 30 min of incubation at room temperature, lysis buffer was added. After 1 h of incubation, cAMP concentration was measured with the HTRF kit according to the manufacturer’s specification. In antagonist tests, 12 μL of cells was mixed with 6 μL of test compound and incubated for 10 min. After that, 6 μL of reference agonist solution was added at a final concentration corresponding to EC<sub>80</sub>. After 30 min of incubation, lysis buffer was added. The concentration of cAMP was measured after 1 h of incubation in the same way as described before.</div><div class="NLM_p">For the long isoform of D2 receptor, an aequorin-based functional assay was used (CHO-K1 recombinant cell line, human recombinant dopamine receptor D2<sub>long</sub>, FAST-0101A) with reference compounds quinpirol and haloperidol for agonist and antagonist tests, respectively. Compound screening was performed in triplicate at a final concentration of 100 and 50 μM in agonist and antagonist modes, respectively. Cells coexpressing mitochondrial apoaequorin and recombinant human D2<sub>long</sub> receptor were grown in antibiotic-free culture media, detached with PDB–EDTA, centrifuged, and resuspended in assay buffer at a concentration of 1 × 10<sup>6</sup> cells/mL. Prior to the tests, cells were incubated at room temperature with coelenterazine for at least 4 h. In agonist tests, 50 μL of cell suspension was mixed with 50 μL of test compound solution and the resulting light emission was detected using a functional drug screening system model 6000 luminometer (Hamamatsu). In antagonist tests, 100 μL of the reference agonist was added to the mix of cells and test compound, at a final concentration corresponding to EC<sub>80</sub>, 15 min after the first injection. Signal detection was performed as described before. We note that the antagonist activity level can be overestimated because of the nature of the aquorin-based tests if the tested compound activates the system during the preincubation period. Such activation was observed in the cases of celexocib, desogestrel, mefloquine, and clomipramine.</div><div class="NLM_p last">For both tests (i.e., D1 and D2<sub>long</sub>), agonist activity of the tested compounds is expressed as the percentage of the activity of the reference agonist at EC<sub>100</sub> concentration. Antagonist activity is expressed as the percentage of the inhibition of the reference agonist activity, applying EC<sub>80</sub> concentration.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Materials</h3><div class="NLM_p">Aminosalicylic acid, furosemide, monobenzone, nitrofurazone, and nitroxoline were purchased from Aldrich. Maraviroc was purchased from AvaChem. Chlorambucil, clavulanate, ethacrynic acid, flucytosine, furazolidone, latamoxef (moxalactam), lipoic acid, nitrofurantoin, novobiocin, paclitaxel, penicillin V, phenazopyridine, and tinidazole were purchased from Fluka. Carbenicillin was purchased from Merck. Chlormezanone and chlorphenesin were purchased from MP Biomedicals, dasatinib and tipranavir from Santa Cruz Biotechnology, acetylsalicylic acid, acitretin, adefovir dipivoxil, adenine, α-linolenic acid, amlexanox, aspartame, atovaquone, azithromycin, captopril, cefuroxime, chloramphenicol, cimetidine, creatine, estrone-sulfate, fluocinonide, flutamide, gemfibrozil, lamivudine, lamotrigine, <span class="smallcaps smallerCapital">l</span>-carnitine, lomustine, L-proline, metronidazole, milrinone, nalidixic acid, natamycin, nateglinide, nelfinavir, nilutamide, penicillin G, pentoxyfiline, pyridoxal phosphate, rosiglitazone, sulpiride, salsalate, telmisartan, ticarcillin, and valproic acid from Sigma, and benzyl benzoate and biotin from Sigma-Aldrich. Ambenonium was purchased from Tocris Bioscience. All tested dopaminergic candidates were purchased from Sigma-Aldrich.</div><div class="NLM_p">Predicted ACE inhibitors pentosan polysulfate, polystyrene sulfonate, and udenafil were commercially not available at the time of testing. Astemizole was omitted from testing because it was withdrawn from the market in most countries.</div><div class="NLM_p last">Predicted COX inhibitors aminohippurate, amlexanox, bexarotene, phenprocoumon, procarbazine, rosoxacin, stepronin, tolcapone, and valrubicin were commercially not available at the time of testing. Gentian violet and sodium lauryl sulfate were excluded from testing because of their limited clinical applicability.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16"><a href="/doi/suppl/10.1021/jm400813y">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60082" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60082" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Chemical structures and plasma concentrations of the studied drugs and activity and inhibition data for compounds predicted with low DPM probability. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm400813y/suppl_file/jm400813y_si_001.pdf">jm400813y_si_001.pdf (453.57 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm400813y" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36232" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36232" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">András Málnási-Csizmadia</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, Institute of Biology, Eötvös
Loránd University, Pázmány Péter sétány 1/C, H-1117 Budapest, Hungary</span>; 
    <span class="hlFld-Affiliation affiliation">Drugmotif
Ltd., Szent Erzsébet
krt 11, H-2112 Veresegyház, Hungary</span>; 
    <span class="hlFld-Affiliation affiliation">Molecular
Biophysics Research Group, Hungarian Academy
of Sciences and Eötvös Loránd
University, Pázmány
Péter sétány 1/C, H-1117 Budapest, Hungary</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c7aaa6aba9a687a2abb3a2e9afb2"><span class="__cf_email__" data-cfemail="315c505d5f5071545d45541f5944">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">László Végner</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, Institute of Biology, Eötvös
Loránd University, Pázmány Péter sétány 1/C, H-1117 Budapest, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ágnes Peragovics</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, Institute of Biology, Eötvös
Loránd University, Pázmány Péter sétány 1/C, H-1117 Budapest, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">László Tombor</span> - <span class="hlFld-Affiliation affiliation">Department
of Psychiatry and Psychotherapy, Semmelweis
University, Balassa Utca
6, H-1083 Budapest, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Balázs Jelinek</span> - <span class="hlFld-Affiliation affiliation">Drugmotif
Ltd., Szent Erzsébet
krt 11, H-2112 Veresegyház, Hungary</span>; 
    <span class="hlFld-Affiliation affiliation">Molecular
Biophysics Research Group, Hungarian Academy
of Sciences and Eötvös Loránd
University, Pázmány
Péter sétány 1/C, H-1117 Budapest, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pál Czobor</span> - <span class="hlFld-Affiliation affiliation">Department
of Psychiatry and Psychotherapy, Semmelweis
University, Balassa Utca
6, H-1083 Budapest, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Bender</span> - <span class="hlFld-Affiliation affiliation">Unilever
Centre for Molecular Science Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zoltán Simon</span> - <span class="hlFld-Affiliation affiliation">Drugmotif
Ltd., Szent Erzsébet
krt 11, H-2112 Veresegyház, Hungary</span>; 
    <span class="hlFld-Affiliation affiliation">Molecular
Biophysics Research Group, Hungarian Academy
of Sciences and Eötvös Loránd
University, Pázmány
Péter sétány 1/C, H-1117 Budapest, Hungary</span>; 
    <span class="hlFld-Affiliation affiliation">Delta Informatika Inc.,
Szentendrei
út 39-53, H-1033, Budapest, Hungary</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>L.V. and Á.P. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d58e949-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83444" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83444" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work has been supported by the National Development Agency (Grant NTP TECH_08_A1/2-2008-0106). The work has also been supported by the European Union and co-financed by the European Social Fund (TÁMOP 4.2.1./B-09/KMR-2010-0003) and the European Regional Development Fund (GOP-1.1.1-08/1-2009-0021). The European Research Council has provided financial support under the European Community’s Seventh Framework Programme (FP7/2007-2013)/ERC Grant 208319. A.B. thanks Unilever for funding. The authors thank Ildikó Brandhuber for her help in collecting plasma concentration data for several compounds.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i19" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i19"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i20" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i20"> Abbreviations Used</h2><tr><td class="NLM_term">ACE</td><td class="NLM_def"><p class="first last">angiotensin-converting enzyme</p></td></tr><tr><td class="NLM_term">ADMET</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, elimination, and toxicity</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">COX</td><td class="NLM_def"><p class="first last">cyclooxygenase</p></td></tr><tr><td class="NLM_term">DPM</td><td class="NLM_def"><p class="first last">Drug Profile Matching</p></td></tr><tr><td class="NLM_term">EP</td><td class="NLM_def"><p class="first last">Effect Profile</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FPR</td><td class="NLM_def"><p class="first last">false positive rate</p></td></tr><tr><td class="NLM_term">IP</td><td class="NLM_def"><p class="first last">Interaction Pattern</p></td></tr><tr><td class="NLM_term">PASS</td><td class="NLM_def"><p class="first last">Prediction of Activity Spectra for Substances</p></td></tr><tr><td class="NLM_term">ROC</td><td class="NLM_def"><p class="first last">Receiver Operating Characteristics</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">TPR</td><td class="NLM_def"><p class="first last">true positive rate</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58627" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58627" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 93 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Kling, J.</span><span> </span><span class="NLM_article-title">Fresh from the biotech pipeline—2011 [corrected]</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">128</span><span class="NLM_x">–</span> <span class="NLM_lpage">131</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=128-131&author=J.+Kling&title=Fresh+from+the+biotech+pipeline%E2%80%942011+%5Bcorrected%5D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKling%26aufirst%3DJ.%26atitle%3DFresh%2520from%2520the%2520biotech%2520pipeline%25E2%2580%25942011%2520%255Bcorrected%255D%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D128%26epage%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Ashburn, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thor, K. B.</span><span> </span><span class="NLM_article-title">Drug repositioning: identifying and developing new uses for existing drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">673</span><span class="NLM_x">–</span> <span class="NLM_lpage">683</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1038%2Fnrd1468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=15286734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=673-683&author=T.+T.+Ashburnauthor=K.+B.+Thor&title=Drug+repositioning%3A+identifying+and+developing+new+uses+for+existing+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repositioning: identifying and developing new uses for existing drugs</span></div><div class="casAuthors">Ashburn, Ted T.; Thor, Karl B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">673-683</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Biopharmaceutical companies attempting to increase productivity through novel discovery technologies have fallen short of achieving the desired results.  Repositioning existing drugs for new indications could deliver the productivity increases that the industry needs while shifting the locus of prodn. to biotechnol. companies.  More and more companies are scanning the existing pharmacopeia for repositioning candidates, and the no. of repositioning success stories is increasing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLkWl3DnePhrVg90H21EOLACvtfcHk0lh-Bx5fwiuasQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtL8%253D&md5=0145c02423ab81ace6e3b3d92585cccc</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd1468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1468%26sid%3Dliteratum%253Aachs%26aulast%3DAshburn%26aufirst%3DT.%2BT.%26aulast%3DThor%26aufirst%3DK.%2BB.%26atitle%3DDrug%2520repositioning%253A%2520identifying%2520and%2520developing%2520new%2520uses%2520for%2520existing%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D673%26epage%3D683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management</span> <span class="citation_source-journal">Am. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">1037</span><span class="NLM_x">–</span> <span class="NLM_lpage">1045</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1002%2Fajh.23282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=23090888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFGqsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2012&pages=1037-1045&author=E.+Jabbourauthor=H.+Kantarjian&title=Chronic+myeloid+leukemia%3A+2012+update+on+diagnosis%2C+monitoring%2C+and+management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management</span></div><div class="casAuthors">Jabbour, Elias; Kantarjian, Hagop</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1037-1045</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Disease overview: : Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of one-two cases per 100,000 adults and accounts for ∼15% of newly diagnosed cases of leukemia in adults.Diagnosis: : CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson oncogene (ABL) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2.  This rearrangement is known as the Philadelphia chromosome.  The mol. consequence of this translocation is the generation of a BCR-ABL fusion oncogene, which in turn translates into a Bcr-Abl oncoprotein.Frontline therapy: : Three tyrosine kinase inhibitors (TKIs), imatinib, nilotinib, and dasatinib, have been approved by the US Food and Drug Administration for the first-line treatment of patients with newly diagnosed CML in chronic phase (CML-CP).  Clin. trials with 2nd generation TKIs reported significantly deeper and faster responses; their impact on long-term survival remains to be detd.Salvage therapy: : For patients who fail std.-dose imatinib therapy, imatinib dose escalation is a second-line option.  Alternative second-line options include 2nd generation TKIs.  Although both are potent and specific BCR-ABL TKIs, dasatinib and nilotinib exhibit unique pharmacol. profiles and response patterns relative to different patient characteristics, such as disease stage and BCR-ABL mutational status.  Patients who develop the T315I "gatekeeper" mutation display resistance to all currently available TKIs and are candidate for clin. trials.  Allogeneic transplantation remains an important therapeutic option for CML-CP harboring the T315I mutation, patients who fail 2nd generation TKIs, and for all patients in advanced phase disease.  Am. J. Hematol., 2012. © 2012 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv0HLutfly_bVg90H21EOLACvtfcHk0lh-Bx5fwiuasQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFGqsbvM&md5=70baa58918a651d515b5249812049672</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fajh.23282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.23282%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DChronic%2520myeloid%2520leukemia%253A%25202012%2520update%2520on%2520diagnosis%252C%2520monitoring%252C%2520and%2520management%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2012%26volume%3D87%26spage%3D1037%26epage%3D1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Eisenberg, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pipas, J. M.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumor—background, pathology, treatment</span> <span class="citation_source-journal">Hematol Oncol Clin North Am.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1239</span><span class="NLM_x">–</span> <span class="NLM_lpage">1259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.hoc.2012.08.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=23116579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FpvFGhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1239-1259&author=B.+L.+Eisenbergauthor=J.+M.+Pipas&title=Gastrointestinal+stromal+tumor%E2%80%94background%2C+pathology%2C+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumor--background, pathology, treatment</span></div><div class="casAuthors">Eisenberg Burton L; Pipas J Marc</div><div class="citationInfo"><span class="NLM_cas:title">Hematology/oncology clinics of North America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1239-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Gastrointestinal stromal tumor (GIST) represents the most common mesechymal tumor of the gastrointestinal tract.  Discovery of the relationship between unregulated KIT kinase and GIST transformation has led to diagnostic and therapeutic targeting.  Imatinib is the recommended first-line treatment of metastatic GIST.  In addition, the combination of surgery and imatinib for primary GIST is indicated in the adjuvant setting of high-risk patients and there may be benefit for this combination in the neoadjuvant setting.  The success of molecular targeted therapy in GIST represents an important and exciting advance in solid tumor oncology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRmEqEoqczuLnl8icjszYl0fW6udTcc2eYyovrxNJJPa7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FpvFGhsA%253D%253D&md5=8da84949b4362fe820ce3d694d319a5c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.hoc.2012.08.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hoc.2012.08.003%26sid%3Dliteratum%253Aachs%26aulast%3DEisenberg%26aufirst%3DB.%2BL.%26aulast%3DPipas%26aufirst%3DJ.%2BM.%26atitle%3DGastrointestinal%2520stromal%2520tumor%25E2%2580%2594background%252C%2520pathology%252C%2520treatment%26jtitle%3DHematol%2520Oncol%2520Clin%2520North%2520Am.%26date%3D2012%26volume%3D26%26spage%3D1239%26epage%3D1259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Ekman, P.</span><span> </span><span class="NLM_article-title">Finasteride in the treatment of benign prostatic hypertrophy: an update. New indications for finasteride therapy</span> <span class="citation_source-journal">Scand. J. Urol. Nephrol., Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">203</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1080%2F00365599950509997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=10636564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD3c7gtVGiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=203&publication_year=1999&pages=15-20&author=P.+Ekman&title=Finasteride+in+the+treatment+of+benign+prostatic+hypertrophy%3A+an+update.+New+indications+for+finasteride+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Finasteride in the treatment of benign prostatic hypertrophy: an update. New indications for finasteride therapy</span></div><div class="casAuthors">Ekman P</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian journal of urology and nephrology. Supplementum</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">203</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-20</span>
        ISSN:<span class="NLM_cas:issn">0300-8886</span>.
    </div><div class="casAbstract">A phenomenon of the prostate gland, which is also shared by hair follicles, is that it is little influenced by testosterone (T) for androgenic stimulation, but instead by its metabolite 5alpha-dihydrotestosterone (DHT).  By blocking the conversion of T to DHT, the circulating level of DHT is reduced by 80%, the size of the prostate gland is reduced by about 20% and the level of prostate-specific antigen (PSA) by about 50%.  Treatment of patients with obstructive benign prostatic hypertrophy (BPH) with the drug Finasteride leads to a moderately improved urinary flow, symptomatic improvement and halts the natural progress of the disease.  Since DHT potentiates the effect of testosterone on erectile function, the side-effects are impotence in 3% of patients, decreased ejaculatory volume, and gynaecomastia in 0.4% of patients.  The drug could be regarded as a safe way to treat moderately symptomatic BPH.  The efficacy of the drug is long-lasting (more than 7 years).  It has also been tried in prostate cancer, but is less effective.  It reduces PSA levels by 50% and, in combination therapy, therefore, PSA levels remain low for longer when Finasteride is added.  An important finding is the efficacy of Finasteride treatment in haematuria from BPH.  The drug interacts with vascular endothelium growth factor and efficiently prevents new bleeding.  It could be regarded as a first-line therapy for this type of haematuria.  Finasteride can also be used to stop male baldness.  It seems particularly effective in men aged 20-40 years; 85% of patients stopped losing hair when given Finasteride.  When the treatment was stopped hair loss continued, thus therapy may have to be "lifelong".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS056xhuBGpsbqxQ2mb9Pu8fW6udTcc2eYyovrxNJJPa7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7gtVGiuw%253D%253D&md5=6626866af877249366b234280bf92de0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1080%2F00365599950509997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00365599950509997%26sid%3Dliteratum%253Aachs%26aulast%3DEkman%26aufirst%3DP.%26atitle%3DFinasteride%2520in%2520the%2520treatment%2520of%2520benign%2520prostatic%2520hypertrophy%253A%2520an%2520update.%2520New%2520indications%2520for%2520finasteride%2520therapy%26jtitle%3DScand.%2520J.%2520Urol.%2520Nephrol.%252C%2520Suppl.%26date%3D1999%26volume%3D203%26spage%3D15%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Cleach, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bocquet, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roujeau, J. C.</span><span> </span><span class="NLM_article-title">Reactions and interactions of some commonly used systemic drugs in dermatology</span> <span class="citation_source-journal">Dermatol. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">429</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2FS0733-8635%2805%2970023-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=9589214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADyaK1c3ltFWjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=421-429&author=L.+L.+Cleachauthor=H.+Bocquetauthor=J.+C.+Roujeau&title=Reactions+and+interactions+of+some+commonly+used+systemic+drugs+in+dermatology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Reactions and interactions of some commonly used systemic drugs in dermatology</span></div><div class="casAuthors">Cleach L L; Bocquet H; Roujeau J C</div><div class="citationInfo"><span class="NLM_cas:title">Dermatologic clinics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">421-9</span>
        ISSN:<span class="NLM_cas:issn">0733-8635</span>.
    </div><div class="casAbstract">This article deals with the main interactions and adverse effects of some drugs that are used daily by dermatologists.  It includes tetracyclines and Minocycline in the treatment of acne; antimalarials and discoid lupus; dapsone; thalidomine; oral retinoids; methotrexate and cyclosporine.  Several of these drugs are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_vw8Lu8LWLSA3UY9EwTNrfW6udTcc2eYyovrxNJJPa7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3ltFWjtA%253D%253D&md5=5e311529dc068fe2d0eb5fc602e18b8c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0733-8635%2805%2970023-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0733-8635%252805%252970023-1%26sid%3Dliteratum%253Aachs%26aulast%3DCleach%26aufirst%3DL.%2BL.%26aulast%3DBocquet%26aufirst%3DH.%26aulast%3DRoujeau%26aufirst%3DJ.%2BC.%26atitle%3DReactions%2520and%2520interactions%2520of%2520some%2520commonly%2520used%2520systemic%2520drugs%2520in%2520dermatology%26jtitle%3DDermatol.%2520Clin.%26date%3D1998%26volume%3D16%26spage%3D421%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Patrono, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia Rodriguez, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landolfi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baigent, C.</span><span> </span><span class="NLM_article-title">Low-dose aspirin for the prevention of atherothrombosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">2373</span><span class="NLM_x">–</span> <span class="NLM_lpage">2383</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1056%2FNEJMra052717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=16319386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1OmsbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=2373-2383&author=C.+Patronoauthor=L.+A.+Garcia+Rodriguezauthor=R.+Landolfiauthor=C.+Baigent&title=Low-dose+aspirin+for+the+prevention+of+atherothrombosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Low-dose aspirin for the prevention of atherothrombosis</span></div><div class="casAuthors">Patrono, Carlo; Garcia Rodriguez, Luis A.; Landolfi, Raffaele; Baigent, Colin</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2373-2383</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The article discusses the mol. mechanism of action of aspirin and the results of clin. trials and epidemiol. studies of aspirin as an antiplatelet agent.  Emphasis is placed on the benefits and risks of low-dose aspirin in various patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZQ1jICSmBdrVg90H21EOLACvtfcHk0lhMi9sCTkepEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1OmsbnM&md5=4d805408cb259263361589fa3a31544f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMra052717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra052717%26sid%3Dliteratum%253Aachs%26aulast%3DPatrono%26aufirst%3DC.%26aulast%3DGarcia%2BRodriguez%26aufirst%3DL.%2BA.%26aulast%3DLandolfi%26aufirst%3DR.%26aulast%3DBaigent%26aufirst%3DC.%26atitle%3DLow-dose%2520aspirin%2520for%2520the%2520prevention%2520of%2520atherothrombosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D2373%26epage%3D2383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Patrono, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocca, B.</span><span> </span><span class="NLM_article-title">Aspirin, 110 years later</span> <span class="citation_source-journal">J. Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">258</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1111%2Fj.1538-7836.2009.03391.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=19630812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvV2isLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=258-261&issue=Suppl.+1&author=C.+Patronoauthor=B.+Rocca&title=Aspirin%2C+110+years+later"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Aspirin, 110 years later</span></div><div class="casAuthors">Patrono, C.; Rocca, B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">258-261</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Although conceived at the end of the 19th century as a synthetic analgesic agent with improved gastric tolerability vs. naturally occurring salicylates, acetylsalicylic acid (marketed as aspirin in 1899) turned out to be an ideal antiplatelet agent about 90 years later, following the understanding of its mechanism of action, the development of a mechanism-based biomarker for dose-finding studies, and the initiation of a series of appropriately sized, randomized clin. trials to test its efficacy and safety at low doses given once daily.  At the turn of its 110th anniversary, aspirin continues to attract heated debates on a no. of issues including (i) the optimal dose to maximize efficacy and minimize toxicity; (ii) the possibility that some patients may be "resistant" to its antiplatelet effects; and (iii) the balance of benefits and risks in primary vs. secondary prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaK1LwyYwfRLVg90H21EOLACvtfcHk0lhMi9sCTkepEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvV2isLg%253D&md5=df16aa2e011b8d573786a4da76edeb99</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1538-7836.2009.03391.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1538-7836.2009.03391.x%26sid%3Dliteratum%253Aachs%26aulast%3DPatrono%26aufirst%3DC.%26aulast%3DRocca%26aufirst%3DB.%26atitle%3DAspirin%252C%2520110%2520years%2520later%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2009%26volume%3D7%26issue%3DSuppl.%25201%26spage%3D258%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Krejsa, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogalski, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penzotti, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migeon, J. C.</span><span> </span><span class="NLM_article-title">Predicting ADME properties and side effects: the BioPrint approach</span> <span class="citation_source-journal">Curr. Opin. Drug Discoveru Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">470</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=12951810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFymsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2003&pages=470-480&author=C.+M.+Krejsaauthor=D.+Horvathauthor=S.+L.+Rogalskiauthor=J.+E.+Penzottiauthor=B.+Maoauthor=F.+Barbosaauthor=J.+C.+Migeon&title=Predicting+ADME+properties+and+side+effects%3A+the+BioPrint+approach"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting ADME properties and side effects: The BioPrint approach</span></div><div class="casAuthors">Krejsa, Cecile M.; Horvath, Dragos; Rogalski, Sherri L.; Penzotti, Julie E.; Mao, Boryeu; Barbosa, Frederique; Migeon, Jacques C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">470-480</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Current Drugs</span>)
        </div><div class="casAbstract">A review.  Computational methods are increasingly used to streamline and enhance the lead discovery and optimization process.  However, accurate prediction of absorption, distribution, metab. and excretion (ADME) and adverse drug reactions (ADR) is often difficult, due to the complexity of underlying physiol. mechanisms.  Modeling approaches have been hampered by the lack of large, robust and standardized training datasets.  In an extensive effort to build such a dataset, the BioPrint database was constructed by systematic profiling of nearly all drugs available on the market, as well as numerous ref. compds.  The database is composed of several large datasets: compd. structures and mol. descriptors, in vitro ADME and pharmacol. profiles, and complementary clin. data including therapeutic use information, pharmacokinetics profiles and ADR profiles.  These data have allowed the development of computational tools designed to integrate a program of computational chem. into library design and lead development.  Models based on chem. structure are strengthened by in vitro results that can be used as addnl. compd. descriptors to predict complex in vivo endpoints.  The BioPrint pharmacoinformatics platform represents a systematic effort to accelerate the process of drug discovery, improve quant. structure-activity relationships and develop in vitro/in vivo assocns.  In this review, we will discuss the importance of training set size and diversity in model development, the implementation of linear and neighborhood modeling approaches, and the use of in silico methods to predict potential clin. liabilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZQ71juUoErrVg90H21EOLACvtfcHk0ljKEI5SHWiLJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFymsLw%253D&md5=f8db4e37cc895d67bf4a82efe021c5c2</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrejsa%26aufirst%3DC.%2BM.%26aulast%3DHorvath%26aufirst%3DD.%26aulast%3DRogalski%26aufirst%3DS.%2BL.%26aulast%3DPenzotti%26aufirst%3DJ.%2BE.%26aulast%3DMao%26aufirst%3DB.%26aulast%3DBarbosa%26aufirst%3DF.%26aulast%3DMigeon%26aufirst%3DJ.%2BC.%26atitle%3DPredicting%2520ADME%2520properties%2520and%2520side%2520effects%253A%2520the%2520BioPrint%2520approach%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discoveru%2520Dev.%26date%3D2003%26volume%3D6%26spage%3D470%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Fliri, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loging, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thadeio, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volkmann, R. A.</span><span> </span><span class="NLM_article-title">Analysis of drug-induced effect patterns to link structure and side effects of medicines</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">–</span> <span class="NLM_lpage">397</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1038%2Fnchembio747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=16370374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1aiu7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=389-397&author=A.+F.+Fliriauthor=W.+T.+Logingauthor=P.+F.+Thadeioauthor=R.+A.+Volkmann&title=Analysis+of+drug-induced+effect+patterns+to+link+structure+and+side+effects+of+medicines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of drug-induced effect patterns to link structure and side effects of medicines</span></div><div class="casAuthors">Fliri, Anton F.; Loging, William T.; Thadeio, Peter F.; Volkmann, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">389-397</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The high failure rate of exptl. medicines in clin. trials accentuates inefficiencies of current drug discovery processes caused by a lack of tools for translating the information exchange between protein and organ system networks.  Recently, the authors reported that biol. activity spectra (biospectra), derived from in vitro protein binding assays, provide a mechanism for assessing a mol.'s capacity to modulate the function of protein-network components.  Herein the authors describe the translation of adverse effect data derived from 1045 prescription drug labels into effect spectra and show their utility for diagnosing drug-induced effects of medicines.  In addn., notwithstanding the limitation imposed by the quality of drug label information, the authors show that biospectrum anal., in concert with effect spectrum anal., provides an alignment between preclin. and clin. drug-induced effects.  The identification of this alignment provides a mechanism for forecasting clin. effect profiles of medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwQngpXzhXtbVg90H21EOLACvtfcHk0ljKEI5SHWiLJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1aiu7rK&md5=c1ef79fe178b6bf0a22fca744773bf00</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnchembio747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio747%26sid%3Dliteratum%253Aachs%26aulast%3DFliri%26aufirst%3DA.%2BF.%26aulast%3DLoging%26aufirst%3DW.%2BT.%26aulast%3DThadeio%26aufirst%3DP.%2BF.%26aulast%3DVolkmann%26aufirst%3DR.%2BA.%26atitle%3DAnalysis%2520of%2520drug-induced%2520effect%2520patterns%2520to%2520link%2520structure%2520and%2520side%2520effects%2520of%2520medicines%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2005%26volume%3D1%26spage%3D389%26epage%3D397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Fliri, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loging, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thadeio, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volkmann, R. A.</span><span> </span><span class="NLM_article-title">Biospectra analysis: model proteome characterizations for linking molecular structure and biological response</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6918</span><span class="NLM_x">–</span> <span class="NLM_lpage">6925</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050494g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGisrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6918-6925&author=A.+F.+Fliriauthor=W.+T.+Logingauthor=P.+F.+Thadeioauthor=R.+A.+Volkmann&title=Biospectra+analysis%3A+model+proteome+characterizations+for+linking+molecular+structure+and+biological+response"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Biospectra Analysis: Model Proteome Characterizations for Linking Molecular Structure and Biological Response</span></div><div class="casAuthors">Fliri, Anton F.; Loging, William T.; Thadeio, Peter F.; Volkmann, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6918-6925</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Establishing quant. relationships between mol. structure and broad biol. effects has been a long-standing goal in drug discovery.  Evaluation of the capacity of mols. to modulate protein functions is a prerequisite for understanding the relationship between mol. structure and in vivo biol. response.  A particular challenge in these investigations is to derive quant. measurements of a mol.'s functional activity pattern across different proteins.  Herein we describe an operationally simple probabilistic structure-activity relationship (SAR) approach, termed biospectra anal., for identifying agonist and antagonist effect profiles of medicinal agents by using pattern similarity between biol. activity spectra (biospectra) of mols. as the determinant.  Accordingly, in vitro binding data (percent inhibition values of mols. detd. at single high drug concn. in a battery of assays representing a cross section of the proteome) are useful for identifying functional effect profile similarity between medicinal agents.  To illustrate this finding, the relationship between biospectra similarity of 24 mols., identified by hierarchical clustering of a 1567 mol. dataset as being most closely aligned with the neurotransmitter dopamine, and their agonist or antagonist properties was probed.  Distinguishing the results described in this study from those obtained with affinity-based methods, the obsd. assocn. between biospectra and biol. response profile similarity remains intact even upon removal of putative drug targets from the dataset (four dopaminergic [D1/D2/D3/D4] and two adrenergic [α1 and α2] receptors).  These findings indicate that biospectra anal. provides an unbiased new tool for forecasting structure-response relationships and for translating broad biol. effect information into chem. structure design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJa5_zvZqHGLVg90H21EOLACvtfcHk0ljM-r4VqOgprg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGisrjE&md5=e899a8db1f2d66dcb7b7c5d656816111</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm050494g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050494g%26sid%3Dliteratum%253Aachs%26aulast%3DFliri%26aufirst%3DA.%2BF.%26aulast%3DLoging%26aufirst%3DW.%2BT.%26aulast%3DThadeio%26aufirst%3DP.%2BF.%26aulast%3DVolkmann%26aufirst%3DR.%2BA.%26atitle%3DBiospectra%2520analysis%253A%2520model%2520proteome%2520characterizations%2520for%2520linking%2520molecular%2520structure%2520and%2520biological%2520response%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6918%26epage%3D6925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Fliri, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loging, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thadeio, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volkmann, R. A.</span><span> </span><span class="NLM_article-title">Biological spectra analysis: linking biological activity profiles to molecular structure</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=261-266&author=A.+F.+Fliriauthor=W.+T.+Logingauthor=P.+F.+Thadeioauthor=R.+A.+Volkmann&title=Biological+spectra+analysis%3A+linking+biological+activity+profiles+to+molecular+structure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFliri%26aufirst%3DA.%2BF.%26aulast%3DLoging%26aufirst%3DW.%2BT.%26aulast%3DThadeio%26aufirst%3DP.%2BF.%26aulast%3DVolkmann%26aufirst%3DR.%2BA.%26atitle%3DBiological%2520spectra%2520analysis%253A%2520linking%2520biological%2520activity%2520profiles%2520to%2520molecular%2520structure%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D261%26epage%3D266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Kauvar, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villar, H. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sportsman, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engqvist-Goldstein, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilley, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocke, D. M.</span><span> </span><span class="NLM_article-title">Predicting ligand binding to proteins by affinity fingerprinting</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2F1074-5521%2895%2990283-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=9383411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADyaK2MXmtVWku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1995&pages=107-118&author=L.+M.+Kauvarauthor=D.+L.+Higginsauthor=H.+O.+Villarauthor=J.+R.+Sportsmanauthor=A.+Engqvist-Goldsteinauthor=R.+Bukarauthor=K.+E.+Bauerauthor=H.+Dilleyauthor=D.+M.+Rocke&title=Predicting+ligand+binding+to+proteins+by+affinity+fingerprinting"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting ligand binding to proteins by affinity fingerprinting</span></div><div class="casAuthors">Kauvar, Lawrence M.; Higgins, Deborah L.; Villar, Hugo O.; Sportsman, J Richard; Engqvist-Goldstein, Asa; Bukar, Robert; Bauer, Karin E.; Dilley, Hara; Rocke, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-18</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    </div><div class="casAbstract">There are many ways to represent a mol.'s properties, including at.-connectivity drawings, NMR spectra, and MO models.  Prior methods for predicting the biol. activity of compds. have largely depended on these phys. representations.  Measuring a compd.'s binding potency against a small ref. panel of diverse proteins defines a very different representation of the mol., which the authors call an affinity fingerprint.  Statistical anal. of such fingerprints provides new insights into aspects of binding interactions that are shared among a wide variety of proteins.  These analyses facilitate prediction of the binding properties of these compds. assayed against new proteins.  Affinity fingerprints are reported for 122 structurally-diverse compds. using a ref. panel of eight proteins that collectively are able to generate unique fingerprints for about 75% of the small org. compds. tested.  Application of multivariate regression techniques to this database enables the creation of computational surrogates to represent new proteins that are surprisingly effective at predicting binding potencies.  The authors illustrate this for two enzymes with no previously recognizable similarity to each other or to any of the ref. proteins.  Fitting of analogous computational surrogates to four other proteins confirms the generality of the method; when applied to a fingerprinted library of 5000 compds., several sub-micromolar hits were correctly predicted.  An affinity fingerprint database, which provides a rich source of data defining operational similarities among proteins, can be used to test theories of cryptic homol. unexpected from current understanding of protein structure.  Practical applications to drug design include efficient pre-screening of large nos. of compds. against target proteins using fingerprint similarities, supplemented by a small no. of empirical measurements, to select promising compds. for further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmBTYEbEBo-7Vg90H21EOLACvtfcHk0liqj6HZawShmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmtVWku70%253D&md5=7fc9345e10262c7ef0bae7acb98d3556</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2F1074-5521%2895%2990283-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F1074-5521%252895%252990283-X%26sid%3Dliteratum%253Aachs%26aulast%3DKauvar%26aufirst%3DL.%2BM.%26aulast%3DHiggins%26aufirst%3DD.%2BL.%26aulast%3DVillar%26aufirst%3DH.%2BO.%26aulast%3DSportsman%26aufirst%3DJ.%2BR.%26aulast%3DEngqvist-Goldstein%26aufirst%3DA.%26aulast%3DBukar%26aufirst%3DR.%26aulast%3DBauer%26aufirst%3DK.%2BE.%26aulast%3DDilley%26aufirst%3DH.%26aulast%3DRocke%26aufirst%3DD.%2BM.%26atitle%3DPredicting%2520ligand%2520binding%2520to%2520proteins%2520by%2520affinity%2520fingerprinting%26jtitle%3DChem.%2520Biol.%26date%3D1995%26volume%3D2%26spage%3D107%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Hsu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damodaran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keck, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laborde, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lum, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macke, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schow, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villar, H. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wick, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beroza, P.</span><span> </span><span class="NLM_article-title">Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4875</span><span class="NLM_x">–</span> <span class="NLM_lpage">4880</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049950b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4875-4880&author=N.+Hsuauthor=D.+Caiauthor=K.+Damodaranauthor=R.+F.+Gomezauthor=J.+G.+Keckauthor=E.+Labordeauthor=R.+T.+Lumauthor=T.+J.+Mackeauthor=G.+Martinauthor=S.+R.+Schowauthor=R.+J.+Simonauthor=H.+O.+Villarauthor=M.+M.+Wickauthor=P.+Beroza&title=Novel+cyclooxygenase-1+inhibitors+discovered+using+affinity+fingerprints"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm049950b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049950b%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DN.%26aulast%3DCai%26aufirst%3DD.%26aulast%3DDamodaran%26aufirst%3DK.%26aulast%3DGomez%26aufirst%3DR.%2BF.%26aulast%3DKeck%26aufirst%3DJ.%2BG.%26aulast%3DLaborde%26aufirst%3DE.%26aulast%3DLum%26aufirst%3DR.%2BT.%26aulast%3DMacke%26aufirst%3DT.%2BJ.%26aulast%3DMartin%26aufirst%3DG.%26aulast%3DSchow%26aufirst%3DS.%2BR.%26aulast%3DSimon%26aufirst%3DR.%2BJ.%26aulast%3DVillar%26aufirst%3DH.%2BO.%26aulast%3DWick%26aufirst%3DM.%2BM.%26aulast%3DBeroza%26aufirst%3DP.%26atitle%3DNovel%2520cyclooxygenase-1%2520inhibitors%2520discovered%2520using%2520affinity%2520fingerprints%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D4875%26epage%3D4880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Koutsoukas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simms, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirchmair, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bond, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitmore, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glen, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, A.</span><span> </span><span class="NLM_article-title">From in silico target prediction to multi-target drug design: current databases, methods and applications</span> <span class="citation_source-journal">J. Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">2554</span><span class="NLM_x">–</span> <span class="NLM_lpage">2574</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.jprot.2011.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=21621023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2011&pages=2554-2574&author=A.+Koutsoukasauthor=B.+Simmsauthor=J.+Kirchmairauthor=P.+J.+Bondauthor=A.+V.+Whitmoreauthor=S.+Zimmerauthor=M.+P.+Youngauthor=J.+L.+Jenkinsauthor=M.+Glickauthor=R.+C.+Glenauthor=A.+Bender&title=From+in+silico+target+prediction+to+multi-target+drug+design%3A+current+databases%2C+methods+and+applications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">From in silico target prediction to multi-target drug design: Current databases, methods and applications</span></div><div class="casAuthors">Koutsoukas, Alexios; Simms, Benjamin; Kirchmair, Johannes; Bond, Peter J.; Whitmore, Alan V.; Zimmer, Steven; Young, Malcolm P.; Jenkins, Jeremy L.; Glick, Meir; Glen, Robert C.; Bender, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2554-2574</span>CODEN:
                <span class="NLM_cas:coden">JPORFQ</span>;
        ISSN:<span class="NLM_cas:issn">1874-3919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Given the tremendous growth of bioactivity databases, the use of computational tools to predict protein targets of small mols. has been gaining importance in recent years.  Applications span a wide range, from the designed polypharmacol.' of compds. to mode-of-action anal.  In this review, we firstly survey databases that can be used for ligand-based target prediction and which have grown tremendously in size in the past.  We furthermore outline methods for target prediction that exist, both based on the knowledge of bioactivities from the ligand side and methods that can be applied in situations when a protein structure is known.  Applications of successful in silico target identification attempts are discussed in detail, which were based partly or in whole on computational target predictions in the first instance.  This includes the authors' own experience using target prediction tools, in this case considering phenotypic antibacterial screens and the anal. of high-throughput screening data.  Finally, we will conclude with the prospective application of databases to not only predict, retrospectively, the protein targets of a small mol., but also how to design ligands with desired polypharmacol. in a prospective manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQAhthzL8wiLVg90H21EOLACvtfcHk0lgWlnL6k4NhdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtrfE&md5=3fd699639ef3faf347537ef400030dd9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jprot.2011.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jprot.2011.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DKoutsoukas%26aufirst%3DA.%26aulast%3DSimms%26aufirst%3DB.%26aulast%3DKirchmair%26aufirst%3DJ.%26aulast%3DBond%26aufirst%3DP.%2BJ.%26aulast%3DWhitmore%26aufirst%3DA.%2BV.%26aulast%3DZimmer%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DM.%2BP.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DBender%26aufirst%3DA.%26atitle%3DFrom%2520in%2520silico%2520target%2520prediction%2520to%2520multi-target%2520drug%2520design%253A%2520current%2520databases%252C%2520methods%2520and%2520applications%26jtitle%3DJ.%2520Proteomics%26date%3D2011%26volume%3D74%26spage%3D2554%26epage%3D2574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overington, J. P.</span><span> </span><span class="NLM_article-title">Can we rationally design promiscuous drugs?</span> <span class="citation_source-journal">Curr. Opin. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.sbi.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=16442279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=127-136&author=A.+L.+Hopkinsauthor=J.+S.+Masonauthor=J.+P.+Overington&title=Can+we+rationally+design+promiscuous+drugs%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Can we rationally design promiscuous drugs?</span></div><div class="casAuthors">Hopkins, Andrew L.; Mason, Jonathan S.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Structure-based drug design is now used widely in modern medicinal chem.  The application of structural biol. to medicinal chem. has heralded the 'rational drug design' vision of discovering exquisitely selective ligands.  However, recent advances in post-genomic biol. are indicating that polypharmacol. may be a necessary trait for the efficacy of many drugs, therefore questioning the 'one drug, one target' assumption of current rational drug design.  By combining advances in chemoinformatics and structural biol., it might be possible to rationally design the next generation of promiscuous drugs with polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWdh60x9AHrVg90H21EOLACvtfcHk0lgWlnL6k4NhdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D&md5=8f9e95a41976b8e3ac790f2fff2c406f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DCan%2520we%2520rationally%2520design%2520promiscuous%2520drugs%253F%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2006%26volume%3D16%26spage%3D127%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Mestres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregori-Puigjane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valverde, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sole, R. V.</span><span> </span><span class="NLM_article-title">The topology of drug–target interaction networks: implicit dependence on drug properties and target families</span> <span class="citation_source-journal">Mol BioSyst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1051</span><span class="NLM_x">–</span> <span class="NLM_lpage">1057</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1039%2Fb905821b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=19668871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1Kksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=1051-1057&author=J.+Mestresauthor=E.+Gregori-Puigjaneauthor=S.+Valverdeauthor=R.+V.+Sole&title=The+topology+of+drug%E2%80%93target+interaction+networks%3A+implicit+dependence+on+drug+properties+and+target+families"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The topology of drug-target interaction networks: Implicit dependence on drug properties and target families</span></div><div class="casAuthors">Mestres, Jordi; Gregori-Puigjane, Elisabet; Valverde, Sergi; Sole, Ricard V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1051-1057</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The availability of interaction data between small mol. drugs and protein targets has increased substantially in recent years.  Using seven different databases, we were able to assemble a total of 4767 unique interactions between 802 drugs and 480 targets, which means that on av. every drug is currently acknowledged to interact with 6 targets.  The application of network theory to the anal. of these data reveals an unexpectedly complex picture of drug-target interactions.  The results confirm that the topol. of drug-target networks depends implicitly on data completeness, drug properties, and target families.  The implications for drug discovery are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNAnnU4e6Jl7Vg90H21EOLACvtfcHk0lgWlnL6k4NhdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1Kksbo%253D&md5=a0999bf0521936fba03400554411e8d7</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1039%2Fb905821b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb905821b%26sid%3Dliteratum%253Aachs%26aulast%3DMestres%26aufirst%3DJ.%26aulast%3DGregori-Puigjane%26aufirst%3DE.%26aulast%3DValverde%26aufirst%3DS.%26aulast%3DSole%26aufirst%3DR.%2BV.%26atitle%3DThe%2520topology%2520of%2520drug%25E2%2580%2593target%2520interaction%2520networks%253A%2520implicit%2520dependence%2520on%2520drug%2520properties%2520and%2520target%2520families%26jtitle%3DMol%2520BioSyst.%26date%3D2009%26volume%3D5%26spage%3D1051%26epage%3D1057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Paolini, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapland, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Hoorn, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Global mapping of pharmacological space</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">805</span><span class="NLM_x">–</span> <span class="NLM_lpage">815</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1038%2Fnbt1228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=16841068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFansb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=805-815&author=G.+V.+Paoliniauthor=R.+H.+Shaplandauthor=W.+P.+van+Hoornauthor=J.+S.+Masonauthor=A.+L.+Hopkins&title=Global+mapping+of+pharmacological+space"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Global mapping of pharmacological space</span></div><div class="casAuthors">Paolini, Gaia V.; Shapland, Richard H. B.; van Hoorn, Willem P.; Mason, Jonathan S.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">805-815</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We present the global mapping of pharmacol. space by the integration of several vast sources of medicinal chem. structure-activity relationships (SAR) data.  Our comprehensive mapping of pharmacol. space enables us to identify confidently the human targets for which chem. tools and drugs have been discovered to date.  The integration of SAR data from diverse sources by unique canonical chem. structure, protein sequence and disease indication enables the construction of a ligand-target matrix to explore the global relationships between chem. structure and biol. targets.  Using the data matrix, we are able to catalog the links between proteins in chem. space as a polypharmacol. interaction network.  We demonstrate that probabilistic models can be used to predict pharmacol. from a large knowledge base.  The relationships between proteins, chem. structures and drug-like properties provide a framework for developing a probabilistic approach to drug discovery that can be exploited to increase research productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV_CE47zZq8LVg90H21EOLACvtfcHk0liPgol9vD9PKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFansb8%253D&md5=f559b34692cc903a1b503deb07030c5d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnbt1228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1228%26sid%3Dliteratum%253Aachs%26aulast%3DPaolini%26aufirst%3DG.%2BV.%26aulast%3DShapland%26aufirst%3DR.%2BH.%26aulast%3Dvan%2BHoorn%26aufirst%3DW.%2BP.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DGlobal%2520mapping%2520of%2520pharmacological%2520space%26jtitle%3DNat.%2520Biotechnol.%26date%3D2006%26volume%3D24%26spage%3D805%26epage%3D815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Fragments, network biology and designing multiple ligands</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">156</span><span class="NLM_x">–</span> <span class="NLM_lpage">160</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=156-160&author=R.+Morphyauthor=Z.+Rankovic&title=Fragments%2C+network+biology+and+designing+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFragments%252C%2520network%2520biology%2520and%2520designing%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D156%26epage%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Mestres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregori-Puigjane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valverde, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sole, R. V.</span><span> </span><span class="NLM_article-title">Data completeness—the Achilles heel of drug–target networks</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">983</span><span class="NLM_x">–</span> <span class="NLM_lpage">984</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=983-984&author=J.+Mestresauthor=E.+Gregori-Puigjaneauthor=S.+Valverdeauthor=R.+V.+Sole&title=Data+completeness%E2%80%94the+Achilles+heel+of+drug%E2%80%93target+networks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMestres%26aufirst%3DJ.%26aulast%3DGregori-Puigjane%26aufirst%3DE.%26aulast%3DValverde%26aufirst%3DS.%26aulast%3DSole%26aufirst%3DR.%2BV.%26atitle%3DData%2520completeness%25E2%2580%2594the%2520Achilles%2520heel%2520of%2520drug%25E2%2580%2593target%2520networks%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D983%26epage%3D984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Lagunin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stepanchikova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filimonov, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poroikov, V.</span><span> </span><span class="NLM_article-title">PASS: prediction of activity spectra for biologically active substances</span> <span class="citation_source-journal">Bioinformatics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">747</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2000&pages=747-748&author=A.+Laguninauthor=A.+Stepanchikovaauthor=D.+Filimonovauthor=V.+Poroikov&title=PASS%3A+prediction+of+activity+spectra+for+biologically+active+substances"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLagunin%26aufirst%3DA.%26aulast%3DStepanchikova%26aufirst%3DA.%26aulast%3DFilimonov%26aufirst%3DD.%26aulast%3DPoroikov%26aufirst%3DV.%26atitle%3DPASS%253A%2520prediction%2520of%2520activity%2520spectra%2520for%2520biologically%2520active%2520substances%26jtitle%3DBioinformatics%26date%3D2000%26volume%3D16%26spage%3D747%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, J. W.</span><span> </span><span class="NLM_article-title">“Bayes affinity fingerprints” improve retrieval rates in virtual screening and define orthogonal bioactivity space: When are multitarget drugs a feasible concept?</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2445</span><span class="NLM_x">–</span> <span class="NLM_lpage">2456</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci600197y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1yqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=2445-2456&author=A.+Benderauthor=J.+L.+Jenkinsauthor=M.+Glickauthor=Z.+Dengauthor=J.+H.+Nettlesauthor=J.+W.+Davies&title=%E2%80%9CBayes+affinity+fingerprints%E2%80%9D+improve+retrieval+rates+in+virtual+screening+and+define+orthogonal+bioactivity+space%3A+When+are+multitarget+drugs+a+feasible+concept%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">"Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept?</span></div><div class="casAuthors">Bender, Andreas; Jenkins, Jeremy L.; Glick, Meir; Deng, Zhan; Nettles, James H.; Davies, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2445-2456</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Conventional similarity searching of mols. compares single (or multiple) active query structures to each other in a relative framework, by means of a structural descriptor and a similarity measure.  While this often works well, depending on the target, the authors show here that retrieval rates can be improved considerably by incorporating an external framework describing ligand bioactivity space for comparisons ("Bayes affinity fingerprints").  Structures are described by Bayes scores for a ligand panel comprising about 1000 activity classes extd. from the WOMBAT database.  The comparison of structures is performed via the Pearson correlation coeff. of activity classes, i.e., the order in which two structures are similar to the panel activity classes.  Compd. retrieval on a recently published data set could be improved by as much as 24% relative (9% abs.).  Knowledge about the shape of the "bioactive chem. universe" is thus beneficial to identifying similar bioactivities.  Principal component anal. was employed to further analyze activity space with the objective to define orthogonal ligand bioactive chem. space, leading to nine major (roughly orthogonal) activity axes.  Employing only those nine activity classes, retrieval rates are still comparable to original Bayes affinity fingerprints; thus, the concept of orthogonal bioactive ligand chem. space was validated as being an information-rich but low-dimensional representation of bioactivity space.  Correlations between activity classes are a major determinant to gauge whether the desired multitarget activity of drugs is (on the basis of current knowledge) a feasible concept because it measures the extent to which activities can be optimized independently, or only by strongly influencing one another.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6IjlYwYDTwLVg90H21EOLACvtfcHk0lhKhR2YJXkc3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1yqsrs%253D&md5=47adb720154f45bda1738963d54c70a5</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fci600197y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci600197y%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DNettles%26aufirst%3DJ.%2BH.%26aulast%3DDavies%26aufirst%3DJ.%2BW.%26atitle%3D%25E2%2580%259CBayes%2520affinity%2520fingerprints%25E2%2580%259D%2520improve%2520retrieval%2520rates%2520in%2520virtual%2520screening%2520and%2520define%2520orthogonal%2520bioactivity%2520space%253A%2520When%2520are%2520multitarget%2520drugs%2520a%2520feasible%2520concept%253F%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2006%26volume%3D46%26spage%3D2445%26epage%3D2456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheiber, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzaoui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span> </span><span class="NLM_article-title">Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">861</span><span class="NLM_x">–</span> <span class="NLM_lpage">873</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1002%2Fcmdc.200700026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=17477341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntVShu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=861-873&author=A.+Benderauthor=J.+Scheiberauthor=M.+Glickauthor=J.+W.+Daviesauthor=K.+Azzaouiauthor=J.+Hamonauthor=L.+Urbanauthor=S.+Whitebreadauthor=J.+L.+Jenkins&title=Analysis+of+pharmacology+data+and+the+prediction+of+adverse+drug+reactions+and+off-target+effects+from+chemical+structure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure</span></div><div class="casAuthors">Bender, Andreas; Scheiber, Josef; Glick, Meir; Davies, John W.; Azzaoui, Kamal; Hamon, Jacques; Urban, Laszlo; Whitebread, Steven; Jenkins, Jeremy L.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">861-873</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Preclin. Safety Pharmacol. (PSP) attempts to anticipate adverse drug reactions (ADRs) during early phases of drug discovery by testing compds. in simple, in vitro binding assays (i.e., preclin. profiling).  The selection of PSP targets is based largely on circumstantial evidence of their contribution to known clin. ADRs, inferred from findings in clin. trials, animal expts., and mol. studies going back more than 40 years.  In this work we explore PSP chem. space and its relevance for the prediction of adverse drug reactions.  Firstly, in silico (computational) Bayesian models for 70 PSP-related targets were built, which are able to detect 93% of the ligands binding at IC50≤ 10 μM at an overall correct classification rate of about 94 %.  Secondly, employing the World Drug Index (WDI), a model for adverse drug reactions was built directly based on normalized side-effect annotations in the WDI, which does not require any underlying functional knowledge.  This is, to our knowledge, the first attempt to predict adverse drug reactions across hundreds of categories from chem. structure alone.  On av. 90 % of the adverse drug reactions obsd. with known, clin. used compds. were detected, an overall correct classification rate of 92 %.  Drugs withdrawn from the market (Rapacuronium, Suprofen) were tested in the model and their predicted ADRs align well with known ADRs.  The anal. was repeated for acetylsalicylic acid and Benperidol which are still on the market.  Importantly, features of the models are interpretable and back-projectable to chem. structure, raising the possibility of rationally engineering out adverse effects.  By combining PSP and ADR models new hypotheses linking targets and adverse effects can be proposed and examples for the opioid μ and the muscarinic M2 receptors, as well as for cyclooxygenase-1 are presented.  It is hoped that the generation of predictive models for adverse drug reactions is able to help support early SAR to accelerate drug discovery and decrease late stage attrition in drug discovery projects.  In addn., models such as the ones presented here can be used for compd. profiling in all development stages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr28cgC-UGC3LVg90H21EOLACvtfcHk0lhKhR2YJXkc3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntVShu74%253D&md5=b04e52a6b745d233415b106e53e6e2c9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700026%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%26aulast%3DScheiber%26aufirst%3DJ.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DJ.%2BW.%26aulast%3DAzzaoui%26aufirst%3DK.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DUrban%26aufirst%3DL.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26atitle%3DAnalysis%2520of%2520pharmacology%2520data%2520and%2520the%2520prediction%2520of%2520adverse%2520drug%2520reactions%2520and%2520off-target%2520effects%2520from%2520chemical%2520structure%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D861%26epage%3D873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armbruster, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernsberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Relating protein pharmacology by ligand chemistry</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1038%2Fnbt1284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=17287757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=197-206&author=M.+J.+Keiserauthor=B.+L.+Rothauthor=B.+N.+Armbrusterauthor=P.+Ernsbergerauthor=J.+J.+Irwinauthor=B.+K.+Shoichet&title=Relating+protein+pharmacology+by+ligand+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Relating protein pharmacology by ligand chemistry</span></div><div class="casAuthors">Keiser, Michael J.; Roth, Bryan L.; Armbruster, Blaine N.; Ernsberger, Paul; Irwin, John J.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-206</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of protein function based on biol. information is an area of intense research.  Here the authors consider a complementary technique that quant. groups and relates proteins based on the chem. similarity of their ligands.  The authors began with 65,000 ligands annotated into sets for hundreds of drug targets.  The similarity score between each set was calcd. using ligand topol.  A statistical model was developed to rank the significance of the resulting similarity scores, which are expressed as a min. spanning tree to map the sets together.  Although these maps are connected solely by chem. similarity, biol. sensible clusters nevertheless emerged.  Links among unexpected targets also emerged, among them that methadone, emetine and loperamide (Imodium) may antagonize muscarinic M3, α2 adrenergic and neurokinin NK2 receptors, resp.  These predictions were subsequently confirmed exptl.  Relating receptors by ligand chem. organizes biol. to reveal unexpected relationships that may be assayed using the ligands themselves.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNKEMguhmluLVg90H21EOLACvtfcHk0lig5f-6jpYe6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOrsLo%253D&md5=1b7373d52563fca5fe1e893d85f70573</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnbt1284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1284%26sid%3Dliteratum%253Aachs%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DArmbruster%26aufirst%3DB.%2BN.%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DRelating%2520protein%2520pharmacology%2520by%2520ligand%2520chemistry%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D197%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laggner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuijer, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matos, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whaley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Predicting new molecular targets for known drugs</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1038%2Fnature08506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=19881490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlers7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=175-181&author=M.+J.+Keiserauthor=V.+Setolaauthor=J.+J.+Irwinauthor=C.+Laggnerauthor=A.+I.+Abbasauthor=S.+J.+Hufeisenauthor=N.+H.+Jensenauthor=M.+B.+Kuijerauthor=R.+C.+Matosauthor=T.+B.+Tranauthor=R.+Whaleyauthor=R.+A.+Glennonauthor=J.+Hertauthor=K.+L.+Thomasauthor=D.+D.+Edwardsauthor=B.+K.+Shoichetauthor=B.+L.+Roth&title=Predicting+new+molecular+targets+for+known+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting new molecular targets for known drugs</span></div><div class="casAuthors">Keiser, Michael J.; Setola, Vincent; Irwin, John J.; Laggner, Christian; Abbas, Atheir I.; Hufeisen, Sandra J.; Jensen, Niels H.; Kuijer, Michael B.; Matos, Roberto C.; Tran, Thuy B.; Whaley, Ryan; Glennon, Richard A.; Hert, Jerome; Thomas, Kelan L. H.; Edwards, Douglas D.; Shoichet, Brian K.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7270</span>),
    <span class="NLM_cas:pages">175-181</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although drugs are intended to be selective, at least some bind to several physiol. targets, explaining side effects and efficacy.  Because many drug-target combinations exist, it would be useful to explore possible interactions computationally.  Here we compared 3665 US Food and Drug Administration (FDA)-approved and investigational drugs against hundreds of targets, defining each target by its ligands.  Chem. similarities between drugs and ligand sets predicted thousands of unanticipated assocns.  Thirty were tested exptl., including the antagonism of the β1 receptor by the transporter inhibitor Prozac, the inhibition of the 5-hydroxytryptamine (5-HT) transporter by the ion channel drug Vadilex, and antagonism of the histamine H4 receptor by the enzyme inhibitor Rescriptor.  Overall, 23 new drug-target assocns. were confirmed, five of which were potent (<100 nM).  The physiol. relevance of one, the drug N,N-dimethyltryptamine (DMT) on serotonergic receptors, was confirmed in a knockout mouse.  The chem. similarity approach is systematic and comprehensive, and may suggest side-effects and new indications for many drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozd-8cCXUskrVg90H21EOLACvtfcHk0lig5f-6jpYe6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlers7vO&md5=974e65f5d5b4dabde1a463c429215546</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature08506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08506%26sid%3Dliteratum%253Aachs%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DAbbas%26aufirst%3DA.%2BI.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DKuijer%26aufirst%3DM.%2BB.%26aulast%3DMatos%26aufirst%3DR.%2BC.%26aulast%3DTran%26aufirst%3DT.%2BB.%26aulast%3DWhaley%26aufirst%3DR.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DK.%2BL.%26aulast%3DEdwards%26aufirst%3DD.%2BD.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DPredicting%2520new%2520molecular%2520targets%2520for%2520known%2520drugs%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D175%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Simon, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peragovics, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigh-Smeller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csukly, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tombor, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahoranszky-Kohalmi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vegner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jelinek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hari, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hetenyi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitter, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czobor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malnasi-Csizmadia, A.</span><span> </span><span class="NLM_article-title">Drug effect prediction by polypharmacology-based interaction profiling</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci2002022" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVyrs73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=134-145&author=Z.+Simonauthor=A.+Peragovicsauthor=M.+Vigh-Smellerauthor=G.+Csuklyauthor=L.+Tomborauthor=Z.+Yangauthor=G.+Zahoranszky-Kohalmiauthor=L.+Vegnerauthor=B.+Jelinekauthor=P.+Hariauthor=C.+Hetenyiauthor=I.+Bitterauthor=P.+Czoborauthor=A.+Malnasi-Csizmadia&title=Drug+effect+prediction+by+polypharmacology-based+interaction+profiling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Effect Prediction by Polypharmacology-Based Interaction Profiling</span></div><div class="casAuthors">Simon, Zoltan; Peragovics, Agnes; Vigh-Smeller, Margit; Csukly, Gabor; Tombor, Laszlo; Yang, Zhenhui; Zahoranszky-Kohalmi, Gergely; Vegner, Laszlo; Jelinek, Balazs; Hari, Peter; Hetenyi, Csaba; Bitter, Istvan; Czobor, Pal; Malnasi-Csizmadia, Andras</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-145</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Most drugs exert their effects via multitarget interactions, as hypothesized by polypharmacol.  While these multitarget interactions are responsible for the clin. effect profiles of drugs, current methods have failed to uncover the complex relationships between them.  Here, we introduce an approach which is able to relate complex drug-protein interaction profiles with effect profiles.  Structural data and registered effect profiles of all small-mol. drugs were collected, and interactions to a series of non-target protein binding sites of each drug were calcd.  Statistical analyses confirmed a close relationship between the studied 177 major effect categories and interaction profiles of ca. 1200 FDA-approved small-mol. drugs.  On the basis of this relationship, the effect profiles of drugs were revealed in their entirety, and hitherto uncovered effects could be predicted in a systematic manner.  Our results show that the prediction power is independent of the compn. of the protein set used for interaction profile generation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH7-WOP-uBWbVg90H21EOLACvtfcHk0ljOZ0wLB0XyJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVyrs73J&md5=50cb9593bcdc09f5cc8be563805a43bd</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fci2002022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci2002022%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DZ.%26aulast%3DPeragovics%26aufirst%3DA.%26aulast%3DVigh-Smeller%26aufirst%3DM.%26aulast%3DCsukly%26aufirst%3DG.%26aulast%3DTombor%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZahoranszky-Kohalmi%26aufirst%3DG.%26aulast%3DVegner%26aufirst%3DL.%26aulast%3DJelinek%26aufirst%3DB.%26aulast%3DHari%26aufirst%3DP.%26aulast%3DHetenyi%26aufirst%3DC.%26aulast%3DBitter%26aufirst%3DI.%26aulast%3DCzobor%26aufirst%3DP.%26aulast%3DMalnasi-Csizmadia%26aufirst%3DA.%26atitle%3DDrug%2520effect%2520prediction%2520by%2520polypharmacology-based%2520interaction%2520profiling%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D134%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Peragovics, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jelinek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hari, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hetenyi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czobor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malnasi-Csizmadia, A.</span><span> </span><span class="NLM_article-title">Contribution of 2D and 3D structural features of drug molecules in the prediction of drug profile matching</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1733</span><span class="NLM_x">–</span> <span class="NLM_lpage">1744</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci3001056" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC38XosV2qs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=1733-1744&author=A.+Peragovicsauthor=Z.+Simonauthor=I.+Brandhuberauthor=B.+Jelinekauthor=P.+Hariauthor=C.+Hetenyiauthor=P.+Czoborauthor=A.+Malnasi-Csizmadia&title=Contribution+of+2D+and+3D+structural+features+of+drug+molecules+in+the+prediction+of+drug+profile+matching"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of 2D and 3D Structural Features of Drug Molecules in the Prediction of Drug Profile Matching</span></div><div class="casAuthors">Peragovics, Agnes; Simon, Zoltan; Brandhuber, Ildiko; Jelinek, Balazs; Hari, Peter; Hetenyi, Csaba; Czobor, Pal; Malnasi-Csizmadia, Andras</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1733-1744</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug Profile Matching (DPM), a novel virtual affinity fingerprinting method capable of predicting the medical effect profiles of small mols., was introduced by our group recently.  The method exploits the information content of interaction patterns generated by flexible docking to a series of rigidly kept non-target protein active sites.  We presented the ability of DPM to classify mols. excellently, and the question arose, what the contribution of 2D and 3D structural features of the small mols. is to the intriguingly high prediction power of DPM.  The present study compared the prediction powers for effect profiles of 1163 FDA-approved drug compds. detd. by DPM and ChemAxon 2D and 3D similarity fingerprinting approaches.  We found that DPM outperformed the 2D and 3D approaches in almost all therapeutic categories for drug classification except for mech. rigid structural categories where high accuracy was obtained by all three methods.  Moreover, we also tested the predictive power of DPM on external data by reducing the parent data set and demonstrated that DPM can overcome the common screening problems of 2D and 3D similarity methods arising from the presence of structurally diverse mols. in certain effect categories.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWNAHp9HkXOrVg90H21EOLACvtfcHk0liSH4kWQ2qLYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosV2qs74%253D&md5=27afe2216f217e1e55e5e7eb40c1bd9a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fci3001056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci3001056%26sid%3Dliteratum%253Aachs%26aulast%3DPeragovics%26aufirst%3DA.%26aulast%3DSimon%26aufirst%3DZ.%26aulast%3DBrandhuber%26aufirst%3DI.%26aulast%3DJelinek%26aufirst%3DB.%26aulast%3DHari%26aufirst%3DP.%26aulast%3DHetenyi%26aufirst%3DC.%26aulast%3DCzobor%26aufirst%3DP.%26aulast%3DMalnasi-Csizmadia%26aufirst%3DA.%26atitle%3DContribution%2520of%25202D%2520and%25203D%2520structural%2520features%2520of%2520drug%2520molecules%2520in%2520the%2520prediction%2520of%2520drug%2520profile%2520matching%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D1733%26epage%3D1744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Ferreira, S. H.</span><span> </span><span class="NLM_article-title">Angiotensin converting enzyme: history and relevance</span> <span class="citation_source-journal">Semin. Perinatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">7</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2FS0146-0005%2800%2980046-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=10709850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD3c7ntlSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2000&pages=7-10&author=S.+H.+Ferreira&title=Angiotensin+converting+enzyme%3A+history+and+relevance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin converting enzyme: history and relevance</span></div><div class="casAuthors">Ferreira S H</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in perinatology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-10</span>
        ISSN:<span class="NLM_cas:issn">0146-0005</span>.
    </div><div class="casAbstract">The renin angiotensin system (RAS) is now recognized as the body's most powerful hormone system for controlling renal hemodynamics and sodium excretion and, therefore, body fluid volumes and arterial pressure.  The discovery of angiotensin converting enzyme inhibitors (ACEi) was a keystone for the understanding of the significance of the RAS since ACEi proved to be effective in controlling hypertension and heart failure and in preventing the development of the vascular injury of chronic diseases like scleroderma and diabetes mellitus.  The success of ACEi stimulated the research into inhibitors of other actors of the RAS like renin or angiotensin receptor antagonists.  It is not often realized that the discovery of ACEi owes a great deal to basic research in which the venom of a Brazilian viper, Bothrops Jararaca, was instrumental for the discovery of bradykinin by Rocha e Silva and the bradykinin potentiating factor.  This article reviews the contribution of the converting enzyme inhibitors for the demonstration of the relevance of the RAS to several human pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQvKBRtMxW_cULxIEhxUjPfW6udTcc2eboXHUYcg4hfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7ntlSrtg%253D%253D&md5=9c929123e8f290674d2d6c34cd0c7dd8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0146-0005%2800%2980046-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0146-0005%252800%252980046-4%26sid%3Dliteratum%253Aachs%26aulast%3DFerreira%26aufirst%3DS.%2BH.%26atitle%3DAngiotensin%2520converting%2520enzyme%253A%2520history%2520and%2520relevance%26jtitle%3DSemin.%2520Perinatol.%26date%3D2000%26volume%3D24%26spage%3D7%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Hackam, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemmelgarn, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabkin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Touyz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padwal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsay, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahon, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffrin, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruzicka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larochelle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moe, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howlett, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trudeau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrella, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milot, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drouin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulanger, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fodor, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dresser, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pylypchuk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiter, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarlane, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegele, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobe, S. W.</span><span> </span><span class="NLM_article-title">The 2010 Canadian hypertension education program recommendations for the management of hypertension: part 2—therapy</span> <span class="citation_source-journal">Can J Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">258</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2FS0828-282X%2810%2970379-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=20485689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnslamu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2010&pages=249-258&author=D.+G.+Hackamauthor=N.+A.+Khanauthor=B.+R.+Hemmelgarnauthor=S.+W.+Rabkinauthor=R.+M.+Touyzauthor=N.+R.+Campbellauthor=R.+Padwalauthor=T.+S.+Campbellauthor=M.+P.+Lindsayauthor=M.+D.+Hillauthor=R.+R.+Quinnauthor=J.+L.+Mahonauthor=R.+J.+Hermanauthor=E.+L.+Schiffrinauthor=M.+Ruzickaauthor=P.+Larochelleauthor=R.+D.+Feldmanauthor=M.+Lebelauthor=L.+Poirierauthor=J.+M.+Arnoldauthor=G.+W.+Moeauthor=J.+G.+Howlettauthor=L.+Trudeauauthor=S.+L.+Baconauthor=R.+J.+Petrellaauthor=A.+Milotauthor=J.+A.+Stoneauthor=D.+Drouinauthor=J.+M.+Boulangerauthor=M.+Sharmaauthor=P.+Hametauthor=G.+Fodorauthor=G.+K.+Dresserauthor=S.+G.+Carruthersauthor=G.+Pylypchukauthor=E.+D.+Burgessauthor=K.+D.+Burnsauthor=M.+Valleeauthor=G.+V.+Prasadauthor=R.+E.+Gilbertauthor=L.+A.+Leiterauthor=C.+Jonesauthor=R.+I.+Ogilvieauthor=V.+Wooauthor=P.+A.+McFarlaneauthor=R.+A.+Hegeleauthor=S.+W.+Tobe&title=The+2010+Canadian+hypertension+education+program+recommendations+for+the+management+of+hypertension%3A+part+2%E2%80%94therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy</span></div><div class="casAuthors">Hackam, Daniel G.; Khan, Nadia A.; Hemmelgarn, Brenda R.; Rabkin, Simon W.; Touyz, Rhian M.; Campbell, Normal R. C.; Padwal, Raj; Campbell, Tavis S.; Lindsay, M. Patrice; Hill, Michael D.; Quinn, Robert R.; Mahon, Jeff L.; Herman, Robert J.; Schiffrin, Ernesto L.; Ruzicka, Marcel; Larochelle, Pierre; Feldman, Ross D.; Lebel, Marcel; Poirier, Luc; Arnold, J. Malcolm O.; Moe, Gordon W.; Howlett, Jonathan G.; Trudeau, Luc; Bacon, Simon L.; Petrella, Robert J.; Milot, Alain; Stone, James A.; Drouin, Denis; Boulanger, Jean-Martin; Sharma, Mukul; Hamet, Pavel; Fodor, George; Dresser, George K.; Carruthers, S. George; Pylypchuk, George; Burgess, Ellen D.; Burns, Kevin D.; Vallee, Michel; Prasad, G. V. Ramesh; Gilbert, Richard E.; Leiter, Lawrence A.; Jones, Charlotte; Ogilvie, Richard I.; Woo, Vincent; McFarlane, Philip A.; Hegele, Robert A.; Tobe, Sheldon W.</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Journal of Cardiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">249-258</span>CODEN:
                <span class="NLM_cas:coden">CJCAEX</span>;
        ISSN:<span class="NLM_cas:issn">0828-282X</span>.
    
            (<span class="NLM_cas:orgname">Pulsus Group Inc.</span>)
        </div><div class="casAbstract">A review.  OBJECTIVE: To update the evidence-based recommendations for the prevention and treatment of hypertension in adults for 2010.  OPTIONS AND OUTCOMES: For lifestyle and pharmacol. interventions, randomized trials and systematic reviews of trials were preferentially reviewed.  Changes in cardiovascular morbidity and mortality were the primary outcomes of interest.  However, for lifestyle interventions, blood pressure lowering was accepted as a primary outcome given the general lack of long-term morbidity and mortality data in this field.  Progressive renal impairment was also accepted as a clin. relevant primary outcome among patients with chronic kidney disease.  EVIDENCE: A Cochrane Collaboration librarian conducted an independent MEDLINE search from 2008 to August 2009 to update the 2009 recommendations.  To identify addnl. studies, ref. lists were reviewed and experts were contacted.  All relevant articles were reviewed and appraised independently by both content and methodol. experts using prespecified levels of evidence.  RECOMMENDATIONS: For lifestyle modifications to prevent and treat hypertension, restrict dietary sodium to 1500 mg (65 mmol) per day in adults 50 years of age or younger, to 1300 mg (57 mmol) per day in adults 51 to 70 years of age, and to 1200 mg (52 mmol) per day in adults older than 70 years of age; perform 30 min to 60 min of moderate aerobic exercise four to seven days per wk; maintain a healthy body wt. (body mass index 18.5 kg/m2 to 24.9 kg/m2) and waist circumference (less than 102 cm for men and less than 88 cm for women); limit alc. consumption to no more than 14 std. drinks per wk for men or nine std. drinks per wk for women; follow a diet that emphasizes fruits, vegetables and low-fat dairy products, dietary and sol. fiber, whole grains and protein from plant sources, and that is low in satd. fat and cholesterol; and consider stress management in selected individuals with hypertension.For the pharmacol. management of hypertension, treatment thresholds and targets should be predicated on the patient's global atherosclerotic risk, target organ damage and comorbid conditions.  Blood pressure should be decreased to less than 140/90 mmHg in all patients, and to less than 130/80 mmHg in patients with diabetes mellitus or chronic kidney disease.  Most patients will require more than one agent to achieve these target blood pressures.  Antihypertensive therapy should be considered in all adult patients regardless of age (caution should be exercised in elderly patients who are frail).  For adults without compelling indications for other agents, considerations for initial therapy should include thiazide diuretics, angiotensin-converting enzyme (ACE) inhibitors (in patients who are not black), long-acting calcium channel blockers (CCBs), angiotensin receptor blockers (ARBs) or beta-blockers (in those younger than 60 years of age).  A combination of two first-line agents may also be considered as initial treatment of hypertension if systolic blood pressure is 20 mmHg above target or if diastolic blood pressure is 10 mmHg above target.  The combination of ACE inhibitors and ARBs should not be used, unless compelling indications are present to suggest consideration of dual therapy.  Agents appropriate for first-line therapy for isolated systolic hypertension include thiazide diuretics, long-acting dihydropyridine CCBs or ARBs.  In patients with coronary artery disease, ACE inhibitors, ARBs or beta-blockers are recommended as first-line therapy; in patients with cerebrovascular disease, an ACE inhibitor/diuretic combination is preferred; in patients with proteinuric nondiabetic chronic kidney disease, ACE inhibitors or ARBs (if intolerant to ACE inhibitors) are recommended; and in patients with diabetes mellitus, ACE inhibitors or ARBs (or, in patients without albuminuria, thiazides or dihydropyridine CCBs) are appropriate first-line therapies.  In selected high-risk patients in whom combination therapy is being considered, an ACE inhibitor plus a long-acting dihydropyridine CCB is preferable to an ACE inhibitor plus a thiazide diuretic.  All hypertensive patients with dyslipidemia should be treated using the thresholds, targets and agents outlined in the Canadian lipid treatment guidelines.  Selected patients with hypertension who do not achieve thresholds for statin therapy, but who are otherwise at high risk for cardiovascular events, should nonetheless receive statin therapy.  Once blood pressure is controlled, low-dose acetylsalicylic acid therapy should be considered.  VALIDATION: All recommendations were graded according to the strength of the evidence and voted on by the 63 members of the Canadian Hypertension Education Program Evidence-Based Recommendations Task Force.  All recommendations reported here achieved at least 80% consensus.  These guidelines will continue to be updated annually.  SPONSORS: The Canadian Hypertension Education Program process is sponsored by the Canadian Hypertension Society, Blood Pressure Canada, the Public Health Agency of Canada, the College of Family Physicians of Canada, the Canadian Pharmacists Assocn., the Canadian Council of Cardiovascular Nurses, and the Heart and Stroke Foundation of Canada.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnt2piftFs37Vg90H21EOLACvtfcHk0lizbnUwgsPU8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnslamu74%253D&md5=c2f3aa5759dcbc3762a1787a25cbc7aa</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0828-282X%2810%2970379-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0828-282X%252810%252970379-2%26sid%3Dliteratum%253Aachs%26aulast%3DHackam%26aufirst%3DD.%2BG.%26aulast%3DKhan%26aufirst%3DN.%2BA.%26aulast%3DHemmelgarn%26aufirst%3DB.%2BR.%26aulast%3DRabkin%26aufirst%3DS.%2BW.%26aulast%3DTouyz%26aufirst%3DR.%2BM.%26aulast%3DCampbell%26aufirst%3DN.%2BR.%26aulast%3DPadwal%26aufirst%3DR.%26aulast%3DCampbell%26aufirst%3DT.%2BS.%26aulast%3DLindsay%26aufirst%3DM.%2BP.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DQuinn%26aufirst%3DR.%2BR.%26aulast%3DMahon%26aufirst%3DJ.%2BL.%26aulast%3DHerman%26aufirst%3DR.%2BJ.%26aulast%3DSchiffrin%26aufirst%3DE.%2BL.%26aulast%3DRuzicka%26aufirst%3DM.%26aulast%3DLarochelle%26aufirst%3DP.%26aulast%3DFeldman%26aufirst%3DR.%2BD.%26aulast%3DLebel%26aufirst%3DM.%26aulast%3DPoirier%26aufirst%3DL.%26aulast%3DArnold%26aufirst%3DJ.%2BM.%26aulast%3DMoe%26aufirst%3DG.%2BW.%26aulast%3DHowlett%26aufirst%3DJ.%2BG.%26aulast%3DTrudeau%26aufirst%3DL.%26aulast%3DBacon%26aufirst%3DS.%2BL.%26aulast%3DPetrella%26aufirst%3DR.%2BJ.%26aulast%3DMilot%26aufirst%3DA.%26aulast%3DStone%26aufirst%3DJ.%2BA.%26aulast%3DDrouin%26aufirst%3DD.%26aulast%3DBoulanger%26aufirst%3DJ.%2BM.%26aulast%3DSharma%26aufirst%3DM.%26aulast%3DHamet%26aufirst%3DP.%26aulast%3DFodor%26aufirst%3DG.%26aulast%3DDresser%26aufirst%3DG.%2BK.%26aulast%3DCarruthers%26aufirst%3DS.%2BG.%26aulast%3DPylypchuk%26aufirst%3DG.%26aulast%3DBurgess%26aufirst%3DE.%2BD.%26aulast%3DBurns%26aufirst%3DK.%2BD.%26aulast%3DVallee%26aufirst%3DM.%26aulast%3DPrasad%26aufirst%3DG.%2BV.%26aulast%3DGilbert%26aufirst%3DR.%2BE.%26aulast%3DLeiter%26aufirst%3DL.%2BA.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DOgilvie%26aufirst%3DR.%2BI.%26aulast%3DWoo%26aufirst%3DV.%26aulast%3DMcFarlane%26aufirst%3DP.%2BA.%26aulast%3DHegele%26aufirst%3DR.%2BA.%26aulast%3DTobe%26aufirst%3DS.%2BW.%26atitle%3DThe%25202010%2520Canadian%2520hypertension%2520education%2520program%2520recommendations%2520for%2520the%2520management%2520of%2520hypertension%253A%2520part%25202%25E2%2580%2594therapy%26jtitle%3DCan%2520J%2520Cardiol.%26date%3D2010%26volume%3D26%26spage%3D249%26epage%3D258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span>DrugBank, Open Data Drug & Drug Target Database: Candoxatril. <a href="http://www.drugbank.ca/drugs/DB00616" class="extLink">http://www.drugbank.ca/drugs/DB00616</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DrugBank%2C+Open+Data+Drug+%26+Drug+Target+Database%3A+Candoxatril.+http%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00616."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Cohen Solal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jondeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauvais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdeaux, A.</span><span> </span><span class="NLM_article-title">Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure</span> <span class="citation_source-journal">Eur. J. Heart Failure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">466</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.ejheart.2003.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=15182772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkslWqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=463-466&author=A.+Cohen+Solalauthor=G.+Jondeauauthor=F.+Beauvaisauthor=A.+Berdeaux&title=Beneficial+effects+of+carvedilol+on+angiotensin-converting+enzyme+activity+and+renin+plasma+levels+in+patients+with+chronic+heart+failure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure</span></div><div class="casAuthors">Cohen Solal, Alain; Jondeau, Guillaume; Beauvais, Florence; Berdeaux, Alain</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Heart Failure</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">463-466</span>CODEN:
                <span class="NLM_cas:coden">EJHFFS</span>;
        ISSN:<span class="NLM_cas:issn">1388-9842</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Objective: To assess the effects of carvedilol treatment on the renin-angiotensin system in patients with chronic heart failure (CHF).  Background: Carvedilol improves survival of patients suffering from CHF but the effects of the drug on angiotensin-converting enzyme (ACE) activity, renin and aldosterone are not well characterized in patients receiving an ACE inhibitor.  Methods: A randomized, multicenter, double-blind, 6-mo, placebo-controlled study of carvedilol vs. placebo was conducted in 64 CHF patients.  Circulating levels of ACE activity, active renin and aldosterone as well as left ventricular diams. and ejection fraction by echog. were assessed.  Results: During the study, left ventricular ejection fraction increased from 25±11% to 31±12% with carvedilol and from 27±12% to 28±12% with placebo (P=0.03).  This beneficial effect was assocd. with marked blunting of active renin secretion (-53% in the carvedilol group vs.-13% in the placebo group, P=0.04).  ACE activity was reduced by 30% in the carvedilol group (P=0.07 vs. placebo).  Aldosterone was not changed.  Conclusion: Carvedilol markedly reduced the increase in active renin obsd. with time despite ACE-inhibitors and tended to decrease ACE activity.  These findings may in part explain the beneficial actions of carvedilol and highlights the profound effect of beta blockade on renin in patients already receiving ACE-inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhhOEMK4AO4LVg90H21EOLACvtfcHk0lh5YpcGbumJ9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkslWqsb8%253D&md5=f01068d4cad6fca68d09f340578a572e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ejheart.2003.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejheart.2003.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%2BSolal%26aufirst%3DA.%26aulast%3DJondeau%26aufirst%3DG.%26aulast%3DBeauvais%26aufirst%3DF.%26aulast%3DBerdeaux%26aufirst%3DA.%26atitle%3DBeneficial%2520effects%2520of%2520carvedilol%2520on%2520angiotensin-converting%2520enzyme%2520activity%2520and%2520renin%2520plasma%2520levels%2520in%2520patients%2520with%2520chronic%2520heart%2520failure%26jtitle%3DEur.%2520J.%2520Heart%2520Failure%26date%3D2004%26volume%3D6%26spage%3D463%26epage%3D466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Flordellis, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goumenos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kourounis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsementzis, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paris, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vlachojiannis, J.</span><span> </span><span class="NLM_article-title">The shift in the “paradigm” of the pharmacology of hypertension</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">487</span><span class="NLM_x">–</span> <span class="NLM_lpage">498</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.2174%2F1568026043451348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=14965315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitV2gur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=487-498&author=C.+S.+Flordellisauthor=D.+Goumenosauthor=G.+Kourounisauthor=S.+A.+Tsementzisauthor=H.+Parisauthor=J.+Vlachojiannis&title=The+shift+in+the+%E2%80%9Cparadigm%E2%80%9D+of+the+pharmacology+of+hypertension"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The shift in the "paradigm" of the pharmacology of hypertension</span></div><div class="casAuthors">Flordellis, Christodoulos S.; Goumenos, Dimitrios; Kourounis, George; Tsementzis, Sotirios A.; Paris, Herve; Vlachojiannis, Jaannis</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">487-498</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  Until recently elevated blood pressure was considered as a hemodynamic entity representing an increase in workload for the heart and the arterial tree.  Control of hypertension meant hemodynamic unloading, through inhibition of vasoconstrictor pathways, principally renin-angiotensin system and sympathetic system.  In recent years however a new pharmacol. approach has evolved as a result of (i) the dissocn. of endothelial dysfunction and vascular pathol. from increased blood pressure; (ii) the recognition that endothelial dysfunction regards not only the vascular reactivity, but also promotes atherosclerosis and thrombosis; and (iii) an improved understanding of the complexity of local-tissue renin angiotensin system and of the vasodilatory and cytoprotective role of natriuretic peptides.  This has led to a reconsideration of existing medicines in terms of specification on endothelial function, more rationalized application of drugs and search for new compds. targeting both vasodilatory and anti-proliferative pathways.  Examples include β1-adrenergic antagonists, such as Nebivolol and Carvedilol, and vasopeptidase inhibitors, such as Omapatrilat, that inhibit simultaneously the angiotensin converting enzyme and neutral endopeptidase.  Furthermore the identification of genetic polymorphisms in the effectors involved in the pathophysiol. of hypertension or in the response to anti-hypertensive drugs, such as the p22phox subunit of NADPH oxidase, α-adducin or adrenergic receptors, has promoted the prospective of both better understanding of hypertension and individualized strategies for its treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog0eYQA2T8k7Vg90H21EOLACvtfcHk0lh5YpcGbumJ9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitV2gur4%253D&md5=e26a7c0e158f12249bdcdc07f7b6fc4d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2174%2F1568026043451348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026043451348%26sid%3Dliteratum%253Aachs%26aulast%3DFlordellis%26aufirst%3DC.%2BS.%26aulast%3DGoumenos%26aufirst%3DD.%26aulast%3DKourounis%26aufirst%3DG.%26aulast%3DTsementzis%26aufirst%3DS.%2BA.%26aulast%3DParis%26aufirst%3DH.%26aulast%3DVlachojiannis%26aufirst%3DJ.%26atitle%3DThe%2520shift%2520in%2520the%2520%25E2%2580%259Cparadigm%25E2%2580%259D%2520of%2520the%2520pharmacology%2520of%2520hypertension%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D487%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Margulies, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrella, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinley, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, J. C.,  Jr.</span><span> </span><span class="NLM_article-title">Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">1636</span><span class="NLM_x">–</span> <span class="NLM_lpage">1642</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=1636-1642&author=K.+B.+Marguliesauthor=M.+A.+Perrellaauthor=L.+J.+McKinleyauthor=J.+C.+Burnett&title=Angiotensin+inhibition+potentiates+the+renal+responses+to+neutral+endopeptidase+inhibition+in+dogs+with+congestive+heart+failure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMargulies%26aufirst%3DK.%2BB.%26aulast%3DPerrella%26aufirst%3DM.%2BA.%26aulast%3DMcKinley%26aufirst%3DL.%2BJ.%26aulast%3DBurnett%26aufirst%3DJ.%2BC.%26atitle%3DAngiotensin%2520inhibition%2520potentiates%2520the%2520renal%2520responses%2520to%2520neutral%2520endopeptidase%2520inhibition%2520in%2520dogs%2520with%2520congestive%2520heart%2520failure%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1991%26volume%3D88%26spage%3D1636%26epage%3D1642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">McGovern, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caselli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grigorieff, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1712</span><span class="NLM_x">–</span> <span class="NLM_lpage">1722</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm010533y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD38Xhslegtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1712-1722&author=S.+L.+McGovernauthor=E.+Caselliauthor=N.+Grigorieffauthor=B.+K.+Shoichet&title=A+common+mechanism+underlying+promiscuous+inhibitors+from+virtual+and+high-throughput+screening"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening</span></div><div class="casAuthors">McGovern, Susan L.; Caselli, Emilia; Grigorieff, Nikolaus; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1712-1722</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High-throughput and virtual screening are widely used to discover novel leads for drug design.  On examn., many screening hits appear non-drug-like: they act noncompetitively, show little relation between structure and activity, and have poor selectivity.  Attempts to develop these peculiar mols. into viable leads are often futile, and much time can be wasted on the characterization of these "phony" hits.  Despite their common occurrence, the mechanism of action of these promiscuous mols. remains unknown.  To investigate this problem, 45 diverse screening hits were studied.  Fifteen of these were previously reported as inhibitors of various receptors, including β-lactamase, malarial protease, dihydrofolate reductase, HIV Tar RNA, thymidylate synthase, kinesin, insulin receptor, tyrosine kinases, farnesyltransferase, gyrase, prions, triosephosphate isomerase, nitric oxide synthase, phosphoinositide 3-kinase, and integrase; 30 were from an inhouse screening library of a major pharmaceutical company.  In addn. to their original targets, 35 of these 45 compds. were shown to inhibit several unrelated model enzymes.  These 35 screening hits included compds., such as fullerenes, dyes, and quercetin, that have repeatedly shown activity against diverse targets.  When tested against the model enzymes, the compds. showed time-dependent but reversible inhibition that was dramatically attenuated by albumin, guanidinium, or urea. Surprisingly, increasing the concn. of the model enzymes 10-fold largely eliminated inhibition, despite a 1000-fold excess of inhibitor; a well-behaved competitive inhibitor did not show this behavior.  One model to explain these observations was that the active form of the promiscuous inhibitors was an aggregate of many individual mols.  To test this hypothesis, light scattering and electron microscopy expts. were performed.  The nonspecific inhibitors were obsd. to form particles of 30-400 nm diam. by both techniques.  In control expts., a well-behaved competitive inhibitor and an inactive dye-like mol. were not obsd. to form aggregates.  Consistent with the hypothesis that the aggregates are the inhibitory species, the particle size and IC50 values of the promiscuous inhibitors varied monotonically with ionic strength; a competitive inhibitor was unaffected by changes in ionic strength. Unexpectedly, aggregate formation appears to explain the activity of many nonspecific inhibitors and may account for the activity of many promiscuous screening hits.  Mols. acting via this mechanism may be widespread in drug discovery screening databases.  Recognition of these compds. may improve screening results in many areas of pharmaceutical interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYFB0NNK2CIbVg90H21EOLACvtfcHk0liDEV3_utPp5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xhslegtrk%253D&md5=b9e6c29f6a1da588a6452859061edfbb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm010533y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010533y%26sid%3Dliteratum%253Aachs%26aulast%3DMcGovern%26aufirst%3DS.%2BL.%26aulast%3DCaselli%26aufirst%3DE.%26aulast%3DGrigorieff%26aufirst%3DN.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DA%2520common%2520mechanism%2520underlying%2520promiscuous%2520inhibitors%2520from%2520virtual%2520and%2520high-throughput%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D1712%26epage%3D1722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Seidler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGovern, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doman, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Identification and prediction of promiscuous aggregating inhibitors among known drugs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4477</span><span class="NLM_x">–</span> <span class="NLM_lpage">4486</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030191r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1Kkt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4477-4486&author=J.+Seidlerauthor=S.+L.+McGovernauthor=T.+N.+Domanauthor=B.+K.+Shoichet&title=Identification+and+prediction+of+promiscuous+aggregating+inhibitors+among+known+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and prediction of promiscuous aggregating inhibitors among known drugs</span></div><div class="casAuthors">Seidler, James; McGovern, Susan L.; Doman, Thompson N.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4477-4486</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Some small mols., often hits from screening, form aggregates in soln. that inhibit many enzymes.  In contrast, drugs are thought to act specifically.  To investigate this assumption, 50 unrelated drugs were tested for promiscuous inhibition via aggregation.  Each drug was tested against three unrelated model enzymes: β-lactamase, chymotrypsin, and malate dehydrogenase, none of which are considered targets of these drugs.  To be judged promiscuous, the drugs had to inhibit all three enzymes, do so in a time-dependent manner, be sensitive to detergent and to enzyme concn., and form particles detectable by light scattering.  Of the 50 drugs tested, 43 were nonpromiscuous by these criteria.  Surprisingly, four of the drugs showed promiscuous, aggregation-based inhibition at concns. below 100 μM: clotrimazole, benzyl benzoate, nicardipine, and delavirdine.  Three other drugs also behaved as aggregation-based inhibitors, but only at high concns. (about 400 μM).  To investigate possible structure-activity relationships among promiscuous drugs, five analogs of the antifungal clotrimazole were studied.  Three of these, miconazole, econazole, and sulconazole, were promiscuous but the other two, fluconazole and ketoconazole, were not.  Using recursive partitioning, these exptl. results were used to develop a model for predicting aggregate-based promiscuity.  This model correctly classified 94% of 111 compds.-- 47 aggregators and 64 nonaggregators-- that have been studied for this effect.  To evaluate the model, it was used to predict the behavior of 75 drugs not previously investigated for aggregation.  Several preliminary points emerge.  Most drugs are not promiscuous, even at high concns.  Nevertheless, at high enough concns. (20-400 μM), some drugs can aggregate and act promiscuously, suggesting that aggregation may be common among small mols. at micromolar concns., at least in biochem. buffers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX6rct1y8KO7Vg90H21EOLACvtfcHk0liDEV3_utPp5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1Kkt74%253D&md5=4bc47e2d426be688a79aa077ce6f9c3b</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm030191r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030191r%26sid%3Dliteratum%253Aachs%26aulast%3DSeidler%26aufirst%3DJ.%26aulast%3DMcGovern%26aufirst%3DS.%2BL.%26aulast%3DDoman%26aufirst%3DT.%2BN.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DIdentification%2520and%2520prediction%2520of%2520promiscuous%2520aggregating%2520inhibitors%2520among%2520known%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4477%26epage%3D4486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Yusuf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pogue, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copland, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumacher, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dagenais, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleight, P.</span><span> </span><span class="NLM_article-title">Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">1174</span><span class="NLM_x">–</span> <span class="NLM_lpage">1183</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2008&pages=1174-1183&author=S.+Yusufauthor=K.+Teoauthor=C.+Andersonauthor=J.+Pogueauthor=L.+Dyalauthor=I.+Coplandauthor=H.+Schumacherauthor=G.+Dagenaisauthor=P.+Sleight&title=Effects+of+the+angiotensin-receptor+blocker+telmisartan+on+cardiovascular+events+in+high-risk+patients+intolerant+to+angiotensin-converting+enzyme+inhibitors%3A+a+randomised+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYusuf%26aufirst%3DS.%26aulast%3DTeo%26aufirst%3DK.%26aulast%3DAnderson%26aufirst%3DC.%26aulast%3DPogue%26aufirst%3DJ.%26aulast%3DDyal%26aufirst%3DL.%26aulast%3DCopland%26aufirst%3DI.%26aulast%3DSchumacher%26aufirst%3DH.%26aulast%3DDagenais%26aufirst%3DG.%26aulast%3DSleight%26aufirst%3DP.%26atitle%3DEffects%2520of%2520the%2520angiotensin-receptor%2520blocker%2520telmisartan%2520on%2520cardiovascular%2520events%2520in%2520high-risk%2520patients%2520intolerant%2520to%2520angiotensin-converting%2520enzyme%2520inhibitors%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2008%26volume%3D372%26spage%3D1174%26epage%3D1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Eder, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeler, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teicher, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnipper, L. E.</span><span> </span><span class="NLM_article-title">A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">510</span><span class="NLM_x">–</span> <span class="NLM_lpage">513</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=510-513&author=J.+P.+Ederauthor=C.+A.+Wheelerauthor=B.+A.+Teicherauthor=L.+E.+Schnipper&title=A+phase+I+clinical+trial+of+novobiocin%2C+a+modulator+of+alkylating+agent+cytotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DWheeler%26aufirst%3DC.%2BA.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DSchnipper%26aufirst%3DL.%2BE.%26atitle%3DA%2520phase%2520I%2520clinical%2520trial%2520of%2520novobiocin%252C%2520a%2520modulator%2520of%2520alkylating%2520agent%2520cytotoxicity%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26spage%3D510%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Takahashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niioka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawada, K.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1186%2F1756-8722-5-23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslyitrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=23&author=N.+Takahashiauthor=M.+Miuraauthor=S.+A.+Scottauthor=T.+Niiokaauthor=K.+Sawada&title=Pharmacokinetics+of+dasatinib+for+Philadelphia-positive+acute+lymphocytic+leukemia+with+acquired+T315I+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation</span></div><div class="casAuthors">Takahashi, Naoto; Miura, Masatomo; Scott, Stuart A.; Niioka, Takenori; Sawada, Kenichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The BCR-ABL T315I kinase domain mutation is insensitive to dasatinib therapy for Philadelphia-pos. acute lymphoid leukemia (Ph + ALL) patients.  Resistant T315I clone may be present prior to initiating dasatinib, which could expand under selective pressures during treatment.  However, it is also possible that Ph + ALL patients newly acquire the T315I mutation during dasatinib therapy.  Despite the potent inhibition of BCR-ABL kinase by dasatinib, little is known about the relationship between dasatinib pharmacokinetics and the emergence of kinase domain mutations in vivo.  Methods: To det. whether plasma dasatinib pharmacokinetics influences the emergence of BCR-ABL mutations, we measured plasma dasatinib levels in 11 Ph + ALL patients undergoing dasatinib monotherapy.  Results: Bone marrow relapse occurred in 5 of the 11 Ph + ALL patients (45%).  Importantly, a T315I mutation was detected in 4 of the 5 relapsed patients, despite the absence of BCR-ABL mutations in any patient at baseline.  The median plasma concn. at 2 h (C2h), the median plasma max. concn. (Cmax) and the median area under the obsd. plasma concn.-time curve from 0 to 4 h (AUC0-4) were all significantly lower in patients with T315I than those without the mutation (C2h, 22.3ng/mL vs. 111.6ng/mL, P = 0.0242; Cmax, 43.8 ng/mL vs. 112.4 ng/mL, P = 0.0242; AUC0-4, 108.3 ng·h/mL vs. 268.3 ng·h/mL, P = 0.0061, resp.).  Conclusions: These data indicate that the emergence of the T315I mutation among Ph + ALL patients treated with dasatinib is, in part, dependent on plasma dasatinib pharmacokinetics.  Notably, these data also suggest that newly acquired BCR-ABL mutations may be inhibited by an increased exposure of dasatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc3M_-ntpO87Vg90H21EOLACvtfcHk0li44OFqnQnpng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslyitrrP&md5=8e29ea3ce17a4fa8b068ad74708b725e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-5-23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-5-23%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DN.%26aulast%3DMiura%26aufirst%3DM.%26aulast%3DScott%26aufirst%3DS.%2BA.%26aulast%3DNiioka%26aufirst%3DT.%26aulast%3DSawada%26aufirst%3DK.%26atitle%3DPharmacokinetics%2520of%2520dasatinib%2520for%2520Philadelphia-positive%2520acute%2520lymphocytic%2520leukemia%2520with%2520acquired%2520T315I%2520mutation%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2012%26volume%3D5%26spage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Blobaum, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marnett, L. J.</span><span> </span><span class="NLM_article-title">Structural and functional basis of cyclooxygenase inhibition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1425</span><span class="NLM_x">–</span> <span class="NLM_lpage">1441</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0613166" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisFeisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1425-1441&author=A.+L.+Blobaumauthor=L.+J.+Marnett&title=Structural+and+functional+basis+of+cyclooxygenase+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Basis of Cyclooxygenase Inhibition</span></div><div class="casAuthors">Blobaum, Anna L.; Marnett, Lawrence J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1425-1441</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review will focus on the structural and functional basis of the inhibition of cyclooxygenase (COX) enzymes by nonselective and COX-2 selective inhibitors.  It will integrate kinetic, mechanistic, and structural information to illustrate not only the range of mols. with COX inhibitory activity but also the diversity of mechanisms by which they act.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8SMg_SRasDLVg90H21EOLACvtfcHk0li44OFqnQnpng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisFeisL8%253D&md5=b9de2eafa7d2b510c866245b09fba546</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm0613166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0613166%26sid%3Dliteratum%253Aachs%26aulast%3DBlobaum%26aufirst%3DA.%2BL.%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26atitle%3DStructural%2520and%2520functional%2520basis%2520of%2520cyclooxygenase%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1425%26epage%3D1441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Pairet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelhardt, G.</span><span> </span><span class="NLM_article-title">Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications</span> <span class="citation_source-journal">Fundam. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1111%2Fj.1472-8206.1996.tb00144.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=8900495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADyaK28XjtFGrurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1996&pages=1-17&author=M.+Pairetauthor=G.+Engelhardt&title=Distinct+isoforms+%28COX-1+and+COX-2%29+of+cyclooxygenase%3A+possible+physiological+and+therapeutic+implications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: Possible physiological and therapeutic implications</span></div><div class="casAuthors">Pairet, M.; Engelhardt, G.</div><div class="citationInfo"><span class="NLM_cas:title">Fundamental & Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-15</span>CODEN:
                <span class="NLM_cas:coden">FCPHEZ</span>;
        ISSN:<span class="NLM_cas:issn">0767-3981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with >150 refs.  The discovery of an inducible isoform of cyclooxygenase (COX-2) requires a refinement of the theory that inhibition of cyclooxygenase activity explains both therapeutic and side effects of non-steroidal anti-inflammatory drugs (NSAIDs).  Indeed, new pharmacol. results suggest that COX-2 inhibition provides the therapeutic (ie, anti-inflammatory) activity of NSAIDs, whereas inhibition of constitutive COX-1 is responsible for their gastric and renal side effects as well as for their antithrombotic activity.  However, a role of COX-1 in inflammation cannot be excluded.  Furthermore, the functional relevance of COX-2 expression and induction in various tissues warrants further investigation.  These studies should help in predicting potential adverse effects as well as new indications for selective COX-2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppIEW1Xkq0u7Vg90H21EOLACvtfcHk0ljUrqcr60H8ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtFGrurk%253D&md5=2151e518ab44a4935ba91f40e63afa49</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fj.1472-8206.1996.tb00144.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1472-8206.1996.tb00144.x%26sid%3Dliteratum%253Aachs%26aulast%3DPairet%26aufirst%3DM.%26aulast%3DEngelhardt%26aufirst%3DG.%26atitle%3DDistinct%2520isoforms%2520%2528COX-1%2520and%2520COX-2%2529%2520of%2520cyclooxygenase%253A%2520possible%2520physiological%2520and%2520therapeutic%2520implications%26jtitle%3DFundam.%2520Clin.%2520Pharmacol.%26date%3D1996%26volume%3D10%26spage%3D1%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span> </span><span class="NLM_article-title">Painful lessons</span>.  <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">800</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Painful+lessons.+Nat.+Rev.+Drug+Discovery+2005%2C+4%2C+800%E2%80%93803."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DPainful%2520lessons%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D800%26epage%3D803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="note"><p class="first last">Information for Healthcare Professionals: valdecoxib (marketed as Bextra).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span>DrugBank, Open Data Drug & Drug Target Database: Ciclopirox. <a href="http://www.drugbank.ca/drugs/DB01188" class="extLink">http://www.drugbank.ca/drugs/DB01188</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DrugBank%2C+Open+Data+Drug+%26+Drug+Target+Database%3A+Ciclopirox.+http%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01188."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Bosetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weerasinghe, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberger, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapoport, S. I.</span><span> </span><span class="NLM_article-title">Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">690</span><span class="NLM_x">–</span> <span class="NLM_lpage">696</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1046%2Fj.1471-4159.2003.01701.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=12694395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslyrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2003&pages=690-696&author=F.+Bosettiauthor=G.+R.+Weerasingheauthor=T.+A.+Rosenbergerauthor=S.+I.+Rapoport&title=Valproic+acid+down-regulates+the+conversion+of+arachidonic+acid+to+eicosanoids+via+cyclooxygenase-1+and+-2+in+rat+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain</span></div><div class="casAuthors">Bosetti, Francesca; Weerasinghe, Gayani R.; Rosenberger, Thad A.; Rapoport, Stanley I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">690-696</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Sodium valproate, a mood stabilizer, when chronically administered to rats (200 mg/kg i.p. daily for 30 days) significantly reduced the brain protein levels of cyclooxygenase (COX)-1 and COX-2, without altering the mRNA levels of these enzymes.  COX activity was decreased, as were the brain concns. of 11-dehydrothromboxane B2 and prostaglandin E2 (PGE2), metabolites of arachidonic acid (AA) produced via COX.  In contrast, the brain protein level of 5-lipoxygenase and the concn. of its AA metabolite leukotriene B4 were unchanged.  In view of published evidence that lithium chloride administered chronically to rats, like chronic valproate, reduces AA turnover within brain phospholipids, and that lithium post-transcriptionally down-regulates COX-2 but not COX-1 protein level and enzyme activity, these observations suggest that mood stabilizers generally modulate the release and recycling of AA within brain phospholipids, and the conversion of AA via COX-2 to PGE2 and related eicosanoids.  If targeting this part of the "AA cascade" accounts for their therapeutic action, non-steroidal anti-inflammatory drugs or selective COX-2 inhibitors might prove effective in bipolar disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQfCKnUD1W6LVg90H21EOLACvtfcHk0ljUrqcr60H8ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslyrsb4%253D&md5=f65bbf6f0857b7749ac7ea826527cf52</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2003.01701.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2003.01701.x%26sid%3Dliteratum%253Aachs%26aulast%3DBosetti%26aufirst%3DF.%26aulast%3DWeerasinghe%26aufirst%3DG.%2BR.%26aulast%3DRosenberger%26aufirst%3DT.%2BA.%26aulast%3DRapoport%26aufirst%3DS.%2BI.%26atitle%3DValproic%2520acid%2520down-regulates%2520the%2520conversion%2520of%2520arachidonic%2520acid%2520to%2520eicosanoids%2520via%2520cyclooxygenase-1%2520and%2520-2%2520in%2520rat%2520brain%26jtitle%3DJ.%2520Neurochem.%26date%3D2003%26volume%3D85%26spage%3D690%26epage%3D696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Jannesson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birkhed, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaffar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renvert, S.</span><span> </span><span class="NLM_article-title">Effect of oxybenzone on PGE2-production in vitro and on plaque and gingivitis in vivo</span> <span class="citation_source-journal">J. Clin. Periodontol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">91</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1111%2Fj.0303-6979.2004.00453.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=15016032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFSgsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2004&pages=91-94&author=L.+Jannessonauthor=D.+Birkhedauthor=D.+Scherlauthor=A.+Gaffarauthor=S.+Renvert&title=Effect+of+oxybenzone+on+PGE2-production+in+vitro+and+on+plaque+and+gingivitis+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of oxybenzone on PGE2-production in vitro and on plaque and gingivitis in vivo</span></div><div class="casAuthors">Jannesson, Lillemor; Birkhed, Dowen; Scherl, Dale; Gaffar, Abdul; Renvert, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Periodontology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-94</span>CODEN:
                <span class="NLM_cas:coden">JCPEDZ</span>;
        ISSN:<span class="NLM_cas:issn">0303-6979</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">To study the effect of oxybenzone on prostaglandin E2 (PGE2) prodn. in cell culture and to evaluate the effect of an oxybenzone-contg. dentifrice on plaque and gingivitis in a 6-wk clin. trial.  Human embryo palatal mesenchyme (HEPM) cells were used for testing the inhibition of IL-1β-stimulated PGE2-prodn. in vitro by different concns. of oxybenzone.  For the in vivo study, a total of 66 individuals with a Quigley and Hein plaque index of at least 1.5 and an Ainamo and Bay gingival index of at least 0.2 were included in a double-blind clin. trial with two cells and a parallel design.  Two compns. of fluoride dentifrice were used, one with the addn. of 0.5% oxybenzone, and one without.  Plaque and gingival index were obtained at three time points: (1) at baseline, (2) after 3 wk, and (3) after 6 wk.  A dose-dependent inhibition of PGE2-prodn. was found in the HEPM cell culture following oxybenzone exposure.  In the clin. trial, a 25% redn. of gingival index was obsd. in the oxybenzone group (p < 0.001) after 6 wk as compared with 2% for the placebo group.  These findings indicate that PGE2-prodn. is reduced by oxybenzone in vitro and that the use of oxybenzone in a dentifrice reduces gingivitis in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGpQ1IB-BA1rVg90H21EOLACvtfcHk0ljaeK9qwOfKrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFSgsbk%253D&md5=bfc71a292569b638618ea6666cff52ae</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1111%2Fj.0303-6979.2004.00453.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.0303-6979.2004.00453.x%26sid%3Dliteratum%253Aachs%26aulast%3DJannesson%26aufirst%3DL.%26aulast%3DBirkhed%26aufirst%3DD.%26aulast%3DScherl%26aufirst%3DD.%26aulast%3DGaffar%26aufirst%3DA.%26aulast%3DRenvert%26aufirst%3DS.%26atitle%3DEffect%2520of%2520oxybenzone%2520on%2520PGE2-production%2520in%2520vitro%2520and%2520on%2520plaque%2520and%2520gingivitis%2520in%2520vivo%26jtitle%3DJ.%2520Clin.%2520Periodontol.%26date%3D2004%26volume%3D31%26spage%3D91%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Ren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, S. H.</span><span> </span><span class="NLM_article-title">Anti-inflammatory effect of alpha-linolenic acid and its mode of action through the inhibition of nitric oxide production and inducible nitric oxide synthase gene expression via NF-kappaB and mitogen-activated protein kinase pathways</span> <span class="citation_source-journal">J. Agric. Food Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5073</span><span class="NLM_x">–</span> <span class="NLM_lpage">5080</span></span><div class="citationLinks">[<a href="/doi/10.1021/jf0702693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2007&pages=5073-5080&author=J.+Renauthor=S.+H.+Chung&title=Anti-inflammatory+effect+of+alpha-linolenic+acid+and+its+mode+of+action+through+the+inhibition+of+nitric+oxide+production+and+inducible+nitric+oxide+synthase+gene+expression+via+NF-kappaB+and+mitogen-activated+protein+kinase+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjf0702693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjf0702693%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DChung%26aufirst%3DS.%2BH.%26atitle%3DAnti-inflammatory%2520effect%2520of%2520alpha-linolenic%2520acid%2520and%2520its%2520mode%2520of%2520action%2520through%2520the%2520inhibition%2520of%2520nitric%2520oxide%2520production%2520and%2520inducible%2520nitric%2520oxide%2520synthase%2520gene%2520expression%2520via%2520NF-kappaB%2520and%2520mitogen-activated%2520protein%2520kinase%2520pathways%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2007%26volume%3D55%26spage%3D5073%26epage%3D5080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Ren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, S. H.</span><span> </span><span class="NLM_article-title">In vivo and in vitro anti-inflammatory activities of alpha-linolenic acid isolated from <i>Actinidia polygama</i> fruits</span> <span class="citation_source-journal">Arch. Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">708</span><span class="NLM_x">–</span> <span class="NLM_lpage">714</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1007%2FBF02977632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=17679548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosV2ltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2007&pages=708-714&author=J.+Renauthor=E.+J.+Hanauthor=S.+H.+Chung&title=In+vivo+and+in+vitro+anti-inflammatory+activities+of+alpha-linolenic+acid+isolated+from+Actinidia+polygama+fruits"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo and in vitro anti-inflammatory activities of α-linolenic acid isolated from Actinidia polygama fruits</span></div><div class="casAuthors">Ren, Jie; Han, Eun Jung; Chung, Sung Hyun</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">708-714</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">The fruit of Actinidia polygama (AP) has long been used as a folk medicine in Korea for the treatment of pain, rheumatoid arthritis and inflammation.  In the present study, bioassay-guided fractionation of AP led to the sepn. and identification of a polyunsatd. fatty acid, α-linolenic acid (ALA), which was found to show anti-inflammatory activity.  The anti-inflammatory effects of ALA, using acetic acid or carrageenan-induced inflammation models, were investigated in mice or rats, resp.  ALA significantly inhibited the acetic acid-induced vascular permeability in a dose dependent manner (34.2 and 37.7% inhibition at doses of 5 and 10 mg/kg, resp.).  ALA also significantly reduced a rat paw edema induced by a single treatment of carrageenan.  To investigate the mechanism of the anti-inflammatory action of ALA, the effects of ALA on lipopolysaccharide (LPS)-induced responses in the murine macrophages cell line, RAW 264.7, were examd.  Exposure of LPS-stimulated cells to ALA inhibited the accumulation of nitrite and prostaglandin E2 (PGE2) in the culture medium.  Consistent with these observations, the protein and mRNA expression levels of iNOS and COX-2 enzyme were markedly inhibited by ALA in a dose dependent manner.  These results suggest that the anti-inflammatory activity of ALA might be due to the suppression of the expressions of iNOS and COX-2 mRNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt4-TMaFd-EbVg90H21EOLACvtfcHk0ljaeK9qwOfKrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosV2ltrY%253D&md5=1e5eb8486f63df7e9c6d53c5eb4cdafc</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2FBF02977632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02977632%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DE.%2BJ.%26aulast%3DChung%26aufirst%3DS.%2BH.%26atitle%3DIn%2520vivo%2520and%2520in%2520vitro%2520anti-inflammatory%2520activities%2520of%2520alpha-linolenic%2520acid%2520isolated%2520from%2520Actinidia%2520polygama%2520fruits%26jtitle%3DArch.%2520Pharm.%2520Res.%26date%3D2007%26volume%3D30%26spage%3D708%26epage%3D714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Naveh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dottan, S. A.</span><span> </span><span class="NLM_article-title">Azathioprine’s inhibitory effect on prostaglandin E2 production is not via cyclooxygenase inhibition</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">157</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">732</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=1988&pages=727-732&author=N.+Navehauthor=C.+Weissmanauthor=S.+A.+Dottan&title=Azathioprine%E2%80%99s+inhibitory+effect+on+prostaglandin+E2+production+is+not+via+cyclooxygenase+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaveh%26aufirst%3DN.%26aulast%3DWeissman%26aufirst%3DC.%26aulast%3DDottan%26aufirst%3DS.%2BA.%26atitle%3DAzathioprine%25E2%2580%2599s%2520inhibitory%2520effect%2520on%2520prostaglandin%2520E2%2520production%2520is%2520not%2520via%2520cyclooxygenase%2520inhibition%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1988%26volume%3D157%26spage%3D727%26epage%3D732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Sharis, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannon, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loscalzo, J.</span><span> </span><span class="NLM_article-title">The antiplatelet effects of ticlopidine and clopidogrel</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">394</span><span class="NLM_x">–</span> <span class="NLM_lpage">405</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.7326%2F0003-4819-129-5-199809010-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=9735068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADyaK1cXmtFWkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=1998&pages=394-405&author=P.+J.+Sharisauthor=C.+P.+Cannonauthor=J.+Loscalzo&title=The+antiplatelet+effects+of+ticlopidine+and+clopidogrel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The antiplatelet effects of ticlopidine and clopidogrel</span></div><div class="casAuthors">Sharis, Peter J.; Cannon, Christopher P.; Loscalzo, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Internal Medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">394-405</span>CODEN:
                <span class="NLM_cas:coden">AIMEAS</span>;
        ISSN:<span class="NLM_cas:issn">0003-4819</span>.
    
            (<span class="NLM_cas:orgname">American College of Physicians</span>)
        </div><div class="casAbstract">A review with 142 refs.  Ticlopidine and clopidogrel achieve antiplatelet effects by inhibiting the binding of adenosine 5'-disphosphate to its platelet receptor.  Ticlopidine was first shown to decrease major events compared with placebo or aspirin in patients with stroke or recent transient ischemic attack.  Randomized studies in patients undergoing coronary artery stenting have shown that ticlopidine reduces the risk for subacute stent thrombosis compared with warfarin-based regimens.  Smaller studies have also shown this drug to have benefit during follow-up in patients with unstable angina, peripheral arterial disease, saphenous vein coronary bypass grafts, and diabetic retinopathy.  Clopidogrel was recently approved by the U.S. Food and Drug Administration for the redn. of ischemic events in patients with recent myocardial infarction, stroke, or peripheral arterial disease (incidence, 5.32% per yr compared with 5.83% per yr for aspirin; P = 0.043) with no added risk for neutropenia.  The combination of clopidogrel and aspirin, as well as the utility of clopidogrel in other patient populations and in stenting, requires further study.  Ticlopidine and clopidogrel seem to have beneficial effects compared with aspirin (the current std.) in a broad range of patients.  These observations highlight the importance of antiplatelet therapy in cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlhFBrtn7subVg90H21EOLACvtfcHk0lhSOxkSEpD5dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtFWkt7o%253D&md5=48725dceaf9094915272fb53aeb6fa7f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-129-5-199809010-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-129-5-199809010-00009%26sid%3Dliteratum%253Aachs%26aulast%3DSharis%26aufirst%3DP.%2BJ.%26aulast%3DCannon%26aufirst%3DC.%2BP.%26aulast%3DLoscalzo%26aufirst%3DJ.%26atitle%3DThe%2520antiplatelet%2520effects%2520of%2520ticlopidine%2520and%2520clopidogrel%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D1998%26volume%3D129%26spage%3D394%26epage%3D405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Richer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giroux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plouin, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maarek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giudicelli, J. F.</span><span> </span><span class="NLM_article-title">Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1111%2Fj.1365-2125.1984.tb02338.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=6324834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADyaL2c7nvVyrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1984&pages=243-250&author=C.+Richerauthor=B.+Girouxauthor=P.+F.+Plouinauthor=B.+Maarekauthor=J.+F.+Giudicelli&title=Captopril%3A+pharmacokinetics%2C+antihypertensive+and+biological+effects+in+hypertensive+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients</span></div><div class="casAuthors">Richer C; Giroux B; Plouin P F; Maarek B; Giudicelli J F</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">243-50</span>
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">The kinetics of captopril plasma levels and of the drug-induced plasma converting enzyme activity (PCEA), plasma renin activity (PRA) and diastolic blood pressure (DBP) modifications were studied over 24 h after oral administration of captopril, 1 mg/kg, to ten hypertensive patients.  Free unchanged captopril pharmacokinetic parameters were: t1/2, alpha: 0.45 +/- 0.06 h; tmax: 0.98 +/- 0.13 h; Cmax: 1.31 +/- 0.20 mg l-1; t1/2,z: 0.66 +/- 0.13 h; V: 0.614 +/- 0.104 1 kg-1 and CLtot: 0.690 +/- 0.082 l h-1 kg-1.  At 6 h captopril was no longer detectable in plasma.  The onset of PCEA inhibition and of DBP decrease closely followed the rise of captopril's plasma levels, while that of PRA increase was delayed.  In contrast, while captopril rapidly disappeared from plasma, its biological and antihypertensive effects were long-lasting.  The lack of correlation between the relative bioavailability of captopril and the induced reduction in DBP (evaluated by the corresponding AUCs) suggests that free unchanged captopril plasma monitoring is not an adequate indicator of hypertensive patients' potential responsiveness to captopril's blood pressure lowering effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjBnXpCO_SOxBrI9DTGjC0fW6udTcc2eaX_KVuIWAf9Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c7nvVyrsg%253D%253D&md5=276a95ba39a47a93fb454c17a4a343dd</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.1984.tb02338.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.1984.tb02338.x%26sid%3Dliteratum%253Aachs%26aulast%3DRicher%26aufirst%3DC.%26aulast%3DGiroux%26aufirst%3DB.%26aulast%3DPlouin%26aufirst%3DP.%2BF.%26aulast%3DMaarek%26aufirst%3DB.%26aulast%3DGiudicelli%26aufirst%3DJ.%2BF.%26atitle%3DCaptopril%253A%2520pharmacokinetics%252C%2520antihypertensive%2520and%2520biological%2520effects%2520in%2520hypertensive%2520patients%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1984%26volume%3D17%26spage%3D243%26epage%3D250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taggart, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benbrook, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lind, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, W. Q.</span><span> </span><span class="NLM_article-title">Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline)</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.canlet.2011.06.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=21899946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1GhsLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2011&pages=11-17&author=H.+Jiangauthor=J.+E.+Taggartauthor=X.+Zhangauthor=D.+M.+Benbrookauthor=S.+E.+Lindauthor=W.+Q.+Ding&title=Nitroxoline+%288-hydroxy-5-nitroquinoline%29+is+more+a+potent+anti-cancer+agent+than+clioquinol+%285-chloro-7-iodo-8-quinoline%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline)</span></div><div class="casAuthors">Jiang, Hongchao; Taggart, Jori E.; Zhang, Xiaoxi; Benbrook, Doris M.; Lind, Stuart E.; Ding, Wei-Qun</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-17</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Clioquinol has been shown to have anticancer activity both in vitro and in vivo.  The present study compared the cytotoxicity of clioquinol with six analogs using human cancer cell lines.  Of the analogs tested, 8-hydroxy-5-nitroquinoline (NQ) was the most toxic, with an IC50 that was five to ten fold lower than that of other congeners.  Its activity was enhanced by copper, but not zinc, and the use of a zinc-sensitive fluorophore showed that unlike clioquinol, NQ is not a zinc ionophore.  NQ increased intracellular reactive oxygen species generation, an effect that was significantly enhanced by the addn. of copper at levels approx. the same as those found in human plasma.  NQ has been used in humans for the treatment of urinary infections.  NQ is an 8-hydroxyquinoline deriv. that is more potent than the halogenated 8-hydroxyquinolines, and it may be less neurotoxic because it lacks zinc ionophore activity.  NQ is another clin. used anti-microbial agent whose properties suggest that it may be useful in treating cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorjDvax3Qu4bVg90H21EOLACvtfcHk0ljqHPWkvTY3JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1GhsLbP&md5=9afce210f9a491bcd70285f087bcba1d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2011.06.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2011.06.032%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DTaggart%26aufirst%3DJ.%2BE.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DBenbrook%26aufirst%3DD.%2BM.%26aulast%3DLind%26aufirst%3DS.%2BE.%26aulast%3DDing%26aufirst%3DW.%2BQ.%26atitle%3DNitroxoline%2520%25288-hydroxy-5-nitroquinoline%2529%2520is%2520more%2520a%2520potent%2520anti-cancer%2520agent%2520than%2520clioquinol%2520%25285-chloro-7-iodo-8-quinoline%2529%26jtitle%3DCancer%2520Lett.%26date%3D2011%26volume%3D312%26spage%3D11%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Sosic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirkovic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arenz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefane, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobec, S.</span><span> </span><span class="NLM_article-title">Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure–activity relationships of nitroxoline derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">521</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301544x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=521-533&author=I.+Sosicauthor=B.+Mirkovicauthor=K.+Arenzauthor=B.+Stefaneauthor=J.+Kosauthor=S.+Gobec&title=Development+of+new+cathepsin+B+inhibitors%3A+combining+bioisosteric+replacements+and+structure-based+design+to+explore+the+structure%E2%80%93activity+relationships+of+nitroxoline+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm301544x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301544x%26sid%3Dliteratum%253Aachs%26aulast%3DSosic%26aufirst%3DI.%26aulast%3DMirkovic%26aufirst%3DB.%26aulast%3DArenz%26aufirst%3DK.%26aulast%3DStefane%26aufirst%3DB.%26aulast%3DKos%26aufirst%3DJ.%26aulast%3DGobec%26aufirst%3DS.%26atitle%3DDevelopment%2520of%2520new%2520cathepsin%2520B%2520inhibitors%253A%2520combining%2520bioisosteric%2520replacements%2520and%2520structure-based%2520design%2520to%2520explore%2520the%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520nitroxoline%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D521%26epage%3D533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Seeman, P.</span><span> </span><span class="NLM_article-title">Dopamine D2 receptors as treatment targets in schizophrenia</span> <span class="citation_source-journal">Clin. Schizophr. Relat. Psychoses</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.3371%2FCSRP.4.1.5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BC3cnosVaqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=56-73&author=P.+Seeman&title=Dopamine+D2+receptors+as+treatment+targets+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D2 receptors as treatment targets in schizophrenia</span></div><div class="casAuthors">Seeman Philip</div><div class="citationInfo"><span class="NLM_cas:title">Clinical schizophrenia & related psychoses</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-73</span>
        ISSN:<span class="NLM_cas:issn">1935-1232</span>.
    </div><div class="casAbstract">The antipsychotic effectiveness of chlorpromazine and haloperidol started a search for their therapeutic targets.  The antipsychotic receptor target turned out to be a dopamine receptor, now cloned as the dopamine D2 receptor.  The D2 receptor is the common target for antipsychotics.  Antipsychotic clinical doses correlate with their affinities for this receptor.  Therapeutic doses of antipsychotics occupy 60 to 80% of brain D2 receptors in patients, but aripiprazole occupies up to 90%.  While antipsychotics may take up to six hours to occupy D2 receptors, much clinical improvement occurs within a few days.  The receptor has high- and low-affinity states.  The D2High state is functional for dopamine-like agonists such as aripiprazole.  Most individuals with schizophrenia are supersensitive to dopamine.  Animal models of psychosis show that a variety of risk factors, genetic and nongenetic, are associated with behavioral supersensitivity to dopamine, reflected in elevated levels of dopamine D2High receptors.  Although antipsychotics such as haloperidol alleviate psychosis and reverse the elevation of D2High receptors, long-term use of traditional antipsychotics can further enhance dopamine supersensitivity in patients.  Therefore, switching from a traditional antipsychotic to an agonist antipsychotic such as aripiprazole can result in the emergence of psychotic signs and symptoms.  Clozapine and quetiapine do not elicit parkinsonism and rarely result in tardive dyskinesia because they are released from D2 within 12 to 24 hours.  Traditional antipsychotics remain attached to D2 receptors for days, preventing relapse, but allowing accumulation that can lead to tardive dyskinesia.  Future goals include imaging D2High receptors and desensitizing them in early-stage psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3lJfKBYPsRWhHGZei4OW9fW6udTcc2ebOCInz7q0SYrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnosVaqtg%253D%253D&md5=14dc6329120a843ddbb3411dc8328229</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.3371%2FCSRP.4.1.5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3371%252FCSRP.4.1.5%26sid%3Dliteratum%253Aachs%26aulast%3DSeeman%26aufirst%3DP.%26atitle%3DDopamine%2520D2%2520receptors%2520as%2520treatment%2520targets%2520in%2520schizophrenia%26jtitle%3DClin.%2520Schizophr.%2520Relat.%2520Psychoses%26date%3D2010%26volume%3D4%26spage%3D56%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Kaizaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tien, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Numazawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatt, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, L. W.</span><span> </span><span class="NLM_article-title">Celecoxib reduces brain dopaminergic neuronaldysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide</span> <span class="citation_source-journal">J Neuroinflammation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1186%2F1742-2094-10-45" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=23561827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFCktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=45&author=A.+Kaizakiauthor=L.+T.+Tienauthor=Y.+Pangauthor=Z.+Caiauthor=S.+Tanakaauthor=S.+Numazawaauthor=A.+J.+Bhattauthor=L.+W.+Fan&title=Celecoxib+reduces+brain+dopaminergic+neuronaldysfunction%2C+and+improves+sensorimotor+behavioral+performance+in+neonatal+rats+exposed+to+systemic+lipopolysaccharide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Celecoxib reduces brain dopaminergic neuronaldysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide</span></div><div class="casAuthors">Kaizaki, Asuka; Tien, Lu-Tai; Pang, Yi; Cai, Zhengwei; Tanaka, Sachiko; Numazawa, Satoshi; Bhatt, Abhay J.; Fan, Lir-Wan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroinflammation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45</span>CODEN:
                <span class="NLM_cas:coden">JNOEB3</span>;
        ISSN:<span class="NLM_cas:issn">1742-2094</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Cyclooxygenase-2 (COX-2) is induced in inflammatory cells in response to cytokines and pro-inflammatory mols., suggesting that COX-2 has a role in the inflammatory process.  The objective of the current study was to examine whether celecoxib, a selective COX-2 inhibitor, could ameliorate lipopolysaccharide (LPS)-induced brain inflammation, dopaminergic neuronal dysfunction and sensorimotor behavioral impairments.  I.p. (i.p.) injection of LPS (2 mg/kg) was performed in rat pups on postnatal Day 5 (P5), and celecoxib (20 mg/kg) or vehicle was administered (i.p.) five minutes after LPS injection.  Sensorimotor behavioral tests were carried out 24 h after LPS exposure, and brain injury was examd. on P6.  Our results showed that LPS exposure resulted in impairment in sensorimotor behavioral performance and injury to brain dopaminergic neurons, as indicated by loss of tyrosine hydroxylase (TH) immunoreactivity, as well as decreases in mitochondria activity in the rat brain.  LPS exposure also led to increases in the expression of α-synuclein and dopamine transporter proteins and enhanced [3H]dopamine uptake.  Treatment with celecoxib significantly reduced LPS-induced sensorimotor behavioral disturbances and dopaminergic neuronal dysfunction.  Celecoxib administration significantly attenuated LPS-induced increases in the nos. of activated microglia and astrocytes and in the concn. of IL-1β in the neonatal rat brain.  The protective effect of celecoxib was also assocd. with an attenuation of LPS-induced COX-2+ cells, which were double labeled with TH + (dopaminergic neuron) or glial fibrillary acidic protein (GFAP) + (astrocyte) cells.  Systemic LPS administration induced brain inflammatory responses in neonatal rats; these inflammatory responses included induction of COX-2 expression in TH neurons and astrocytes.  Application of the COX-2 inhibitor celecoxib after LPS treatment attenuated the inflammatory response and improved LPS-induced impairment, both biochem. and behaviorally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzxcgbV6ZKnrVg90H21EOLACvtfcHk0ljWEcYy5JAROA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFCktrc%253D&md5=24edf38dbf7e8df83d909a2598c08b1c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1186%2F1742-2094-10-45&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-2094-10-45%26sid%3Dliteratum%253Aachs%26aulast%3DKaizaki%26aufirst%3DA.%26aulast%3DTien%26aufirst%3DL.%2BT.%26aulast%3DPang%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DNumazawa%26aufirst%3DS.%26aulast%3DBhatt%26aufirst%3DA.%2BJ.%26aulast%3DFan%26aufirst%3DL.%2BW.%26atitle%3DCelecoxib%2520reduces%2520brain%2520dopaminergic%2520neuronaldysfunction%252C%2520and%2520improves%2520sensorimotor%2520behavioral%2520performance%2520in%2520neonatal%2520rats%2520exposed%2520to%2520systemic%2520lipopolysaccharide%26jtitle%3DJ%2520Neuroinflammation%26date%3D2013%26volume%3D10%26spage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Akhondzadeh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jafari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raisi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasehi, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghoreishi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salehi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohebbi-Rasa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raznahan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamalipour, A.</span><span> </span><span class="NLM_article-title">Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial</span> <span class="citation_source-journal">Depression Anxiety</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">607</span><span class="NLM_x">–</span> <span class="NLM_lpage">611</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1002%2Fda.20589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=19496103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1aqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=607-611&author=S.+Akhondzadehauthor=S.+Jafariauthor=F.+Raisiauthor=A.+A.+Nasehiauthor=A.+Ghoreishiauthor=B.+Salehiauthor=S.+Mohebbi-Rasaauthor=M.+Raznahanauthor=A.+Kamalipour&title=Clinical+trial+of+adjunctive+celecoxib+treatment+in+patients+with+major+depression%3A+a+double+blind+and+placebo+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial</span></div><div class="casAuthors">Akhondzadeh, Shahin; Jafari, Sara; Raisi, Firoozeh; Nasehi, Abbas Ali; Ghoreishi, Aboulfazl; Salehi, Bahman; Mohebbi-Rasa, Soodeh; Raznahan, Maedeh; Kamalipour, Abbas</div><div class="citationInfo"><span class="NLM_cas:title">Depression and Anxiety</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">607-611</span>CODEN:
                <span class="NLM_cas:coden">DEANF5</span>;
        ISSN:<span class="NLM_cas:issn">1091-4269</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The pathophysiol. of depression is assocd. with the hyperactivity of immune inflammatory responses.  Cyclooxygenase-2 inhibitors such as celecoxib reduce the prodn. of pro-inflammatory cytokines.  The purpose of the present investigation was to assess the efficacy of celecoxib as an adjuvant agent in the treatment of major depression in a six-week double blind and placebo controlled trial.  Forty adult outpatients who met the DSM-IV-TR criteria for major depression participated in the trial.  Patients have a baseline Hamilton Rating Scale for Depression score of at least 18.  Patients were allocated in a random fashion: 20 to fluoxetine 40 mg/day plus celecoxib 400 mg/day (200 mg bid) (morning and evening) and 20 to fluoxetine 40 mg/day plus placebo.  Patients were assessed by a psychiatrist at baseline and after 1, 2, 4, and 6 wk after the medication started.  Although both protocols significantly decreased the score of Hamilton Rating Scale for Depression over the trial period, the combination of fluoxetine and celecoxib showed a significant superiority over fluoxetine alone in the treatment of symptoms of major depression.  There were no significant differences in the two groups in terms of obsd. side effects.  The results of this study suggest that celecoxib may be an effective adjuvant agent in the management of patients with major depression and anti-inflammatory therapies should be further investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkHZysSCewtrVg90H21EOLACvtfcHk0lg3Oi5YFohw2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1aqtb0%253D&md5=e45bc52353041c5d4aab9ebbe289232f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fda.20589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fda.20589%26sid%3Dliteratum%253Aachs%26aulast%3DAkhondzadeh%26aufirst%3DS.%26aulast%3DJafari%26aufirst%3DS.%26aulast%3DRaisi%26aufirst%3DF.%26aulast%3DNasehi%26aufirst%3DA.%2BA.%26aulast%3DGhoreishi%26aufirst%3DA.%26aulast%3DSalehi%26aufirst%3DB.%26aulast%3DMohebbi-Rasa%26aufirst%3DS.%26aulast%3DRaznahan%26aufirst%3DM.%26aulast%3DKamalipour%26aufirst%3DA.%26atitle%3DClinical%2520trial%2520of%2520adjunctive%2520celecoxib%2520treatment%2520in%2520patients%2520with%2520major%2520depression%253A%2520a%2520double%2520blind%2520and%2520placebo%2520controlled%2520trial%26jtitle%3DDepression%2520Anxiety%26date%3D2009%26volume%3D26%26spage%3D607%26epage%3D611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Akhondzadeh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabatabaee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amini, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abhari, S. A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbasi, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnam, B.</span><span> </span><span class="NLM_article-title">Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.schres.2006.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=17208413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FnsFKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2007&pages=179&author=S.+Akhondzadehauthor=M.+Tabatabaeeauthor=H.+Aminiauthor=S.+A.+A.+Abhariauthor=S.+H.+Abbasiauthor=B.+Behnam&title=Celecoxib+as+adjunctive+therapy+in+schizophrenia%3A+a+double-blind%2C+randomized+and+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial</span></div><div class="casAuthors">Akhondzadeh Shahin; Tabatabaee Maryam; Amini Homayoun; Ahmadi Abhari Seyed Ali; Abbasi Seyed Hesamedin; Behnam Behnaz</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">179-85</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Some evidence suggests that the pathophysiology of schizophrenia is associated with the abnormal immune system, and cytokines may be important in schizophrenia.  Cyclooxygenase-2 (COX-2) inhibitors such as celecoxib reduce the production of proinflammatory cytokines including Th1-like cytokines.  Indeed, COX-2 inhibitors rebalance type-1 and type-2 immune response.  The purpose of the present investigation was to assess the efficacy of celecoxib as an adjuvant agent in the treatment of chronic schizophrenia in an eight-week, double-blind and placebo-controlled trial.  Eligible participants in this study were 60 patients with chronic schizophrenia.  All patients were inpatients and were in the active phase of the illness, and met DSM-IV criteria for schizophrenia.  Patients were allocated in a random fashion, 30 to risperidone 6 mg/day plus celecoxib 400 mg/day (200 mg bid) (morning and evening) and 30 to risperidone 6 mg/day plus placebo.  Although both protocols significantly decreased the score of the positive, negative and general psychopathological symptoms over the trial period, the combination of risperidone and celecoxib showed a significant superiority over risperidone alone in the treatment of positive symptoms, general psychopathology symptoms as well as PANSS total scores.  The means Extrapyramidal Symptoms Rating Scale for the placebo group were higher than in the celecoxib group over the trial.  However, the differences were not significant.  The results of this study suggest that celecoxib may be an effective adjuvant agent in the management of patients with chronic schizophrenia and anti-inflammatory therapies should be further investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKRlaq_gfxtA20zIbnCCI3fW6udTcc2eZNY-PYLQxxxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FnsFKjtA%253D%253D&md5=ccbbc9523ec8698ddfde8a38889aa333</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2006.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2006.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DAkhondzadeh%26aufirst%3DS.%26aulast%3DTabatabaee%26aufirst%3DM.%26aulast%3DAmini%26aufirst%3DH.%26aulast%3DAbhari%26aufirst%3DS.%2BA.%2BA.%26aulast%3DAbbasi%26aufirst%3DS.%2BH.%26aulast%3DBehnam%26aufirst%3DB.%26atitle%3DCelecoxib%2520as%2520adjunctive%2520therapy%2520in%2520schizophrenia%253A%2520a%2520double-blind%252C%2520randomized%2520and%2520placebo-controlled%2520trial%26jtitle%3DSchizophr.%2520Res.%26date%3D2007%26volume%3D90%26spage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Gattaz, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrahao, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foccacia, R.</span><span> </span><span class="NLM_article-title">Childhood meningitis, brain maturation and the risk of psychosis</span> <span class="citation_source-journal">Eur. Arch. Psychiatry Clin. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">254</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1007%2Fs00406-004-0431-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=14991375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD2c7gtVaqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=2004&pages=23-26&author=W.+F.+Gattazauthor=A.+L.+Abrahaoauthor=R.+Foccacia&title=Childhood+meningitis%2C+brain+maturation+and+the+risk+of+psychosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Childhood meningitis, brain maturation and the risk of psychosis</span></div><div class="casAuthors">Gattaz Wagner F; Abrahao Andre L; Foccacia Roberto</div><div class="citationInfo"><span class="NLM_cas:title">European archives of psychiatry and clinical neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-6</span>
        ISSN:<span class="NLM_cas:issn">0940-1334</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXQfoFnlhTBXy-c-E1v-fmfW6udTcc2eaglo7TkXG5U7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7gtVaqsA%253D%253D&md5=e56c666b11d61e3e02b05fcd347fe079</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1007%2Fs00406-004-0431-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00406-004-0431-3%26sid%3Dliteratum%253Aachs%26aulast%3DGattaz%26aufirst%3DW.%2BF.%26aulast%3DAbrahao%26aufirst%3DA.%2BL.%26aulast%3DFoccacia%26aufirst%3DR.%26atitle%3DChildhood%2520meningitis%252C%2520brain%2520maturation%2520and%2520the%2520risk%2520of%2520psychosis%26jtitle%3DEur.%2520Arch.%2520Psychiatry%2520Clin.%2520Neurosci.%26date%3D2004%26volume%3D254%26spage%3D23%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Muller, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehning, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musil, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schennach-Wolff, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obermeier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moller, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klauss, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedel, M.</span><span> </span><span class="NLM_article-title">Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">118</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.schres.2010.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=20570110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BC3cjhtFyiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2010&pages=118-124&author=N.+Mullerauthor=D.+Krauseauthor=S.+Dehningauthor=R.+Musilauthor=R.+Schennach-Wolffauthor=M.+Obermeierauthor=H.+J.+Mollerauthor=V.+Klaussauthor=M.+J.+Schwarzauthor=M.+Riedel&title=Celecoxib+treatment+in+an+early+stage+of+schizophrenia%3A+results+of+a+randomized%2C+double-blind%2C+placebo-controlled+trial+of+celecoxib+augmentation+of+amisulpride+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment</span></div><div class="casAuthors">Muller Norbert; Krause Daniela; Dehning Sandra; Musil Richard; Schennach-Wolff Rebecca; Obermeier Michael; Moller Hans-Jurgen; Klauss Volker; Schwarz Markus J; Riedel Michael</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">118-24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recent trials support the hypothesis of the role of inflammation in the pathogenesis of schizophrenia.  The overall therapeutic benefit of anti-inflammatory medication, in particular cyclo-oxygenase-2 (COX-2) inhibitors in schizophrenia, is still controversial.  There are suggestions that therapy with COX-2 inhibitors may influence the early stages of the disease.  Taking these findings into account, we conducted a double-blind, placebo-controlled, randomized trial of celecoxib augmentation to amisulpride treatment in patients with a first manifestation of schizophrenia.  Forty-nine patients diagnosed with schizophrenia were randomly assigned.  They were treated either with amisulpride (200-1000 mg) plus celecoxib (400 mg) or amisulpride (200-1000 mg) plus placebo.  Inclusion criterion was the diagnosis of schizophrenia during the past two years according to DSM-IV.  The trial lasted six weeks.  At weekly intervals an assessment of the psychopathology was performed using the Positive and Negative Symptom Scale (PANSS) and the Global Clinical Impression Scale (CGI).  A significantly better outcome was observed in the patient group treated with amisulpride plus celecoxib compared to the group with amisulpride plus placebo (PANSS negative: p=0.03; PANSS global; p=0.05 and PANSS total: p=0.02).  In addition, ratings by the CGI scale during therapy with amisulpride and celecoxib showed a significantly better result (p< or =0.001).  A significantly superior therapeutic effect could be observed in the celecoxib group compared to placebo in the treatment of early stage schizophrenia.  This is the first time an improvement in patients' negative symptoms has been demonstrated with celecoxib.  In future, further trials are needed to investigate the effect of COX-2 inhibitors on prodromal and negative symptoms of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOQ9gKuPc8iK-9TkgmBqTqfW6udTcc2eaglo7TkXG5U7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjhtFyiug%253D%253D&md5=1ca45316f470390af04cddf0562529f3</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2010.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2010.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DN.%26aulast%3DKrause%26aufirst%3DD.%26aulast%3DDehning%26aufirst%3DS.%26aulast%3DMusil%26aufirst%3DR.%26aulast%3DSchennach-Wolff%26aufirst%3DR.%26aulast%3DObermeier%26aufirst%3DM.%26aulast%3DMoller%26aufirst%3DH.%2BJ.%26aulast%3DKlauss%26aufirst%3DV.%26aulast%3DSchwarz%26aufirst%3DM.%2BJ.%26aulast%3DRiedel%26aufirst%3DM.%26atitle%3DCelecoxib%2520treatment%2520in%2520an%2520early%2520stage%2520of%2520schizophrenia%253A%2520results%2520of%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520celecoxib%2520augmentation%2520of%2520amisulpride%2520treatment%26jtitle%3DSchizophr.%2520Res.%26date%3D2010%26volume%3D121%26spage%3D118%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Muller, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M.</span><span> </span><span class="NLM_article-title">Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission</span> <span class="citation_source-journal">Neurotoxic Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1007%2FBF03033242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=17062375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD28nivFKmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=131-148&author=N.+Mullerauthor=M.+Schwarz&title=Schizophrenia+as+an+inflammation-mediated+dysbalance+of+glutamatergic+neurotransmission"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission</span></div><div class="casAuthors">Muller N; Schwarz M</div><div class="citationInfo"><span class="NLM_cas:title">Neurotoxicity research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-48</span>
        ISSN:<span class="NLM_cas:issn">1029-8428</span>.
    </div><div class="casAbstract">This overview tries to bridge the gap between psychoneuroimmunological findings and recent results from pharmacological, neurochemical and genetic studies in schizophrenia.  Schizophrenia is a disorder of dopaminergic neurotransmission, but modulation of the dopaminergic system by glutamatergic neurotransmission seems to play a key role.  This view is supported by genetic findings of the neuregulin- and dysbindin genes, which have functional impact on the glutamatergic system.  Glutamatergic hypofunction, however, is mediated by the N-methyl-D-aspartate (NMDA)-receptor antagonism.  The only endogenous NMDA receptor antagonist identified up to now is kynurenic acid (KYNA).  Despite the NMDA receptor antagonism, KYNA also blocks, in lower doses, the nicotinergic acetycholine receptor, i.e., increased KYNA levels can explain psychotic symptoms and cognitive deterioration.  KYNA levels are described to be higher in the cerebrospinal fluid (CSF) and in critical central nervous system (CNS) regions of schizophrenics as compared to controls.  Another line of evidence suggests that a (prenatal) infection is involved in the pathogenesis of schizophrenia.  Due to an early sensitization process of the immune system or to a (chronic) infection, which is not cleared through the immune response, an immune imbalance between the type-1 and the type-2 immune responses takes place in schizophrenia.  The type-1 response is partially inhibited, while the type-2 response is over-activated.  This immune constellation is associated with inhibition of the enzyme indoleamine dioxygenase (IDO), because IDO - located in astrocytes and microglial cells - is inhibited by type-2 cytokines.  IDO catalyzes the first step in tryptophan metabolism, the degradation from tryptophan to kynurenine, as does tryptophan 2,3-dioxygenase (TDO).  Due to the inhibition of IDO, tryptophan-kynurenine is predominantly metabolized by TDO, which is located in astrocytes, not in microglial or other CNS cells.  In schizophrenia, astrocytes in particular are activated, as increased levels of S100B appear.  Additionally, they do not have the enzymatic equipment for the normal metabolism-route of tryptophan.  Due to the lack of kynurenine hydroxylase (KYN-OHase) in astrocytes, KYNA accumulates in the CNS, while the metabolic pathway in microglial cells is blocked.  Accordingly, an increase of TDO activity has been observed in critical CNS regions of schizophrenics.  These mechanisms result in an accumulation of KYNA in critical CNS regions.  Thus, the immune-mediated glutamatergic-dopaminergic dysregulation may lead to the clinical symptoms of schizophrenia.  Therapeutic consequences, e.g., the use of anti-inflammatory cyclo-oxygenase-2 inhibitors, which can also decrease KYNA directly, are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWdjXoFfOT9tTiMd2aNQVUfW6udTcc2eb7dCCGq0NgM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nivFKmsQ%253D%253D&md5=4a05e1868fb906518686e21f0463c888</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1007%2FBF03033242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03033242%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DN.%26aulast%3DSchwarz%26aufirst%3DM.%26atitle%3DSchizophrenia%2520as%2520an%2520inflammation-mediated%2520dysbalance%2520of%2520glutamatergic%2520neurotransmission%26jtitle%3DNeurotoxic%2520Res.%26date%3D2006%26volume%3D10%26spage%3D131%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Potvin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepehry, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gendron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bah, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouassi, E.</span><span> </span><span class="NLM_article-title">Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">801</span><span class="NLM_x">–</span> <span class="NLM_lpage">808</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.biopsych.2007.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=18005941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVKgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2008&pages=801-808&author=S.+Potvinauthor=E.+Stipauthor=A.+A.+Sepehryauthor=A.+Gendronauthor=R.+Bahauthor=E.+Kouassi&title=Inflammatory+cytokine+alterations+in+schizophrenia%3A+a+systematic+quantitative+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review</span></div><div class="casAuthors">Potvin, Stephane; Stip, Emmanuel; Sepehry, Amir A.; Gendron, Alain; Bah, Ramatoulaye; Kouassi, Edouard</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">801-808</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Cytokines play an important role in infection and inflammation and are crucial mediators of the cross-talk between the brain and the immune system.  Schizophrenia would be assocd. with an imbalance in inflammatory cytokines, leading to a decrease in Th1 and an increase in Th2 cytokine secretion.  However, data published so far have been inconsistent.  The primary objective of the present meta-anal. was to verify whether the cytokine imbalance hypothesis of schizophrenia is substantiated by evidence.  Cross-sectional studies were included if they assessed in vivo plasma or serum cytokine concns. and/or in vitro secretion of cytokines by peripheral blood leukocytes from schizophrenia patients and healthy volunteers.  Data from 62 studies involving a total sample size of 2298 schizophrenia patients and 1858 healthy volunteers remained for anal.  Ten cytokines were assessed, including the prototypic Th1 and Th2 cytokines gamma interferon (IFN-γ) and interleukin 4 (IL-4) as well as IL-2, sol. IL-2 receptor (sIL-2R), IL-1β, IL-1 receptor antagonist (IL-1RA), tumor necrosis factor-alpha (TNF-α), IL-6, sol. IL-6 receptor (sIL-6R), and IL-10.  The results show that an increase occurs in in vivo IL-1RA, sIL-2R, and IL-6 and a decrease occurs in in vitro IL-2 in schizophrenia.  No significant effect sizes were obtained for the other cytokines.  These findings provide the first evidence of establishment of an inflammatory syndrome in schizophrenia, which refutes the current hypothesis of a Th2 slant.  Caveats are presented to data interpretation, including the role of stress and the effect of wt. gain that develops in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Pagv4uBWBbVg90H21EOLACvtfcHk0liIcxAmQevXgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVKgurs%253D&md5=907016c1c9f638f5854878b23e246d7a</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2007.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2007.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DPotvin%26aufirst%3DS.%26aulast%3DStip%26aufirst%3DE.%26aulast%3DSepehry%26aufirst%3DA.%2BA.%26aulast%3DGendron%26aufirst%3DA.%26aulast%3DBah%26aufirst%3DR.%26aulast%3DKouassi%26aufirst%3DE.%26atitle%3DInflammatory%2520cytokine%2520alterations%2520in%2520schizophrenia%253A%2520a%2520systematic%2520quantitative%2520review%26jtitle%3DBiol.%2520Psychiatry%26date%3D2008%26volume%3D63%26spage%3D801%26epage%3D808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Akhondzadeh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabatabaee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amini, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi Abhari, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbasi, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnam, B.</span><span> </span><span class="NLM_article-title">Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.schres.2006.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=17208413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FnsFKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2007&pages=179-185&author=S.+Akhondzadehauthor=M.+Tabatabaeeauthor=H.+Aminiauthor=S.+A.+Ahmadi+Abhariauthor=S.+H.+Abbasiauthor=B.+Behnam&title=Celecoxib+as+adjunctive+therapy+in+schizophrenia%3A+a+double-blind%2C+randomized+and+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial</span></div><div class="casAuthors">Akhondzadeh Shahin; Tabatabaee Maryam; Amini Homayoun; Ahmadi Abhari Seyed Ali; Abbasi Seyed Hesamedin; Behnam Behnaz</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">179-85</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Some evidence suggests that the pathophysiology of schizophrenia is associated with the abnormal immune system, and cytokines may be important in schizophrenia.  Cyclooxygenase-2 (COX-2) inhibitors such as celecoxib reduce the production of proinflammatory cytokines including Th1-like cytokines.  Indeed, COX-2 inhibitors rebalance type-1 and type-2 immune response.  The purpose of the present investigation was to assess the efficacy of celecoxib as an adjuvant agent in the treatment of chronic schizophrenia in an eight-week, double-blind and placebo-controlled trial.  Eligible participants in this study were 60 patients with chronic schizophrenia.  All patients were inpatients and were in the active phase of the illness, and met DSM-IV criteria for schizophrenia.  Patients were allocated in a random fashion, 30 to risperidone 6 mg/day plus celecoxib 400 mg/day (200 mg bid) (morning and evening) and 30 to risperidone 6 mg/day plus placebo.  Although both protocols significantly decreased the score of the positive, negative and general psychopathological symptoms over the trial period, the combination of risperidone and celecoxib showed a significant superiority over risperidone alone in the treatment of positive symptoms, general psychopathology symptoms as well as PANSS total scores.  The means Extrapyramidal Symptoms Rating Scale for the placebo group were higher than in the celecoxib group over the trial.  However, the differences were not significant.  The results of this study suggest that celecoxib may be an effective adjuvant agent in the management of patients with chronic schizophrenia and anti-inflammatory therapies should be further investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKRlaq_gfxtA20zIbnCCI3fW6udTcc2ebQnjVc4HHqcbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FnsFKjtA%253D%253D&md5=ccbbc9523ec8698ddfde8a38889aa333</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2006.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2006.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DAkhondzadeh%26aufirst%3DS.%26aulast%3DTabatabaee%26aufirst%3DM.%26aulast%3DAmini%26aufirst%3DH.%26aulast%3DAhmadi%2BAbhari%26aufirst%3DS.%2BA.%26aulast%3DAbbasi%26aufirst%3DS.%2BH.%26aulast%3DBehnam%26aufirst%3DB.%26atitle%3DCelecoxib%2520as%2520adjunctive%2520therapy%2520in%2520schizophrenia%253A%2520a%2520double-blind%252C%2520randomized%2520and%2520placebo-controlled%2520trial%26jtitle%3DSchizophr.%2520Res.%26date%3D2007%26volume%3D90%26spage%3D179%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Muller, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheppach, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandstatter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sokullu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krampe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulmschneider, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moller, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. J.</span><span> </span><span class="NLM_article-title">Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">1029</span><span class="NLM_x">–</span> <span class="NLM_lpage">1034</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1176%2Fappi.ajp.159.6.1029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=12042193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD38zgtVyquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2002&pages=1029-1034&author=N.+Mullerauthor=M.+Riedelauthor=C.+Scheppachauthor=B.+Brandstatterauthor=S.+Sokulluauthor=K.+Krampeauthor=M.+Ulmschneiderauthor=R.+R.+Engelauthor=H.+J.+Mollerauthor=M.+J.+Schwarz&title=Beneficial+antipsychotic+effects+of+celecoxib+add-on+therapy+compared+to+risperidone+alone+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia</span></div><div class="casAuthors">Muller Norbert; Riedel Michael; Scheppach Constanze; Brandstatter Bernd; Sokullu Safet; Krampe Karin; Ulmschneider Markus; Engel Rolf R; Moller Hans-Jurgen; Schwarz Markus J</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1029-34</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Abnormalities in the immune system in schizophrenia have been described.  However, important findings such as high levels of activating cytokines in the CSF and signs of CNS inflammation have been controversial.  The authors conducted a trial of the new selective cyclooxygenase-2 inhibitor celecoxib, an immunomodulatory drug, in schizophrenic patients to evaluate its therapeutic effects.  METHOD:  In a prospective, double-blind evaluation, 50 patients with an acute exacerbation of schizophrenia were randomly assigned to either risperidone plus celecoxib or risperidone plus placebo.  After a washout period, 25 patients received 2-6 mg/day of risperidone plus placebo and 25 received risperidone plus 400 mg/day of celecoxib for 5 weeks.  The treatment effect was calculated by analysis of covariance.  There were no significant differences between groups in age, sex, duration or severity of disease or psychopathology, or risperidone dose or plasma level.  RESULTS:  Over 5 weeks, both groups of patients showed significant improvement in scores on the Positive and Negative Syndrome Scale and on all subscales.  However, the celecoxib group showed significantly greater improvement in the total score.  CONCLUSIONS:  Additional treatment with celecoxib has significant positive effects on the therapeutic action of risperidone with regard to total schizophrenia psychopathology.  Moreover, the fact that treatment with an immunomodulatory drug showed beneficial effects on schizophrenia symptoms indicates that immune dysfunction in schizophrenia is not just an epiphenomenon but is related to the pathomechanism of the disorder.  However, a nonimmunological therapeutic effect of celecoxib mediated by the N-methyl-D-aspartic acid receptor has to be taken into account.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZu6Rnvk4sMpPq5LRczm8ffW6udTcc2ebQnjVc4HHqcbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zgtVyquw%253D%253D&md5=b632958b76b4d7e0cc2421ac7ea2c193</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.159.6.1029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.159.6.1029%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DN.%26aulast%3DRiedel%26aufirst%3DM.%26aulast%3DScheppach%26aufirst%3DC.%26aulast%3DBrandstatter%26aufirst%3DB.%26aulast%3DSokullu%26aufirst%3DS.%26aulast%3DKrampe%26aufirst%3DK.%26aulast%3DUlmschneider%26aufirst%3DM.%26aulast%3DEngel%26aufirst%3DR.%2BR.%26aulast%3DMoller%26aufirst%3DH.%2BJ.%26aulast%3DSchwarz%26aufirst%3DM.%2BJ.%26atitle%3DBeneficial%2520antipsychotic%2520effects%2520of%2520celecoxib%2520add-on%2520therapy%2520compared%2520to%2520risperidone%2520alone%2520in%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2002%26volume%3D159%26spage%3D1029%26epage%3D1034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Muller, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehning, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerovecki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein-Muller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spellmann, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hetzel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maino, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleindienst, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moller, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arolt, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedel, M.</span><span> </span><span class="NLM_article-title">The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">680</span><span class="NLM_x">–</span> <span class="NLM_lpage">684</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=680-684&author=N.+Mullerauthor=M.+J.+Schwarzauthor=S.+Dehningauthor=A.+Douheauthor=A.+Ceroveckiauthor=B.+Goldstein-Mullerauthor=I.+Spellmannauthor=G.+Hetzelauthor=K.+Mainoauthor=N.+Kleindienstauthor=H.+J.+Mollerauthor=V.+Aroltauthor=M.+Riedel&title=The+cyclooxygenase-2+inhibitor+celecoxib+has+therapeutic+effects+in+major+depression%3A+results+of+a+double-blind%2C+randomized%2C+placebo+controlled%2C+add-on+pilot+study+to+reboxetine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DN.%26aulast%3DSchwarz%26aufirst%3DM.%2BJ.%26aulast%3DDehning%26aufirst%3DS.%26aulast%3DDouhe%26aufirst%3DA.%26aulast%3DCerovecki%26aufirst%3DA.%26aulast%3DGoldstein-Muller%26aufirst%3DB.%26aulast%3DSpellmann%26aufirst%3DI.%26aulast%3DHetzel%26aufirst%3DG.%26aulast%3DMaino%26aufirst%3DK.%26aulast%3DKleindienst%26aufirst%3DN.%26aulast%3DMoller%26aufirst%3DH.%2BJ.%26aulast%3DArolt%26aufirst%3DV.%26aulast%3DRiedel%26aufirst%3DM.%26atitle%3DThe%2520cyclooxygenase-2%2520inhibitor%2520celecoxib%2520has%2520therapeutic%2520effects%2520in%2520major%2520depression%253A%2520results%2520of%2520a%2520double-blind%252C%2520randomized%252C%2520placebo%2520controlled%252C%2520add-on%2520pilot%2520study%2520to%2520reboxetine%26jtitle%3DMol.%2520Psychiatry%26date%3D2006%26volume%3D11%26spage%3D680%26epage%3D684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Brumbaugh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H.</span><span> </span><span class="NLM_article-title">Psychotic mania associated with mefloquine in a bipolar patient</span> <span class="citation_source-journal">South. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">550</span><span class="NLM_x">–</span> <span class="NLM_lpage">551</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1097%2FSMJ.0b013e318167a9e2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=18414180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD1c3pslKluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2008&pages=550-551&author=M.+Brumbaughauthor=P.+Priceauthor=N.+Faganauthor=H.+Hsieh&title=Psychotic+mania+associated+with+mefloquine+in+a+bipolar+patient"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Psychotic mania associated with mefloquine in a bipolar patient</span></div><div class="casAuthors">Brumbaugh Meredith; Price Paul; Fagan Nancy; Hsieh Hudson</div><div class="citationInfo"><span class="NLM_cas:title">Southern medical journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">550-1</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A 63-year-old male patient with a history of bipolar I disorder presented to the emergency department in an acutely psychotic state.  The patient had just returned from vacation in a malarial high-risk area and, as a result, had taken five weekly doses of mefloquine for prophylaxis.  The patient's bipolar disorder was being treated with lithium, and he had been stable for about 8 years.  All organic causes of psychosis were ruled out.  The patient was admitted to the inpatient psychiatric unit and was treated with quetiapine until he was stable enough to return home.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRQ8iPuynTdBFw2ofyr07jXfW6udTcc2eb3lYxpMfbg0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3pslKluw%253D%253D&md5=3c6f376d3c5baffbb6a8fd0c16bec9bc</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1097%2FSMJ.0b013e318167a9e2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FSMJ.0b013e318167a9e2%26sid%3Dliteratum%253Aachs%26aulast%3DBrumbaugh%26aufirst%3DM.%26aulast%3DPrice%26aufirst%3DP.%26aulast%3DFagan%26aufirst%3DN.%26aulast%3DHsieh%26aufirst%3DH.%26atitle%3DPsychotic%2520mania%2520associated%2520with%2520mefloquine%2520in%2520a%2520bipolar%2520patient%26jtitle%3DSouth.%2520Med.%2520J.%26date%3D2008%26volume%3D101%26spage%3D550%26epage%3D551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Tran, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browning, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dell, M. L.</span><span> </span><span class="NLM_article-title">Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report</span> <span class="citation_source-journal">Malar. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">74</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1186%2F1475-2875-5-74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=16925829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD28rktFyltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=74&author=T.+M.+Tranauthor=J.+Browningauthor=M.+L.+Dell&title=Psychosis+with+paranoid+delusions+after+a+therapeutic+dose+of+mefloquine%3A+a+case+report"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report</span></div><div class="casAuthors">Tran Tuan M; Browning Joseph; Dell Mary L</div><div class="citationInfo"><span class="NLM_cas:title">Malaria journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Convenient once-a-week dosing has made mefloquine a popular choice as malaria prophylaxis for travel to countries with chloroquine-resistant malaria.  However, the increased use of mefloquine over the past decade has resulted in reports of rare, but severe, neuropsychiatric adverse reactions, such as anxiety, depression, hallucinations and psychosis.  A direct causality between mefloquine and severe reactions among travelers has been partly confounded by factors associated with foreign travel and, in the case of therapeutic doses of mefloquine, the central nervous system manifestations of Plasmodium infection itself.  The present case provides a unique natural history of mefloquine-induced neuropsychiatric toxicity and revisits its dose-dependent nature.  CASE PRESENTATION:  This report describes an acute exacerbation of neuropsychiatric symptoms after an unwarranted therapeutic dose (1250 mg) of mefloquine in a 37-year-old male previously on a once-a-week prophylactic regimen.  Neuropsychiatric symptoms began as dizziness and insomnia of several days duration, which was followed by one week of escalating anxiety and subtle alterations in behaviour.  The patient's anxiety culminated into a panic episode with profound sympathetic activation.  One week later, he was hospitalized after developing frank psychosis with psychomotor agitation and paranoid delusions.  His psychosis remitted with low-dose quetiapine.  CONCLUSION:  This report suggests that an overt mefloquine-induced psychosis can be preceded by a prodromal phase of moderate symptoms such as dizziness, insomnia, and generalized anxiety.  It is important that physicians advise patients taking mefloquine prophylaxis and their relatives to recognize such symptoms, especially when they are accompanied by abrupt, but subtle, changes in behaviour.  Patients with a history of psychiatric illness, however minor, may be at increased risk for a mefloquine-induced neuropsychiatric toxicity.  Physicians must explicitly caution patients not to self-medicate with a therapeutic course of mefloquine when a malaria diagnosis has not been confirmed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGs4-TUZBEC0EgZCMqtRBifW6udTcc2eb3lYxpMfbg0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rktFyltQ%253D%253D&md5=d63606804c411c52d7cde027065e28a7</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1186%2F1475-2875-5-74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2875-5-74%26sid%3Dliteratum%253Aachs%26aulast%3DTran%26aufirst%3DT.%2BM.%26aulast%3DBrowning%26aufirst%3DJ.%26aulast%3DDell%26aufirst%3DM.%2BL.%26atitle%3DPsychosis%2520with%2520paranoid%2520delusions%2520after%2520a%2520therapeutic%2520dose%2520of%2520mefloquine%253A%2520a%2520case%2520report%26jtitle%3DMalar.%2520J.%26date%3D2006%26volume%3D5%26spage%3D74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Alisky, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chertkova, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iczkowski, K. A.</span><span> </span><span class="NLM_article-title">Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis</span> <span class="citation_source-journal">Med. Hypotheses</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">1090</span><span class="NLM_x">–</span> <span class="NLM_lpage">1094</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.mehy.2006.01.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=16843615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVKlt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2006&pages=1090-1094&author=J.+M.+Aliskyauthor=E.+L.+Chertkovaauthor=K.+A.+Iczkowski&title=Drug+interactions+and+pharmacogenetic+reactions+are+the+basis+for+chloroquine+and+mefloquine-induced+psychosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis</span></div><div class="casAuthors">Alisky, Joseph M.; Chertkova, Elena L.; Iczkowski, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Medical Hypotheses</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1090-1094</span>CODEN:
                <span class="NLM_cas:coden">MEHYDY</span>;
        ISSN:<span class="NLM_cas:issn">0306-9877</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Chloroquine and mefloquine used for prophylaxis and treatment of malaria sometimes causes severe mental status changes, through mechanisms that are poorly understood.  Psychosis is caused by interactions with other drugs or by pharmacogenetic vulnerabilities that cause heightened responses to chloroquine or mefloquine alone, mediated through dopamine, acetylcholine, serotonin, P-glycoprotein, inhibited cortical activity, deranged calcium homeostasis, and impaired synaptogenesis.  Retrospective studies can identify all other drugs taken coincident with chloroquine or mefloquine psychosis.  Various genes from patients could be cloned and compared to those from individuals who tolerated chloroquine and mefloquine, culminating with transgenic animal studies.  Identification of candidate genes may be aided by pharmacogenomic anal. of single nucleotide polymorphism maps.  Finally, prospective studies with cerebrospinal fluid anal. and PET scanning could help verify the hypothesis.  If this hypothesis is correct, the incidence of chloroquine and mefloquine psychosis can be greatly reduced by avoiding interacting medications and by conducting genetic screening prior to initiating chloroquine and mefloquine.  Validation of the hypothesis would also provide a paradigm to follow for avoiding neuropsychiatric side effects if antidepressants and neuroleptics are used to overcome chloroquine resistance, if new antimalarial drugs chem. related to chloroquine and mefloquine are developed and if chloroquine and mefloquine are used for non-malarial applications such as HIV and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoud_A6w4q-6rVg90H21EOLACvtfcHk0lild8zgp2WcGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVKlt7g%253D&md5=abf984795f847d453bf14ffa71dcd9ac</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.mehy.2006.01.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mehy.2006.01.059%26sid%3Dliteratum%253Aachs%26aulast%3DAlisky%26aufirst%3DJ.%2BM.%26aulast%3DChertkova%26aufirst%3DE.%2BL.%26aulast%3DIczkowski%26aufirst%3DK.%2BA.%26atitle%3DDrug%2520interactions%2520and%2520pharmacogenetic%2520reactions%2520are%2520the%2520basis%2520for%2520chloroquine%2520and%2520mefloquine-induced%2520psychosis%26jtitle%3DMed.%2520Hypotheses%26date%3D2006%26volume%3D67%26spage%3D1090%26epage%3D1094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Akhondzadeh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nejatisafa, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amini, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammadi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larijani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raisi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamalipour, A.</span><span> </span><span class="NLM_article-title">Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial</span> <span class="citation_source-journal">Prog. Neuro-Psychopharmacol. Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1007</span><span class="NLM_x">–</span> <span class="NLM_lpage">1012</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2FS0278-5846%2803%2900161-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=14499318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1Grsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2003&pages=1007-1012&author=S.+Akhondzadehauthor=A.+A.+Nejatisafaauthor=H.+Aminiauthor=M.+R.+Mohammadiauthor=B.+Larijaniauthor=L.+Kashaniauthor=F.+Raisiauthor=A.+Kamalipour&title=Adjunctive+estrogen+treatment+in+women+with+chronic+schizophrenia%3A+a+double-blind%2C+randomized%2C+and+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial</span></div><div class="casAuthors">Akhondzadeh, Shahin; Nejatisafa, Ali Akbar; Amini, Homayoun; Mohammadi, Mohammad Reza; Larijani, Bagher; Kashani, Ladan; Raisi, Firoozeh; Kamalipour, Abbas</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1007-1012</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The estrogen hypothesis of schizophrenia postulates that estrogen exerts a protective effect against schizophrenia and that this partly explains the obsd. sex differences in premorbid adjustment, onset age, treatment response, and illness course.  It has been suggested that estrogen supplementation can augment the treatment effects of antipsychotics.  The purpose of the present investigation was to access the efficacy of ethinyl estradiol as an adjuvant agent in the treatment of premenopausal women with chronic schizophrenia in an 8-wk, double-blind, and placebo-controlled trial.  Eligible participants in the study were 32 women of childbearing age with schizophrenia.  All patients were inpatients, in the active phase of illness, and met DSM-IV criteria for chronic schizophrenia.  Patients were allocated in a random fashion, 16 to haloperidol 15 mg/day plus ethinyl estradiol 0.05 mg/day and 16 to haloperidol 15 mg/day plus placebo for an 8-wk, double-blind, placebo-controlled study.  Although both protocols significantly decreased the score of the pos., neg., and general psychopathol. symptoms over the trial period, the combination of haloperidol and ethinyl estradiol showed a significant superiority over haloperidol alone in the treatment of pos. and general psychopathol. symptoms as well as Pos. and Neg. Syndrome Scale (PANSS) total scores.  Although the means Extrapyramidal Symptoms Rating Scale (ESRS) for the placebo group were higher than ethinyl estradiol group, the differences were not significant over the trial.  A significant difference was obsd. between the overall mean biperiden dosages in the two groups.  The results of this study suggest that estrogen may be an effective adjuvant agent in the management of women of childbearing age with chronic schizophrenia.  Nevertheless, results of larger controlled trials are needed before recommendation for a broad clin. application can be made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKxRwAe3ciYLVg90H21EOLACvtfcHk0lild8zgp2WcGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1Grsbo%253D&md5=4f45255c2695d4693e13eea5fecfcac8</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2FS0278-5846%2803%2900161-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0278-5846%252803%252900161-1%26sid%3Dliteratum%253Aachs%26aulast%3DAkhondzadeh%26aufirst%3DS.%26aulast%3DNejatisafa%26aufirst%3DA.%2BA.%26aulast%3DAmini%26aufirst%3DH.%26aulast%3DMohammadi%26aufirst%3DM.%2BR.%26aulast%3DLarijani%26aufirst%3DB.%26aulast%3DKashani%26aufirst%3DL.%26aulast%3DRaisi%26aufirst%3DF.%26aulast%3DKamalipour%26aufirst%3DA.%26atitle%3DAdjunctive%2520estrogen%2520treatment%2520in%2520women%2520with%2520chronic%2520schizophrenia%253A%2520a%2520double-blind%252C%2520randomized%252C%2520and%2520placebo-controlled%2520trial%26jtitle%3DProg.%2520Neuro-Psychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2003%26volume%3D27%26spage%3D1007%26epage%3D1012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Kulkarni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Castella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzgerald, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurvich, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartholomeusz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span> </span><span class="NLM_article-title">Estrogen in severe mental illness: a potential new treatment approach</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">955</span><span class="NLM_x">–</span> <span class="NLM_lpage">960</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1001%2Farchpsyc.65.8.955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=18678800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD1cvpvFegtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=955-960&author=J.+Kulkarniauthor=A.+de+Castellaauthor=P.+B.+Fitzgeraldauthor=C.+T.+Gurvichauthor=M.+Baileyauthor=C.+Bartholomeuszauthor=H.+Burger&title=Estrogen+in+severe+mental+illness%3A+a+potential+new+treatment+approach"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen in severe mental illness: a potential new treatment approach</span></div><div class="casAuthors">Kulkarni Jayashri; de Castella Anthony; Fitzgerald Paul B; Gurvich Caroline T; Bailey Michael; Bartholomeusz Cali; Burger Henry</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">955-60</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CONTEXT:  Accumulating evidence suggests that estrogens may have therapeutic effects in severe mental illnesses, including schizophrenia, via neuromodulatory and neuroprotective activity.  OBJECTIVE:  To compare the efficacy of adjunctive transdermal estradiol with that of adjunctive placebo in the treatment of acute psychotic symptoms.  DESIGN:  Randomized, double-blind study.  SETTING:  Patients were recruited from inpatient acute hospital wards and outpatient clinics of 2 metropolitan Melbourne general hospitals.  PARTICIPANTS:  One hundred two women of childbearing age with schizophrenia.  All participants were in an acute or chronic phase of their illness; 73 participants were outpatients and the rest were inpatients.  Intervention Patients were randomized to receive 100 microg of transdermal estradiol (n = 56) or transdermal placebo (n = 46) for 28 days.  MAIN OUTCOME MEASURES:  Psychopathological symptoms were assessed weekly with the Positive and Negative Syndrome Scale.  RESULTS:  The addition of 100 microg of transdermal estradiol significantly reduced positive (P < .05) and general psychopathological (P < .05) symptoms during the 28-day trial period compared with women receiving antipsychotic medication alone.  CONCLUSION:  Estradiol appears to be a useful treatment for women with schizophrenia and may provide a new adjunctive therapeutic option for severe mental illness.  TRIAL REGISTRATION:  clinicaltrials.gov Identifier: NCT00206570.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ66w6qDcPMQZagfuraLLzSfW6udTcc2ebNDcniWl64kbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvpvFegtQ%253D%253D&md5=5b3ddcbe3b6133a1067217946976c4c8</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.65.8.955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.65.8.955%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DJ.%26aulast%3Dde%2BCastella%26aufirst%3DA.%26aulast%3DFitzgerald%26aufirst%3DP.%2BB.%26aulast%3DGurvich%26aufirst%3DC.%2BT.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DBartholomeusz%26aufirst%3DC.%26aulast%3DBurger%26aufirst%3DH.%26atitle%3DEstrogen%2520in%2520severe%2520mental%2520illness%253A%2520a%2520potential%2520new%2520treatment%2520approach%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2008%26volume%3D65%26spage%3D955%26epage%3D960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Kulkarni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Castella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headey, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marston, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinclair, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurvich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzgerald, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span> </span><span class="NLM_article-title">Estrogens and men with schizophrenia: Is there a case for adjunctive therapy?</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.schres.2010.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=21062669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BC3M7ltF2gug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2011&pages=278-283&author=J.+Kulkarniauthor=A.+de+Castellaauthor=B.+Headeyauthor=N.+Marstonauthor=K.+Sinclairauthor=S.+Leeauthor=C.+Gurvichauthor=P.+B.+Fitzgeraldauthor=H.+Burger&title=Estrogens+and+men+with+schizophrenia%3A+Is+there+a+case+for+adjunctive+therapy%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogens and men with schizophrenia: is there a case for adjunctive therapy?</span></div><div class="casAuthors">Kulkarni Jayashri; de Castella Anthony; Headey Barbara; Marston Natasha; Sinclair Kelly; Lee Stuart; Gurvich Caroline; Fitzgerald Paul B; Burger Henry</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">278-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Adjunctive use of estrogen therapy has been shown to be effective in enhancing the treatment of schizophrenia in women.  In men, consideration of estrogen therapy has been impacted by concerns of feminising side effects, however, clinical trials of the use of estrogen in treating prostate cancer, bone density loss and even aggression and psychosis in dementia or traumatic brain injury, show this to be a safe and effective therapy.  The current 14-day randomised placebo-controlled trial in 53 men with schizophrenia was conducted to evaluate the efficacy of 2 mg oral estradiol valerate as an adjunct to atypical antipsychotic treatment.  Results demonstrated for estradiol participants a more rapid reduction in general psychopathology that occurred in the context of greater increases in serum estrogen levels and reductions in FSH and testosterone levels.  Approximately 28% of estradiol participants did not achieve an increase (at least a 50% from baseline) in serum estrogen suggesting that further research is needed to refine the type, dose and administration route for estrogen therapy in men.  Findings do, however, suggest further exploration of a therapeutic role for adjunctive estradiol treatment in men with schizophrenia is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKFUGAu5OVVEEksK8CslK8fW6udTcc2ebNDcniWl64kbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7ltF2gug%253D%253D&md5=0de3a6f5363cad4f066b5710a2808b8e</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2010.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2010.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DJ.%26aulast%3Dde%2BCastella%26aufirst%3DA.%26aulast%3DHeadey%26aufirst%3DB.%26aulast%3DMarston%26aufirst%3DN.%26aulast%3DSinclair%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DGurvich%26aufirst%3DC.%26aulast%3DFitzgerald%26aufirst%3DP.%2BB.%26aulast%3DBurger%26aufirst%3DH.%26atitle%3DEstrogens%2520and%2520men%2520with%2520schizophrenia%253A%2520Is%2520there%2520a%2520case%2520for%2520adjunctive%2520therapy%253F%26jtitle%3DSchizophr.%2520Res.%26date%3D2011%26volume%3D125%26spage%3D278%26epage%3D283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Kulkarni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deCastella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taffe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keks, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copolov, D.</span><span> </span><span class="NLM_article-title">A clinical trial of the effects of estrogen in acutely psychotic women</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2F0920-9964%2896%2982949-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=8827850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADyaK28visFCjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1996&pages=247&author=J.+Kulkarniauthor=A.+deCastellaauthor=D.+Smithauthor=J.+Taffeauthor=N.+Keksauthor=D.+Copolov&title=A+clinical+trial+of+the+effects+of+estrogen+in+acutely+psychotic+women"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">A clinical trial of the effects of estrogen in acutely psychotic women</span></div><div class="casAuthors">Kulkarni J; de Castella A; Smith D; Taffe J; Keks N; Copolov D</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">247-52</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">This study was a preliminary open clinical trial aimed at exploring the hypothesis that estrogen may provide protection against schizophrenia in women.  Eleven women with acute psychotic symptoms, as scored on the BPRS, SAPS and SANS, had 0.02 mg estradiol added to neuroleptic treatment for eight weeks.  Their response was compared to seven women with similar symptom severity receiving neuroleptic treatment alone.  Both groups had baseline hormonal assays of estrogen, progesterone, LH and FSH and underwent regular psychopathology ratings during the eight weeks.  The group receiving the estradiol adjunct showed more rapid improvement in psychotic symptoms compared with the group receiving neuroleptics only.  This difference was not sustained for the entirety of the trial.  Both groups reached similar levels of recovery by the eighth week.  These results suggest that estradiol may have antipsychotic properties and/or act as a catalyst for neuroleptic responsiveness in women with schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQJshNUbW-IRBrI9DTGjC0fW6udTcc2ebIRHxR1GCSoLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28visFCjug%253D%253D&md5=bc77a43edf1df8c1996e6953c1f18372</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2F0920-9964%2896%2982949-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0920-9964%252896%252982949-5%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DJ.%26aulast%3DdeCastella%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DTaffe%26aufirst%3DJ.%26aulast%3DKeks%26aufirst%3DN.%26aulast%3DCopolov%26aufirst%3DD.%26atitle%3DA%2520clinical%2520trial%2520of%2520the%2520effects%2520of%2520estrogen%2520in%2520acutely%2520psychotic%2520women%26jtitle%3DSchizophr.%2520Res.%26date%3D1996%26volume%3D20%26spage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Kulkarni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurvich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavrilidis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzgerald, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S. R.</span><span> </span><span class="NLM_article-title">Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia</span> <span class="citation_source-journal">Psychoneuroendocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1142</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=1142&author=J.+Kulkarniauthor=C.+Gurvichauthor=S.+J.+Leeauthor=H.+Gilbertauthor=E.+Gavrilidisauthor=C.+A.+deauthor=M.+Berkauthor=S.+Doddauthor=P.+B.+Fitzgeraldauthor=S.+R.+Davis&title=Piloting+the+effective+therapeutic+dose+of+adjunctive+selective+estrogen+receptor+modulator+treatment+in+postmenopausal+women+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DJ.%26aulast%3DGurvich%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DGilbert%26aufirst%3DH.%26aulast%3DGavrilidis%26aufirst%3DE.%26aulast%3Dde%26aufirst%3DC.%2BA.%26aulast%3DBerk%26aufirst%3DM.%26aulast%3DDodd%26aufirst%3DS.%26aulast%3DFitzgerald%26aufirst%3DP.%2BB.%26aulast%3DDavis%26aufirst%3DS.%2BR.%26atitle%3DPiloting%2520the%2520effective%2520therapeutic%2520dose%2520of%2520adjunctive%2520selective%2520estrogen%2520receptor%2520modulator%2520treatment%2520in%2520postmenopausal%2520women%2520with%2520schizophrenia%26jtitle%3DPsychoneuroendocrinology%26date%3D2010%26volume%3D35%26spage%3D1142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Usall, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huerta-Ramos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iniesta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roca, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Blanco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teba, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochoa, S.</span><span> </span><span class="NLM_article-title">Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial</span> <span class="citation_source-journal">J. Clin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1552</span><span class="NLM_x">–</span> <span class="NLM_lpage">1557</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.4088%2FJCP.10m06610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=21903021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC38XktV2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2011&pages=1552-1557&author=J.+Usallauthor=E.+Huerta-Ramosauthor=R.+Iniestaauthor=J.+Coboauthor=S.+Arayaauthor=M.+Rocaauthor=A.+Serrano-Blancoauthor=F.+Tebaauthor=S.+Ochoa&title=Raloxifene+as+an+adjunctive+treatment+for+postmenopausal+women+with+schizophrenia%3A+a+double-blind%2C+randomized%2C+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial</span></div><div class="casAuthors">Usall, Judith; Huerta-Ramos, Elena; Iniesta, Raquel; Cobo, Jesus; Araya, Susana; Roca, Mercedes; Serrano-Blanco, Antoni; Teba, Fernando; Ochoa, Susana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychiatry (Memphis, TN, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1552-1557</span>CODEN:
                <span class="NLM_cas:coden">JCLPDE</span>;
        ISSN:<span class="NLM_cas:issn">0160-6689</span>.
    
            (<span class="NLM_cas:orgname">Physicians Postgraduate Press, Inc.</span>)
        </div><div class="casAbstract">Objective: The potential therapeutic utility of estrogens in schizophrenia is increasingly being recognized.  Raloxifene, a selective estrogen receptor modulator, appears to act similarly to conjugated estrogens on dopamine and serotonin brain systems and may be a better option since it lacks the possible neg. effects of estrogen on breast and uterine tissue.  In this study, we assess the utility of raloxifene as an adjunctive treatment for neg. symptoms and other psychotic symptoms in postmenopausal women with schizophrenia.  Method: This was a 12-wk, double-blind, randomized, placebo-controlled study.  Patients were recruited from both the inpatient and outpatient departments of Parc Sanitari Sant Joan de Deu, Barcelona, Spain, and Corporacio Sanitaria Parc Tauli, Sabadell, Spain.  Thirty-three postmenopausal women with schizophrenia (DSM-IV criteria) who exhibited prominent neg. symptoms were randomized to either adjunctive raloxifene (16 women; mean age = 60.14 years, SD = 6.41 years) or adjunctive placebo (17 women; mean age = 62.66 years, SD = 4.54 years) for 12 wk.  The period of recruitment lasted from Jan. 2005 through June 2009.  Psychopathol. symptoms were assessed at baseline and weeks 4, 8, and 12 by means of the Pos. and Neg. Syndrome Scale.  Results: The addn. of raloxifene (60 mg/d) to regular antipsychotic treatment significantly reduced neg. (P=.044), pos. (P=.031), and general psychopathol. (P=.045) symptoms during the 12-wk trial as compared with women receiving placebo.  Conclusions: Raloxifene as an adjuvant treatment in postmenopausal women with schizophrenia who exhibit prominent neg. symptoms appears to be useful in improving neg., pos., and general psychopathol. symptoms.  If more extensive and longer-term studies confirm and expand upon these pos. results, the use of raloxifene could be recommended in postmenopausal patients with schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-3JjKvkzZwrVg90H21EOLACvtfcHk0lg46pACdpcz7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktV2ktg%253D%253D&md5=3231444780d748a615c042b6c9f3ebca</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.4088%2FJCP.10m06610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FJCP.10m06610%26sid%3Dliteratum%253Aachs%26aulast%3DUsall%26aufirst%3DJ.%26aulast%3DHuerta-Ramos%26aufirst%3DE.%26aulast%3DIniesta%26aufirst%3DR.%26aulast%3DCobo%26aufirst%3DJ.%26aulast%3DAraya%26aufirst%3DS.%26aulast%3DRoca%26aufirst%3DM.%26aulast%3DSerrano-Blanco%26aufirst%3DA.%26aulast%3DTeba%26aufirst%3DF.%26aulast%3DOchoa%26aufirst%3DS.%26atitle%3DRaloxifene%2520as%2520an%2520adjunctive%2520treatment%2520for%2520postmenopausal%2520women%2520with%2520schizophrenia%253A%2520a%2520double-blind%252C%2520randomized%252C%2520placebo-controlled%2520trial%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D2011%26volume%3D72%26spage%3D1552%26epage%3D1557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Muramatsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawanishi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwasaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakiuchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, Y.</span><span> </span><span class="NLM_article-title">Study on zwitter-ionization of drugs. II. Synthesis and pharmacological activity of some <i>N</i>-[3-(5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>]cyclohepten-5-ylidene)propyl]-<i>N</i>-methylamino- and <i>N</i>-[3-(6<i>H</i>-dibenz[<i>b</i>,<i>e</i>]oxepin-11-ylidene)propyl]-<i>N</i>-methylamino-alkanoic acid derivatives and related compounds</span> <span class="citation_source-journal">Chem. Pharm. Bull. (Tokyo)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1987</span><span class="NLM_x">–</span> <span class="NLM_lpage">1993</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1993&pages=1987-1993&author=H.+Muramatsuauthor=H.+Sawanishiauthor=N.+Iwasakiauthor=M.+Kakiuchiauthor=T.+Ohashiauthor=H.+Katoauthor=Y.+Ito&title=Study+on+zwitter-ionization+of+drugs.+II.+Synthesis+and+pharmacological+activity+of+some+N-%5B3-%285H-dibenzo%5Ba%2Cd%5Dcyclohepten-5-ylidene%29propyl%5D-N-methylamino-+and+N-%5B3-%286H-dibenz%5Bb%2Ce%5Doxepin-11-ylidene%29propyl%5D-N-methylamino-alkanoic+acid+derivatives+and+related+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuramatsu%26aufirst%3DH.%26aulast%3DSawanishi%26aufirst%3DH.%26aulast%3DIwasaki%26aufirst%3DN.%26aulast%3DKakiuchi%26aufirst%3DM.%26aulast%3DOhashi%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DY.%26atitle%3DStudy%2520on%2520zwitter-ionization%2520of%2520drugs.%2520II.%2520Synthesis%2520and%2520pharmacological%2520activity%2520of%2520some%2520N-%255B3-%25285H-dibenzo%255Ba%252Cd%255Dcyclohepten-5-ylidene%2529propyl%255D-N-methylamino-%2520and%2520N-%255B3-%25286H-dibenz%255Bb%252Ce%255Doxepin-11-ylidene%2529propyl%255D-N-methylamino-alkanoic%2520acid%2520derivatives%2520and%2520related%2520compounds%26jtitle%3DChem.%2520Pharm.%2520Bull.%2520%2528Tokyo%2529%26date%3D1993%26volume%3D41%26spage%3D1987%26epage%3D1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Stevenson, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyakonova, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rillich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schildberger, K.</span><span> </span><span class="NLM_article-title">Octopamine and experience-dependent modulation of aggression in crickets</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1431</span><span class="NLM_x">–</span> <span class="NLM_lpage">1441</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1523%2FJNEUROSCI.4258-04.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=15703397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhs1Kmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=1431-1441&author=P.+A.+Stevensonauthor=V.+Dyakonovaauthor=J.+Rillichauthor=K.+Schildberger&title=Octopamine+and+experience-dependent+modulation+of+aggression+in+crickets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Octopamine and experience-dependent modulation of aggression in crickets</span></div><div class="casAuthors">Stevenson, Paul A.; Dyakonova, Varya; Rillich, Jan; Schildberger, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1431-1441</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Intraspecific aggression is influenced in numerous animal groups by the previous behavioral experiences of the competitors.  The underlying mechanisms are, however, mostly obscure.  The authors present evidence that a form of experience-dependent plasticity of aggression in crickets (Gryllus bimaculatus) is mediated by octopamine, the invertebrate counterpart of noradrenaline.  In a forced-fight paradigm, the experience of flying maximized the aggressiveness of crickets at their first encounter and accelerated the subsequent recovery of aggressiveness of the normally submissive losers, without enhancing general excitability as evaluated from the animals' startle responses to wind stimulation.  This effect is transitory and concurrent with the activation of the octopaminergic system that accompanies flight.  Hemocoel injections of the octopamine agonist chlordimeform (CDM) had similar effects on aggression but also enhanced startle responses.  Serotonin depletion, achieved using α-methyl-tryptophan, enhanced startle responses without influencing aggression, indicating that the effect of CDM on aggression is not attributable to increased general excitation.  Contrasting this, aggressiveness was depressed, and the effect of flying was essentially abolished, in crickets depleted of octopamine and dopamine using α-methyl-p-tyrosine (AMT).  CDM restored aggressiveness in AMT-treated crickets, indicating that their depressed aggressiveness is attributable to octopamine depletion rather than to dopamine depletion or nonspecific defects.  Finally, the flight effect was blocked in crickets treated with the octopamine receptor antagonist epinastine, or with the α-adrenoceptor and octopamine receptor antagonist phentolamine, but not with the β-adrenoceptor antagonist propranolol.  The idea that activity-specific induction of the octopaminergic system underlies other forms of experience-dependent plasticity of aggressive motivation in insects is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3hDy37wu1mbVg90H21EOLACvtfcHk0lg46pACdpcz7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhs1Kmu78%253D&md5=f4283fb22b8cbbf9a00042ecb51bc746</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4258-04.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4258-04.2005%26sid%3Dliteratum%253Aachs%26aulast%3DStevenson%26aufirst%3DP.%2BA.%26aulast%3DDyakonova%26aufirst%3DV.%26aulast%3DRillich%26aufirst%3DJ.%26aulast%3DSchildberger%26aufirst%3DK.%26atitle%3DOctopamine%2520and%2520experience-dependent%2520modulation%2520of%2520aggression%2520in%2520crickets%26jtitle%3DJ.%2520Neurosci.%26date%3D2005%26volume%3D25%26spage%3D1431%26epage%3D1441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Roeder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gewecke, M.</span><span> </span><span class="NLM_article-title">Epinastine, a highly specific antagonist of insect neuronal octopamine receptors</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">349</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2FS0014-2999%2898%2900192-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=9671095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADyaK1cXjvVSlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=1998&pages=171-177&author=T.+Roederauthor=J.+Degenauthor=M.+Gewecke&title=Epinastine%2C+a+highly+specific+antagonist+of+insect+neuronal+octopamine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Epinastine, a highly specific antagonist of insect neuronal octopamine receptors</span></div><div class="casAuthors">Roeder, Thomas; Degen, Jorn; Gewecke, Michael</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">2/3</span>),
    <span class="NLM_cas:pages">171-177</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The tetracyclic compd. epinastine, recently introduced as a vertebrate histamine H1 receptor antagonist, has also high affinity for insect neuronal octopamine receptors.  This was true for the neuronal octopamine receptor from the locust (Ki = 2 nM) as well as the honey bee (Ki = 1.1 nM).  In addn. to its high affinity, it had a high degree of specificity.  Its affinity for other insect receptors for biogenic amines, such as 5-hydroxytryptamine, dopamine, histamine, and tyramine, was ≥4 orders of magnitude lower.  Therefore, epinastine could serve as a highly specific antagonist of octopamine receptors to enable physiol. dissection of octopaminergic neurotransmission within the nervous system of insects.  To demonstrate these abilities, epinastine was used to inhibit the visually evoked activity of an identified interneuron in the locust visual pathway which is known to be modulated by octopamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbYSlMiNCQfbVg90H21EOLACvtfcHk0lirYNyU-n7QBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjvVSlsrw%253D&md5=6036ebcb2108489b894588983ff76395</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2898%2900192-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252898%252900192-7%26sid%3Dliteratum%253Aachs%26aulast%3DRoeder%26aufirst%3DT.%26aulast%3DDegen%26aufirst%3DJ.%26aulast%3DGewecke%26aufirst%3DM.%26atitle%3DEpinastine%252C%2520a%2520highly%2520specific%2520antagonist%2520of%2520insect%2520neuronal%2520octopamine%2520receptors%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1998%26volume%3D349%26spage%3D171%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Unoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizunami, M.</span><span> </span><span class="NLM_article-title">Participation of octopaminergic reward system and dopaminergic punishment system in insect olfactory learning revealed by pharmacological study</span> <span class="citation_source-journal">Eur. J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1409</span><span class="NLM_x">–</span> <span class="NLM_lpage">1416</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1111%2Fj.1460-9568.2005.04318.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=16190895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD2MrhvVGnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2005&pages=1409-1416&author=S.+Unokiauthor=Y.+Matsumotoauthor=M.+Mizunami&title=Participation+of+octopaminergic+reward+system+and+dopaminergic+punishment+system+in+insect+olfactory+learning+revealed+by+pharmacological+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Participation of octopaminergic reward system and dopaminergic punishment system in insect olfactory learning revealed by pharmacological study</span></div><div class="casAuthors">Unoki Sae; Matsumoto Yukihisa; Mizunami Makoto</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1409-16</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Biogenic amines play major roles in the regulation of behavior in vertebrates and invertebrates.  Previous studies in honey bees and fruit-flies Drosophila suggested that octopamine (OA, invertebrate counterpart of noradrenaline) and dopamine (DA) participate in appetitive olfactory conditioning with sucrose reward and aversive olfactory conditioning with electric shock punishment, respectively.  In order to determine whether the effects of the two chatecholamines on electric shock and sugar learning can be generalized to other kinds of appetitive and aversive reinforcers, we studied the effects of OA and DA receptor antagonists on appetitive olfactory learning with water reward, and aversive olfactory learning with saline punishment in the cricket Gryllus bimaculatus.  Crickets injected with epinastine or mianserin, OA receptor antagonists, into the hemolymph exhibited an impairment of appetitive learning with water reward, while aversive learning with saline punishment remained intact.  In contrast, fluphenazine, chlorpromazine or spiperone, DA receptor antagonists, impaired aversive learning without affecting appetitive learning.  This finding, combined with findings in previous studies, suggests that the octopaminergic reward system and dopaminergic punishment system participate in insect olfactory learning with various appetitive and aversive reinforcements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTt_VtG4hwKOTAyhZbj3lKdfW6udTcc2eb14ZDq4RF55bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MrhvVGnug%253D%253D&md5=df9029bb283543a65d08e35ce833b80f</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.2005.04318.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.2005.04318.x%26sid%3Dliteratum%253Aachs%26aulast%3DUnoki%26aufirst%3DS.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DMizunami%26aufirst%3DM.%26atitle%3DParticipation%2520of%2520octopaminergic%2520reward%2520system%2520and%2520dopaminergic%2520punishment%2520system%2520in%2520insect%2520olfactory%2520learning%2520revealed%2520by%2520pharmacological%2520study%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2005%26volume%3D22%26spage%3D1409%26epage%3D1416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Unoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizunami, M.</span><span> </span><span class="NLM_article-title">Roles of octopaminergic and dopaminergic neurons in mediating reward and punishment signals in insect visual learning</span> <span class="citation_source-journal">Eur. J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2031</span><span class="NLM_x">–</span> <span class="NLM_lpage">2038</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1111%2Fj.1460-9568.2006.05099.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=17067299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD28nktFemtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=2031-2038&author=S.+Unokiauthor=Y.+Matsumotoauthor=M.+Mizunami&title=Roles+of+octopaminergic+and+dopaminergic+neurons+in+mediating+reward+and+punishment+signals+in+insect+visual+learning"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of octopaminergic and dopaminergic neurons in mediating reward and punishment signals in insect visual learning</span></div><div class="casAuthors">Unoki Sae; Matsumoto Yukihisa; Mizunami Makoto</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2031-8</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Insects, like vertebrates, have considerable ability to associate visual, olfactory or other sensory signals with reward or punishment.  Previous studies in crickets, honey bees and fruit-flies have suggested that octopamine (OA, invertebrate counterpart of noradrenaline) and dopamine (DA) mediate various kinds of reward and punishment signals in olfactory learning.  However, whether the roles of OA and DA in mediating positive and negative reinforcing signals can be generalized to learning of sensory signals other than odors remained unknown.  Here we first established a visual learning paradigm in which to associate a visual pattern with water reward or saline punishment for crickets and found that memory after aversive conditioning decayed much faster than that after appetitive conditioning.  Then, we pharmacologically studied the roles of OA and DA in appetitive and aversive forms of visual learning.  Crickets injected with epinastine or mianserin, OA receptor antagonists, into the hemolymph exhibited a complete impairment of appetitive learning to associate a visual pattern with water reward, but aversive learning with saline punishment was unaffected.  By contrast, fluphenazine, chlorpromazine or spiperone, DA receptor antagonists, completely impaired aversive learning without affecting appetitive learning.  The results demonstrate that OA and DA participate in reward and punishment conditioning in visual learning.  This finding, together with results of previous studies on the roles of OA and DA in olfactory learning, suggests ubiquitous roles of the octopaminergic reward system and dopaminergic punishment system in insect learning.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSCFx9m_qixeWLFM_lbR1VmfW6udTcc2eYbES-cCOgyabntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nktFemtw%253D%253D&md5=44c446db4a267ad6355842273de476b8</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.2006.05099.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.2006.05099.x%26sid%3Dliteratum%253Aachs%26aulast%3DUnoki%26aufirst%3DS.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DMizunami%26aufirst%3DM.%26atitle%3DRoles%2520of%2520octopaminergic%2520and%2520dopaminergic%2520neurons%2520in%2520mediating%2520reward%2520and%2520punishment%2520signals%2520in%2520insect%2520visual%2520learning%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2006%26volume%3D24%26spage%3D2031%26epage%3D2038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Yokoyama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, T.</span><span> </span><span class="NLM_article-title">Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice</span> <span class="citation_source-journal">Metab. Brain Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1007%2Fs11011-008-9096-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=18648914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVSrsr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2008&pages=335-349&author=H.+Yokoyamaauthor=R.+Yanoauthor=E.+Aokiauthor=H.+Katoauthor=T.+Araki&title=Comparative+pharmacological+study+of+free+radical+scavenger%2C+nitric+oxide+synthase+inhibitor%2C+nitric+oxide+synthase+activator+and+cyclooxygenase+inhibitor+against+MPTP+neurotoxicity+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice</span></div><div class="casAuthors">Yokoyama, Hironori; Yano, Ryohei; Aoki, Eriko; Kato, Hiroyuki; Araki, Tsutomu</div><div class="citationInfo"><span class="NLM_cas:title">Metabolic Brain Disease</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-349</span>CODEN:
                <span class="NLM_cas:coden">MBDIEE</span>;
        ISSN:<span class="NLM_cas:issn">0885-7490</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The biochem. and cellular changes that occur following the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are remarkably similar to that seen in idiopathic Parkinson's disease(PD).  There is growing evidence indicating that reactive oxygen species (ROS), reactive nitrogen species (RNS) and inflammation are a major contributor to the pathogenesis and progression of PD.  Hence, we investigated whether 7-nitroindazole [neuronal nitric oxide synthase (nNOS) inhibitor], edaravone (free radical scavenger), minocycline [inducible NOS (iNOS) inhibitor], fluvastatin [endothelial NOS (eNOS) activator], pitavastatin (eNOS activator), etodolac [cyclooxygenase-2 (COX-2) inhibitor] and indomethacin (COX inhibitor) can protect against MPTP neurotoxicity in mice under the same conditions.  For the evaluation of each drug, the levels of dopamine, DOPAC and HVA were quantified using HPLC with an electrochem. detector.  Four administrations of MPTP at 1-h intervals to mice produced marked depletion of dopamine, DOPAC (3,4-dihydroxyphenylacetic acid) and HVA (homovanilic acid) in the striatum after 5 days. 7-Nitroindazole prevented dose-dependently a significant redn. in dopamine contents of the striatum 5 days after MPTP treatment.  In contrast, edaravone, minocycline, fluvastatin, pitavastatin, etodolac and indomethacin did not show the neuroprotective effect on MPTP-induced striatal dopamine, DOPAC and HVA depletions after 5 days.  The present study demonstrates that the overexpression of nNOS may play a major role in the neurotoxic processes of MPTP, as compared with the prodn. of ROS, the overexpression of iNOS, the modulation of eNOS and the involvement of inflammatory response.  Thus our pharmacol. findings provide further information for progressive neurodegeneration of the nigrostriatal dopaminergic neuronal pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3vDF5kMIOhLVg90H21EOLACvtfcHk0liUuFyYXFdr5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVSrsr3L&md5=9de71b1163e80b50c18c22a031b77894</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1007%2Fs11011-008-9096-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11011-008-9096-3%26sid%3Dliteratum%253Aachs%26aulast%3DYokoyama%26aufirst%3DH.%26aulast%3DYano%26aufirst%3DR.%26aulast%3DAoki%26aufirst%3DE.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DAraki%26aufirst%3DT.%26atitle%3DComparative%2520pharmacological%2520study%2520of%2520free%2520radical%2520scavenger%252C%2520nitric%2520oxide%2520synthase%2520inhibitor%252C%2520nitric%2520oxide%2520synthase%2520activator%2520and%2520cyclooxygenase%2520inhibitor%2520against%2520MPTP%2520neurotoxicity%2520in%2520mice%26jtitle%3DMetab.%2520Brain%2520Dis.%26date%3D2008%26volume%3D23%26spage%3D335%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Brown, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomikos, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fibiger, H. C.</span><span> </span><span class="NLM_article-title">Chronic desipramine enhances the effect of locally applied amphetamine on interstitial concentrations of dopamine in the nucleus accumbens</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">202</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2F0014-2999%2891%2990266-S" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=1786799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADyaK3MXlvFynsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=1991&pages=125-127&author=E.+E.+Brownauthor=G.+G.+Nomikosauthor=C.+Wilsonauthor=H.+C.+Fibiger&title=Chronic+desipramine+enhances+the+effect+of+locally+applied+amphetamine+on+interstitial+concentrations+of+dopamine+in+the+nucleus+accumbens"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic desipramine enhances the effect of locally applied amphetamine on interstitial concentrations of dopamine in the nucleus accumbens</span></div><div class="casAuthors">Brown, Erin E.; Nomikos, George G.; Wilson, Catriona; Fibiger, Hans C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-7</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">In vivo microdialysis was used to study the effect of chronic desipramine (DMI, 5 mg/kg, twice daily for 21 days) on increases in interstitial dopamine (DA) produced by local administration of d-amphetamine (1.0, 3.3 and 10.0 μM) in the nucleus accumbens.  Locally applied amphetamine increased interstitial DA in a dose-dependent manner.  The amphetamine-induced increase was significantly greater in the DMI treated animals.  These data suggest that chronic DMI may directly influence the functional status of the DA terminals in the nucleus accumbens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoROhhIu9SkA7Vg90H21EOLACvtfcHk0lgYmOWPhpi5sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlvFynsbk%253D&md5=5ac8ab022e9f76b3a5cfdfae48a57fe1</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2891%2990266-S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252891%252990266-S%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DE.%2BE.%26aulast%3DNomikos%26aufirst%3DG.%2BG.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DFibiger%26aufirst%3DH.%2BC.%26atitle%3DChronic%2520desipramine%2520enhances%2520the%2520effect%2520of%2520locally%2520applied%2520amphetamine%2520on%2520interstitial%2520concentrations%2520of%2520dopamine%2520in%2520the%2520nucleus%2520accumbens%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1991%26volume%3D202%26spage%3D125%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Nomikos, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damsma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenkstern, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fibiger, H. C.</span><span> </span><span class="NLM_article-title">Chronic desipramine enhances amphetamine-induced increases in interstitial concentrations of dopamine in the nucleus accumbens</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">195</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2F0014-2999%2891%2990382-Z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=2065713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADyaK3MXhvF2murs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=1991&pages=63-73&author=G.+G.+Nomikosauthor=G.+Damsmaauthor=D.+Wenksternauthor=H.+C.+Fibiger&title=Chronic+desipramine+enhances+amphetamine-induced+increases+in+interstitial+concentrations+of+dopamine+in+the+nucleus+accumbens"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic desipramine enhances amphetamine-induced increases in interstitial concentrations of dopamine in the nucleus accumbens</span></div><div class="casAuthors">Nomikos, George G.; Damsma, Geert; Wenkstern, Danielle; Fibiger, Hans C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-73</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">There is accumulating evidence that some antidepressant treatments can increase the functional output of the mesoaccumbens dopaminergic system.  For example, chronic administration of tricyclic antidepressant drugs such as imipramine and desipramine (DMI) enhances the locomotor stimulant effects of d-amphetamine.  Subsensitivity of inhibitory dopamine (DA) autoreceptors and supersensitivity of postsynaptic DA receptor mechanisms are among the mechanisms that have been suggested to underlie these observations.  The present expts. investigated the effects of acute and chronic DMI treatment on interstitial DA concns. in the nucleus accumbens and striatum using in vivo microdialysis in awake freely moving rats (48 h following implantation of a microdialysis probe).  Neither acute (5 mg/kg b.i.d. for 2 days followed by 72 h withdrawal) nor chronic (5 mg/kg b.i.d. for 21 days followed by 72 h withdrawal) DMI influenced the ability of apomorphine (25 μg/kg s.c.) to decrease extracellular concns. of DA or its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the nucleus accumbens.  In contrast, d-amphetamine (1.5 mg/kg s.c.)-induced increases in extracellular DA were significantly enhanced in the nucleus accumbens of the chronic but not the acute DMI group.  This effect was at least partially regionally selective, as significant effects were not obsd. in the striatum.  In accordance with previous reports, the locomotor stimulant effects of d-amphetamine were also enhanced in the chronic DMI groups.  DMI itself failed to alter the interstitial concns. of DA and its metabolites in the nucleus accumbens of the control and chronic DMI groups.  These results provide in vivo neurochem. confirmation that chronically administered DMI does not produce DA autoreceptor subsensitivity.  They also demonstrate that chronic DMI-induced increases in the locomotor stimulant effects of d-amphetamine are accompanied by a selective potentiation of the effects of this stimulant on interstitial DA concns. in the nucleus accumbens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa1qF02tJxrLVg90H21EOLACvtfcHk0lgYmOWPhpi5sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhvF2murs%253D&md5=5384f058135299064c3cee4391246b26</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2891%2990382-Z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252891%252990382-Z%26sid%3Dliteratum%253Aachs%26aulast%3DNomikos%26aufirst%3DG.%2BG.%26aulast%3DDamsma%26aufirst%3DG.%26aulast%3DWenkstern%26aufirst%3DD.%26aulast%3DFibiger%26aufirst%3DH.%2BC.%26atitle%3DChronic%2520desipramine%2520enhances%2520amphetamine-induced%2520increases%2520in%2520interstitial%2520concentrations%2520of%2520dopamine%2520in%2520the%2520nucleus%2520accumbens%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1991%26volume%3D195%26spage%3D63%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Smialowski, A.</span><span> </span><span class="NLM_article-title">Dopamine D2 receptor blocking effect of imipramine in the rat hippocampus</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1991&pages=105-108&author=A.+Smialowski&title=Dopamine+D2+receptor+blocking+effect+of+imipramine+in+the+rat+hippocampus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmialowski%26aufirst%3DA.%26atitle%3DDopamine%2520D2%2520receptor%2520blocking%2520effect%2520of%2520imipramine%2520in%2520the%2520rat%2520hippocampus%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D1991%26volume%3D39%26spage%3D105%26epage%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Tadokoro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekine, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanahara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyo, M.</span><span> </span><span class="NLM_article-title">Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis</span> <span class="citation_source-journal">Schizophr Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1012</span><span class="NLM_x">–</span> <span class="NLM_lpage">1020</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1093%2Fschbul%2Fsbr006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=21402722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BC38zjvVCgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2012&pages=1012-1020&author=S.+Tadokoroauthor=N.+Okamuraauthor=Y.+Sekineauthor=N.+Kanaharaauthor=K.+Hashimotoauthor=M.+Iyo&title=Chronic+treatment+with+aripiprazole+prevents+development+of+dopamine+supersensitivity+and+potentially+supersensitivity+psychosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis</span></div><div class="casAuthors">Tadokoro Shigenori; Okamura Naoe; Sekine Yoshimoto; Kanahara Nobuhisa; Hashimoto Kenji; Iyo Masaomi</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1012-20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Long-term treatment of schizophrenia with antipsychotics is crucial for relapse prevention, but a prolonged blockade of D(2) dopamine receptors may lead to the development of supersensitivity psychosis.  We investigated the chronic effects of aripiprazole (ARI) on dopamine sensitivity.  METHODS:  We administered ARI (1.5 mg/kg/d), haloperidol (HAL; 0.75 mg/kg/d), or vehicle (VEH) via minipump for 14 days to drug-naive rats or to rats pretreated with HAL (0.75 mg/kg/d) or VEH via minipump for 14 days.  On the seventh day following treatment cessation, we examined the effects of the treatment conditions on the locomotor response to methamphetamine and on striatal D(2) receptor density (N = 4-10/condition/experiment).  RESULTS:  Chronic treatment with HAL led to significant increases in locomotor response and D(2) receptor density, compared with the effects of chronic treatment with either VEH or ARI; there were no significant differences in either locomotor response or D(2) density between the VEH- and ARI-treated groups.  We also investigated the effects of chronic treatment with HAL, ARI, or VEH preceded by HAL or VEH treatment on locomotor response and D(2) density.  ANOVA analysis indicated that the rank ordering of groups for both locomotor response and D(2) density was HAL-HAL > HAL-VEH > HAL-ARI > VEH-VEH.  CONCLUSIONS:  Chronic treatment with ARI prevents development of dopamine supersensitivity and potentially supersensitivity psychosis, suggesting that by reducing excessive sensitivity to dopamine and by stabilizing sensitivity for an extended period of time, ARI may be helpful for some patients with treatment-resistant schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9CqGZtdt2nzUE-swuRqsHfW6udTcc2eYIE4ST0WdpXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zjvVCgtA%253D%253D&md5=e2902305fec7a55ca511d41b880ede5b</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbr006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbr006%26sid%3Dliteratum%253Aachs%26aulast%3DTadokoro%26aufirst%3DS.%26aulast%3DOkamura%26aufirst%3DN.%26aulast%3DSekine%26aufirst%3DY.%26aulast%3DKanahara%26aufirst%3DN.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DIyo%26aufirst%3DM.%26atitle%3DChronic%2520treatment%2520with%2520aripiprazole%2520prevents%2520development%2520of%2520dopamine%2520supersensitivity%2520and%2520potentially%2520supersensitivity%2520psychosis%26jtitle%3DSchizophr%2520Bull.%26date%3D2012%26volume%3D38%26spage%3D1012%26epage%3D1020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Golembiewski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, D.</span><span> </span><span class="NLM_article-title">A systematic approach to the management of postoperative nausea and vomiting</span> <span class="citation_source-journal">J. Perianesth. Nurs.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">364</span><span class="NLM_x">–</span> <span class="NLM_lpage">376</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1053%2Fjpan.2002.36596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=12476402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252FivFahsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2002&pages=364-376&author=J.+A.+Golembiewskiauthor=D.+O%E2%80%99Brien&title=A+systematic+approach+to+the+management+of+postoperative+nausea+and+vomiting"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">A systematic approach to the management of postoperative nausea and vomiting</span></div><div class="casAuthors">Golembiewski Julie A; O'Brien Denise</div><div class="citationInfo"><span class="NLM_cas:title">Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses / American Society of PeriAnesthesia Nurses</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">364-76</span>
        ISSN:<span class="NLM_cas:issn">1089-9472</span>.
    </div><div class="casAbstract">Postoperative nausea and vomiting (PONV), a common complication after anesthesia and surgery, often results in delayed discharge with the patient's unpleasant symptoms continuing at home.  To effectively prevent and treat PONV, it is important to understand the factors implicated in PONV, the mechanisms of PONV, the pharmacology of the antiemetic agents, and the nonpharmacologic measures that have been shown to be effective.  The cause of PONV is likely to be multifactorial, with important predictors being female gender, history of PONV, and history of motion sickness.  The vomiting center can be triggered by activation of dopamine, serotonin (type 3), histamine (type 1), and muscarinic cholingergic receptors in the chemoreceptor trigger zone and the nucleus tractus solitarus, as well as acetylcholine receptors in the vestibular apparatus, vagal afferents from the periphery, and the endocrine environment.  Antiemetic agents such as the serotonin antagonists (eg, ondansetron, dolasetron), droperidol, antihistamines (eg, diphenhydramine, dimenhydrinate), and promethazine can prevent and treat PONV effectively.  Transdermal scopolamine and dexamethasone have a role in the prevention of PONV, particularly for certain high-risk patients.  Nonpharmacologic measures and alternative treatments such as hydration, maintaining blood pressure, acupressure techniques, trancutaneous acupoint stimulation, and isopropyl alcohol must not be overlooked.  Finally, an evidence-based algorithm for the prevention and treatment of PONV in adults is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlMu-FS70fHLGbPKh4T9eAfW6udTcc2eYIE4ST0WdpXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252FivFahsg%253D%253D&md5=d8ebb0e90ed273bbccae4240531f1889</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1053%2Fjpan.2002.36596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fjpan.2002.36596%26sid%3Dliteratum%253Aachs%26aulast%3DGolembiewski%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DD.%26atitle%3DA%2520systematic%2520approach%2520to%2520the%2520management%2520of%2520postoperative%2520nausea%2520and%2520vomiting%26jtitle%3DJ.%2520Perianesth.%2520Nurs.%26date%3D2002%26volume%3D17%26spage%3D364%26epage%3D376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Oka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ukai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshikuni, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, K.</span><span> </span><span class="NLM_article-title">Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">727</span><span class="NLM_x">, </span> <span class="NLM_fpage">91</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2F0006-8993%2896%2900355-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=8842386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADyaK28Xkt12lurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=727&publication_year=1996&pages=91-98&author=M.+Okaauthor=Y.+Kimuraauthor=Y.+Itohauthor=Y.+Sasakiauthor=N.+Taniguchiauthor=Y.+Ukaiauthor=Y.+Yoshikuniauthor=K.+Kimura&title=Brain+pertussis+toxin-sensitive+G+proteins+are+involved+in+the+flavoxate+hydrochloride-induced+suppression+of+the+micturition+reflex+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats</span></div><div class="casAuthors">Oka, Michiko; Kimura, Yutaka; Itoh, Yoshinori; Sasaki, Yasuo; Taniguchi, Norihisa; Ukai, Yojiro; Yoshikuni, Yoshiaki; Kimura, Kiyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">727</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">91-98</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The effect of flavoxate hydrochloride (flavoxate), an anti-pollakiurea agent, on cAMP formation was investigated in the rat brain and a possible involvement of brain G proteins in the action of flavoxate on the bladder function was subsequently examd.  Flavoxate (10-8-10-5 M) inhibited cAMP formation in a concn.-dependent manner, an action which was completely abolished by pretreating the membranes with pertussis toxin (PTX).  The inhibitory effect of flavoxate was also completely antagonized by combined treatment with any two antagonists for adenosine A1 (8-cyclopentyl-1,3-dipropylxanthine), dopamine D2 (sulpiride) or adrenergic α2 (yohimbine) receptors, although each antagonist alone did not significantly block the flavoxate-induced inhibition of cAMP formation.  Radioligand binding studies indicated that flavoxate at micro- or submicromolar concns. has affinity for Gi-coupled receptors such as A1, D2 and α2 receptors.  Therefore, flavoxate may inhibit cAMP formation by the stimulation of A1, D2 and α2 receptors.  To clarify the involvement of brain Gi proteins in the flavoxate-induced inhibition of the micturition reflex, the effect of pretreatment with PTX (i.c.v.) on the flavoxate-induced inhibition of isovolumetric rhythmic bladder contractions was examd. in rats.  Flavoxate (3 mg/kg, i.v.) completely abolished rhythmic bladder contractions in vehicle-pretreated rats, but not in PTX-pretreated rats.  These findings suggest that signal transduction via Gi-coupled receptors is involved, at least in part, in the inhibition of the micturition reflex by flavoxate in rats.  These results also provide the first evidence suggesting a neg. role of brain PTX-sensitive G proteins in the micturition reflex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsT0ClRUprjbVg90H21EOLACvtfcHk0lg8j5MBs09zLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt12lurg%253D&md5=d6d7990db5c3199076631b65b5352d7c</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2896%2900355-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252896%252900355-1%26sid%3Dliteratum%253Aachs%26aulast%3DOka%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DTaniguchi%26aufirst%3DN.%26aulast%3DUkai%26aufirst%3DY.%26aulast%3DYoshikuni%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DK.%26atitle%3DBrain%2520pertussis%2520toxin-sensitive%2520G%2520proteins%2520are%2520involved%2520in%2520the%2520flavoxate%2520hydrochloride-induced%2520suppression%2520of%2520the%2520micturition%2520reflex%2520in%2520rats%26jtitle%3DBrain%2520Res.%26date%3D1996%26volume%3D727%26spage%3D91%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Simon, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigh-Smeller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peragovics, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csukly, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahoranszky-Kohalmi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauscher, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jelinek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hari, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitter, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malnasi-Csizmadia, A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czobor, P.</span><span> </span><span class="NLM_article-title">Relating the shape of protein binding sites to binding affinity profiles: Is there an association?</span> <span class="citation_source-journal">BMC Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1186%2F1472-6807-10-32" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=20923553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BC3cbntFSjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=32&author=Z.+Simonauthor=M.+Vigh-Smellerauthor=A.+Peragovicsauthor=G.+Csuklyauthor=G.+Zahoranszky-Kohalmiauthor=A.+A.+Rauscherauthor=B.+Jelinekauthor=P.+Hariauthor=I.+Bitterauthor=A+Malnasi-Csizmadiaauthor=P.+Czobor&title=Relating+the+shape+of+protein+binding+sites+to+binding+affinity+profiles%3A+Is+there+an+association%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Relating the shape of protein binding sites to binding affinity profiles: is there an association?</span></div><div class="casAuthors">Simon Zoltan; Vigh-Smeller Margit; Peragovics Agnes; Csukly Gabor; Zahoranszky-Kohalmi Gergely; Rauscher Anna A; Jelinek Balazs; Hari Peter; Bitter Istvan; Malnasi-Csizmadia Andras; Czobor Pal</div><div class="citationInfo"><span class="NLM_cas:title">BMC structural biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Various pattern-based methods exist that use in vitro or in silico affinity profiles for classification and functional examination of proteins.  Nevertheless, the connection between the protein affinity profiles and the structural characteristics of the binding sites is still unclear.  Our aim was to investigate the association between virtual drug screening results (calculated binding free energy values) and the geometry of protein binding sites.  Molecular Affinity Fingerprints (MAFs) were determined for 154 proteins based on their molecular docking energy results for 1,255 FDA-approved drugs.  Protein binding site geometries were characterized by 420 PocketPicker descriptors.  The basic underlying component structure of MAFs and binding site geometries, respectively, were examined by principal component analysis; association between principal components extracted from these two sets of variables was then investigated by canonical correlation and redundancy analyses.  RESULTS:  PCA analysis of the MAF variables provided 30 factors which explained 71.4% of the total variance of the energy values while 13 factors were obtained from the PocketPicker descriptors which cumulatively explained 94.1% of the total variance.  Canonical correlation analysis resulted in 3 statistically significant canonical factor pairs with correlation values of 0.87, 0.84 and 0.77, respectively.  Redundancy analysis indicated that PocketPicker descriptor factors explain 6.9% of the variance of the MAF factor set while MAF factors explain 15.9% of the total variance of PocketPicker descriptor factors.  Based on the salient structures of the factor pairs, we identified a clear-cut association between the shape and bulkiness of the drug molecules and the protein binding site descriptors.  CONCLUSIONS:  This is the first study to investigate complex multivariate associations between affinity profiles and the geometric properties of protein binding sites.  We found that, except for few specific cases, the shapes of the binding pockets have relatively low weights in the determination of the affinity profiles of proteins.  Since the MAF profile is closely related to the target specificity of ligand binding sites we can conclude that the shape of the binding site is not a pivotal factor in selecting drug targets.  Nonetheless, based on strong specific associations between certain MAF profiles and specific geometric descriptors we identified, the shapes of the binding sites do have a crucial role in virtual drug design for certain drug categories, including morphine derivatives, benzodiazepines, barbiturates and antihistamines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThdv0NUE0QxLZpSb_XWfMrfW6udTcc2ebLt7pZNyuZ0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbntFSjsA%253D%253D&md5=afefcdafa264681ccfb4dc08157862ca</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1186%2F1472-6807-10-32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6807-10-32%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DZ.%26aulast%3DVigh-Smeller%26aufirst%3DM.%26aulast%3DPeragovics%26aufirst%3DA.%26aulast%3DCsukly%26aufirst%3DG.%26aulast%3DZahoranszky-Kohalmi%26aufirst%3DG.%26aulast%3DRauscher%26aufirst%3DA.%2BA.%26aulast%3DJelinek%26aufirst%3DB.%26aulast%3DHari%26aufirst%3DP.%26aulast%3DBitter%26aufirst%3DI.%26aulast%3DMalnasi-Csizmadia%26aufirst%3DA%26aulast%3DCzobor%26aufirst%3DP.%26atitle%3DRelating%2520the%2520shape%2520of%2520protein%2520binding%2520sites%2520to%2520binding%2520affinity%2520profiles%253A%2520Is%2520there%2520an%2520association%253F%26jtitle%3DBMC%2520Struct.%2520Biol.%26date%3D2010%26volume%3D10%26spage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Wishart, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrivastava, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tzur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gautam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassanali, M.</span><span> </span><span class="NLM_article-title">DrugBank: a knowledgebase for drugs, drug actions and drug targets</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">D901</span><span class="NLM_x">–</span> <span class="NLM_lpage">D906</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1093%2Fnar%2Fgkm958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=18048412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVSrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=D901-D906&author=D.+S.+Wishartauthor=C.+Knoxauthor=A.+C.+Guoauthor=D.+Chengauthor=S.+Shrivastavaauthor=D.+Tzurauthor=B.+Gautamauthor=M.+Hassanali&title=DrugBank%3A+a+knowledgebase+for+drugs%2C+drug+actions+and+drug+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">DrugBank: a knowledgebase for drugs, drug actions and drug targets</span></div><div class="casAuthors">Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">Database Iss</span>),
    <span class="NLM_cas:pages">D901-D906</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">DrugBank is a richly annotated resource that combines detailed drug data with comprehensive drug target and drug action information.  Since its first release in 2006, DrugBank has been widely used to facilitate in silico drug target discovery, drug design, drug docking or screening, drug metab. prediction, drug interaction prediction and general pharmaceutical education.  The latest version of DrugBank (release 2.0) has been expanded significantly over the previous release.  With ∼4900 drug entries, it now contains 60% more FDA-approved small mol. and biotech drugs including 10% more exptl.' drugs.  Significantly, more protein target data has also been added to the database, with the latest version of DrugBank contg. three times as many non-redundant protein or drug target sequences as before (1565 vs. 524).  Each DrugCard entry now contains more than 100 data fields with half of the information being devoted to drug/chem. data and the other half devoted to pharmacol., pharmacogenomic and mol. biol. data.  A no. of new data fields, including food-drug interactions, drug-drug interactions and exptl. ADME data have been added in response to numerous user requests.  DrugBank has also significantly improved the power and simplicity of its structure query and text query searches.  DrugBank is available at http://www.drugbank.ca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonqKjSWZe1ULVg90H21EOLACvtfcHk0lhiOlzyrMcI2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVSrs7Y%253D&md5=f8f8ca15f248b8c8b9c6d3bd0e85eec8</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkm958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkm958%26sid%3Dliteratum%253Aachs%26aulast%3DWishart%26aufirst%3DD.%2BS.%26aulast%3DKnox%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DA.%2BC.%26aulast%3DCheng%26aufirst%3DD.%26aulast%3DShrivastava%26aufirst%3DS.%26aulast%3DTzur%26aufirst%3DD.%26aulast%3DGautam%26aufirst%3DB.%26aulast%3DHassanali%26aufirst%3DM.%26atitle%3DDrugBank%253A%2520a%2520knowledgebase%2520for%2520drugs%252C%2520drug%2520actions%2520and%2520drug%2520targets%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2008%26volume%3D36%26spage%3DD901%26epage%3DD906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallqvist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reifman, J.</span><span> </span><span class="NLM_article-title">DOVIS 2.0: an efficient and easy to use parallel virtual screening tool based on AutoDock 4.0</span> <span class="citation_source-journal">Chem. Cent. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1186%2F1752-153X-2-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=18778471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD1cnht1Wkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2008&pages=18&author=X.+Jiangauthor=K.+Kumarauthor=X.+Huauthor=A.+Wallqvistauthor=J.+Reifman&title=DOVIS+2.0%3A+an+efficient+and+easy+to+use+parallel+virtual+screening+tool+based+on+AutoDock+4.0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">DOVIS 2.0: an efficient and easy to use parallel virtual screening tool based on AutoDock 4.0</span></div><div class="casAuthors">Jiang Xiaohui; Kumar Kamal; Hu Xin; Wallqvist Anders; Reifman Jaques</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry Central journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Small-molecule docking is an important tool in studying receptor-ligand interactions and in identifying potential drug candidates.  Previously, we developed a software tool (DOVIS) to perform large-scale virtual screening of small molecules in parallel on Linux clusters, using AutoDock 3.05 as the docking engine.  DOVIS enables the seamless screening of millions of compounds on high-performance computing platforms.  In this paper, we report significant advances in the software implementation of DOVIS 2.0, including enhanced screening capability, improved file system efficiency, and extended usability.  IMPLEMENTATION:  To keep DOVIS up-to-date, we upgraded the software's docking engine to the more accurate AutoDock 4.0 code.  We developed a new parallelization scheme to improve runtime efficiency and modified the AutoDock code to reduce excessive file operations during large-scale virtual screening jobs.  We also implemented an algorithm to output docked ligands in an industry standard format, sd-file format, which can be easily interfaced with other modeling programs.  Finally, we constructed a wrapper-script interface to enable automatic rescoring of docked ligands by arbitrarily selected third-party scoring programs.  CONCLUSION:  The significance of the new DOVIS 2.0 software compared with the previous version lies in its improved performance and usability.  The new version makes the computation highly efficient by automating load balancing, significantly reducing excessive file operations by more than 95%, providing outputs that conform to industry standard sd-file format, and providing a general wrapper-script interface for rescoring of docked ligands.  The new DOVIS 2.0 package is freely available to the public under the GNU General Public License.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrUMPR06SazzDnmmyUf5qOfW6udTcc2eY6JMx_tQokYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnht1Wkuw%253D%253D&md5=a803731aaab1b2d6ecc47b5f24315c83</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1186%2F1752-153X-2-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1752-153X-2-18%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DWallqvist%26aufirst%3DA.%26aulast%3DReifman%26aufirst%3DJ.%26atitle%3DDOVIS%25202.0%253A%2520an%2520efficient%2520and%2520easy%2520to%2520use%2520parallel%2520virtual%2520screening%2520tool%2520based%2520on%2520AutoDock%25204.0%26jtitle%3DChem.%2520Cent.%2520J.%26date%3D2008%26volume%3D2%26spage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Huey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodsell, D. S.</span><span> </span><span class="NLM_article-title">A semiempirical free energy force field with charge-based desolvation</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1145</span><span class="NLM_x">–</span> <span class="NLM_lpage">1152</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1002%2Fjcc.20634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=17274016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVSms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=1145-1152&author=R.+Hueyauthor=G.+M.+Morrisauthor=A.+J.+Olsonauthor=D.+S.+Goodsell&title=A+semiempirical+free+energy+force+field+with+charge-based+desolvation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">A semiempirical free energy force field with charge-based desolvation</span></div><div class="casAuthors">Huey, Ruth; Morris, Garrett M.; Olson, Arthur J.; Goodsell, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1145-1152</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The authors describe the development and testing of a semiempirical free energy force field for use in AutoDock4 and similar grid-based docking methods.  The force field is based on a comprehensive thermodn. model that allows incorporation of intramol. energies into the predicted free energy of binding.  It also incorporates a charge-based method for evaluation of desolvation designed to use a typical set of atom types.  The method has been calibrated on a set of 188 diverse protein-ligand complexes of known structure and binding energy, and tested on a set of 100 complexes of ligands with retroviral proteases.  The force field shows improvement in redocking simulations over the previous AutoDock3 force field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonvP0et7yst7Vg90H21EOLACvtfcHk0lhiOlzyrMcI2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVSms78%253D&md5=6fe6ef9bc0bd8149203a2b7351a2f15c</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1002%2Fjcc.20634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.20634%26sid%3Dliteratum%253Aachs%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26atitle%3DA%2520semiempirical%2520free%2520energy%2520force%2520field%2520with%2520charge-based%2520desolvation%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2007%26volume%3D28%26spage%3D1145%26epage%3D1152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Further development and validation of empirical scoring functions for structure-based binding affinity prediction</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1023%2FA%3A1016357811882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=12197663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlSqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=11-26&author=R.+Wangauthor=L.+Laiauthor=S.+Wang&title=Further+development+and+validation+of+empirical+scoring+functions+for+structure-based+binding+affinity+prediction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Further development and validation of empirical scoring functions for structure-based binding affinity prediction</span></div><div class="casAuthors">Wang, Renxiao; Lai, Luhua; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-26</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">New empirical scoring functions have been developed to est. the binding affinity of a given protein-ligand complex with known three-dimensional structure.  These scoring functions include terms accounting for van der Waals interaction, hydrogen bonding, deformation penalty, and hydrophobic effect.  A special feature is that three different algorithms have been implemented to calc. the hydrophobic effect term, which results in three parallel scoring functions.  All three scoring functions are calibrated through multivariate regression anal. of a set of 200 protein-ligand complexes and they reproduce the binding free energies of the entire training set with std. deviations of 2.2 kcal/mol, 2.1 kcal/mol, and 2.0 kcal/mol, resp.  These three scoring functions are further combined into a consensus scoring function, X-CSCORE.  When tested on an independent set of 30 protein-ligand complexes, X-CSCORE is able to predict their binding free energies with a std. deviation of 2.2 kcal/mol.  The potential application of X-CSCORE to mol. docking is also investigated.  Our results show that this consensus scoring function improves the docking accuracy considerably when compared to the conventional force field computation used for mol. docking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqULje6PqR73rVg90H21EOLACvtfcHk0lhM74JYZfvceg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlSqs7k%253D&md5=f77fd72d168df67d7fb66a88bc3b6cd9</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1023%2FA%3A1016357811882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1016357811882%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLai%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DFurther%2520development%2520and%2520validation%2520of%2520empirical%2520scoring%2520functions%2520for%2520structure-based%2520binding%2520affinity%2520prediction%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2002%26volume%3D16%26spage%3D11%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Lam le, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ukeda, H.</span><span> </span><span class="NLM_article-title">Assay of angiotensin I-converting enzyme-inhibiting activity based on the detection of 3-hydroxybutyrate with water-soluble tetrazolium salt</span> <span class="citation_source-journal">Anal. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1057</span><span class="NLM_x">–</span> <span class="NLM_lpage">1060</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.2116%2Fanalsci.24.1057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=18689950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvFKrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2008&pages=1057-1060&author=H.+Lam+leauthor=T.+Shimamuraauthor=S.+Manabeauthor=M.+Ishiyamaauthor=H.+Ukeda&title=Assay+of+angiotensin+I-converting+enzyme-inhibiting+activity+based+on+the+detection+of+3-hydroxybutyrate+with+water-soluble+tetrazolium+salt"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Assay of angiotensin I-converting enzyme-inhibiting activity based on the detection of 3-hydroxybutyrate with water-soluble tetrazolium salt</span></div><div class="casAuthors">Lam, Le Hoang; Shimamura, Tomoko; Manabe, Sachiyo; Ishiyama, Munetaka; Ukeda, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1057-1060</span>CODEN:
                <span class="NLM_cas:coden">ANSCEN</span>;
        ISSN:<span class="NLM_cas:issn">0910-6340</span>.
    
            (<span class="NLM_cas:orgname">Japan Society for Analytical Chemistry</span>)
        </div><div class="casAbstract">A newly synthesized substrate, 3-hydroxybutyrylglycyl-glycyl-glycine (3HB-GGG), was applied to the assay of ACE-inhibiting activity to overcome the smaller selectivity and sensitivity of the conventional method.  In this study, an ACE-inhibiting assay was improved by the use of a water-sol. tetrazolium salt, 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate sodium salt (WST-1), for the detection of 3-hydroxybutyrate, derived from 3HB-GGG.  The optimized conditions were as follows: 0.333 mM NAD+, 0.333 mM WST-1, 0.1 mM EDTA, 0.633 U ml-1 diaphorase, and 0.700 U ml-1 3-hydroxybutyrate dehydrogenase.  The developed assay was efficiently applicable to evaluate the ACE-inhibiting activity of practical ACE inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV7ibH0DLU5rVg90H21EOLACvtfcHk0lhM74JYZfvceg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvFKrt7Y%253D&md5=d54647c972709d8cd87c40c195cff351</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.2116%2Fanalsci.24.1057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2116%252Fanalsci.24.1057%26sid%3Dliteratum%253Aachs%26aulast%3DLam%2Ble%26aufirst%3DH.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DManabe%26aufirst%3DS.%26aulast%3DIshiyama%26aufirst%3DM.%26aulast%3DUkeda%26aufirst%3DH.%26atitle%3DAssay%2520of%2520angiotensin%2520I-converting%2520enzyme-inhibiting%2520activity%2520based%2520on%2520the%2520detection%2520of%25203-hydroxybutyrate%2520with%2520water-soluble%2520tetrazolium%2520salt%26jtitle%3DAnal.%2520Sci.%26date%3D2008%26volume%3D24%26spage%3D1057%26epage%3D1060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Lam le, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ukeda, H.</span><span> </span><span class="NLM_article-title">Assay of angiotensin I-converting enzyme-inhibiting activity based on the detection of 3-hydroxybutyric acid</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2007&pages=104-111&author=H.+Lam+leauthor=T.+Shimamuraauthor=K.+Sakaguchiauthor=K.+Noguchiauthor=M.+Ishiyamaauthor=Y.+Fujimuraauthor=H.+Ukeda&title=Assay+of+angiotensin+I-converting+enzyme-inhibiting+activity+based+on+the+detection+of+3-hydroxybutyric+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLam%2Ble%26aufirst%3DH.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DSakaguchi%26aufirst%3DK.%26aulast%3DNoguchi%26aufirst%3DK.%26aulast%3DIshiyama%26aufirst%3DM.%26aulast%3DFujimura%26aufirst%3DY.%26aulast%3DUkeda%26aufirst%3DH.%26atitle%3DAssay%2520of%2520angiotensin%2520I-converting%2520enzyme-inhibiting%2520activity%2520based%2520on%2520the%2520detection%2520of%25203-hydroxybutyric%2520acid%26jtitle%3DAnal.%2520Biochem.%26date%3D2007%26volume%3D364%26spage%3D104%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Nurtjahja-Tjendraputra, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ammit, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roufogalis, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, V. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duke, C. C.</span><span> </span><span class="NLM_article-title">Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger</span> <span class="citation_source-journal">Thromb. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">265</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.thromres.2003.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=14693173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2003&pages=259-265&author=E.+Nurtjahja-Tjendraputraauthor=A.+J.+Ammitauthor=B.+D.+Roufogalisauthor=V.+H.+Tranauthor=C.+C.+Duke&title=Effective+anti-platelet+and+COX-1+enzyme+inhibitors+from+pungent+constituents+of+ginger"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger</span></div><div class="casAuthors">Nurtjahja-Tjendraputra, Effie; Ammit, Alaina J.; Roufogalis, Basil D.; Tran, Van H.; Duke, Colin C.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">4-5</span>),
    <span class="NLM_cas:pages">259-265</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Background: Based on recent studies, pungent constituents of ginger (Zingiber officinale) and related substances represent a potential new class of anti-platelet agents.  The ability of 20 pungent constituents of ginger and related substances to inhibit arachidonic acid (AA) induced platelet activation in human whole blood was studied.  Methods: Anti-platelet activity of the compds. was measured in vitro by the Chrono Log whole blood platelet aggregometer.  Mol. hydrophobicity (log P) was measured by reversed-phase high-performance liq. chromatog.  COX-1 (ovine) inhibitory effect of [8]-paradol and analogs was carried out using a COX-1 inhibitor assay kit.  Results: [8]-Gingerol, [8]-shogaol, [8]-paradol and gingerol analogs exhibited anti-platelet activities with IC50 values ranging from 3 to 7 μM, while under similar conditions the IC50 value for aspirin was 20±11 μM.  The COX-1 inhibitory activity of [8]-paradol (IC50=4±1 μM) was more potent than the gingerol analogs (IC50 approx. 20 μM).  Conclusion: The above findings show that gingerol compds. and their derivs. are more potent anti-platelet agents than aspirin under the conditions described in this study.  [8]-Paradol, a natural constituent of ginger, was found to be the most potent COX-1 inhibitor and anti platelet aggregation agent.  The mechanism underlying AA-induced platelet aggregation inhibition may be related to attenuation of COX-1/Tx synthase enzymic activity.  Lastly, important features of phenolic compds. for inhibition of AA-induced platelet aggregation and COX-1 activity were revealed in this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9nd4ba0jGL7Vg90H21EOLACvtfcHk0ljvHAEWVpyYzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtbfM&md5=bf6f24890257fe1898a00883f5f640fa</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2003.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2003.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DNurtjahja-Tjendraputra%26aufirst%3DE.%26aulast%3DAmmit%26aufirst%3DA.%2BJ.%26aulast%3DRoufogalis%26aufirst%3DB.%2BD.%26aulast%3DTran%26aufirst%3DV.%2BH.%26aulast%3DDuke%26aufirst%3DC.%2BC.%26atitle%3DEffective%2520anti-platelet%2520and%2520COX-1%2520enzyme%2520inhibitors%2520from%2520pungent%2520constituents%2520of%2520ginger%26jtitle%3DThromb.%2520Res.%26date%3D2003%26volume%3D111%26spage%3D259%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Zykova, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ermakova, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Z.</span><span> </span><span class="NLM_article-title">Resveratrol directly targets COX-2 to inhibit carcinogenesis</span> <span class="citation_source-journal">Mol. Carcinog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">–</span> <span class="NLM_lpage">805</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1002%2Fmc.20437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=18381589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1agurjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=797-805&author=T.+A.+Zykovaauthor=F.+Zhuauthor=X.+Zhaiauthor=W.+Y.+Maauthor=S.+P.+Ermakovaauthor=K.+W.+Leeauthor=A.+M.+Bodeauthor=Z.+Dong&title=Resveratrol+directly+targets+COX-2+to+inhibit+carcinogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol directly targets COX-2 to inhibit carcinogenesis</span></div><div class="casAuthors">Zykova, Tatyana A.; Zhu, Feng; Zhai, Xiuhong; Ma, Wei-Ya; Ermakova, Svetlana P.; Lee, Ki Won; Bode, Ann M.; Dong, Zigang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">797-805</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Targeted mol. cancer therapies can potentially deliver treatment directly to a specific protein or gene to optimize efficacy and reduce adverse side effects often assocd. with traditional chemotherapy.  Key oncoprotein and oncogene targets are rapidly being identified based on their expression, pathogenesis and clin. outcome.  One such protein target is cyclooxygenase-2 (COX-2), which is highly expressed in various cancers.  Research findings suggest that resveratrol (RSVL; 3,5,4'-trihydroxy-trans-stilbene) demonstrates nonselective COX-2 inhibition.  We report herein that RSVL directly binds with COX-2 and this binding is absolutely required for RSVL's inhibition of the ability of human colon adenocarcinoma HT-29 cells to form colonies in soft agar.  Binding of COX-2 with RSVL was compared with two RSVL analogs, 3,3',4',5',5-pentahydroxy-trans-stilbene (RSVL-2) or 3,4',5-trimethoxy-trans-stilbene (RSVL-3).  The results indicated that COX-2 binds with RSVL-2 more strongly than with RSVL, but does not bind with RSVL-3.  RSVL or RSVL-2, but not RSVL-3, inhibited COX-2-mediated PGE2 prodn. in vitro and ex vivo.  HT-29 human colon adenocarcinoma cells express high levels of COX-2 and either RSVL or RSVL-2, but not RSVL-3, suppressed anchorage independent growth of these cells in soft agar.  RSVL or RSVL-2 (not RSVL-3) suppressed growth of COX-2+/+ cells by 60% or 80%, resp.  Notably, cells deficient in COX-2 were unresponsive to RSVL or RSVL-2.  These data suggest that the anticancer effects of RSVL or RSLV-2 might be mediated directly through COX-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBfmZcwFvhNLVg90H21EOLACvtfcHk0lj7fSU5C7pa2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1agurjN&md5=12260cd20de1f1fffa6f79855065761b</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1002%2Fmc.20437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.20437%26sid%3Dliteratum%253Aachs%26aulast%3DZykova%26aufirst%3DT.%2BA.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DZhai%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DW.%2BY.%26aulast%3DErmakova%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DK.%2BW.%26aulast%3DBode%26aufirst%3DA.%2BM.%26aulast%3DDong%26aufirst%3DZ.%26atitle%3DResveratrol%2520directly%2520targets%2520COX-2%2520to%2520inhibit%2520carcinogenesis%26jtitle%3DMol.%2520Carcinog.%26date%3D2008%26volume%3D47%26spage%3D797%26epage%3D805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':[],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 12 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Gaochan Wu, Tong Zhao, Dongwei Kang, Jian Zhang, Yuning Song, Vigneshwaran Namasivayam, Jacob Kongsted, Christophe Pannecouque, Erik De Clercq, Vasanthanathan Poongavanam, Xinyong Liu, <span class="NLM_string-name hlFld-ContribAuthor">Peng Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Overview of Recent Strategic Advances in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (21)
                                     , 9375-9414. <a href="https://doi.org/10.1021/acs.jmedchem.9b00359" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00359</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00359%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOverview%252Bof%252BRecent%252BStrategic%252BAdvances%252Bin%252BMedicinal%252BChemistry%26aulast%3DWu%26aufirst%3DGaochan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D26022019%26date%3D28052019%26date%3D03052019%26volume%3D62%26issue%3D21%26spage%3D9375%26epage%3D9414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tianyun  Liu</span> and <span class="hlFld-ContribAuthor ">Russ B.  Altman</span>  . </span><span class="cited-content_cbyCitation_article-title">Relating Essential Proteins to Drug Side-Effects Using Canonical Component Analysis: A Structure-Based Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2015,</strong> <em>55 </em>
                                    (7)
                                     , 1483-1494. <a href="https://doi.org/10.1021/acs.jcim.5b00030" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00030%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DRelating%252BEssential%252BProteins%252Bto%252BDrug%252BSide-Effects%252BUsing%252BCanonical%252BComponent%252BAnalysis%25253A%252BA%252BStructure-Based%252BApproach%26aulast%3DLiu%26aufirst%3DTianyun%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D20012015%26date%3D16072015%26date%3D27072015%26date%3D29062015%26volume%3D55%26issue%3D7%26spage%3D1483%26epage%3D1494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">C.  Škuta</span>, <span class="hlFld-ContribAuthor ">I.  Cortés-Ciriano</span>, <span class="hlFld-ContribAuthor ">W.  Dehaen</span>, <span class="hlFld-ContribAuthor ">P.  Kříž</span>, <span class="hlFld-ContribAuthor ">G. J. P.  van Westen</span>, <span class="hlFld-ContribAuthor ">I. V.  Tetko</span>, <span class="hlFld-ContribAuthor ">A.  Bender</span>, <span class="hlFld-ContribAuthor ">D.  Svozil</span>. </span><span class="cited-content_cbyCitation_article-title">QSAR-derived affinity fingerprints (part 1): fingerprint construction and modeling performance for similarity searching, bioactivity classification and scaffold hopping. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cheminformatics</span><span> <strong>2020,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13321-020-00443-6" title="DOI URL">https://doi.org/10.1186/s13321-020-00443-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13321-020-00443-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13321-020-00443-6%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cheminformatics%26atitle%3DQSAR-derived%252Baffinity%252Bfingerprints%252B%252528part%252B1%252529%25253A%252Bfingerprint%252Bconstruction%252Band%252Bmodeling%252Bperformance%252Bfor%252Bsimilarity%252Bsearching%25252C%252Bbioactivity%252Bclassification%252Band%252Bscaffold%252Bhopping%26aulast%3D%25C5%25A0kuta%26aufirst%3DC.%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soo Youn  Lee</span>, <span class="hlFld-ContribAuthor ">Min-Young  Song</span>, <span class="hlFld-ContribAuthor ">Dain  Kim</span>, <span class="hlFld-ContribAuthor ">Chaewon  Park</span>, <span class="hlFld-ContribAuthor ">Da Kyeong  Park</span>, <span class="hlFld-ContribAuthor ">Dong Geun  Kim</span>, <span class="hlFld-ContribAuthor ">Jong Shin  Yoo</span>, <span class="hlFld-ContribAuthor ">Young Hye  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.3389/fphar.2019.01653" title="DOI URL">https://doi.org/10.3389/fphar.2019.01653</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2019.01653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2019.01653%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DA%252BProteotranscriptomic-Based%252BComputational%252BDrug-Repositioning%252BMethod%252Bfor%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DLee%26aufirst%3DSoo%2BYoun%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leandro S.  Sangenito</span>, <span class="hlFld-ContribAuthor ">Rubem F.S.  Menna-Barreto</span>, <span class="hlFld-ContribAuthor ">Cláudia M.  d'Avila-Levy</span>, <span class="hlFld-ContribAuthor ">Marta H.  Branquinha</span>, <span class="hlFld-ContribAuthor ">André L.S.  Santos</span>. </span><span class="cited-content_cbyCitation_article-title">Repositioning of HIV Aspartyl Peptidase Inhibitors for Combating the Neglected Human Pathogen Trypanosoma cruzi. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2019,</strong> <em>26 </em>
                                    (36)
                                     , 6590-6613. <a href="https://doi.org/10.2174/0929867326666190610152934" title="DOI URL">https://doi.org/10.2174/0929867326666190610152934</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867326666190610152934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867326666190610152934%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DRepositioning%252Bof%252BHIV%252BAspartyl%252BPeptidase%252BInhibitors%252Bfor%252BCombating%252Bthe%252BNeglected%252BHuman%252BPathogen%252BTrypanosoma%252Bcruzi%26aulast%3DSangenito%26aufirst%3DLeandro%2BS.%26date%3D2019%26volume%3D26%26issue%3D36%26spage%3D6590%26epage%3D6613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gerhard  Hessler</span>, <span class="hlFld-ContribAuthor ">Christoph  Grebner</span>, <span class="hlFld-ContribAuthor ">Hans  Matter</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Approaches for Target Inference. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 277-322. <a href="https://doi.org/10.1002/9783527818242.ch10" title="DOI URL">https://doi.org/10.1002/9783527818242.ch10</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527818242.ch10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527818242.ch10%26sid%3Dliteratum%253Aachs%26atitle%3DComputational%252BApproaches%252Bfor%252BTarget%252BInference%26aulast%3DHessler%26aufirst%3DGerhard%26date%3D2019%26date%3D2019%26spage%3D277%26epage%3D322%26pub%3DWiley%26atitle%3DTarget%252BDiscovery%252Band%252BValidation%26aulast%3DPlowright%26aufirst%3DAlleyn%2BT%26date%3D2019%26date%3D2019%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Naiem T.  Issa</span>, <span class="hlFld-ContribAuthor ">Stephen W.  Byers</span>, <span class="hlFld-ContribAuthor ">Sivanesan  Dakshanamurthy</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery Technologies for Drug Repurposing. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 79-100. <a href="https://doi.org/10.1002/9783527674381.ch4" title="DOI URL">https://doi.org/10.1002/9783527674381.ch4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527674381.ch4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527674381.ch4%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252BTechnologies%252Bfor%252BDrug%252BRepurposing%26aulast%3DIssa%26aufirst%3DNaiem%2BT.%26date%3D2017%26date%3D2017%26spage%3D79%26epage%3D100%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DDrug%252BSelectivity%26aulast%3DHandler%26aufirst%3DNorbert%26date%3D2017%26volume%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongming  Chen</span>, <span class="hlFld-ContribAuthor ">Udo  Bauer</span>, <span class="hlFld-ContribAuthor ">Ola  Engkvist</span>. </span><span class="cited-content_cbyCitation_article-title">Merged Multiple Ligands. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 247-274. <a href="https://doi.org/10.1002/9783527674381.ch9" title="DOI URL">https://doi.org/10.1002/9783527674381.ch9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527674381.ch9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527674381.ch9%26sid%3Dliteratum%253Aachs%26atitle%3DMerged%252BMultiple%252BLigands%26aulast%3DChen%26aufirst%3DHongming%26date%3D2017%26date%3D2017%26spage%3D247%26epage%3D274%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DDrug%252BSelectivity%26aulast%3DHandler%26aufirst%3DNorbert%26date%3D2017%26volume%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D. S.  Druzhilovskiy</span>, <span class="hlFld-ContribAuthor ">A. V.  Rudik</span>, <span class="hlFld-ContribAuthor ">D. A.  Filimonov</span>, <span class="hlFld-ContribAuthor ">T. A.  Gloriozova</span>, <span class="hlFld-ContribAuthor ">A. A.  Lagunin</span>, <span class="hlFld-ContribAuthor ">A. V.  Dmitriev</span>, <span class="hlFld-ContribAuthor ">P. V.  Pogodin</span>, <span class="hlFld-ContribAuthor ">V. I.  Dubovskaya</span>, <span class="hlFld-ContribAuthor ">S. M.  Ivanov</span>, <span class="hlFld-ContribAuthor ">O. A.  Tarasova</span>, <span class="hlFld-ContribAuthor ">V. M.  Bezhentsev</span>, <span class="hlFld-ContribAuthor ">K. A.  Murtazalieva</span>, <span class="hlFld-ContribAuthor ">M. I.  Semin</span>, <span class="hlFld-ContribAuthor ">I. S.  Maiorov</span>, <span class="hlFld-ContribAuthor ">A. S.  Gaur</span>, <span class="hlFld-ContribAuthor ">G. N.  Sastry</span>, <span class="hlFld-ContribAuthor ">V. V.  Poroikov</span>. </span><span class="cited-content_cbyCitation_article-title">Computational platform Way2Drug: from the prediction of biological activity to drug repurposing. </span><span class="cited-content_cbyCitation_journal-name">Russian Chemical Bulletin</span><span> <strong>2017,</strong> <em>66 </em>
                                    (10)
                                     , 1832-1841. <a href="https://doi.org/10.1007/s11172-017-1954-x" title="DOI URL">https://doi.org/10.1007/s11172-017-1954-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11172-017-1954-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11172-017-1954-x%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Chemical%2520Bulletin%26atitle%3DComputational%252Bplatform%252BWay2Drug%25253A%252Bfrom%252Bthe%252Bprediction%252Bof%252Bbiological%252Bactivity%252Bto%252Bdrug%252Brepurposing%26aulast%3DDruzhilovskiy%26aufirst%3DD.%2BS.%26date%3D2017%26date%3D2018%26volume%3D66%26issue%3D10%26spage%3D1832%26epage%3D1841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiao  Li</span>, <span class="hlFld-ContribAuthor ">Si  Zheng</span>, <span class="hlFld-ContribAuthor ">Bin  Chen</span>, <span class="hlFld-ContribAuthor ">Atul J.  Butte</span>, <span class="hlFld-ContribAuthor ">S. Joshua  Swamidass</span>, <span class="hlFld-ContribAuthor ">Zhiyong  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">A survey of current trends in computational drug repositioning. </span><span class="cited-content_cbyCitation_journal-name">Briefings in Bioinformatics</span><span> <strong>2016,</strong> <em>17 </em>
                                    (1)
                                     , 2-12. <a href="https://doi.org/10.1093/bib/bbv020" title="DOI URL">https://doi.org/10.1093/bib/bbv020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/bib/bbv020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fbib%2Fbbv020%26sid%3Dliteratum%253Aachs%26jtitle%3DBriefings%2520in%2520Bioinformatics%26atitle%3DA%252Bsurvey%252Bof%252Bcurrent%252Btrends%252Bin%252Bcomputational%252Bdrug%252Brepositioning%26aulast%3DLi%26aufirst%3DJiao%26date%3D2016%26date%3D2015%26volume%3D17%26issue%3D1%26spage%3D2%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hitesh  Patel</span>, <span class="hlFld-ContribAuthor ">Xavier  Lucas</span>, <span class="hlFld-ContribAuthor ">Igor  Bendik</span>, <span class="hlFld-ContribAuthor ">Stefan  Günther</span>, <span class="hlFld-ContribAuthor ">Irmgard  Merfort</span>. </span><span class="cited-content_cbyCitation_article-title">Target Fishing by Cross-Docking to Explain Polypharmacological Effects. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2015,</strong> <em>10 </em>
                                    (7)
                                     , 1209-1217. <a href="https://doi.org/10.1002/cmdc.201500123" title="DOI URL">https://doi.org/10.1002/cmdc.201500123</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201500123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201500123%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DTarget%252BFishing%252Bby%252BCross-Docking%252Bto%252BExplain%252BPolypharmacological%252BEffects%26aulast%3DPatel%26aufirst%3DHitesh%26date%3D2015%26date%3D2015%26volume%3D10%26issue%3D7%26spage%3D1209%26epage%3D1217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew G.  Leach</span>. </span><span class="cited-content_cbyCitation_article-title">Predicting the activity and toxicity of new psychoactive substances: a pharmaceutical industry perspective. </span><span class="cited-content_cbyCitation_journal-name">Drug Testing and Analysis</span><span> <strong>2014,</strong> <em>6 </em>
                                    (7-8)
                                     , 739-745. <a href="https://doi.org/10.1002/dta.1593" title="DOI URL">https://doi.org/10.1002/dta.1593</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/dta.1593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fdta.1593%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Testing%2520and%2520Analysis%26atitle%3DPredicting%252Bthe%252Bactivity%252Band%252Btoxicity%252Bof%252Bnew%252Bpsychoactive%252Bsubstances%25253A%252Ba%252Bpharmaceutical%252Bindustry%252Bperspective%26aulast%3DLeach%26aufirst%3DAndrew%2BG.%26date%3D2014%26date%3D2013%26volume%3D6%26issue%3D7-8%26spage%3D739%26epage%3D745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/medium/jm-2013-00813y_0004.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/large/jm-2013-00813y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400813y&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/medium/jm-2013-00813y_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/large/jm-2013-00813y_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Graphical summary of the Drug Profile Matching method. The Interaction Pattern (IP) matrix consists of the calculated binding free energies for the 1177 drugs studied on the reference panel of 149 nontarget proteins (i.e., proteins that are not known to be involved in the mechanism of action of the drugs). The Effect Profile (EP) matrix contains pharmacological effect information on the drug set in a binary form (blue and white cells represent the presence and the absence of a given effect from the 177 categories, respectively). A two-step multidimensional analysis (canonical correlation analysis, CCA, and linear discriminant analysis, LDA) was performed using the IP and EP matrices as inputs to calculate the Effect Probability matrix. This matrix displays the probability values for each drug–effect pair. The darker is a given cell, the higher is the predicted probability. Comparison of the same effect (i.e., same column) in both effect matrices reveals those predictions that are already known (marked as valid) and highlights the predictions that need to be validated via literature search or experimental testing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/large/jm-2013-00813y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400813y&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/medium/jm-2013-00813y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/large/jm-2013-00813y_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. In vitro ACE inhibition curves for telmisartan (a) , L-proline (b) , novobiocin (c), and dasatinib (d). All compounds show dose dependent response with resulting <i>K</i><sub>i</sub> values ranging from 6 to 715 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/large/jm-2013-00813y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400813y&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/medium/jm-2013-00813y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/large/jm-2013-00813y_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. COX-1 and COX-2 inhibition curves for captopril (panels a and b, respectively), COX-1 inhibition curve for α-linolenic acid (c), and COX-2 inhibition curve for nitroxoline (d). All compounds show dose dependent response, and the determined <i>K</i><sub>i</sub> values range from 1 to 17 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400813y/production/images/large/jm-2013-00813y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400813y&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i21">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75614" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75614" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 93 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Kling, J.</span><span> </span><span class="NLM_article-title">Fresh from the biotech pipeline—2011 [corrected]</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">128</span><span class="NLM_x">–</span> <span class="NLM_lpage">131</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=128-131&author=J.+Kling&title=Fresh+from+the+biotech+pipeline%E2%80%942011+%5Bcorrected%5D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKling%26aufirst%3DJ.%26atitle%3DFresh%2520from%2520the%2520biotech%2520pipeline%25E2%2580%25942011%2520%255Bcorrected%255D%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D128%26epage%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Ashburn, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thor, K. B.</span><span> </span><span class="NLM_article-title">Drug repositioning: identifying and developing new uses for existing drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">673</span><span class="NLM_x">–</span> <span class="NLM_lpage">683</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1038%2Fnrd1468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=15286734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=673-683&author=T.+T.+Ashburnauthor=K.+B.+Thor&title=Drug+repositioning%3A+identifying+and+developing+new+uses+for+existing+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repositioning: identifying and developing new uses for existing drugs</span></div><div class="casAuthors">Ashburn, Ted T.; Thor, Karl B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">673-683</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Biopharmaceutical companies attempting to increase productivity through novel discovery technologies have fallen short of achieving the desired results.  Repositioning existing drugs for new indications could deliver the productivity increases that the industry needs while shifting the locus of prodn. to biotechnol. companies.  More and more companies are scanning the existing pharmacopeia for repositioning candidates, and the no. of repositioning success stories is increasing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLkWl3DnePhrVg90H21EOLACvtfcHk0lhFRhuHOJMW7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtL8%253D&md5=0145c02423ab81ace6e3b3d92585cccc</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd1468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1468%26sid%3Dliteratum%253Aachs%26aulast%3DAshburn%26aufirst%3DT.%2BT.%26aulast%3DThor%26aufirst%3DK.%2BB.%26atitle%3DDrug%2520repositioning%253A%2520identifying%2520and%2520developing%2520new%2520uses%2520for%2520existing%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D673%26epage%3D683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management</span> <span class="citation_source-journal">Am. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">1037</span><span class="NLM_x">–</span> <span class="NLM_lpage">1045</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1002%2Fajh.23282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=23090888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFGqsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2012&pages=1037-1045&author=E.+Jabbourauthor=H.+Kantarjian&title=Chronic+myeloid+leukemia%3A+2012+update+on+diagnosis%2C+monitoring%2C+and+management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management</span></div><div class="casAuthors">Jabbour, Elias; Kantarjian, Hagop</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1037-1045</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Disease overview: : Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of one-two cases per 100,000 adults and accounts for ∼15% of newly diagnosed cases of leukemia in adults.Diagnosis: : CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson oncogene (ABL) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2.  This rearrangement is known as the Philadelphia chromosome.  The mol. consequence of this translocation is the generation of a BCR-ABL fusion oncogene, which in turn translates into a Bcr-Abl oncoprotein.Frontline therapy: : Three tyrosine kinase inhibitors (TKIs), imatinib, nilotinib, and dasatinib, have been approved by the US Food and Drug Administration for the first-line treatment of patients with newly diagnosed CML in chronic phase (CML-CP).  Clin. trials with 2nd generation TKIs reported significantly deeper and faster responses; their impact on long-term survival remains to be detd.Salvage therapy: : For patients who fail std.-dose imatinib therapy, imatinib dose escalation is a second-line option.  Alternative second-line options include 2nd generation TKIs.  Although both are potent and specific BCR-ABL TKIs, dasatinib and nilotinib exhibit unique pharmacol. profiles and response patterns relative to different patient characteristics, such as disease stage and BCR-ABL mutational status.  Patients who develop the T315I "gatekeeper" mutation display resistance to all currently available TKIs and are candidate for clin. trials.  Allogeneic transplantation remains an important therapeutic option for CML-CP harboring the T315I mutation, patients who fail 2nd generation TKIs, and for all patients in advanced phase disease.  Am. J. Hematol., 2012. © 2012 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv0HLutfly_bVg90H21EOLACvtfcHk0lhMA_-AaflAPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFGqsbvM&md5=70baa58918a651d515b5249812049672</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fajh.23282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.23282%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DChronic%2520myeloid%2520leukemia%253A%25202012%2520update%2520on%2520diagnosis%252C%2520monitoring%252C%2520and%2520management%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2012%26volume%3D87%26spage%3D1037%26epage%3D1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Eisenberg, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pipas, J. M.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumor—background, pathology, treatment</span> <span class="citation_source-journal">Hematol Oncol Clin North Am.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1239</span><span class="NLM_x">–</span> <span class="NLM_lpage">1259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.hoc.2012.08.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=23116579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FpvFGhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1239-1259&author=B.+L.+Eisenbergauthor=J.+M.+Pipas&title=Gastrointestinal+stromal+tumor%E2%80%94background%2C+pathology%2C+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumor--background, pathology, treatment</span></div><div class="casAuthors">Eisenberg Burton L; Pipas J Marc</div><div class="citationInfo"><span class="NLM_cas:title">Hematology/oncology clinics of North America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1239-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Gastrointestinal stromal tumor (GIST) represents the most common mesechymal tumor of the gastrointestinal tract.  Discovery of the relationship between unregulated KIT kinase and GIST transformation has led to diagnostic and therapeutic targeting.  Imatinib is the recommended first-line treatment of metastatic GIST.  In addition, the combination of surgery and imatinib for primary GIST is indicated in the adjuvant setting of high-risk patients and there may be benefit for this combination in the neoadjuvant setting.  The success of molecular targeted therapy in GIST represents an important and exciting advance in solid tumor oncology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRmEqEoqczuLnl8icjszYl0fW6udTcc2eaTeUIIEQD2Wbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FpvFGhsA%253D%253D&md5=8da84949b4362fe820ce3d694d319a5c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.hoc.2012.08.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hoc.2012.08.003%26sid%3Dliteratum%253Aachs%26aulast%3DEisenberg%26aufirst%3DB.%2BL.%26aulast%3DPipas%26aufirst%3DJ.%2BM.%26atitle%3DGastrointestinal%2520stromal%2520tumor%25E2%2580%2594background%252C%2520pathology%252C%2520treatment%26jtitle%3DHematol%2520Oncol%2520Clin%2520North%2520Am.%26date%3D2012%26volume%3D26%26spage%3D1239%26epage%3D1259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Ekman, P.</span><span> </span><span class="NLM_article-title">Finasteride in the treatment of benign prostatic hypertrophy: an update. New indications for finasteride therapy</span> <span class="citation_source-journal">Scand. J. Urol. Nephrol., Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">203</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1080%2F00365599950509997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=10636564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD3c7gtVGiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=203&publication_year=1999&pages=15-20&author=P.+Ekman&title=Finasteride+in+the+treatment+of+benign+prostatic+hypertrophy%3A+an+update.+New+indications+for+finasteride+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Finasteride in the treatment of benign prostatic hypertrophy: an update. New indications for finasteride therapy</span></div><div class="casAuthors">Ekman P</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian journal of urology and nephrology. Supplementum</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">203</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-20</span>
        ISSN:<span class="NLM_cas:issn">0300-8886</span>.
    </div><div class="casAbstract">A phenomenon of the prostate gland, which is also shared by hair follicles, is that it is little influenced by testosterone (T) for androgenic stimulation, but instead by its metabolite 5alpha-dihydrotestosterone (DHT).  By blocking the conversion of T to DHT, the circulating level of DHT is reduced by 80%, the size of the prostate gland is reduced by about 20% and the level of prostate-specific antigen (PSA) by about 50%.  Treatment of patients with obstructive benign prostatic hypertrophy (BPH) with the drug Finasteride leads to a moderately improved urinary flow, symptomatic improvement and halts the natural progress of the disease.  Since DHT potentiates the effect of testosterone on erectile function, the side-effects are impotence in 3% of patients, decreased ejaculatory volume, and gynaecomastia in 0.4% of patients.  The drug could be regarded as a safe way to treat moderately symptomatic BPH.  The efficacy of the drug is long-lasting (more than 7 years).  It has also been tried in prostate cancer, but is less effective.  It reduces PSA levels by 50% and, in combination therapy, therefore, PSA levels remain low for longer when Finasteride is added.  An important finding is the efficacy of Finasteride treatment in haematuria from BPH.  The drug interacts with vascular endothelium growth factor and efficiently prevents new bleeding.  It could be regarded as a first-line therapy for this type of haematuria.  Finasteride can also be used to stop male baldness.  It seems particularly effective in men aged 20-40 years; 85% of patients stopped losing hair when given Finasteride.  When the treatment was stopped hair loss continued, thus therapy may have to be "lifelong".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS056xhuBGpsbqxQ2mb9Pu8fW6udTcc2eaTeUIIEQD2Wbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7gtVGiuw%253D%253D&md5=6626866af877249366b234280bf92de0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1080%2F00365599950509997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00365599950509997%26sid%3Dliteratum%253Aachs%26aulast%3DEkman%26aufirst%3DP.%26atitle%3DFinasteride%2520in%2520the%2520treatment%2520of%2520benign%2520prostatic%2520hypertrophy%253A%2520an%2520update.%2520New%2520indications%2520for%2520finasteride%2520therapy%26jtitle%3DScand.%2520J.%2520Urol.%2520Nephrol.%252C%2520Suppl.%26date%3D1999%26volume%3D203%26spage%3D15%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Cleach, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bocquet, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roujeau, J. C.</span><span> </span><span class="NLM_article-title">Reactions and interactions of some commonly used systemic drugs in dermatology</span> <span class="citation_source-journal">Dermatol. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">429</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2FS0733-8635%2805%2970023-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=9589214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADyaK1c3ltFWjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=421-429&author=L.+L.+Cleachauthor=H.+Bocquetauthor=J.+C.+Roujeau&title=Reactions+and+interactions+of+some+commonly+used+systemic+drugs+in+dermatology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Reactions and interactions of some commonly used systemic drugs in dermatology</span></div><div class="casAuthors">Cleach L L; Bocquet H; Roujeau J C</div><div class="citationInfo"><span class="NLM_cas:title">Dermatologic clinics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">421-9</span>
        ISSN:<span class="NLM_cas:issn">0733-8635</span>.
    </div><div class="casAbstract">This article deals with the main interactions and adverse effects of some drugs that are used daily by dermatologists.  It includes tetracyclines and Minocycline in the treatment of acne; antimalarials and discoid lupus; dapsone; thalidomine; oral retinoids; methotrexate and cyclosporine.  Several of these drugs are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_vw8Lu8LWLSA3UY9EwTNrfW6udTcc2eYbij8wGtRET7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3ltFWjtA%253D%253D&md5=5e311529dc068fe2d0eb5fc602e18b8c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0733-8635%2805%2970023-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0733-8635%252805%252970023-1%26sid%3Dliteratum%253Aachs%26aulast%3DCleach%26aufirst%3DL.%2BL.%26aulast%3DBocquet%26aufirst%3DH.%26aulast%3DRoujeau%26aufirst%3DJ.%2BC.%26atitle%3DReactions%2520and%2520interactions%2520of%2520some%2520commonly%2520used%2520systemic%2520drugs%2520in%2520dermatology%26jtitle%3DDermatol.%2520Clin.%26date%3D1998%26volume%3D16%26spage%3D421%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Patrono, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia Rodriguez, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landolfi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baigent, C.</span><span> </span><span class="NLM_article-title">Low-dose aspirin for the prevention of atherothrombosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">2373</span><span class="NLM_x">–</span> <span class="NLM_lpage">2383</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1056%2FNEJMra052717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=16319386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1OmsbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=2373-2383&author=C.+Patronoauthor=L.+A.+Garcia+Rodriguezauthor=R.+Landolfiauthor=C.+Baigent&title=Low-dose+aspirin+for+the+prevention+of+atherothrombosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Low-dose aspirin for the prevention of atherothrombosis</span></div><div class="casAuthors">Patrono, Carlo; Garcia Rodriguez, Luis A.; Landolfi, Raffaele; Baigent, Colin</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2373-2383</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The article discusses the mol. mechanism of action of aspirin and the results of clin. trials and epidemiol. studies of aspirin as an antiplatelet agent.  Emphasis is placed on the benefits and risks of low-dose aspirin in various patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZQ1jICSmBdrVg90H21EOLACvtfcHk0ljDCHjWUXE1WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1OmsbnM&md5=4d805408cb259263361589fa3a31544f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMra052717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra052717%26sid%3Dliteratum%253Aachs%26aulast%3DPatrono%26aufirst%3DC.%26aulast%3DGarcia%2BRodriguez%26aufirst%3DL.%2BA.%26aulast%3DLandolfi%26aufirst%3DR.%26aulast%3DBaigent%26aufirst%3DC.%26atitle%3DLow-dose%2520aspirin%2520for%2520the%2520prevention%2520of%2520atherothrombosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D2373%26epage%3D2383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Patrono, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocca, B.</span><span> </span><span class="NLM_article-title">Aspirin, 110 years later</span> <span class="citation_source-journal">J. Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">258</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1111%2Fj.1538-7836.2009.03391.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=19630812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvV2isLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=258-261&issue=Suppl.+1&author=C.+Patronoauthor=B.+Rocca&title=Aspirin%2C+110+years+later"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Aspirin, 110 years later</span></div><div class="casAuthors">Patrono, C.; Rocca, B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">258-261</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Although conceived at the end of the 19th century as a synthetic analgesic agent with improved gastric tolerability vs. naturally occurring salicylates, acetylsalicylic acid (marketed as aspirin in 1899) turned out to be an ideal antiplatelet agent about 90 years later, following the understanding of its mechanism of action, the development of a mechanism-based biomarker for dose-finding studies, and the initiation of a series of appropriately sized, randomized clin. trials to test its efficacy and safety at low doses given once daily.  At the turn of its 110th anniversary, aspirin continues to attract heated debates on a no. of issues including (i) the optimal dose to maximize efficacy and minimize toxicity; (ii) the possibility that some patients may be "resistant" to its antiplatelet effects; and (iii) the balance of benefits and risks in primary vs. secondary prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaK1LwyYwfRLVg90H21EOLACvtfcHk0lil_tlzgjmRoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvV2isLg%253D&md5=df16aa2e011b8d573786a4da76edeb99</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1538-7836.2009.03391.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1538-7836.2009.03391.x%26sid%3Dliteratum%253Aachs%26aulast%3DPatrono%26aufirst%3DC.%26aulast%3DRocca%26aufirst%3DB.%26atitle%3DAspirin%252C%2520110%2520years%2520later%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2009%26volume%3D7%26issue%3DSuppl.%25201%26spage%3D258%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Krejsa, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogalski, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penzotti, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migeon, J. C.</span><span> </span><span class="NLM_article-title">Predicting ADME properties and side effects: the BioPrint approach</span> <span class="citation_source-journal">Curr. Opin. Drug Discoveru Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">470</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=12951810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFymsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2003&pages=470-480&author=C.+M.+Krejsaauthor=D.+Horvathauthor=S.+L.+Rogalskiauthor=J.+E.+Penzottiauthor=B.+Maoauthor=F.+Barbosaauthor=J.+C.+Migeon&title=Predicting+ADME+properties+and+side+effects%3A+the+BioPrint+approach"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting ADME properties and side effects: The BioPrint approach</span></div><div class="casAuthors">Krejsa, Cecile M.; Horvath, Dragos; Rogalski, Sherri L.; Penzotti, Julie E.; Mao, Boryeu; Barbosa, Frederique; Migeon, Jacques C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">470-480</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Current Drugs</span>)
        </div><div class="casAbstract">A review.  Computational methods are increasingly used to streamline and enhance the lead discovery and optimization process.  However, accurate prediction of absorption, distribution, metab. and excretion (ADME) and adverse drug reactions (ADR) is often difficult, due to the complexity of underlying physiol. mechanisms.  Modeling approaches have been hampered by the lack of large, robust and standardized training datasets.  In an extensive effort to build such a dataset, the BioPrint database was constructed by systematic profiling of nearly all drugs available on the market, as well as numerous ref. compds.  The database is composed of several large datasets: compd. structures and mol. descriptors, in vitro ADME and pharmacol. profiles, and complementary clin. data including therapeutic use information, pharmacokinetics profiles and ADR profiles.  These data have allowed the development of computational tools designed to integrate a program of computational chem. into library design and lead development.  Models based on chem. structure are strengthened by in vitro results that can be used as addnl. compd. descriptors to predict complex in vivo endpoints.  The BioPrint pharmacoinformatics platform represents a systematic effort to accelerate the process of drug discovery, improve quant. structure-activity relationships and develop in vitro/in vivo assocns.  In this review, we will discuss the importance of training set size and diversity in model development, the implementation of linear and neighborhood modeling approaches, and the use of in silico methods to predict potential clin. liabilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZQ71juUoErrVg90H21EOLACvtfcHk0lil_tlzgjmRoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFymsLw%253D&md5=f8db4e37cc895d67bf4a82efe021c5c2</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrejsa%26aufirst%3DC.%2BM.%26aulast%3DHorvath%26aufirst%3DD.%26aulast%3DRogalski%26aufirst%3DS.%2BL.%26aulast%3DPenzotti%26aufirst%3DJ.%2BE.%26aulast%3DMao%26aufirst%3DB.%26aulast%3DBarbosa%26aufirst%3DF.%26aulast%3DMigeon%26aufirst%3DJ.%2BC.%26atitle%3DPredicting%2520ADME%2520properties%2520and%2520side%2520effects%253A%2520the%2520BioPrint%2520approach%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discoveru%2520Dev.%26date%3D2003%26volume%3D6%26spage%3D470%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Fliri, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loging, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thadeio, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volkmann, R. A.</span><span> </span><span class="NLM_article-title">Analysis of drug-induced effect patterns to link structure and side effects of medicines</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">–</span> <span class="NLM_lpage">397</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1038%2Fnchembio747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=16370374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1aiu7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=389-397&author=A.+F.+Fliriauthor=W.+T.+Logingauthor=P.+F.+Thadeioauthor=R.+A.+Volkmann&title=Analysis+of+drug-induced+effect+patterns+to+link+structure+and+side+effects+of+medicines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of drug-induced effect patterns to link structure and side effects of medicines</span></div><div class="casAuthors">Fliri, Anton F.; Loging, William T.; Thadeio, Peter F.; Volkmann, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">389-397</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The high failure rate of exptl. medicines in clin. trials accentuates inefficiencies of current drug discovery processes caused by a lack of tools for translating the information exchange between protein and organ system networks.  Recently, the authors reported that biol. activity spectra (biospectra), derived from in vitro protein binding assays, provide a mechanism for assessing a mol.'s capacity to modulate the function of protein-network components.  Herein the authors describe the translation of adverse effect data derived from 1045 prescription drug labels into effect spectra and show their utility for diagnosing drug-induced effects of medicines.  In addn., notwithstanding the limitation imposed by the quality of drug label information, the authors show that biospectrum anal., in concert with effect spectrum anal., provides an alignment between preclin. and clin. drug-induced effects.  The identification of this alignment provides a mechanism for forecasting clin. effect profiles of medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwQngpXzhXtbVg90H21EOLACvtfcHk0ljjLqrUN6I-qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1aiu7rK&md5=c1ef79fe178b6bf0a22fca744773bf00</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnchembio747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio747%26sid%3Dliteratum%253Aachs%26aulast%3DFliri%26aufirst%3DA.%2BF.%26aulast%3DLoging%26aufirst%3DW.%2BT.%26aulast%3DThadeio%26aufirst%3DP.%2BF.%26aulast%3DVolkmann%26aufirst%3DR.%2BA.%26atitle%3DAnalysis%2520of%2520drug-induced%2520effect%2520patterns%2520to%2520link%2520structure%2520and%2520side%2520effects%2520of%2520medicines%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2005%26volume%3D1%26spage%3D389%26epage%3D397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Fliri, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loging, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thadeio, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volkmann, R. A.</span><span> </span><span class="NLM_article-title">Biospectra analysis: model proteome characterizations for linking molecular structure and biological response</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6918</span><span class="NLM_x">–</span> <span class="NLM_lpage">6925</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050494g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGisrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6918-6925&author=A.+F.+Fliriauthor=W.+T.+Logingauthor=P.+F.+Thadeioauthor=R.+A.+Volkmann&title=Biospectra+analysis%3A+model+proteome+characterizations+for+linking+molecular+structure+and+biological+response"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Biospectra Analysis: Model Proteome Characterizations for Linking Molecular Structure and Biological Response</span></div><div class="casAuthors">Fliri, Anton F.; Loging, William T.; Thadeio, Peter F.; Volkmann, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6918-6925</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Establishing quant. relationships between mol. structure and broad biol. effects has been a long-standing goal in drug discovery.  Evaluation of the capacity of mols. to modulate protein functions is a prerequisite for understanding the relationship between mol. structure and in vivo biol. response.  A particular challenge in these investigations is to derive quant. measurements of a mol.'s functional activity pattern across different proteins.  Herein we describe an operationally simple probabilistic structure-activity relationship (SAR) approach, termed biospectra anal., for identifying agonist and antagonist effect profiles of medicinal agents by using pattern similarity between biol. activity spectra (biospectra) of mols. as the determinant.  Accordingly, in vitro binding data (percent inhibition values of mols. detd. at single high drug concn. in a battery of assays representing a cross section of the proteome) are useful for identifying functional effect profile similarity between medicinal agents.  To illustrate this finding, the relationship between biospectra similarity of 24 mols., identified by hierarchical clustering of a 1567 mol. dataset as being most closely aligned with the neurotransmitter dopamine, and their agonist or antagonist properties was probed.  Distinguishing the results described in this study from those obtained with affinity-based methods, the obsd. assocn. between biospectra and biol. response profile similarity remains intact even upon removal of putative drug targets from the dataset (four dopaminergic [D1/D2/D3/D4] and two adrenergic [α1 and α2] receptors).  These findings indicate that biospectra anal. provides an unbiased new tool for forecasting structure-response relationships and for translating broad biol. effect information into chem. structure design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJa5_zvZqHGLVg90H21EOLACvtfcHk0ljjLqrUN6I-qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGisrjE&md5=e899a8db1f2d66dcb7b7c5d656816111</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm050494g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050494g%26sid%3Dliteratum%253Aachs%26aulast%3DFliri%26aufirst%3DA.%2BF.%26aulast%3DLoging%26aufirst%3DW.%2BT.%26aulast%3DThadeio%26aufirst%3DP.%2BF.%26aulast%3DVolkmann%26aufirst%3DR.%2BA.%26atitle%3DBiospectra%2520analysis%253A%2520model%2520proteome%2520characterizations%2520for%2520linking%2520molecular%2520structure%2520and%2520biological%2520response%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6918%26epage%3D6925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Fliri, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loging, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thadeio, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volkmann, R. A.</span><span> </span><span class="NLM_article-title">Biological spectra analysis: linking biological activity profiles to molecular structure</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=261-266&author=A.+F.+Fliriauthor=W.+T.+Logingauthor=P.+F.+Thadeioauthor=R.+A.+Volkmann&title=Biological+spectra+analysis%3A+linking+biological+activity+profiles+to+molecular+structure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFliri%26aufirst%3DA.%2BF.%26aulast%3DLoging%26aufirst%3DW.%2BT.%26aulast%3DThadeio%26aufirst%3DP.%2BF.%26aulast%3DVolkmann%26aufirst%3DR.%2BA.%26atitle%3DBiological%2520spectra%2520analysis%253A%2520linking%2520biological%2520activity%2520profiles%2520to%2520molecular%2520structure%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D261%26epage%3D266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Kauvar, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villar, H. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sportsman, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engqvist-Goldstein, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilley, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocke, D. M.</span><span> </span><span class="NLM_article-title">Predicting ligand binding to proteins by affinity fingerprinting</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2F1074-5521%2895%2990283-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=9383411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADyaK2MXmtVWku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1995&pages=107-118&author=L.+M.+Kauvarauthor=D.+L.+Higginsauthor=H.+O.+Villarauthor=J.+R.+Sportsmanauthor=A.+Engqvist-Goldsteinauthor=R.+Bukarauthor=K.+E.+Bauerauthor=H.+Dilleyauthor=D.+M.+Rocke&title=Predicting+ligand+binding+to+proteins+by+affinity+fingerprinting"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting ligand binding to proteins by affinity fingerprinting</span></div><div class="casAuthors">Kauvar, Lawrence M.; Higgins, Deborah L.; Villar, Hugo O.; Sportsman, J Richard; Engqvist-Goldstein, Asa; Bukar, Robert; Bauer, Karin E.; Dilley, Hara; Rocke, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-18</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    </div><div class="casAbstract">There are many ways to represent a mol.'s properties, including at.-connectivity drawings, NMR spectra, and MO models.  Prior methods for predicting the biol. activity of compds. have largely depended on these phys. representations.  Measuring a compd.'s binding potency against a small ref. panel of diverse proteins defines a very different representation of the mol., which the authors call an affinity fingerprint.  Statistical anal. of such fingerprints provides new insights into aspects of binding interactions that are shared among a wide variety of proteins.  These analyses facilitate prediction of the binding properties of these compds. assayed against new proteins.  Affinity fingerprints are reported for 122 structurally-diverse compds. using a ref. panel of eight proteins that collectively are able to generate unique fingerprints for about 75% of the small org. compds. tested.  Application of multivariate regression techniques to this database enables the creation of computational surrogates to represent new proteins that are surprisingly effective at predicting binding potencies.  The authors illustrate this for two enzymes with no previously recognizable similarity to each other or to any of the ref. proteins.  Fitting of analogous computational surrogates to four other proteins confirms the generality of the method; when applied to a fingerprinted library of 5000 compds., several sub-micromolar hits were correctly predicted.  An affinity fingerprint database, which provides a rich source of data defining operational similarities among proteins, can be used to test theories of cryptic homol. unexpected from current understanding of protein structure.  Practical applications to drug design include efficient pre-screening of large nos. of compds. against target proteins using fingerprint similarities, supplemented by a small no. of empirical measurements, to select promising compds. for further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmBTYEbEBo-7Vg90H21EOLACvtfcHk0lhKsD3POte0eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmtVWku70%253D&md5=7fc9345e10262c7ef0bae7acb98d3556</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2F1074-5521%2895%2990283-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F1074-5521%252895%252990283-X%26sid%3Dliteratum%253Aachs%26aulast%3DKauvar%26aufirst%3DL.%2BM.%26aulast%3DHiggins%26aufirst%3DD.%2BL.%26aulast%3DVillar%26aufirst%3DH.%2BO.%26aulast%3DSportsman%26aufirst%3DJ.%2BR.%26aulast%3DEngqvist-Goldstein%26aufirst%3DA.%26aulast%3DBukar%26aufirst%3DR.%26aulast%3DBauer%26aufirst%3DK.%2BE.%26aulast%3DDilley%26aufirst%3DH.%26aulast%3DRocke%26aufirst%3DD.%2BM.%26atitle%3DPredicting%2520ligand%2520binding%2520to%2520proteins%2520by%2520affinity%2520fingerprinting%26jtitle%3DChem.%2520Biol.%26date%3D1995%26volume%3D2%26spage%3D107%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Hsu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damodaran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keck, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laborde, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lum, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macke, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schow, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villar, H. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wick, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beroza, P.</span><span> </span><span class="NLM_article-title">Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4875</span><span class="NLM_x">–</span> <span class="NLM_lpage">4880</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049950b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4875-4880&author=N.+Hsuauthor=D.+Caiauthor=K.+Damodaranauthor=R.+F.+Gomezauthor=J.+G.+Keckauthor=E.+Labordeauthor=R.+T.+Lumauthor=T.+J.+Mackeauthor=G.+Martinauthor=S.+R.+Schowauthor=R.+J.+Simonauthor=H.+O.+Villarauthor=M.+M.+Wickauthor=P.+Beroza&title=Novel+cyclooxygenase-1+inhibitors+discovered+using+affinity+fingerprints"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm049950b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049950b%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DN.%26aulast%3DCai%26aufirst%3DD.%26aulast%3DDamodaran%26aufirst%3DK.%26aulast%3DGomez%26aufirst%3DR.%2BF.%26aulast%3DKeck%26aufirst%3DJ.%2BG.%26aulast%3DLaborde%26aufirst%3DE.%26aulast%3DLum%26aufirst%3DR.%2BT.%26aulast%3DMacke%26aufirst%3DT.%2BJ.%26aulast%3DMartin%26aufirst%3DG.%26aulast%3DSchow%26aufirst%3DS.%2BR.%26aulast%3DSimon%26aufirst%3DR.%2BJ.%26aulast%3DVillar%26aufirst%3DH.%2BO.%26aulast%3DWick%26aufirst%3DM.%2BM.%26aulast%3DBeroza%26aufirst%3DP.%26atitle%3DNovel%2520cyclooxygenase-1%2520inhibitors%2520discovered%2520using%2520affinity%2520fingerprints%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D4875%26epage%3D4880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Koutsoukas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simms, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirchmair, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bond, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitmore, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glen, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, A.</span><span> </span><span class="NLM_article-title">From in silico target prediction to multi-target drug design: current databases, methods and applications</span> <span class="citation_source-journal">J. Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">2554</span><span class="NLM_x">–</span> <span class="NLM_lpage">2574</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.jprot.2011.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=21621023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2011&pages=2554-2574&author=A.+Koutsoukasauthor=B.+Simmsauthor=J.+Kirchmairauthor=P.+J.+Bondauthor=A.+V.+Whitmoreauthor=S.+Zimmerauthor=M.+P.+Youngauthor=J.+L.+Jenkinsauthor=M.+Glickauthor=R.+C.+Glenauthor=A.+Bender&title=From+in+silico+target+prediction+to+multi-target+drug+design%3A+current+databases%2C+methods+and+applications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">From in silico target prediction to multi-target drug design: Current databases, methods and applications</span></div><div class="casAuthors">Koutsoukas, Alexios; Simms, Benjamin; Kirchmair, Johannes; Bond, Peter J.; Whitmore, Alan V.; Zimmer, Steven; Young, Malcolm P.; Jenkins, Jeremy L.; Glick, Meir; Glen, Robert C.; Bender, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2554-2574</span>CODEN:
                <span class="NLM_cas:coden">JPORFQ</span>;
        ISSN:<span class="NLM_cas:issn">1874-3919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Given the tremendous growth of bioactivity databases, the use of computational tools to predict protein targets of small mols. has been gaining importance in recent years.  Applications span a wide range, from the designed polypharmacol.' of compds. to mode-of-action anal.  In this review, we firstly survey databases that can be used for ligand-based target prediction and which have grown tremendously in size in the past.  We furthermore outline methods for target prediction that exist, both based on the knowledge of bioactivities from the ligand side and methods that can be applied in situations when a protein structure is known.  Applications of successful in silico target identification attempts are discussed in detail, which were based partly or in whole on computational target predictions in the first instance.  This includes the authors' own experience using target prediction tools, in this case considering phenotypic antibacterial screens and the anal. of high-throughput screening data.  Finally, we will conclude with the prospective application of databases to not only predict, retrospectively, the protein targets of a small mol., but also how to design ligands with desired polypharmacol. in a prospective manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQAhthzL8wiLVg90H21EOLACvtfcHk0lhwE2TRaQgFtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtrfE&md5=3fd699639ef3faf347537ef400030dd9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jprot.2011.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jprot.2011.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DKoutsoukas%26aufirst%3DA.%26aulast%3DSimms%26aufirst%3DB.%26aulast%3DKirchmair%26aufirst%3DJ.%26aulast%3DBond%26aufirst%3DP.%2BJ.%26aulast%3DWhitmore%26aufirst%3DA.%2BV.%26aulast%3DZimmer%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DM.%2BP.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DBender%26aufirst%3DA.%26atitle%3DFrom%2520in%2520silico%2520target%2520prediction%2520to%2520multi-target%2520drug%2520design%253A%2520current%2520databases%252C%2520methods%2520and%2520applications%26jtitle%3DJ.%2520Proteomics%26date%3D2011%26volume%3D74%26spage%3D2554%26epage%3D2574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overington, J. P.</span><span> </span><span class="NLM_article-title">Can we rationally design promiscuous drugs?</span> <span class="citation_source-journal">Curr. Opin. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.sbi.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=16442279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=127-136&author=A.+L.+Hopkinsauthor=J.+S.+Masonauthor=J.+P.+Overington&title=Can+we+rationally+design+promiscuous+drugs%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Can we rationally design promiscuous drugs?</span></div><div class="casAuthors">Hopkins, Andrew L.; Mason, Jonathan S.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Structure-based drug design is now used widely in modern medicinal chem.  The application of structural biol. to medicinal chem. has heralded the 'rational drug design' vision of discovering exquisitely selective ligands.  However, recent advances in post-genomic biol. are indicating that polypharmacol. may be a necessary trait for the efficacy of many drugs, therefore questioning the 'one drug, one target' assumption of current rational drug design.  By combining advances in chemoinformatics and structural biol., it might be possible to rationally design the next generation of promiscuous drugs with polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWdh60x9AHrVg90H21EOLACvtfcHk0lhwE2TRaQgFtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D&md5=8f9e95a41976b8e3ac790f2fff2c406f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DCan%2520we%2520rationally%2520design%2520promiscuous%2520drugs%253F%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2006%26volume%3D16%26spage%3D127%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Mestres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregori-Puigjane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valverde, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sole, R. V.</span><span> </span><span class="NLM_article-title">The topology of drug–target interaction networks: implicit dependence on drug properties and target families</span> <span class="citation_source-journal">Mol BioSyst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1051</span><span class="NLM_x">–</span> <span class="NLM_lpage">1057</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1039%2Fb905821b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=19668871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1Kksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=1051-1057&author=J.+Mestresauthor=E.+Gregori-Puigjaneauthor=S.+Valverdeauthor=R.+V.+Sole&title=The+topology+of+drug%E2%80%93target+interaction+networks%3A+implicit+dependence+on+drug+properties+and+target+families"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The topology of drug-target interaction networks: Implicit dependence on drug properties and target families</span></div><div class="casAuthors">Mestres, Jordi; Gregori-Puigjane, Elisabet; Valverde, Sergi; Sole, Ricard V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1051-1057</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The availability of interaction data between small mol. drugs and protein targets has increased substantially in recent years.  Using seven different databases, we were able to assemble a total of 4767 unique interactions between 802 drugs and 480 targets, which means that on av. every drug is currently acknowledged to interact with 6 targets.  The application of network theory to the anal. of these data reveals an unexpectedly complex picture of drug-target interactions.  The results confirm that the topol. of drug-target networks depends implicitly on data completeness, drug properties, and target families.  The implications for drug discovery are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNAnnU4e6Jl7Vg90H21EOLACvtfcHk0lgA0VLI26oiQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1Kksbo%253D&md5=a0999bf0521936fba03400554411e8d7</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1039%2Fb905821b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb905821b%26sid%3Dliteratum%253Aachs%26aulast%3DMestres%26aufirst%3DJ.%26aulast%3DGregori-Puigjane%26aufirst%3DE.%26aulast%3DValverde%26aufirst%3DS.%26aulast%3DSole%26aufirst%3DR.%2BV.%26atitle%3DThe%2520topology%2520of%2520drug%25E2%2580%2593target%2520interaction%2520networks%253A%2520implicit%2520dependence%2520on%2520drug%2520properties%2520and%2520target%2520families%26jtitle%3DMol%2520BioSyst.%26date%3D2009%26volume%3D5%26spage%3D1051%26epage%3D1057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Paolini, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapland, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Hoorn, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Global mapping of pharmacological space</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">805</span><span class="NLM_x">–</span> <span class="NLM_lpage">815</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1038%2Fnbt1228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=16841068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFansb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=805-815&author=G.+V.+Paoliniauthor=R.+H.+Shaplandauthor=W.+P.+van+Hoornauthor=J.+S.+Masonauthor=A.+L.+Hopkins&title=Global+mapping+of+pharmacological+space"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Global mapping of pharmacological space</span></div><div class="casAuthors">Paolini, Gaia V.; Shapland, Richard H. B.; van Hoorn, Willem P.; Mason, Jonathan S.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">805-815</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We present the global mapping of pharmacol. space by the integration of several vast sources of medicinal chem. structure-activity relationships (SAR) data.  Our comprehensive mapping of pharmacol. space enables us to identify confidently the human targets for which chem. tools and drugs have been discovered to date.  The integration of SAR data from diverse sources by unique canonical chem. structure, protein sequence and disease indication enables the construction of a ligand-target matrix to explore the global relationships between chem. structure and biol. targets.  Using the data matrix, we are able to catalog the links between proteins in chem. space as a polypharmacol. interaction network.  We demonstrate that probabilistic models can be used to predict pharmacol. from a large knowledge base.  The relationships between proteins, chem. structures and drug-like properties provide a framework for developing a probabilistic approach to drug discovery that can be exploited to increase research productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV_CE47zZq8LVg90H21EOLACvtfcHk0lgA0VLI26oiQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFansb8%253D&md5=f559b34692cc903a1b503deb07030c5d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnbt1228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1228%26sid%3Dliteratum%253Aachs%26aulast%3DPaolini%26aufirst%3DG.%2BV.%26aulast%3DShapland%26aufirst%3DR.%2BH.%26aulast%3Dvan%2BHoorn%26aufirst%3DW.%2BP.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DGlobal%2520mapping%2520of%2520pharmacological%2520space%26jtitle%3DNat.%2520Biotechnol.%26date%3D2006%26volume%3D24%26spage%3D805%26epage%3D815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Fragments, network biology and designing multiple ligands</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">156</span><span class="NLM_x">–</span> <span class="NLM_lpage">160</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=156-160&author=R.+Morphyauthor=Z.+Rankovic&title=Fragments%2C+network+biology+and+designing+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFragments%252C%2520network%2520biology%2520and%2520designing%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D156%26epage%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Mestres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregori-Puigjane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valverde, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sole, R. V.</span><span> </span><span class="NLM_article-title">Data completeness—the Achilles heel of drug–target networks</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">983</span><span class="NLM_x">–</span> <span class="NLM_lpage">984</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=983-984&author=J.+Mestresauthor=E.+Gregori-Puigjaneauthor=S.+Valverdeauthor=R.+V.+Sole&title=Data+completeness%E2%80%94the+Achilles+heel+of+drug%E2%80%93target+networks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMestres%26aufirst%3DJ.%26aulast%3DGregori-Puigjane%26aufirst%3DE.%26aulast%3DValverde%26aufirst%3DS.%26aulast%3DSole%26aufirst%3DR.%2BV.%26atitle%3DData%2520completeness%25E2%2580%2594the%2520Achilles%2520heel%2520of%2520drug%25E2%2580%2593target%2520networks%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D983%26epage%3D984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Lagunin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stepanchikova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filimonov, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poroikov, V.</span><span> </span><span class="NLM_article-title">PASS: prediction of activity spectra for biologically active substances</span> <span class="citation_source-journal">Bioinformatics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">747</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2000&pages=747-748&author=A.+Laguninauthor=A.+Stepanchikovaauthor=D.+Filimonovauthor=V.+Poroikov&title=PASS%3A+prediction+of+activity+spectra+for+biologically+active+substances"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLagunin%26aufirst%3DA.%26aulast%3DStepanchikova%26aufirst%3DA.%26aulast%3DFilimonov%26aufirst%3DD.%26aulast%3DPoroikov%26aufirst%3DV.%26atitle%3DPASS%253A%2520prediction%2520of%2520activity%2520spectra%2520for%2520biologically%2520active%2520substances%26jtitle%3DBioinformatics%26date%3D2000%26volume%3D16%26spage%3D747%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, J. W.</span><span> </span><span class="NLM_article-title">“Bayes affinity fingerprints” improve retrieval rates in virtual screening and define orthogonal bioactivity space: When are multitarget drugs a feasible concept?</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2445</span><span class="NLM_x">–</span> <span class="NLM_lpage">2456</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci600197y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1yqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=2445-2456&author=A.+Benderauthor=J.+L.+Jenkinsauthor=M.+Glickauthor=Z.+Dengauthor=J.+H.+Nettlesauthor=J.+W.+Davies&title=%E2%80%9CBayes+affinity+fingerprints%E2%80%9D+improve+retrieval+rates+in+virtual+screening+and+define+orthogonal+bioactivity+space%3A+When+are+multitarget+drugs+a+feasible+concept%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">"Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept?</span></div><div class="casAuthors">Bender, Andreas; Jenkins, Jeremy L.; Glick, Meir; Deng, Zhan; Nettles, James H.; Davies, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2445-2456</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Conventional similarity searching of mols. compares single (or multiple) active query structures to each other in a relative framework, by means of a structural descriptor and a similarity measure.  While this often works well, depending on the target, the authors show here that retrieval rates can be improved considerably by incorporating an external framework describing ligand bioactivity space for comparisons ("Bayes affinity fingerprints").  Structures are described by Bayes scores for a ligand panel comprising about 1000 activity classes extd. from the WOMBAT database.  The comparison of structures is performed via the Pearson correlation coeff. of activity classes, i.e., the order in which two structures are similar to the panel activity classes.  Compd. retrieval on a recently published data set could be improved by as much as 24% relative (9% abs.).  Knowledge about the shape of the "bioactive chem. universe" is thus beneficial to identifying similar bioactivities.  Principal component anal. was employed to further analyze activity space with the objective to define orthogonal ligand bioactive chem. space, leading to nine major (roughly orthogonal) activity axes.  Employing only those nine activity classes, retrieval rates are still comparable to original Bayes affinity fingerprints; thus, the concept of orthogonal bioactive ligand chem. space was validated as being an information-rich but low-dimensional representation of bioactivity space.  Correlations between activity classes are a major determinant to gauge whether the desired multitarget activity of drugs is (on the basis of current knowledge) a feasible concept because it measures the extent to which activities can be optimized independently, or only by strongly influencing one another.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6IjlYwYDTwLVg90H21EOLACvtfcHk0liHNFdb8O_OFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1yqsrs%253D&md5=47adb720154f45bda1738963d54c70a5</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fci600197y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci600197y%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DNettles%26aufirst%3DJ.%2BH.%26aulast%3DDavies%26aufirst%3DJ.%2BW.%26atitle%3D%25E2%2580%259CBayes%2520affinity%2520fingerprints%25E2%2580%259D%2520improve%2520retrieval%2520rates%2520in%2520virtual%2520screening%2520and%2520define%2520orthogonal%2520bioactivity%2520space%253A%2520When%2520are%2520multitarget%2520drugs%2520a%2520feasible%2520concept%253F%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2006%26volume%3D46%26spage%3D2445%26epage%3D2456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheiber, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzaoui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span> </span><span class="NLM_article-title">Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">861</span><span class="NLM_x">–</span> <span class="NLM_lpage">873</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1002%2Fcmdc.200700026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=17477341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntVShu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=861-873&author=A.+Benderauthor=J.+Scheiberauthor=M.+Glickauthor=J.+W.+Daviesauthor=K.+Azzaouiauthor=J.+Hamonauthor=L.+Urbanauthor=S.+Whitebreadauthor=J.+L.+Jenkins&title=Analysis+of+pharmacology+data+and+the+prediction+of+adverse+drug+reactions+and+off-target+effects+from+chemical+structure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure</span></div><div class="casAuthors">Bender, Andreas; Scheiber, Josef; Glick, Meir; Davies, John W.; Azzaoui, Kamal; Hamon, Jacques; Urban, Laszlo; Whitebread, Steven; Jenkins, Jeremy L.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">861-873</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Preclin. Safety Pharmacol. (PSP) attempts to anticipate adverse drug reactions (ADRs) during early phases of drug discovery by testing compds. in simple, in vitro binding assays (i.e., preclin. profiling).  The selection of PSP targets is based largely on circumstantial evidence of their contribution to known clin. ADRs, inferred from findings in clin. trials, animal expts., and mol. studies going back more than 40 years.  In this work we explore PSP chem. space and its relevance for the prediction of adverse drug reactions.  Firstly, in silico (computational) Bayesian models for 70 PSP-related targets were built, which are able to detect 93% of the ligands binding at IC50≤ 10 μM at an overall correct classification rate of about 94 %.  Secondly, employing the World Drug Index (WDI), a model for adverse drug reactions was built directly based on normalized side-effect annotations in the WDI, which does not require any underlying functional knowledge.  This is, to our knowledge, the first attempt to predict adverse drug reactions across hundreds of categories from chem. structure alone.  On av. 90 % of the adverse drug reactions obsd. with known, clin. used compds. were detected, an overall correct classification rate of 92 %.  Drugs withdrawn from the market (Rapacuronium, Suprofen) were tested in the model and their predicted ADRs align well with known ADRs.  The anal. was repeated for acetylsalicylic acid and Benperidol which are still on the market.  Importantly, features of the models are interpretable and back-projectable to chem. structure, raising the possibility of rationally engineering out adverse effects.  By combining PSP and ADR models new hypotheses linking targets and adverse effects can be proposed and examples for the opioid μ and the muscarinic M2 receptors, as well as for cyclooxygenase-1 are presented.  It is hoped that the generation of predictive models for adverse drug reactions is able to help support early SAR to accelerate drug discovery and decrease late stage attrition in drug discovery projects.  In addn., models such as the ones presented here can be used for compd. profiling in all development stages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr28cgC-UGC3LVg90H21EOLACvtfcHk0liHNFdb8O_OFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntVShu74%253D&md5=b04e52a6b745d233415b106e53e6e2c9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700026%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%26aulast%3DScheiber%26aufirst%3DJ.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DJ.%2BW.%26aulast%3DAzzaoui%26aufirst%3DK.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DUrban%26aufirst%3DL.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26atitle%3DAnalysis%2520of%2520pharmacology%2520data%2520and%2520the%2520prediction%2520of%2520adverse%2520drug%2520reactions%2520and%2520off-target%2520effects%2520from%2520chemical%2520structure%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D861%26epage%3D873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armbruster, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernsberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Relating protein pharmacology by ligand chemistry</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1038%2Fnbt1284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=17287757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=197-206&author=M.+J.+Keiserauthor=B.+L.+Rothauthor=B.+N.+Armbrusterauthor=P.+Ernsbergerauthor=J.+J.+Irwinauthor=B.+K.+Shoichet&title=Relating+protein+pharmacology+by+ligand+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Relating protein pharmacology by ligand chemistry</span></div><div class="casAuthors">Keiser, Michael J.; Roth, Bryan L.; Armbruster, Blaine N.; Ernsberger, Paul; Irwin, John J.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-206</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of protein function based on biol. information is an area of intense research.  Here the authors consider a complementary technique that quant. groups and relates proteins based on the chem. similarity of their ligands.  The authors began with 65,000 ligands annotated into sets for hundreds of drug targets.  The similarity score between each set was calcd. using ligand topol.  A statistical model was developed to rank the significance of the resulting similarity scores, which are expressed as a min. spanning tree to map the sets together.  Although these maps are connected solely by chem. similarity, biol. sensible clusters nevertheless emerged.  Links among unexpected targets also emerged, among them that methadone, emetine and loperamide (Imodium) may antagonize muscarinic M3, α2 adrenergic and neurokinin NK2 receptors, resp.  These predictions were subsequently confirmed exptl.  Relating receptors by ligand chem. organizes biol. to reveal unexpected relationships that may be assayed using the ligands themselves.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNKEMguhmluLVg90H21EOLACvtfcHk0liTMR00EsV0aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOrsLo%253D&md5=1b7373d52563fca5fe1e893d85f70573</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnbt1284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1284%26sid%3Dliteratum%253Aachs%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DArmbruster%26aufirst%3DB.%2BN.%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DRelating%2520protein%2520pharmacology%2520by%2520ligand%2520chemistry%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D197%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laggner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuijer, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matos, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whaley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Predicting new molecular targets for known drugs</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1038%2Fnature08506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=19881490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlers7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=175-181&author=M.+J.+Keiserauthor=V.+Setolaauthor=J.+J.+Irwinauthor=C.+Laggnerauthor=A.+I.+Abbasauthor=S.+J.+Hufeisenauthor=N.+H.+Jensenauthor=M.+B.+Kuijerauthor=R.+C.+Matosauthor=T.+B.+Tranauthor=R.+Whaleyauthor=R.+A.+Glennonauthor=J.+Hertauthor=K.+L.+Thomasauthor=D.+D.+Edwardsauthor=B.+K.+Shoichetauthor=B.+L.+Roth&title=Predicting+new+molecular+targets+for+known+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting new molecular targets for known drugs</span></div><div class="casAuthors">Keiser, Michael J.; Setola, Vincent; Irwin, John J.; Laggner, Christian; Abbas, Atheir I.; Hufeisen, Sandra J.; Jensen, Niels H.; Kuijer, Michael B.; Matos, Roberto C.; Tran, Thuy B.; Whaley, Ryan; Glennon, Richard A.; Hert, Jerome; Thomas, Kelan L. H.; Edwards, Douglas D.; Shoichet, Brian K.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7270</span>),
    <span class="NLM_cas:pages">175-181</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although drugs are intended to be selective, at least some bind to several physiol. targets, explaining side effects and efficacy.  Because many drug-target combinations exist, it would be useful to explore possible interactions computationally.  Here we compared 3665 US Food and Drug Administration (FDA)-approved and investigational drugs against hundreds of targets, defining each target by its ligands.  Chem. similarities between drugs and ligand sets predicted thousands of unanticipated assocns.  Thirty were tested exptl., including the antagonism of the β1 receptor by the transporter inhibitor Prozac, the inhibition of the 5-hydroxytryptamine (5-HT) transporter by the ion channel drug Vadilex, and antagonism of the histamine H4 receptor by the enzyme inhibitor Rescriptor.  Overall, 23 new drug-target assocns. were confirmed, five of which were potent (<100 nM).  The physiol. relevance of one, the drug N,N-dimethyltryptamine (DMT) on serotonergic receptors, was confirmed in a knockout mouse.  The chem. similarity approach is systematic and comprehensive, and may suggest side-effects and new indications for many drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozd-8cCXUskrVg90H21EOLACvtfcHk0liTMR00EsV0aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlers7vO&md5=974e65f5d5b4dabde1a463c429215546</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature08506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08506%26sid%3Dliteratum%253Aachs%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DAbbas%26aufirst%3DA.%2BI.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DKuijer%26aufirst%3DM.%2BB.%26aulast%3DMatos%26aufirst%3DR.%2BC.%26aulast%3DTran%26aufirst%3DT.%2BB.%26aulast%3DWhaley%26aufirst%3DR.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DK.%2BL.%26aulast%3DEdwards%26aufirst%3DD.%2BD.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DPredicting%2520new%2520molecular%2520targets%2520for%2520known%2520drugs%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D175%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Simon, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peragovics, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigh-Smeller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csukly, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tombor, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahoranszky-Kohalmi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vegner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jelinek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hari, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hetenyi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitter, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czobor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malnasi-Csizmadia, A.</span><span> </span><span class="NLM_article-title">Drug effect prediction by polypharmacology-based interaction profiling</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci2002022" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVyrs73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=134-145&author=Z.+Simonauthor=A.+Peragovicsauthor=M.+Vigh-Smellerauthor=G.+Csuklyauthor=L.+Tomborauthor=Z.+Yangauthor=G.+Zahoranszky-Kohalmiauthor=L.+Vegnerauthor=B.+Jelinekauthor=P.+Hariauthor=C.+Hetenyiauthor=I.+Bitterauthor=P.+Czoborauthor=A.+Malnasi-Csizmadia&title=Drug+effect+prediction+by+polypharmacology-based+interaction+profiling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Effect Prediction by Polypharmacology-Based Interaction Profiling</span></div><div class="casAuthors">Simon, Zoltan; Peragovics, Agnes; Vigh-Smeller, Margit; Csukly, Gabor; Tombor, Laszlo; Yang, Zhenhui; Zahoranszky-Kohalmi, Gergely; Vegner, Laszlo; Jelinek, Balazs; Hari, Peter; Hetenyi, Csaba; Bitter, Istvan; Czobor, Pal; Malnasi-Csizmadia, Andras</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-145</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Most drugs exert their effects via multitarget interactions, as hypothesized by polypharmacol.  While these multitarget interactions are responsible for the clin. effect profiles of drugs, current methods have failed to uncover the complex relationships between them.  Here, we introduce an approach which is able to relate complex drug-protein interaction profiles with effect profiles.  Structural data and registered effect profiles of all small-mol. drugs were collected, and interactions to a series of non-target protein binding sites of each drug were calcd.  Statistical analyses confirmed a close relationship between the studied 177 major effect categories and interaction profiles of ca. 1200 FDA-approved small-mol. drugs.  On the basis of this relationship, the effect profiles of drugs were revealed in their entirety, and hitherto uncovered effects could be predicted in a systematic manner.  Our results show that the prediction power is independent of the compn. of the protein set used for interaction profile generation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH7-WOP-uBWbVg90H21EOLACvtfcHk0liTMR00EsV0aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVyrs73J&md5=50cb9593bcdc09f5cc8be563805a43bd</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fci2002022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci2002022%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DZ.%26aulast%3DPeragovics%26aufirst%3DA.%26aulast%3DVigh-Smeller%26aufirst%3DM.%26aulast%3DCsukly%26aufirst%3DG.%26aulast%3DTombor%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZahoranszky-Kohalmi%26aufirst%3DG.%26aulast%3DVegner%26aufirst%3DL.%26aulast%3DJelinek%26aufirst%3DB.%26aulast%3DHari%26aufirst%3DP.%26aulast%3DHetenyi%26aufirst%3DC.%26aulast%3DBitter%26aufirst%3DI.%26aulast%3DCzobor%26aufirst%3DP.%26aulast%3DMalnasi-Csizmadia%26aufirst%3DA.%26atitle%3DDrug%2520effect%2520prediction%2520by%2520polypharmacology-based%2520interaction%2520profiling%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D134%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Peragovics, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jelinek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hari, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hetenyi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czobor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malnasi-Csizmadia, A.</span><span> </span><span class="NLM_article-title">Contribution of 2D and 3D structural features of drug molecules in the prediction of drug profile matching</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1733</span><span class="NLM_x">–</span> <span class="NLM_lpage">1744</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci3001056" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC38XosV2qs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=1733-1744&author=A.+Peragovicsauthor=Z.+Simonauthor=I.+Brandhuberauthor=B.+Jelinekauthor=P.+Hariauthor=C.+Hetenyiauthor=P.+Czoborauthor=A.+Malnasi-Csizmadia&title=Contribution+of+2D+and+3D+structural+features+of+drug+molecules+in+the+prediction+of+drug+profile+matching"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of 2D and 3D Structural Features of Drug Molecules in the Prediction of Drug Profile Matching</span></div><div class="casAuthors">Peragovics, Agnes; Simon, Zoltan; Brandhuber, Ildiko; Jelinek, Balazs; Hari, Peter; Hetenyi, Csaba; Czobor, Pal; Malnasi-Csizmadia, Andras</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1733-1744</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug Profile Matching (DPM), a novel virtual affinity fingerprinting method capable of predicting the medical effect profiles of small mols., was introduced by our group recently.  The method exploits the information content of interaction patterns generated by flexible docking to a series of rigidly kept non-target protein active sites.  We presented the ability of DPM to classify mols. excellently, and the question arose, what the contribution of 2D and 3D structural features of the small mols. is to the intriguingly high prediction power of DPM.  The present study compared the prediction powers for effect profiles of 1163 FDA-approved drug compds. detd. by DPM and ChemAxon 2D and 3D similarity fingerprinting approaches.  We found that DPM outperformed the 2D and 3D approaches in almost all therapeutic categories for drug classification except for mech. rigid structural categories where high accuracy was obtained by all three methods.  Moreover, we also tested the predictive power of DPM on external data by reducing the parent data set and demonstrated that DPM can overcome the common screening problems of 2D and 3D similarity methods arising from the presence of structurally diverse mols. in certain effect categories.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWNAHp9HkXOrVg90H21EOLACvtfcHk0lgcIETxDz_ODA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosV2qs74%253D&md5=27afe2216f217e1e55e5e7eb40c1bd9a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fci3001056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci3001056%26sid%3Dliteratum%253Aachs%26aulast%3DPeragovics%26aufirst%3DA.%26aulast%3DSimon%26aufirst%3DZ.%26aulast%3DBrandhuber%26aufirst%3DI.%26aulast%3DJelinek%26aufirst%3DB.%26aulast%3DHari%26aufirst%3DP.%26aulast%3DHetenyi%26aufirst%3DC.%26aulast%3DCzobor%26aufirst%3DP.%26aulast%3DMalnasi-Csizmadia%26aufirst%3DA.%26atitle%3DContribution%2520of%25202D%2520and%25203D%2520structural%2520features%2520of%2520drug%2520molecules%2520in%2520the%2520prediction%2520of%2520drug%2520profile%2520matching%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D1733%26epage%3D1744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Ferreira, S. H.</span><span> </span><span class="NLM_article-title">Angiotensin converting enzyme: history and relevance</span> <span class="citation_source-journal">Semin. Perinatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">7</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2FS0146-0005%2800%2980046-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=10709850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD3c7ntlSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2000&pages=7-10&author=S.+H.+Ferreira&title=Angiotensin+converting+enzyme%3A+history+and+relevance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin converting enzyme: history and relevance</span></div><div class="casAuthors">Ferreira S H</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in perinatology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-10</span>
        ISSN:<span class="NLM_cas:issn">0146-0005</span>.
    </div><div class="casAbstract">The renin angiotensin system (RAS) is now recognized as the body's most powerful hormone system for controlling renal hemodynamics and sodium excretion and, therefore, body fluid volumes and arterial pressure.  The discovery of angiotensin converting enzyme inhibitors (ACEi) was a keystone for the understanding of the significance of the RAS since ACEi proved to be effective in controlling hypertension and heart failure and in preventing the development of the vascular injury of chronic diseases like scleroderma and diabetes mellitus.  The success of ACEi stimulated the research into inhibitors of other actors of the RAS like renin or angiotensin receptor antagonists.  It is not often realized that the discovery of ACEi owes a great deal to basic research in which the venom of a Brazilian viper, Bothrops Jararaca, was instrumental for the discovery of bradykinin by Rocha e Silva and the bradykinin potentiating factor.  This article reviews the contribution of the converting enzyme inhibitors for the demonstration of the relevance of the RAS to several human pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQvKBRtMxW_cULxIEhxUjPfW6udTcc2eYd7vmtmVvjf7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7ntlSrtg%253D%253D&md5=9c929123e8f290674d2d6c34cd0c7dd8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0146-0005%2800%2980046-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0146-0005%252800%252980046-4%26sid%3Dliteratum%253Aachs%26aulast%3DFerreira%26aufirst%3DS.%2BH.%26atitle%3DAngiotensin%2520converting%2520enzyme%253A%2520history%2520and%2520relevance%26jtitle%3DSemin.%2520Perinatol.%26date%3D2000%26volume%3D24%26spage%3D7%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Hackam, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemmelgarn, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabkin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Touyz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padwal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsay, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahon, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffrin, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruzicka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larochelle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moe, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howlett, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trudeau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrella, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milot, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drouin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulanger, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fodor, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dresser, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pylypchuk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiter, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarlane, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegele, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobe, S. W.</span><span> </span><span class="NLM_article-title">The 2010 Canadian hypertension education program recommendations for the management of hypertension: part 2—therapy</span> <span class="citation_source-journal">Can J Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">258</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2FS0828-282X%2810%2970379-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=20485689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnslamu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2010&pages=249-258&author=D.+G.+Hackamauthor=N.+A.+Khanauthor=B.+R.+Hemmelgarnauthor=S.+W.+Rabkinauthor=R.+M.+Touyzauthor=N.+R.+Campbellauthor=R.+Padwalauthor=T.+S.+Campbellauthor=M.+P.+Lindsayauthor=M.+D.+Hillauthor=R.+R.+Quinnauthor=J.+L.+Mahonauthor=R.+J.+Hermanauthor=E.+L.+Schiffrinauthor=M.+Ruzickaauthor=P.+Larochelleauthor=R.+D.+Feldmanauthor=M.+Lebelauthor=L.+Poirierauthor=J.+M.+Arnoldauthor=G.+W.+Moeauthor=J.+G.+Howlettauthor=L.+Trudeauauthor=S.+L.+Baconauthor=R.+J.+Petrellaauthor=A.+Milotauthor=J.+A.+Stoneauthor=D.+Drouinauthor=J.+M.+Boulangerauthor=M.+Sharmaauthor=P.+Hametauthor=G.+Fodorauthor=G.+K.+Dresserauthor=S.+G.+Carruthersauthor=G.+Pylypchukauthor=E.+D.+Burgessauthor=K.+D.+Burnsauthor=M.+Valleeauthor=G.+V.+Prasadauthor=R.+E.+Gilbertauthor=L.+A.+Leiterauthor=C.+Jonesauthor=R.+I.+Ogilvieauthor=V.+Wooauthor=P.+A.+McFarlaneauthor=R.+A.+Hegeleauthor=S.+W.+Tobe&title=The+2010+Canadian+hypertension+education+program+recommendations+for+the+management+of+hypertension%3A+part+2%E2%80%94therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy</span></div><div class="casAuthors">Hackam, Daniel G.; Khan, Nadia A.; Hemmelgarn, Brenda R.; Rabkin, Simon W.; Touyz, Rhian M.; Campbell, Normal R. C.; Padwal, Raj; Campbell, Tavis S.; Lindsay, M. Patrice; Hill, Michael D.; Quinn, Robert R.; Mahon, Jeff L.; Herman, Robert J.; Schiffrin, Ernesto L.; Ruzicka, Marcel; Larochelle, Pierre; Feldman, Ross D.; Lebel, Marcel; Poirier, Luc; Arnold, J. Malcolm O.; Moe, Gordon W.; Howlett, Jonathan G.; Trudeau, Luc; Bacon, Simon L.; Petrella, Robert J.; Milot, Alain; Stone, James A.; Drouin, Denis; Boulanger, Jean-Martin; Sharma, Mukul; Hamet, Pavel; Fodor, George; Dresser, George K.; Carruthers, S. George; Pylypchuk, George; Burgess, Ellen D.; Burns, Kevin D.; Vallee, Michel; Prasad, G. V. Ramesh; Gilbert, Richard E.; Leiter, Lawrence A.; Jones, Charlotte; Ogilvie, Richard I.; Woo, Vincent; McFarlane, Philip A.; Hegele, Robert A.; Tobe, Sheldon W.</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Journal of Cardiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">249-258</span>CODEN:
                <span class="NLM_cas:coden">CJCAEX</span>;
        ISSN:<span class="NLM_cas:issn">0828-282X</span>.
    
            (<span class="NLM_cas:orgname">Pulsus Group Inc.</span>)
        </div><div class="casAbstract">A review.  OBJECTIVE: To update the evidence-based recommendations for the prevention and treatment of hypertension in adults for 2010.  OPTIONS AND OUTCOMES: For lifestyle and pharmacol. interventions, randomized trials and systematic reviews of trials were preferentially reviewed.  Changes in cardiovascular morbidity and mortality were the primary outcomes of interest.  However, for lifestyle interventions, blood pressure lowering was accepted as a primary outcome given the general lack of long-term morbidity and mortality data in this field.  Progressive renal impairment was also accepted as a clin. relevant primary outcome among patients with chronic kidney disease.  EVIDENCE: A Cochrane Collaboration librarian conducted an independent MEDLINE search from 2008 to August 2009 to update the 2009 recommendations.  To identify addnl. studies, ref. lists were reviewed and experts were contacted.  All relevant articles were reviewed and appraised independently by both content and methodol. experts using prespecified levels of evidence.  RECOMMENDATIONS: For lifestyle modifications to prevent and treat hypertension, restrict dietary sodium to 1500 mg (65 mmol) per day in adults 50 years of age or younger, to 1300 mg (57 mmol) per day in adults 51 to 70 years of age, and to 1200 mg (52 mmol) per day in adults older than 70 years of age; perform 30 min to 60 min of moderate aerobic exercise four to seven days per wk; maintain a healthy body wt. (body mass index 18.5 kg/m2 to 24.9 kg/m2) and waist circumference (less than 102 cm for men and less than 88 cm for women); limit alc. consumption to no more than 14 std. drinks per wk for men or nine std. drinks per wk for women; follow a diet that emphasizes fruits, vegetables and low-fat dairy products, dietary and sol. fiber, whole grains and protein from plant sources, and that is low in satd. fat and cholesterol; and consider stress management in selected individuals with hypertension.For the pharmacol. management of hypertension, treatment thresholds and targets should be predicated on the patient's global atherosclerotic risk, target organ damage and comorbid conditions.  Blood pressure should be decreased to less than 140/90 mmHg in all patients, and to less than 130/80 mmHg in patients with diabetes mellitus or chronic kidney disease.  Most patients will require more than one agent to achieve these target blood pressures.  Antihypertensive therapy should be considered in all adult patients regardless of age (caution should be exercised in elderly patients who are frail).  For adults without compelling indications for other agents, considerations for initial therapy should include thiazide diuretics, angiotensin-converting enzyme (ACE) inhibitors (in patients who are not black), long-acting calcium channel blockers (CCBs), angiotensin receptor blockers (ARBs) or beta-blockers (in those younger than 60 years of age).  A combination of two first-line agents may also be considered as initial treatment of hypertension if systolic blood pressure is 20 mmHg above target or if diastolic blood pressure is 10 mmHg above target.  The combination of ACE inhibitors and ARBs should not be used, unless compelling indications are present to suggest consideration of dual therapy.  Agents appropriate for first-line therapy for isolated systolic hypertension include thiazide diuretics, long-acting dihydropyridine CCBs or ARBs.  In patients with coronary artery disease, ACE inhibitors, ARBs or beta-blockers are recommended as first-line therapy; in patients with cerebrovascular disease, an ACE inhibitor/diuretic combination is preferred; in patients with proteinuric nondiabetic chronic kidney disease, ACE inhibitors or ARBs (if intolerant to ACE inhibitors) are recommended; and in patients with diabetes mellitus, ACE inhibitors or ARBs (or, in patients without albuminuria, thiazides or dihydropyridine CCBs) are appropriate first-line therapies.  In selected high-risk patients in whom combination therapy is being considered, an ACE inhibitor plus a long-acting dihydropyridine CCB is preferable to an ACE inhibitor plus a thiazide diuretic.  All hypertensive patients with dyslipidemia should be treated using the thresholds, targets and agents outlined in the Canadian lipid treatment guidelines.  Selected patients with hypertension who do not achieve thresholds for statin therapy, but who are otherwise at high risk for cardiovascular events, should nonetheless receive statin therapy.  Once blood pressure is controlled, low-dose acetylsalicylic acid therapy should be considered.  VALIDATION: All recommendations were graded according to the strength of the evidence and voted on by the 63 members of the Canadian Hypertension Education Program Evidence-Based Recommendations Task Force.  All recommendations reported here achieved at least 80% consensus.  These guidelines will continue to be updated annually.  SPONSORS: The Canadian Hypertension Education Program process is sponsored by the Canadian Hypertension Society, Blood Pressure Canada, the Public Health Agency of Canada, the College of Family Physicians of Canada, the Canadian Pharmacists Assocn., the Canadian Council of Cardiovascular Nurses, and the Heart and Stroke Foundation of Canada.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnt2piftFs37Vg90H21EOLACvtfcHk0lgaV7HgxyKgXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnslamu74%253D&md5=c2f3aa5759dcbc3762a1787a25cbc7aa</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0828-282X%2810%2970379-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0828-282X%252810%252970379-2%26sid%3Dliteratum%253Aachs%26aulast%3DHackam%26aufirst%3DD.%2BG.%26aulast%3DKhan%26aufirst%3DN.%2BA.%26aulast%3DHemmelgarn%26aufirst%3DB.%2BR.%26aulast%3DRabkin%26aufirst%3DS.%2BW.%26aulast%3DTouyz%26aufirst%3DR.%2BM.%26aulast%3DCampbell%26aufirst%3DN.%2BR.%26aulast%3DPadwal%26aufirst%3DR.%26aulast%3DCampbell%26aufirst%3DT.%2BS.%26aulast%3DLindsay%26aufirst%3DM.%2BP.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DQuinn%26aufirst%3DR.%2BR.%26aulast%3DMahon%26aufirst%3DJ.%2BL.%26aulast%3DHerman%26aufirst%3DR.%2BJ.%26aulast%3DSchiffrin%26aufirst%3DE.%2BL.%26aulast%3DRuzicka%26aufirst%3DM.%26aulast%3DLarochelle%26aufirst%3DP.%26aulast%3DFeldman%26aufirst%3DR.%2BD.%26aulast%3DLebel%26aufirst%3DM.%26aulast%3DPoirier%26aufirst%3DL.%26aulast%3DArnold%26aufirst%3DJ.%2BM.%26aulast%3DMoe%26aufirst%3DG.%2BW.%26aulast%3DHowlett%26aufirst%3DJ.%2BG.%26aulast%3DTrudeau%26aufirst%3DL.%26aulast%3DBacon%26aufirst%3DS.%2BL.%26aulast%3DPetrella%26aufirst%3DR.%2BJ.%26aulast%3DMilot%26aufirst%3DA.%26aulast%3DStone%26aufirst%3DJ.%2BA.%26aulast%3DDrouin%26aufirst%3DD.%26aulast%3DBoulanger%26aufirst%3DJ.%2BM.%26aulast%3DSharma%26aufirst%3DM.%26aulast%3DHamet%26aufirst%3DP.%26aulast%3DFodor%26aufirst%3DG.%26aulast%3DDresser%26aufirst%3DG.%2BK.%26aulast%3DCarruthers%26aufirst%3DS.%2BG.%26aulast%3DPylypchuk%26aufirst%3DG.%26aulast%3DBurgess%26aufirst%3DE.%2BD.%26aulast%3DBurns%26aufirst%3DK.%2BD.%26aulast%3DVallee%26aufirst%3DM.%26aulast%3DPrasad%26aufirst%3DG.%2BV.%26aulast%3DGilbert%26aufirst%3DR.%2BE.%26aulast%3DLeiter%26aufirst%3DL.%2BA.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DOgilvie%26aufirst%3DR.%2BI.%26aulast%3DWoo%26aufirst%3DV.%26aulast%3DMcFarlane%26aufirst%3DP.%2BA.%26aulast%3DHegele%26aufirst%3DR.%2BA.%26aulast%3DTobe%26aufirst%3DS.%2BW.%26atitle%3DThe%25202010%2520Canadian%2520hypertension%2520education%2520program%2520recommendations%2520for%2520the%2520management%2520of%2520hypertension%253A%2520part%25202%25E2%2580%2594therapy%26jtitle%3DCan%2520J%2520Cardiol.%26date%3D2010%26volume%3D26%26spage%3D249%26epage%3D258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span>DrugBank, Open Data Drug & Drug Target Database: Candoxatril. <a href="http://www.drugbank.ca/drugs/DB00616" class="extLink">http://www.drugbank.ca/drugs/DB00616</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DrugBank%2C+Open+Data+Drug+%26+Drug+Target+Database%3A+Candoxatril.+http%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00616."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Cohen Solal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jondeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauvais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdeaux, A.</span><span> </span><span class="NLM_article-title">Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure</span> <span class="citation_source-journal">Eur. J. Heart Failure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">466</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.ejheart.2003.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=15182772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkslWqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=463-466&author=A.+Cohen+Solalauthor=G.+Jondeauauthor=F.+Beauvaisauthor=A.+Berdeaux&title=Beneficial+effects+of+carvedilol+on+angiotensin-converting+enzyme+activity+and+renin+plasma+levels+in+patients+with+chronic+heart+failure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure</span></div><div class="casAuthors">Cohen Solal, Alain; Jondeau, Guillaume; Beauvais, Florence; Berdeaux, Alain</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Heart Failure</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">463-466</span>CODEN:
                <span class="NLM_cas:coden">EJHFFS</span>;
        ISSN:<span class="NLM_cas:issn">1388-9842</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Objective: To assess the effects of carvedilol treatment on the renin-angiotensin system in patients with chronic heart failure (CHF).  Background: Carvedilol improves survival of patients suffering from CHF but the effects of the drug on angiotensin-converting enzyme (ACE) activity, renin and aldosterone are not well characterized in patients receiving an ACE inhibitor.  Methods: A randomized, multicenter, double-blind, 6-mo, placebo-controlled study of carvedilol vs. placebo was conducted in 64 CHF patients.  Circulating levels of ACE activity, active renin and aldosterone as well as left ventricular diams. and ejection fraction by echog. were assessed.  Results: During the study, left ventricular ejection fraction increased from 25±11% to 31±12% with carvedilol and from 27±12% to 28±12% with placebo (P=0.03).  This beneficial effect was assocd. with marked blunting of active renin secretion (-53% in the carvedilol group vs.-13% in the placebo group, P=0.04).  ACE activity was reduced by 30% in the carvedilol group (P=0.07 vs. placebo).  Aldosterone was not changed.  Conclusion: Carvedilol markedly reduced the increase in active renin obsd. with time despite ACE-inhibitors and tended to decrease ACE activity.  These findings may in part explain the beneficial actions of carvedilol and highlights the profound effect of beta blockade on renin in patients already receiving ACE-inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhhOEMK4AO4LVg90H21EOLACvtfcHk0lgaV7HgxyKgXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkslWqsb8%253D&md5=f01068d4cad6fca68d09f340578a572e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ejheart.2003.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejheart.2003.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%2BSolal%26aufirst%3DA.%26aulast%3DJondeau%26aufirst%3DG.%26aulast%3DBeauvais%26aufirst%3DF.%26aulast%3DBerdeaux%26aufirst%3DA.%26atitle%3DBeneficial%2520effects%2520of%2520carvedilol%2520on%2520angiotensin-converting%2520enzyme%2520activity%2520and%2520renin%2520plasma%2520levels%2520in%2520patients%2520with%2520chronic%2520heart%2520failure%26jtitle%3DEur.%2520J.%2520Heart%2520Failure%26date%3D2004%26volume%3D6%26spage%3D463%26epage%3D466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Flordellis, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goumenos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kourounis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsementzis, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paris, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vlachojiannis, J.</span><span> </span><span class="NLM_article-title">The shift in the “paradigm” of the pharmacology of hypertension</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">487</span><span class="NLM_x">–</span> <span class="NLM_lpage">498</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.2174%2F1568026043451348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=14965315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitV2gur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=487-498&author=C.+S.+Flordellisauthor=D.+Goumenosauthor=G.+Kourounisauthor=S.+A.+Tsementzisauthor=H.+Parisauthor=J.+Vlachojiannis&title=The+shift+in+the+%E2%80%9Cparadigm%E2%80%9D+of+the+pharmacology+of+hypertension"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The shift in the "paradigm" of the pharmacology of hypertension</span></div><div class="casAuthors">Flordellis, Christodoulos S.; Goumenos, Dimitrios; Kourounis, George; Tsementzis, Sotirios A.; Paris, Herve; Vlachojiannis, Jaannis</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">487-498</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  Until recently elevated blood pressure was considered as a hemodynamic entity representing an increase in workload for the heart and the arterial tree.  Control of hypertension meant hemodynamic unloading, through inhibition of vasoconstrictor pathways, principally renin-angiotensin system and sympathetic system.  In recent years however a new pharmacol. approach has evolved as a result of (i) the dissocn. of endothelial dysfunction and vascular pathol. from increased blood pressure; (ii) the recognition that endothelial dysfunction regards not only the vascular reactivity, but also promotes atherosclerosis and thrombosis; and (iii) an improved understanding of the complexity of local-tissue renin angiotensin system and of the vasodilatory and cytoprotective role of natriuretic peptides.  This has led to a reconsideration of existing medicines in terms of specification on endothelial function, more rationalized application of drugs and search for new compds. targeting both vasodilatory and anti-proliferative pathways.  Examples include β1-adrenergic antagonists, such as Nebivolol and Carvedilol, and vasopeptidase inhibitors, such as Omapatrilat, that inhibit simultaneously the angiotensin converting enzyme and neutral endopeptidase.  Furthermore the identification of genetic polymorphisms in the effectors involved in the pathophysiol. of hypertension or in the response to anti-hypertensive drugs, such as the p22phox subunit of NADPH oxidase, α-adducin or adrenergic receptors, has promoted the prospective of both better understanding of hypertension and individualized strategies for its treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog0eYQA2T8k7Vg90H21EOLACvtfcHk0lhiVHX0th3osw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitV2gur4%253D&md5=e26a7c0e158f12249bdcdc07f7b6fc4d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2174%2F1568026043451348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026043451348%26sid%3Dliteratum%253Aachs%26aulast%3DFlordellis%26aufirst%3DC.%2BS.%26aulast%3DGoumenos%26aufirst%3DD.%26aulast%3DKourounis%26aufirst%3DG.%26aulast%3DTsementzis%26aufirst%3DS.%2BA.%26aulast%3DParis%26aufirst%3DH.%26aulast%3DVlachojiannis%26aufirst%3DJ.%26atitle%3DThe%2520shift%2520in%2520the%2520%25E2%2580%259Cparadigm%25E2%2580%259D%2520of%2520the%2520pharmacology%2520of%2520hypertension%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D487%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Margulies, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrella, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinley, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, J. C.,  Jr.</span><span> </span><span class="NLM_article-title">Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">1636</span><span class="NLM_x">–</span> <span class="NLM_lpage">1642</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=1636-1642&author=K.+B.+Marguliesauthor=M.+A.+Perrellaauthor=L.+J.+McKinleyauthor=J.+C.+Burnett&title=Angiotensin+inhibition+potentiates+the+renal+responses+to+neutral+endopeptidase+inhibition+in+dogs+with+congestive+heart+failure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMargulies%26aufirst%3DK.%2BB.%26aulast%3DPerrella%26aufirst%3DM.%2BA.%26aulast%3DMcKinley%26aufirst%3DL.%2BJ.%26aulast%3DBurnett%26aufirst%3DJ.%2BC.%26atitle%3DAngiotensin%2520inhibition%2520potentiates%2520the%2520renal%2520responses%2520to%2520neutral%2520endopeptidase%2520inhibition%2520in%2520dogs%2520with%2520congestive%2520heart%2520failure%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1991%26volume%3D88%26spage%3D1636%26epage%3D1642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">McGovern, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caselli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grigorieff, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1712</span><span class="NLM_x">–</span> <span class="NLM_lpage">1722</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm010533y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD38Xhslegtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1712-1722&author=S.+L.+McGovernauthor=E.+Caselliauthor=N.+Grigorieffauthor=B.+K.+Shoichet&title=A+common+mechanism+underlying+promiscuous+inhibitors+from+virtual+and+high-throughput+screening"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening</span></div><div class="casAuthors">McGovern, Susan L.; Caselli, Emilia; Grigorieff, Nikolaus; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1712-1722</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High-throughput and virtual screening are widely used to discover novel leads for drug design.  On examn., many screening hits appear non-drug-like: they act noncompetitively, show little relation between structure and activity, and have poor selectivity.  Attempts to develop these peculiar mols. into viable leads are often futile, and much time can be wasted on the characterization of these "phony" hits.  Despite their common occurrence, the mechanism of action of these promiscuous mols. remains unknown.  To investigate this problem, 45 diverse screening hits were studied.  Fifteen of these were previously reported as inhibitors of various receptors, including β-lactamase, malarial protease, dihydrofolate reductase, HIV Tar RNA, thymidylate synthase, kinesin, insulin receptor, tyrosine kinases, farnesyltransferase, gyrase, prions, triosephosphate isomerase, nitric oxide synthase, phosphoinositide 3-kinase, and integrase; 30 were from an inhouse screening library of a major pharmaceutical company.  In addn. to their original targets, 35 of these 45 compds. were shown to inhibit several unrelated model enzymes.  These 35 screening hits included compds., such as fullerenes, dyes, and quercetin, that have repeatedly shown activity against diverse targets.  When tested against the model enzymes, the compds. showed time-dependent but reversible inhibition that was dramatically attenuated by albumin, guanidinium, or urea. Surprisingly, increasing the concn. of the model enzymes 10-fold largely eliminated inhibition, despite a 1000-fold excess of inhibitor; a well-behaved competitive inhibitor did not show this behavior.  One model to explain these observations was that the active form of the promiscuous inhibitors was an aggregate of many individual mols.  To test this hypothesis, light scattering and electron microscopy expts. were performed.  The nonspecific inhibitors were obsd. to form particles of 30-400 nm diam. by both techniques.  In control expts., a well-behaved competitive inhibitor and an inactive dye-like mol. were not obsd. to form aggregates.  Consistent with the hypothesis that the aggregates are the inhibitory species, the particle size and IC50 values of the promiscuous inhibitors varied monotonically with ionic strength; a competitive inhibitor was unaffected by changes in ionic strength. Unexpectedly, aggregate formation appears to explain the activity of many nonspecific inhibitors and may account for the activity of many promiscuous screening hits.  Mols. acting via this mechanism may be widespread in drug discovery screening databases.  Recognition of these compds. may improve screening results in many areas of pharmaceutical interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYFB0NNK2CIbVg90H21EOLACvtfcHk0lhiVHX0th3osw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xhslegtrk%253D&md5=b9e6c29f6a1da588a6452859061edfbb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm010533y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010533y%26sid%3Dliteratum%253Aachs%26aulast%3DMcGovern%26aufirst%3DS.%2BL.%26aulast%3DCaselli%26aufirst%3DE.%26aulast%3DGrigorieff%26aufirst%3DN.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DA%2520common%2520mechanism%2520underlying%2520promiscuous%2520inhibitors%2520from%2520virtual%2520and%2520high-throughput%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D1712%26epage%3D1722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Seidler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGovern, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doman, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Identification and prediction of promiscuous aggregating inhibitors among known drugs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4477</span><span class="NLM_x">–</span> <span class="NLM_lpage">4486</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030191r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1Kkt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4477-4486&author=J.+Seidlerauthor=S.+L.+McGovernauthor=T.+N.+Domanauthor=B.+K.+Shoichet&title=Identification+and+prediction+of+promiscuous+aggregating+inhibitors+among+known+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and prediction of promiscuous aggregating inhibitors among known drugs</span></div><div class="casAuthors">Seidler, James; McGovern, Susan L.; Doman, Thompson N.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4477-4486</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Some small mols., often hits from screening, form aggregates in soln. that inhibit many enzymes.  In contrast, drugs are thought to act specifically.  To investigate this assumption, 50 unrelated drugs were tested for promiscuous inhibition via aggregation.  Each drug was tested against three unrelated model enzymes: β-lactamase, chymotrypsin, and malate dehydrogenase, none of which are considered targets of these drugs.  To be judged promiscuous, the drugs had to inhibit all three enzymes, do so in a time-dependent manner, be sensitive to detergent and to enzyme concn., and form particles detectable by light scattering.  Of the 50 drugs tested, 43 were nonpromiscuous by these criteria.  Surprisingly, four of the drugs showed promiscuous, aggregation-based inhibition at concns. below 100 μM: clotrimazole, benzyl benzoate, nicardipine, and delavirdine.  Three other drugs also behaved as aggregation-based inhibitors, but only at high concns. (about 400 μM).  To investigate possible structure-activity relationships among promiscuous drugs, five analogs of the antifungal clotrimazole were studied.  Three of these, miconazole, econazole, and sulconazole, were promiscuous but the other two, fluconazole and ketoconazole, were not.  Using recursive partitioning, these exptl. results were used to develop a model for predicting aggregate-based promiscuity.  This model correctly classified 94% of 111 compds.-- 47 aggregators and 64 nonaggregators-- that have been studied for this effect.  To evaluate the model, it was used to predict the behavior of 75 drugs not previously investigated for aggregation.  Several preliminary points emerge.  Most drugs are not promiscuous, even at high concns.  Nevertheless, at high enough concns. (20-400 μM), some drugs can aggregate and act promiscuously, suggesting that aggregation may be common among small mols. at micromolar concns., at least in biochem. buffers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX6rct1y8KO7Vg90H21EOLACvtfcHk0liLn2zpnCYuww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1Kkt74%253D&md5=4bc47e2d426be688a79aa077ce6f9c3b</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm030191r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030191r%26sid%3Dliteratum%253Aachs%26aulast%3DSeidler%26aufirst%3DJ.%26aulast%3DMcGovern%26aufirst%3DS.%2BL.%26aulast%3DDoman%26aufirst%3DT.%2BN.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DIdentification%2520and%2520prediction%2520of%2520promiscuous%2520aggregating%2520inhibitors%2520among%2520known%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4477%26epage%3D4486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Yusuf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pogue, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copland, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumacher, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dagenais, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleight, P.</span><span> </span><span class="NLM_article-title">Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">1174</span><span class="NLM_x">–</span> <span class="NLM_lpage">1183</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2008&pages=1174-1183&author=S.+Yusufauthor=K.+Teoauthor=C.+Andersonauthor=J.+Pogueauthor=L.+Dyalauthor=I.+Coplandauthor=H.+Schumacherauthor=G.+Dagenaisauthor=P.+Sleight&title=Effects+of+the+angiotensin-receptor+blocker+telmisartan+on+cardiovascular+events+in+high-risk+patients+intolerant+to+angiotensin-converting+enzyme+inhibitors%3A+a+randomised+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYusuf%26aufirst%3DS.%26aulast%3DTeo%26aufirst%3DK.%26aulast%3DAnderson%26aufirst%3DC.%26aulast%3DPogue%26aufirst%3DJ.%26aulast%3DDyal%26aufirst%3DL.%26aulast%3DCopland%26aufirst%3DI.%26aulast%3DSchumacher%26aufirst%3DH.%26aulast%3DDagenais%26aufirst%3DG.%26aulast%3DSleight%26aufirst%3DP.%26atitle%3DEffects%2520of%2520the%2520angiotensin-receptor%2520blocker%2520telmisartan%2520on%2520cardiovascular%2520events%2520in%2520high-risk%2520patients%2520intolerant%2520to%2520angiotensin-converting%2520enzyme%2520inhibitors%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2008%26volume%3D372%26spage%3D1174%26epage%3D1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Eder, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeler, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teicher, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnipper, L. E.</span><span> </span><span class="NLM_article-title">A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">510</span><span class="NLM_x">–</span> <span class="NLM_lpage">513</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=510-513&author=J.+P.+Ederauthor=C.+A.+Wheelerauthor=B.+A.+Teicherauthor=L.+E.+Schnipper&title=A+phase+I+clinical+trial+of+novobiocin%2C+a+modulator+of+alkylating+agent+cytotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DWheeler%26aufirst%3DC.%2BA.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DSchnipper%26aufirst%3DL.%2BE.%26atitle%3DA%2520phase%2520I%2520clinical%2520trial%2520of%2520novobiocin%252C%2520a%2520modulator%2520of%2520alkylating%2520agent%2520cytotoxicity%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26spage%3D510%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Takahashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niioka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawada, K.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1186%2F1756-8722-5-23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslyitrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=23&author=N.+Takahashiauthor=M.+Miuraauthor=S.+A.+Scottauthor=T.+Niiokaauthor=K.+Sawada&title=Pharmacokinetics+of+dasatinib+for+Philadelphia-positive+acute+lymphocytic+leukemia+with+acquired+T315I+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation</span></div><div class="casAuthors">Takahashi, Naoto; Miura, Masatomo; Scott, Stuart A.; Niioka, Takenori; Sawada, Kenichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The BCR-ABL T315I kinase domain mutation is insensitive to dasatinib therapy for Philadelphia-pos. acute lymphoid leukemia (Ph + ALL) patients.  Resistant T315I clone may be present prior to initiating dasatinib, which could expand under selective pressures during treatment.  However, it is also possible that Ph + ALL patients newly acquire the T315I mutation during dasatinib therapy.  Despite the potent inhibition of BCR-ABL kinase by dasatinib, little is known about the relationship between dasatinib pharmacokinetics and the emergence of kinase domain mutations in vivo.  Methods: To det. whether plasma dasatinib pharmacokinetics influences the emergence of BCR-ABL mutations, we measured plasma dasatinib levels in 11 Ph + ALL patients undergoing dasatinib monotherapy.  Results: Bone marrow relapse occurred in 5 of the 11 Ph + ALL patients (45%).  Importantly, a T315I mutation was detected in 4 of the 5 relapsed patients, despite the absence of BCR-ABL mutations in any patient at baseline.  The median plasma concn. at 2 h (C2h), the median plasma max. concn. (Cmax) and the median area under the obsd. plasma concn.-time curve from 0 to 4 h (AUC0-4) were all significantly lower in patients with T315I than those without the mutation (C2h, 22.3ng/mL vs. 111.6ng/mL, P = 0.0242; Cmax, 43.8 ng/mL vs. 112.4 ng/mL, P = 0.0242; AUC0-4, 108.3 ng·h/mL vs. 268.3 ng·h/mL, P = 0.0061, resp.).  Conclusions: These data indicate that the emergence of the T315I mutation among Ph + ALL patients treated with dasatinib is, in part, dependent on plasma dasatinib pharmacokinetics.  Notably, these data also suggest that newly acquired BCR-ABL mutations may be inhibited by an increased exposure of dasatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc3M_-ntpO87Vg90H21EOLACvtfcHk0liLn2zpnCYuww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslyitrrP&md5=8e29ea3ce17a4fa8b068ad74708b725e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-5-23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-5-23%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DN.%26aulast%3DMiura%26aufirst%3DM.%26aulast%3DScott%26aufirst%3DS.%2BA.%26aulast%3DNiioka%26aufirst%3DT.%26aulast%3DSawada%26aufirst%3DK.%26atitle%3DPharmacokinetics%2520of%2520dasatinib%2520for%2520Philadelphia-positive%2520acute%2520lymphocytic%2520leukemia%2520with%2520acquired%2520T315I%2520mutation%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2012%26volume%3D5%26spage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Blobaum, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marnett, L. J.</span><span> </span><span class="NLM_article-title">Structural and functional basis of cyclooxygenase inhibition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1425</span><span class="NLM_x">–</span> <span class="NLM_lpage">1441</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0613166" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisFeisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1425-1441&author=A.+L.+Blobaumauthor=L.+J.+Marnett&title=Structural+and+functional+basis+of+cyclooxygenase+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Basis of Cyclooxygenase Inhibition</span></div><div class="casAuthors">Blobaum, Anna L.; Marnett, Lawrence J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1425-1441</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review will focus on the structural and functional basis of the inhibition of cyclooxygenase (COX) enzymes by nonselective and COX-2 selective inhibitors.  It will integrate kinetic, mechanistic, and structural information to illustrate not only the range of mols. with COX inhibitory activity but also the diversity of mechanisms by which they act.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8SMg_SRasDLVg90H21EOLACvtfcHk0ljMNwqu7Yk_kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisFeisL8%253D&md5=b9de2eafa7d2b510c866245b09fba546</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm0613166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0613166%26sid%3Dliteratum%253Aachs%26aulast%3DBlobaum%26aufirst%3DA.%2BL.%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26atitle%3DStructural%2520and%2520functional%2520basis%2520of%2520cyclooxygenase%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1425%26epage%3D1441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Pairet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelhardt, G.</span><span> </span><span class="NLM_article-title">Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications</span> <span class="citation_source-journal">Fundam. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1111%2Fj.1472-8206.1996.tb00144.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=8900495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADyaK28XjtFGrurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1996&pages=1-17&author=M.+Pairetauthor=G.+Engelhardt&title=Distinct+isoforms+%28COX-1+and+COX-2%29+of+cyclooxygenase%3A+possible+physiological+and+therapeutic+implications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: Possible physiological and therapeutic implications</span></div><div class="casAuthors">Pairet, M.; Engelhardt, G.</div><div class="citationInfo"><span class="NLM_cas:title">Fundamental & Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-15</span>CODEN:
                <span class="NLM_cas:coden">FCPHEZ</span>;
        ISSN:<span class="NLM_cas:issn">0767-3981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with >150 refs.  The discovery of an inducible isoform of cyclooxygenase (COX-2) requires a refinement of the theory that inhibition of cyclooxygenase activity explains both therapeutic and side effects of non-steroidal anti-inflammatory drugs (NSAIDs).  Indeed, new pharmacol. results suggest that COX-2 inhibition provides the therapeutic (ie, anti-inflammatory) activity of NSAIDs, whereas inhibition of constitutive COX-1 is responsible for their gastric and renal side effects as well as for their antithrombotic activity.  However, a role of COX-1 in inflammation cannot be excluded.  Furthermore, the functional relevance of COX-2 expression and induction in various tissues warrants further investigation.  These studies should help in predicting potential adverse effects as well as new indications for selective COX-2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppIEW1Xkq0u7Vg90H21EOLACvtfcHk0ljMNwqu7Yk_kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtFGrurk%253D&md5=2151e518ab44a4935ba91f40e63afa49</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fj.1472-8206.1996.tb00144.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1472-8206.1996.tb00144.x%26sid%3Dliteratum%253Aachs%26aulast%3DPairet%26aufirst%3DM.%26aulast%3DEngelhardt%26aufirst%3DG.%26atitle%3DDistinct%2520isoforms%2520%2528COX-1%2520and%2520COX-2%2529%2520of%2520cyclooxygenase%253A%2520possible%2520physiological%2520and%2520therapeutic%2520implications%26jtitle%3DFundam.%2520Clin.%2520Pharmacol.%26date%3D1996%26volume%3D10%26spage%3D1%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span> </span><span class="NLM_article-title">Painful lessons</span>.  <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">800</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Painful+lessons.+Nat.+Rev.+Drug+Discovery+2005%2C+4%2C+800%E2%80%93803."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DPainful%2520lessons%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D800%26epage%3D803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="note"><p class="first last">Information for Healthcare Professionals: valdecoxib (marketed as Bextra).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span>DrugBank, Open Data Drug & Drug Target Database: Ciclopirox. <a href="http://www.drugbank.ca/drugs/DB01188" class="extLink">http://www.drugbank.ca/drugs/DB01188</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DrugBank%2C+Open+Data+Drug+%26+Drug+Target+Database%3A+Ciclopirox.+http%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01188."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Bosetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weerasinghe, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberger, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapoport, S. I.</span><span> </span><span class="NLM_article-title">Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">690</span><span class="NLM_x">–</span> <span class="NLM_lpage">696</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1046%2Fj.1471-4159.2003.01701.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=12694395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslyrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2003&pages=690-696&author=F.+Bosettiauthor=G.+R.+Weerasingheauthor=T.+A.+Rosenbergerauthor=S.+I.+Rapoport&title=Valproic+acid+down-regulates+the+conversion+of+arachidonic+acid+to+eicosanoids+via+cyclooxygenase-1+and+-2+in+rat+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain</span></div><div class="casAuthors">Bosetti, Francesca; Weerasinghe, Gayani R.; Rosenberger, Thad A.; Rapoport, Stanley I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">690-696</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Sodium valproate, a mood stabilizer, when chronically administered to rats (200 mg/kg i.p. daily for 30 days) significantly reduced the brain protein levels of cyclooxygenase (COX)-1 and COX-2, without altering the mRNA levels of these enzymes.  COX activity was decreased, as were the brain concns. of 11-dehydrothromboxane B2 and prostaglandin E2 (PGE2), metabolites of arachidonic acid (AA) produced via COX.  In contrast, the brain protein level of 5-lipoxygenase and the concn. of its AA metabolite leukotriene B4 were unchanged.  In view of published evidence that lithium chloride administered chronically to rats, like chronic valproate, reduces AA turnover within brain phospholipids, and that lithium post-transcriptionally down-regulates COX-2 but not COX-1 protein level and enzyme activity, these observations suggest that mood stabilizers generally modulate the release and recycling of AA within brain phospholipids, and the conversion of AA via COX-2 to PGE2 and related eicosanoids.  If targeting this part of the "AA cascade" accounts for their therapeutic action, non-steroidal anti-inflammatory drugs or selective COX-2 inhibitors might prove effective in bipolar disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQfCKnUD1W6LVg90H21EOLACvtfcHk0lhxgyrZxO9b1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslyrsb4%253D&md5=f65bbf6f0857b7749ac7ea826527cf52</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2003.01701.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2003.01701.x%26sid%3Dliteratum%253Aachs%26aulast%3DBosetti%26aufirst%3DF.%26aulast%3DWeerasinghe%26aufirst%3DG.%2BR.%26aulast%3DRosenberger%26aufirst%3DT.%2BA.%26aulast%3DRapoport%26aufirst%3DS.%2BI.%26atitle%3DValproic%2520acid%2520down-regulates%2520the%2520conversion%2520of%2520arachidonic%2520acid%2520to%2520eicosanoids%2520via%2520cyclooxygenase-1%2520and%2520-2%2520in%2520rat%2520brain%26jtitle%3DJ.%2520Neurochem.%26date%3D2003%26volume%3D85%26spage%3D690%26epage%3D696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Jannesson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birkhed, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaffar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renvert, S.</span><span> </span><span class="NLM_article-title">Effect of oxybenzone on PGE2-production in vitro and on plaque and gingivitis in vivo</span> <span class="citation_source-journal">J. Clin. Periodontol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">91</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1111%2Fj.0303-6979.2004.00453.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=15016032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFSgsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2004&pages=91-94&author=L.+Jannessonauthor=D.+Birkhedauthor=D.+Scherlauthor=A.+Gaffarauthor=S.+Renvert&title=Effect+of+oxybenzone+on+PGE2-production+in+vitro+and+on+plaque+and+gingivitis+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of oxybenzone on PGE2-production in vitro and on plaque and gingivitis in vivo</span></div><div class="casAuthors">Jannesson, Lillemor; Birkhed, Dowen; Scherl, Dale; Gaffar, Abdul; Renvert, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Periodontology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-94</span>CODEN:
                <span class="NLM_cas:coden">JCPEDZ</span>;
        ISSN:<span class="NLM_cas:issn">0303-6979</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">To study the effect of oxybenzone on prostaglandin E2 (PGE2) prodn. in cell culture and to evaluate the effect of an oxybenzone-contg. dentifrice on plaque and gingivitis in a 6-wk clin. trial.  Human embryo palatal mesenchyme (HEPM) cells were used for testing the inhibition of IL-1β-stimulated PGE2-prodn. in vitro by different concns. of oxybenzone.  For the in vivo study, a total of 66 individuals with a Quigley and Hein plaque index of at least 1.5 and an Ainamo and Bay gingival index of at least 0.2 were included in a double-blind clin. trial with two cells and a parallel design.  Two compns. of fluoride dentifrice were used, one with the addn. of 0.5% oxybenzone, and one without.  Plaque and gingival index were obtained at three time points: (1) at baseline, (2) after 3 wk, and (3) after 6 wk.  A dose-dependent inhibition of PGE2-prodn. was found in the HEPM cell culture following oxybenzone exposure.  In the clin. trial, a 25% redn. of gingival index was obsd. in the oxybenzone group (p < 0.001) after 6 wk as compared with 2% for the placebo group.  These findings indicate that PGE2-prodn. is reduced by oxybenzone in vitro and that the use of oxybenzone in a dentifrice reduces gingivitis in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGpQ1IB-BA1rVg90H21EOLACvtfcHk0lhxgyrZxO9b1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFSgsbk%253D&md5=bfc71a292569b638618ea6666cff52ae</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1111%2Fj.0303-6979.2004.00453.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.0303-6979.2004.00453.x%26sid%3Dliteratum%253Aachs%26aulast%3DJannesson%26aufirst%3DL.%26aulast%3DBirkhed%26aufirst%3DD.%26aulast%3DScherl%26aufirst%3DD.%26aulast%3DGaffar%26aufirst%3DA.%26aulast%3DRenvert%26aufirst%3DS.%26atitle%3DEffect%2520of%2520oxybenzone%2520on%2520PGE2-production%2520in%2520vitro%2520and%2520on%2520plaque%2520and%2520gingivitis%2520in%2520vivo%26jtitle%3DJ.%2520Clin.%2520Periodontol.%26date%3D2004%26volume%3D31%26spage%3D91%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Ren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, S. H.</span><span> </span><span class="NLM_article-title">Anti-inflammatory effect of alpha-linolenic acid and its mode of action through the inhibition of nitric oxide production and inducible nitric oxide synthase gene expression via NF-kappaB and mitogen-activated protein kinase pathways</span> <span class="citation_source-journal">J. Agric. Food Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5073</span><span class="NLM_x">–</span> <span class="NLM_lpage">5080</span></span><div class="citationLinks">[<a href="/doi/10.1021/jf0702693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2007&pages=5073-5080&author=J.+Renauthor=S.+H.+Chung&title=Anti-inflammatory+effect+of+alpha-linolenic+acid+and+its+mode+of+action+through+the+inhibition+of+nitric+oxide+production+and+inducible+nitric+oxide+synthase+gene+expression+via+NF-kappaB+and+mitogen-activated+protein+kinase+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjf0702693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjf0702693%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DChung%26aufirst%3DS.%2BH.%26atitle%3DAnti-inflammatory%2520effect%2520of%2520alpha-linolenic%2520acid%2520and%2520its%2520mode%2520of%2520action%2520through%2520the%2520inhibition%2520of%2520nitric%2520oxide%2520production%2520and%2520inducible%2520nitric%2520oxide%2520synthase%2520gene%2520expression%2520via%2520NF-kappaB%2520and%2520mitogen-activated%2520protein%2520kinase%2520pathways%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2007%26volume%3D55%26spage%3D5073%26epage%3D5080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Ren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, S. H.</span><span> </span><span class="NLM_article-title">In vivo and in vitro anti-inflammatory activities of alpha-linolenic acid isolated from <i>Actinidia polygama</i> fruits</span> <span class="citation_source-journal">Arch. Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">708</span><span class="NLM_x">–</span> <span class="NLM_lpage">714</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1007%2FBF02977632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=17679548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosV2ltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2007&pages=708-714&author=J.+Renauthor=E.+J.+Hanauthor=S.+H.+Chung&title=In+vivo+and+in+vitro+anti-inflammatory+activities+of+alpha-linolenic+acid+isolated+from+Actinidia+polygama+fruits"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo and in vitro anti-inflammatory activities of α-linolenic acid isolated from Actinidia polygama fruits</span></div><div class="casAuthors">Ren, Jie; Han, Eun Jung; Chung, Sung Hyun</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">708-714</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">The fruit of Actinidia polygama (AP) has long been used as a folk medicine in Korea for the treatment of pain, rheumatoid arthritis and inflammation.  In the present study, bioassay-guided fractionation of AP led to the sepn. and identification of a polyunsatd. fatty acid, α-linolenic acid (ALA), which was found to show anti-inflammatory activity.  The anti-inflammatory effects of ALA, using acetic acid or carrageenan-induced inflammation models, were investigated in mice or rats, resp.  ALA significantly inhibited the acetic acid-induced vascular permeability in a dose dependent manner (34.2 and 37.7% inhibition at doses of 5 and 10 mg/kg, resp.).  ALA also significantly reduced a rat paw edema induced by a single treatment of carrageenan.  To investigate the mechanism of the anti-inflammatory action of ALA, the effects of ALA on lipopolysaccharide (LPS)-induced responses in the murine macrophages cell line, RAW 264.7, were examd.  Exposure of LPS-stimulated cells to ALA inhibited the accumulation of nitrite and prostaglandin E2 (PGE2) in the culture medium.  Consistent with these observations, the protein and mRNA expression levels of iNOS and COX-2 enzyme were markedly inhibited by ALA in a dose dependent manner.  These results suggest that the anti-inflammatory activity of ALA might be due to the suppression of the expressions of iNOS and COX-2 mRNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt4-TMaFd-EbVg90H21EOLACvtfcHk0lgTIUw1fXrGzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosV2ltrY%253D&md5=1e5eb8486f63df7e9c6d53c5eb4cdafc</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2FBF02977632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02977632%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DE.%2BJ.%26aulast%3DChung%26aufirst%3DS.%2BH.%26atitle%3DIn%2520vivo%2520and%2520in%2520vitro%2520anti-inflammatory%2520activities%2520of%2520alpha-linolenic%2520acid%2520isolated%2520from%2520Actinidia%2520polygama%2520fruits%26jtitle%3DArch.%2520Pharm.%2520Res.%26date%3D2007%26volume%3D30%26spage%3D708%26epage%3D714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Naveh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dottan, S. A.</span><span> </span><span class="NLM_article-title">Azathioprine’s inhibitory effect on prostaglandin E2 production is not via cyclooxygenase inhibition</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">157</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">732</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=1988&pages=727-732&author=N.+Navehauthor=C.+Weissmanauthor=S.+A.+Dottan&title=Azathioprine%E2%80%99s+inhibitory+effect+on+prostaglandin+E2+production+is+not+via+cyclooxygenase+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaveh%26aufirst%3DN.%26aulast%3DWeissman%26aufirst%3DC.%26aulast%3DDottan%26aufirst%3DS.%2BA.%26atitle%3DAzathioprine%25E2%2580%2599s%2520inhibitory%2520effect%2520on%2520prostaglandin%2520E2%2520production%2520is%2520not%2520via%2520cyclooxygenase%2520inhibition%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1988%26volume%3D157%26spage%3D727%26epage%3D732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Sharis, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannon, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loscalzo, J.</span><span> </span><span class="NLM_article-title">The antiplatelet effects of ticlopidine and clopidogrel</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">394</span><span class="NLM_x">–</span> <span class="NLM_lpage">405</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.7326%2F0003-4819-129-5-199809010-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=9735068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADyaK1cXmtFWkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=1998&pages=394-405&author=P.+J.+Sharisauthor=C.+P.+Cannonauthor=J.+Loscalzo&title=The+antiplatelet+effects+of+ticlopidine+and+clopidogrel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The antiplatelet effects of ticlopidine and clopidogrel</span></div><div class="casAuthors">Sharis, Peter J.; Cannon, Christopher P.; Loscalzo, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Internal Medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">394-405</span>CODEN:
                <span class="NLM_cas:coden">AIMEAS</span>;
        ISSN:<span class="NLM_cas:issn">0003-4819</span>.
    
            (<span class="NLM_cas:orgname">American College of Physicians</span>)
        </div><div class="casAbstract">A review with 142 refs.  Ticlopidine and clopidogrel achieve antiplatelet effects by inhibiting the binding of adenosine 5'-disphosphate to its platelet receptor.  Ticlopidine was first shown to decrease major events compared with placebo or aspirin in patients with stroke or recent transient ischemic attack.  Randomized studies in patients undergoing coronary artery stenting have shown that ticlopidine reduces the risk for subacute stent thrombosis compared with warfarin-based regimens.  Smaller studies have also shown this drug to have benefit during follow-up in patients with unstable angina, peripheral arterial disease, saphenous vein coronary bypass grafts, and diabetic retinopathy.  Clopidogrel was recently approved by the U.S. Food and Drug Administration for the redn. of ischemic events in patients with recent myocardial infarction, stroke, or peripheral arterial disease (incidence, 5.32% per yr compared with 5.83% per yr for aspirin; P = 0.043) with no added risk for neutropenia.  The combination of clopidogrel and aspirin, as well as the utility of clopidogrel in other patient populations and in stenting, requires further study.  Ticlopidine and clopidogrel seem to have beneficial effects compared with aspirin (the current std.) in a broad range of patients.  These observations highlight the importance of antiplatelet therapy in cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlhFBrtn7subVg90H21EOLACvtfcHk0lhWtufcYxMp6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtFWkt7o%253D&md5=48725dceaf9094915272fb53aeb6fa7f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-129-5-199809010-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-129-5-199809010-00009%26sid%3Dliteratum%253Aachs%26aulast%3DSharis%26aufirst%3DP.%2BJ.%26aulast%3DCannon%26aufirst%3DC.%2BP.%26aulast%3DLoscalzo%26aufirst%3DJ.%26atitle%3DThe%2520antiplatelet%2520effects%2520of%2520ticlopidine%2520and%2520clopidogrel%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D1998%26volume%3D129%26spage%3D394%26epage%3D405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Richer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giroux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plouin, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maarek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giudicelli, J. F.</span><span> </span><span class="NLM_article-title">Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1111%2Fj.1365-2125.1984.tb02338.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=6324834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADyaL2c7nvVyrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1984&pages=243-250&author=C.+Richerauthor=B.+Girouxauthor=P.+F.+Plouinauthor=B.+Maarekauthor=J.+F.+Giudicelli&title=Captopril%3A+pharmacokinetics%2C+antihypertensive+and+biological+effects+in+hypertensive+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients</span></div><div class="casAuthors">Richer C; Giroux B; Plouin P F; Maarek B; Giudicelli J F</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">243-50</span>
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">The kinetics of captopril plasma levels and of the drug-induced plasma converting enzyme activity (PCEA), plasma renin activity (PRA) and diastolic blood pressure (DBP) modifications were studied over 24 h after oral administration of captopril, 1 mg/kg, to ten hypertensive patients.  Free unchanged captopril pharmacokinetic parameters were: t1/2, alpha: 0.45 +/- 0.06 h; tmax: 0.98 +/- 0.13 h; Cmax: 1.31 +/- 0.20 mg l-1; t1/2,z: 0.66 +/- 0.13 h; V: 0.614 +/- 0.104 1 kg-1 and CLtot: 0.690 +/- 0.082 l h-1 kg-1.  At 6 h captopril was no longer detectable in plasma.  The onset of PCEA inhibition and of DBP decrease closely followed the rise of captopril's plasma levels, while that of PRA increase was delayed.  In contrast, while captopril rapidly disappeared from plasma, its biological and antihypertensive effects were long-lasting.  The lack of correlation between the relative bioavailability of captopril and the induced reduction in DBP (evaluated by the corresponding AUCs) suggests that free unchanged captopril plasma monitoring is not an adequate indicator of hypertensive patients' potential responsiveness to captopril's blood pressure lowering effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjBnXpCO_SOxBrI9DTGjC0fW6udTcc2eYpBoADsiLEKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c7nvVyrsg%253D%253D&md5=276a95ba39a47a93fb454c17a4a343dd</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.1984.tb02338.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.1984.tb02338.x%26sid%3Dliteratum%253Aachs%26aulast%3DRicher%26aufirst%3DC.%26aulast%3DGiroux%26aufirst%3DB.%26aulast%3DPlouin%26aufirst%3DP.%2BF.%26aulast%3DMaarek%26aufirst%3DB.%26aulast%3DGiudicelli%26aufirst%3DJ.%2BF.%26atitle%3DCaptopril%253A%2520pharmacokinetics%252C%2520antihypertensive%2520and%2520biological%2520effects%2520in%2520hypertensive%2520patients%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1984%26volume%3D17%26spage%3D243%26epage%3D250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taggart, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benbrook, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lind, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, W. Q.</span><span> </span><span class="NLM_article-title">Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline)</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.canlet.2011.06.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=21899946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1GhsLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2011&pages=11-17&author=H.+Jiangauthor=J.+E.+Taggartauthor=X.+Zhangauthor=D.+M.+Benbrookauthor=S.+E.+Lindauthor=W.+Q.+Ding&title=Nitroxoline+%288-hydroxy-5-nitroquinoline%29+is+more+a+potent+anti-cancer+agent+than+clioquinol+%285-chloro-7-iodo-8-quinoline%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline)</span></div><div class="casAuthors">Jiang, Hongchao; Taggart, Jori E.; Zhang, Xiaoxi; Benbrook, Doris M.; Lind, Stuart E.; Ding, Wei-Qun</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-17</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Clioquinol has been shown to have anticancer activity both in vitro and in vivo.  The present study compared the cytotoxicity of clioquinol with six analogs using human cancer cell lines.  Of the analogs tested, 8-hydroxy-5-nitroquinoline (NQ) was the most toxic, with an IC50 that was five to ten fold lower than that of other congeners.  Its activity was enhanced by copper, but not zinc, and the use of a zinc-sensitive fluorophore showed that unlike clioquinol, NQ is not a zinc ionophore.  NQ increased intracellular reactive oxygen species generation, an effect that was significantly enhanced by the addn. of copper at levels approx. the same as those found in human plasma.  NQ has been used in humans for the treatment of urinary infections.  NQ is an 8-hydroxyquinoline deriv. that is more potent than the halogenated 8-hydroxyquinolines, and it may be less neurotoxic because it lacks zinc ionophore activity.  NQ is another clin. used anti-microbial agent whose properties suggest that it may be useful in treating cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorjDvax3Qu4bVg90H21EOLACvtfcHk0lgaU7o3IspDSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1GhsLbP&md5=9afce210f9a491bcd70285f087bcba1d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2011.06.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2011.06.032%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DTaggart%26aufirst%3DJ.%2BE.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DBenbrook%26aufirst%3DD.%2BM.%26aulast%3DLind%26aufirst%3DS.%2BE.%26aulast%3DDing%26aufirst%3DW.%2BQ.%26atitle%3DNitroxoline%2520%25288-hydroxy-5-nitroquinoline%2529%2520is%2520more%2520a%2520potent%2520anti-cancer%2520agent%2520than%2520clioquinol%2520%25285-chloro-7-iodo-8-quinoline%2529%26jtitle%3DCancer%2520Lett.%26date%3D2011%26volume%3D312%26spage%3D11%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Sosic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirkovic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arenz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefane, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobec, S.</span><span> </span><span class="NLM_article-title">Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure–activity relationships of nitroxoline derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">521</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301544x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=521-533&author=I.+Sosicauthor=B.+Mirkovicauthor=K.+Arenzauthor=B.+Stefaneauthor=J.+Kosauthor=S.+Gobec&title=Development+of+new+cathepsin+B+inhibitors%3A+combining+bioisosteric+replacements+and+structure-based+design+to+explore+the+structure%E2%80%93activity+relationships+of+nitroxoline+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm301544x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301544x%26sid%3Dliteratum%253Aachs%26aulast%3DSosic%26aufirst%3DI.%26aulast%3DMirkovic%26aufirst%3DB.%26aulast%3DArenz%26aufirst%3DK.%26aulast%3DStefane%26aufirst%3DB.%26aulast%3DKos%26aufirst%3DJ.%26aulast%3DGobec%26aufirst%3DS.%26atitle%3DDevelopment%2520of%2520new%2520cathepsin%2520B%2520inhibitors%253A%2520combining%2520bioisosteric%2520replacements%2520and%2520structure-based%2520design%2520to%2520explore%2520the%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520nitroxoline%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D521%26epage%3D533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Seeman, P.</span><span> </span><span class="NLM_article-title">Dopamine D2 receptors as treatment targets in schizophrenia</span> <span class="citation_source-journal">Clin. Schizophr. Relat. Psychoses</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.3371%2FCSRP.4.1.5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BC3cnosVaqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=56-73&author=P.+Seeman&title=Dopamine+D2+receptors+as+treatment+targets+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D2 receptors as treatment targets in schizophrenia</span></div><div class="casAuthors">Seeman Philip</div><div class="citationInfo"><span class="NLM_cas:title">Clinical schizophrenia & related psychoses</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-73</span>
        ISSN:<span class="NLM_cas:issn">1935-1232</span>.
    </div><div class="casAbstract">The antipsychotic effectiveness of chlorpromazine and haloperidol started a search for their therapeutic targets.  The antipsychotic receptor target turned out to be a dopamine receptor, now cloned as the dopamine D2 receptor.  The D2 receptor is the common target for antipsychotics.  Antipsychotic clinical doses correlate with their affinities for this receptor.  Therapeutic doses of antipsychotics occupy 60 to 80% of brain D2 receptors in patients, but aripiprazole occupies up to 90%.  While antipsychotics may take up to six hours to occupy D2 receptors, much clinical improvement occurs within a few days.  The receptor has high- and low-affinity states.  The D2High state is functional for dopamine-like agonists such as aripiprazole.  Most individuals with schizophrenia are supersensitive to dopamine.  Animal models of psychosis show that a variety of risk factors, genetic and nongenetic, are associated with behavioral supersensitivity to dopamine, reflected in elevated levels of dopamine D2High receptors.  Although antipsychotics such as haloperidol alleviate psychosis and reverse the elevation of D2High receptors, long-term use of traditional antipsychotics can further enhance dopamine supersensitivity in patients.  Therefore, switching from a traditional antipsychotic to an agonist antipsychotic such as aripiprazole can result in the emergence of psychotic signs and symptoms.  Clozapine and quetiapine do not elicit parkinsonism and rarely result in tardive dyskinesia because they are released from D2 within 12 to 24 hours.  Traditional antipsychotics remain attached to D2 receptors for days, preventing relapse, but allowing accumulation that can lead to tardive dyskinesia.  Future goals include imaging D2High receptors and desensitizing them in early-stage psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3lJfKBYPsRWhHGZei4OW9fW6udTcc2eYGTmO3SjhLQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnosVaqtg%253D%253D&md5=14dc6329120a843ddbb3411dc8328229</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.3371%2FCSRP.4.1.5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3371%252FCSRP.4.1.5%26sid%3Dliteratum%253Aachs%26aulast%3DSeeman%26aufirst%3DP.%26atitle%3DDopamine%2520D2%2520receptors%2520as%2520treatment%2520targets%2520in%2520schizophrenia%26jtitle%3DClin.%2520Schizophr.%2520Relat.%2520Psychoses%26date%3D2010%26volume%3D4%26spage%3D56%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Kaizaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tien, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Numazawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatt, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, L. W.</span><span> </span><span class="NLM_article-title">Celecoxib reduces brain dopaminergic neuronaldysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide</span> <span class="citation_source-journal">J Neuroinflammation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1186%2F1742-2094-10-45" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=23561827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFCktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=45&author=A.+Kaizakiauthor=L.+T.+Tienauthor=Y.+Pangauthor=Z.+Caiauthor=S.+Tanakaauthor=S.+Numazawaauthor=A.+J.+Bhattauthor=L.+W.+Fan&title=Celecoxib+reduces+brain+dopaminergic+neuronaldysfunction%2C+and+improves+sensorimotor+behavioral+performance+in+neonatal+rats+exposed+to+systemic+lipopolysaccharide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Celecoxib reduces brain dopaminergic neuronaldysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide</span></div><div class="casAuthors">Kaizaki, Asuka; Tien, Lu-Tai; Pang, Yi; Cai, Zhengwei; Tanaka, Sachiko; Numazawa, Satoshi; Bhatt, Abhay J.; Fan, Lir-Wan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroinflammation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45</span>CODEN:
                <span class="NLM_cas:coden">JNOEB3</span>;
        ISSN:<span class="NLM_cas:issn">1742-2094</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Cyclooxygenase-2 (COX-2) is induced in inflammatory cells in response to cytokines and pro-inflammatory mols., suggesting that COX-2 has a role in the inflammatory process.  The objective of the current study was to examine whether celecoxib, a selective COX-2 inhibitor, could ameliorate lipopolysaccharide (LPS)-induced brain inflammation, dopaminergic neuronal dysfunction and sensorimotor behavioral impairments.  I.p. (i.p.) injection of LPS (2 mg/kg) was performed in rat pups on postnatal Day 5 (P5), and celecoxib (20 mg/kg) or vehicle was administered (i.p.) five minutes after LPS injection.  Sensorimotor behavioral tests were carried out 24 h after LPS exposure, and brain injury was examd. on P6.  Our results showed that LPS exposure resulted in impairment in sensorimotor behavioral performance and injury to brain dopaminergic neurons, as indicated by loss of tyrosine hydroxylase (TH) immunoreactivity, as well as decreases in mitochondria activity in the rat brain.  LPS exposure also led to increases in the expression of α-synuclein and dopamine transporter proteins and enhanced [3H]dopamine uptake.  Treatment with celecoxib significantly reduced LPS-induced sensorimotor behavioral disturbances and dopaminergic neuronal dysfunction.  Celecoxib administration significantly attenuated LPS-induced increases in the nos. of activated microglia and astrocytes and in the concn. of IL-1β in the neonatal rat brain.  The protective effect of celecoxib was also assocd. with an attenuation of LPS-induced COX-2+ cells, which were double labeled with TH + (dopaminergic neuron) or glial fibrillary acidic protein (GFAP) + (astrocyte) cells.  Systemic LPS administration induced brain inflammatory responses in neonatal rats; these inflammatory responses included induction of COX-2 expression in TH neurons and astrocytes.  Application of the COX-2 inhibitor celecoxib after LPS treatment attenuated the inflammatory response and improved LPS-induced impairment, both biochem. and behaviorally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzxcgbV6ZKnrVg90H21EOLACvtfcHk0lgEBFJzwsav9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFCktrc%253D&md5=24edf38dbf7e8df83d909a2598c08b1c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1186%2F1742-2094-10-45&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-2094-10-45%26sid%3Dliteratum%253Aachs%26aulast%3DKaizaki%26aufirst%3DA.%26aulast%3DTien%26aufirst%3DL.%2BT.%26aulast%3DPang%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DNumazawa%26aufirst%3DS.%26aulast%3DBhatt%26aufirst%3DA.%2BJ.%26aulast%3DFan%26aufirst%3DL.%2BW.%26atitle%3DCelecoxib%2520reduces%2520brain%2520dopaminergic%2520neuronaldysfunction%252C%2520and%2520improves%2520sensorimotor%2520behavioral%2520performance%2520in%2520neonatal%2520rats%2520exposed%2520to%2520systemic%2520lipopolysaccharide%26jtitle%3DJ%2520Neuroinflammation%26date%3D2013%26volume%3D10%26spage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Akhondzadeh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jafari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raisi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasehi, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghoreishi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salehi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohebbi-Rasa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raznahan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamalipour, A.</span><span> </span><span class="NLM_article-title">Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial</span> <span class="citation_source-journal">Depression Anxiety</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">607</span><span class="NLM_x">–</span> <span class="NLM_lpage">611</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1002%2Fda.20589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=19496103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1aqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=607-611&author=S.+Akhondzadehauthor=S.+Jafariauthor=F.+Raisiauthor=A.+A.+Nasehiauthor=A.+Ghoreishiauthor=B.+Salehiauthor=S.+Mohebbi-Rasaauthor=M.+Raznahanauthor=A.+Kamalipour&title=Clinical+trial+of+adjunctive+celecoxib+treatment+in+patients+with+major+depression%3A+a+double+blind+and+placebo+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial</span></div><div class="casAuthors">Akhondzadeh, Shahin; Jafari, Sara; Raisi, Firoozeh; Nasehi, Abbas Ali; Ghoreishi, Aboulfazl; Salehi, Bahman; Mohebbi-Rasa, Soodeh; Raznahan, Maedeh; Kamalipour, Abbas</div><div class="citationInfo"><span class="NLM_cas:title">Depression and Anxiety</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">607-611</span>CODEN:
                <span class="NLM_cas:coden">DEANF5</span>;
        ISSN:<span class="NLM_cas:issn">1091-4269</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The pathophysiol. of depression is assocd. with the hyperactivity of immune inflammatory responses.  Cyclooxygenase-2 inhibitors such as celecoxib reduce the prodn. of pro-inflammatory cytokines.  The purpose of the present investigation was to assess the efficacy of celecoxib as an adjuvant agent in the treatment of major depression in a six-week double blind and placebo controlled trial.  Forty adult outpatients who met the DSM-IV-TR criteria for major depression participated in the trial.  Patients have a baseline Hamilton Rating Scale for Depression score of at least 18.  Patients were allocated in a random fashion: 20 to fluoxetine 40 mg/day plus celecoxib 400 mg/day (200 mg bid) (morning and evening) and 20 to fluoxetine 40 mg/day plus placebo.  Patients were assessed by a psychiatrist at baseline and after 1, 2, 4, and 6 wk after the medication started.  Although both protocols significantly decreased the score of Hamilton Rating Scale for Depression over the trial period, the combination of fluoxetine and celecoxib showed a significant superiority over fluoxetine alone in the treatment of symptoms of major depression.  There were no significant differences in the two groups in terms of obsd. side effects.  The results of this study suggest that celecoxib may be an effective adjuvant agent in the management of patients with major depression and anti-inflammatory therapies should be further investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkHZysSCewtrVg90H21EOLACvtfcHk0lg4zR2TqHm9zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1aqtb0%253D&md5=e45bc52353041c5d4aab9ebbe289232f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fda.20589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fda.20589%26sid%3Dliteratum%253Aachs%26aulast%3DAkhondzadeh%26aufirst%3DS.%26aulast%3DJafari%26aufirst%3DS.%26aulast%3DRaisi%26aufirst%3DF.%26aulast%3DNasehi%26aufirst%3DA.%2BA.%26aulast%3DGhoreishi%26aufirst%3DA.%26aulast%3DSalehi%26aufirst%3DB.%26aulast%3DMohebbi-Rasa%26aufirst%3DS.%26aulast%3DRaznahan%26aufirst%3DM.%26aulast%3DKamalipour%26aufirst%3DA.%26atitle%3DClinical%2520trial%2520of%2520adjunctive%2520celecoxib%2520treatment%2520in%2520patients%2520with%2520major%2520depression%253A%2520a%2520double%2520blind%2520and%2520placebo%2520controlled%2520trial%26jtitle%3DDepression%2520Anxiety%26date%3D2009%26volume%3D26%26spage%3D607%26epage%3D611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Akhondzadeh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabatabaee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amini, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abhari, S. A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbasi, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnam, B.</span><span> </span><span class="NLM_article-title">Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.schres.2006.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=17208413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FnsFKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2007&pages=179&author=S.+Akhondzadehauthor=M.+Tabatabaeeauthor=H.+Aminiauthor=S.+A.+A.+Abhariauthor=S.+H.+Abbasiauthor=B.+Behnam&title=Celecoxib+as+adjunctive+therapy+in+schizophrenia%3A+a+double-blind%2C+randomized+and+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial</span></div><div class="casAuthors">Akhondzadeh Shahin; Tabatabaee Maryam; Amini Homayoun; Ahmadi Abhari Seyed Ali; Abbasi Seyed Hesamedin; Behnam Behnaz</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">179-85</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Some evidence suggests that the pathophysiology of schizophrenia is associated with the abnormal immune system, and cytokines may be important in schizophrenia.  Cyclooxygenase-2 (COX-2) inhibitors such as celecoxib reduce the production of proinflammatory cytokines including Th1-like cytokines.  Indeed, COX-2 inhibitors rebalance type-1 and type-2 immune response.  The purpose of the present investigation was to assess the efficacy of celecoxib as an adjuvant agent in the treatment of chronic schizophrenia in an eight-week, double-blind and placebo-controlled trial.  Eligible participants in this study were 60 patients with chronic schizophrenia.  All patients were inpatients and were in the active phase of the illness, and met DSM-IV criteria for schizophrenia.  Patients were allocated in a random fashion, 30 to risperidone 6 mg/day plus celecoxib 400 mg/day (200 mg bid) (morning and evening) and 30 to risperidone 6 mg/day plus placebo.  Although both protocols significantly decreased the score of the positive, negative and general psychopathological symptoms over the trial period, the combination of risperidone and celecoxib showed a significant superiority over risperidone alone in the treatment of positive symptoms, general psychopathology symptoms as well as PANSS total scores.  The means Extrapyramidal Symptoms Rating Scale for the placebo group were higher than in the celecoxib group over the trial.  However, the differences were not significant.  The results of this study suggest that celecoxib may be an effective adjuvant agent in the management of patients with chronic schizophrenia and anti-inflammatory therapies should be further investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKRlaq_gfxtA20zIbnCCI3fW6udTcc2ebkTXx4D75Ho7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FnsFKjtA%253D%253D&md5=ccbbc9523ec8698ddfde8a38889aa333</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2006.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2006.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DAkhondzadeh%26aufirst%3DS.%26aulast%3DTabatabaee%26aufirst%3DM.%26aulast%3DAmini%26aufirst%3DH.%26aulast%3DAbhari%26aufirst%3DS.%2BA.%2BA.%26aulast%3DAbbasi%26aufirst%3DS.%2BH.%26aulast%3DBehnam%26aufirst%3DB.%26atitle%3DCelecoxib%2520as%2520adjunctive%2520therapy%2520in%2520schizophrenia%253A%2520a%2520double-blind%252C%2520randomized%2520and%2520placebo-controlled%2520trial%26jtitle%3DSchizophr.%2520Res.%26date%3D2007%26volume%3D90%26spage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Gattaz, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrahao, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foccacia, R.</span><span> </span><span class="NLM_article-title">Childhood meningitis, brain maturation and the risk of psychosis</span> <span class="citation_source-journal">Eur. Arch. Psychiatry Clin. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">254</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1007%2Fs00406-004-0431-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=14991375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD2c7gtVaqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=2004&pages=23-26&author=W.+F.+Gattazauthor=A.+L.+Abrahaoauthor=R.+Foccacia&title=Childhood+meningitis%2C+brain+maturation+and+the+risk+of+psychosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Childhood meningitis, brain maturation and the risk of psychosis</span></div><div class="casAuthors">Gattaz Wagner F; Abrahao Andre L; Foccacia Roberto</div><div class="citationInfo"><span class="NLM_cas:title">European archives of psychiatry and clinical neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-6</span>
        ISSN:<span class="NLM_cas:issn">0940-1334</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXQfoFnlhTBXy-c-E1v-fmfW6udTcc2ebkTXx4D75Ho7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7gtVaqsA%253D%253D&md5=e56c666b11d61e3e02b05fcd347fe079</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1007%2Fs00406-004-0431-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00406-004-0431-3%26sid%3Dliteratum%253Aachs%26aulast%3DGattaz%26aufirst%3DW.%2BF.%26aulast%3DAbrahao%26aufirst%3DA.%2BL.%26aulast%3DFoccacia%26aufirst%3DR.%26atitle%3DChildhood%2520meningitis%252C%2520brain%2520maturation%2520and%2520the%2520risk%2520of%2520psychosis%26jtitle%3DEur.%2520Arch.%2520Psychiatry%2520Clin.%2520Neurosci.%26date%3D2004%26volume%3D254%26spage%3D23%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Muller, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehning, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musil, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schennach-Wolff, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obermeier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moller, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klauss, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedel, M.</span><span> </span><span class="NLM_article-title">Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">118</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.schres.2010.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=20570110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BC3cjhtFyiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2010&pages=118-124&author=N.+Mullerauthor=D.+Krauseauthor=S.+Dehningauthor=R.+Musilauthor=R.+Schennach-Wolffauthor=M.+Obermeierauthor=H.+J.+Mollerauthor=V.+Klaussauthor=M.+J.+Schwarzauthor=M.+Riedel&title=Celecoxib+treatment+in+an+early+stage+of+schizophrenia%3A+results+of+a+randomized%2C+double-blind%2C+placebo-controlled+trial+of+celecoxib+augmentation+of+amisulpride+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment</span></div><div class="casAuthors">Muller Norbert; Krause Daniela; Dehning Sandra; Musil Richard; Schennach-Wolff Rebecca; Obermeier Michael; Moller Hans-Jurgen; Klauss Volker; Schwarz Markus J; Riedel Michael</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">118-24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recent trials support the hypothesis of the role of inflammation in the pathogenesis of schizophrenia.  The overall therapeutic benefit of anti-inflammatory medication, in particular cyclo-oxygenase-2 (COX-2) inhibitors in schizophrenia, is still controversial.  There are suggestions that therapy with COX-2 inhibitors may influence the early stages of the disease.  Taking these findings into account, we conducted a double-blind, placebo-controlled, randomized trial of celecoxib augmentation to amisulpride treatment in patients with a first manifestation of schizophrenia.  Forty-nine patients diagnosed with schizophrenia were randomly assigned.  They were treated either with amisulpride (200-1000 mg) plus celecoxib (400 mg) or amisulpride (200-1000 mg) plus placebo.  Inclusion criterion was the diagnosis of schizophrenia during the past two years according to DSM-IV.  The trial lasted six weeks.  At weekly intervals an assessment of the psychopathology was performed using the Positive and Negative Symptom Scale (PANSS) and the Global Clinical Impression Scale (CGI).  A significantly better outcome was observed in the patient group treated with amisulpride plus celecoxib compared to the group with amisulpride plus placebo (PANSS negative: p=0.03; PANSS global; p=0.05 and PANSS total: p=0.02).  In addition, ratings by the CGI scale during therapy with amisulpride and celecoxib showed a significantly better result (p< or =0.001).  A significantly superior therapeutic effect could be observed in the celecoxib group compared to placebo in the treatment of early stage schizophrenia.  This is the first time an improvement in patients' negative symptoms has been demonstrated with celecoxib.  In future, further trials are needed to investigate the effect of COX-2 inhibitors on prodromal and negative symptoms of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOQ9gKuPc8iK-9TkgmBqTqfW6udTcc2ebkTXx4D75Ho7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjhtFyiug%253D%253D&md5=1ca45316f470390af04cddf0562529f3</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2010.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2010.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DN.%26aulast%3DKrause%26aufirst%3DD.%26aulast%3DDehning%26aufirst%3DS.%26aulast%3DMusil%26aufirst%3DR.%26aulast%3DSchennach-Wolff%26aufirst%3DR.%26aulast%3DObermeier%26aufirst%3DM.%26aulast%3DMoller%26aufirst%3DH.%2BJ.%26aulast%3DKlauss%26aufirst%3DV.%26aulast%3DSchwarz%26aufirst%3DM.%2BJ.%26aulast%3DRiedel%26aufirst%3DM.%26atitle%3DCelecoxib%2520treatment%2520in%2520an%2520early%2520stage%2520of%2520schizophrenia%253A%2520results%2520of%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520celecoxib%2520augmentation%2520of%2520amisulpride%2520treatment%26jtitle%3DSchizophr.%2520Res.%26date%3D2010%26volume%3D121%26spage%3D118%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Muller, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M.</span><span> </span><span class="NLM_article-title">Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission</span> <span class="citation_source-journal">Neurotoxic Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1007%2FBF03033242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=17062375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD28nivFKmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=131-148&author=N.+Mullerauthor=M.+Schwarz&title=Schizophrenia+as+an+inflammation-mediated+dysbalance+of+glutamatergic+neurotransmission"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission</span></div><div class="casAuthors">Muller N; Schwarz M</div><div class="citationInfo"><span class="NLM_cas:title">Neurotoxicity research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-48</span>
        ISSN:<span class="NLM_cas:issn">1029-8428</span>.
    </div><div class="casAbstract">This overview tries to bridge the gap between psychoneuroimmunological findings and recent results from pharmacological, neurochemical and genetic studies in schizophrenia.  Schizophrenia is a disorder of dopaminergic neurotransmission, but modulation of the dopaminergic system by glutamatergic neurotransmission seems to play a key role.  This view is supported by genetic findings of the neuregulin- and dysbindin genes, which have functional impact on the glutamatergic system.  Glutamatergic hypofunction, however, is mediated by the N-methyl-D-aspartate (NMDA)-receptor antagonism.  The only endogenous NMDA receptor antagonist identified up to now is kynurenic acid (KYNA).  Despite the NMDA receptor antagonism, KYNA also blocks, in lower doses, the nicotinergic acetycholine receptor, i.e., increased KYNA levels can explain psychotic symptoms and cognitive deterioration.  KYNA levels are described to be higher in the cerebrospinal fluid (CSF) and in critical central nervous system (CNS) regions of schizophrenics as compared to controls.  Another line of evidence suggests that a (prenatal) infection is involved in the pathogenesis of schizophrenia.  Due to an early sensitization process of the immune system or to a (chronic) infection, which is not cleared through the immune response, an immune imbalance between the type-1 and the type-2 immune responses takes place in schizophrenia.  The type-1 response is partially inhibited, while the type-2 response is over-activated.  This immune constellation is associated with inhibition of the enzyme indoleamine dioxygenase (IDO), because IDO - located in astrocytes and microglial cells - is inhibited by type-2 cytokines.  IDO catalyzes the first step in tryptophan metabolism, the degradation from tryptophan to kynurenine, as does tryptophan 2,3-dioxygenase (TDO).  Due to the inhibition of IDO, tryptophan-kynurenine is predominantly metabolized by TDO, which is located in astrocytes, not in microglial or other CNS cells.  In schizophrenia, astrocytes in particular are activated, as increased levels of S100B appear.  Additionally, they do not have the enzymatic equipment for the normal metabolism-route of tryptophan.  Due to the lack of kynurenine hydroxylase (KYN-OHase) in astrocytes, KYNA accumulates in the CNS, while the metabolic pathway in microglial cells is blocked.  Accordingly, an increase of TDO activity has been observed in critical CNS regions of schizophrenics.  These mechanisms result in an accumulation of KYNA in critical CNS regions.  Thus, the immune-mediated glutamatergic-dopaminergic dysregulation may lead to the clinical symptoms of schizophrenia.  Therapeutic consequences, e.g., the use of anti-inflammatory cyclo-oxygenase-2 inhibitors, which can also decrease KYNA directly, are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWdjXoFfOT9tTiMd2aNQVUfW6udTcc2eYr0skT5G-efbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nivFKmsQ%253D%253D&md5=4a05e1868fb906518686e21f0463c888</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1007%2FBF03033242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03033242%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DN.%26aulast%3DSchwarz%26aufirst%3DM.%26atitle%3DSchizophrenia%2520as%2520an%2520inflammation-mediated%2520dysbalance%2520of%2520glutamatergic%2520neurotransmission%26jtitle%3DNeurotoxic%2520Res.%26date%3D2006%26volume%3D10%26spage%3D131%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Potvin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepehry, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gendron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bah, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouassi, E.</span><span> </span><span class="NLM_article-title">Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">801</span><span class="NLM_x">–</span> <span class="NLM_lpage">808</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.biopsych.2007.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=18005941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVKgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2008&pages=801-808&author=S.+Potvinauthor=E.+Stipauthor=A.+A.+Sepehryauthor=A.+Gendronauthor=R.+Bahauthor=E.+Kouassi&title=Inflammatory+cytokine+alterations+in+schizophrenia%3A+a+systematic+quantitative+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review</span></div><div class="casAuthors">Potvin, Stephane; Stip, Emmanuel; Sepehry, Amir A.; Gendron, Alain; Bah, Ramatoulaye; Kouassi, Edouard</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">801-808</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Cytokines play an important role in infection and inflammation and are crucial mediators of the cross-talk between the brain and the immune system.  Schizophrenia would be assocd. with an imbalance in inflammatory cytokines, leading to a decrease in Th1 and an increase in Th2 cytokine secretion.  However, data published so far have been inconsistent.  The primary objective of the present meta-anal. was to verify whether the cytokine imbalance hypothesis of schizophrenia is substantiated by evidence.  Cross-sectional studies were included if they assessed in vivo plasma or serum cytokine concns. and/or in vitro secretion of cytokines by peripheral blood leukocytes from schizophrenia patients and healthy volunteers.  Data from 62 studies involving a total sample size of 2298 schizophrenia patients and 1858 healthy volunteers remained for anal.  Ten cytokines were assessed, including the prototypic Th1 and Th2 cytokines gamma interferon (IFN-γ) and interleukin 4 (IL-4) as well as IL-2, sol. IL-2 receptor (sIL-2R), IL-1β, IL-1 receptor antagonist (IL-1RA), tumor necrosis factor-alpha (TNF-α), IL-6, sol. IL-6 receptor (sIL-6R), and IL-10.  The results show that an increase occurs in in vivo IL-1RA, sIL-2R, and IL-6 and a decrease occurs in in vitro IL-2 in schizophrenia.  No significant effect sizes were obtained for the other cytokines.  These findings provide the first evidence of establishment of an inflammatory syndrome in schizophrenia, which refutes the current hypothesis of a Th2 slant.  Caveats are presented to data interpretation, including the role of stress and the effect of wt. gain that develops in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Pagv4uBWBbVg90H21EOLACvtfcHk0liaOJqxg0zkeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVKgurs%253D&md5=907016c1c9f638f5854878b23e246d7a</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2007.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2007.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DPotvin%26aufirst%3DS.%26aulast%3DStip%26aufirst%3DE.%26aulast%3DSepehry%26aufirst%3DA.%2BA.%26aulast%3DGendron%26aufirst%3DA.%26aulast%3DBah%26aufirst%3DR.%26aulast%3DKouassi%26aufirst%3DE.%26atitle%3DInflammatory%2520cytokine%2520alterations%2520in%2520schizophrenia%253A%2520a%2520systematic%2520quantitative%2520review%26jtitle%3DBiol.%2520Psychiatry%26date%3D2008%26volume%3D63%26spage%3D801%26epage%3D808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Akhondzadeh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabatabaee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amini, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi Abhari, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbasi, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnam, B.</span><span> </span><span class="NLM_article-title">Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.schres.2006.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=17208413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FnsFKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2007&pages=179-185&author=S.+Akhondzadehauthor=M.+Tabatabaeeauthor=H.+Aminiauthor=S.+A.+Ahmadi+Abhariauthor=S.+H.+Abbasiauthor=B.+Behnam&title=Celecoxib+as+adjunctive+therapy+in+schizophrenia%3A+a+double-blind%2C+randomized+and+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial</span></div><div class="casAuthors">Akhondzadeh Shahin; Tabatabaee Maryam; Amini Homayoun; Ahmadi Abhari Seyed Ali; Abbasi Seyed Hesamedin; Behnam Behnaz</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">179-85</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Some evidence suggests that the pathophysiology of schizophrenia is associated with the abnormal immune system, and cytokines may be important in schizophrenia.  Cyclooxygenase-2 (COX-2) inhibitors such as celecoxib reduce the production of proinflammatory cytokines including Th1-like cytokines.  Indeed, COX-2 inhibitors rebalance type-1 and type-2 immune response.  The purpose of the present investigation was to assess the efficacy of celecoxib as an adjuvant agent in the treatment of chronic schizophrenia in an eight-week, double-blind and placebo-controlled trial.  Eligible participants in this study were 60 patients with chronic schizophrenia.  All patients were inpatients and were in the active phase of the illness, and met DSM-IV criteria for schizophrenia.  Patients were allocated in a random fashion, 30 to risperidone 6 mg/day plus celecoxib 400 mg/day (200 mg bid) (morning and evening) and 30 to risperidone 6 mg/day plus placebo.  Although both protocols significantly decreased the score of the positive, negative and general psychopathological symptoms over the trial period, the combination of risperidone and celecoxib showed a significant superiority over risperidone alone in the treatment of positive symptoms, general psychopathology symptoms as well as PANSS total scores.  The means Extrapyramidal Symptoms Rating Scale for the placebo group were higher than in the celecoxib group over the trial.  However, the differences were not significant.  The results of this study suggest that celecoxib may be an effective adjuvant agent in the management of patients with chronic schizophrenia and anti-inflammatory therapies should be further investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKRlaq_gfxtA20zIbnCCI3fW6udTcc2eYtTiWPrMEHmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FnsFKjtA%253D%253D&md5=ccbbc9523ec8698ddfde8a38889aa333</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2006.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2006.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DAkhondzadeh%26aufirst%3DS.%26aulast%3DTabatabaee%26aufirst%3DM.%26aulast%3DAmini%26aufirst%3DH.%26aulast%3DAhmadi%2BAbhari%26aufirst%3DS.%2BA.%26aulast%3DAbbasi%26aufirst%3DS.%2BH.%26aulast%3DBehnam%26aufirst%3DB.%26atitle%3DCelecoxib%2520as%2520adjunctive%2520therapy%2520in%2520schizophrenia%253A%2520a%2520double-blind%252C%2520randomized%2520and%2520placebo-controlled%2520trial%26jtitle%3DSchizophr.%2520Res.%26date%3D2007%26volume%3D90%26spage%3D179%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Muller, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheppach, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandstatter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sokullu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krampe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulmschneider, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moller, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. J.</span><span> </span><span class="NLM_article-title">Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">1029</span><span class="NLM_x">–</span> <span class="NLM_lpage">1034</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1176%2Fappi.ajp.159.6.1029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=12042193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD38zgtVyquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2002&pages=1029-1034&author=N.+Mullerauthor=M.+Riedelauthor=C.+Scheppachauthor=B.+Brandstatterauthor=S.+Sokulluauthor=K.+Krampeauthor=M.+Ulmschneiderauthor=R.+R.+Engelauthor=H.+J.+Mollerauthor=M.+J.+Schwarz&title=Beneficial+antipsychotic+effects+of+celecoxib+add-on+therapy+compared+to+risperidone+alone+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia</span></div><div class="casAuthors">Muller Norbert; Riedel Michael; Scheppach Constanze; Brandstatter Bernd; Sokullu Safet; Krampe Karin; Ulmschneider Markus; Engel Rolf R; Moller Hans-Jurgen; Schwarz Markus J</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1029-34</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Abnormalities in the immune system in schizophrenia have been described.  However, important findings such as high levels of activating cytokines in the CSF and signs of CNS inflammation have been controversial.  The authors conducted a trial of the new selective cyclooxygenase-2 inhibitor celecoxib, an immunomodulatory drug, in schizophrenic patients to evaluate its therapeutic effects.  METHOD:  In a prospective, double-blind evaluation, 50 patients with an acute exacerbation of schizophrenia were randomly assigned to either risperidone plus celecoxib or risperidone plus placebo.  After a washout period, 25 patients received 2-6 mg/day of risperidone plus placebo and 25 received risperidone plus 400 mg/day of celecoxib for 5 weeks.  The treatment effect was calculated by analysis of covariance.  There were no significant differences between groups in age, sex, duration or severity of disease or psychopathology, or risperidone dose or plasma level.  RESULTS:  Over 5 weeks, both groups of patients showed significant improvement in scores on the Positive and Negative Syndrome Scale and on all subscales.  However, the celecoxib group showed significantly greater improvement in the total score.  CONCLUSIONS:  Additional treatment with celecoxib has significant positive effects on the therapeutic action of risperidone with regard to total schizophrenia psychopathology.  Moreover, the fact that treatment with an immunomodulatory drug showed beneficial effects on schizophrenia symptoms indicates that immune dysfunction in schizophrenia is not just an epiphenomenon but is related to the pathomechanism of the disorder.  However, a nonimmunological therapeutic effect of celecoxib mediated by the N-methyl-D-aspartic acid receptor has to be taken into account.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZu6Rnvk4sMpPq5LRczm8ffW6udTcc2eYtTiWPrMEHmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zgtVyquw%253D%253D&md5=b632958b76b4d7e0cc2421ac7ea2c193</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.159.6.1029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.159.6.1029%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DN.%26aulast%3DRiedel%26aufirst%3DM.%26aulast%3DScheppach%26aufirst%3DC.%26aulast%3DBrandstatter%26aufirst%3DB.%26aulast%3DSokullu%26aufirst%3DS.%26aulast%3DKrampe%26aufirst%3DK.%26aulast%3DUlmschneider%26aufirst%3DM.%26aulast%3DEngel%26aufirst%3DR.%2BR.%26aulast%3DMoller%26aufirst%3DH.%2BJ.%26aulast%3DSchwarz%26aufirst%3DM.%2BJ.%26atitle%3DBeneficial%2520antipsychotic%2520effects%2520of%2520celecoxib%2520add-on%2520therapy%2520compared%2520to%2520risperidone%2520alone%2520in%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2002%26volume%3D159%26spage%3D1029%26epage%3D1034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Muller, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehning, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerovecki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein-Muller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spellmann, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hetzel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maino, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleindienst, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moller, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arolt, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedel, M.</span><span> </span><span class="NLM_article-title">The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">680</span><span class="NLM_x">–</span> <span class="NLM_lpage">684</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=680-684&author=N.+Mullerauthor=M.+J.+Schwarzauthor=S.+Dehningauthor=A.+Douheauthor=A.+Ceroveckiauthor=B.+Goldstein-Mullerauthor=I.+Spellmannauthor=G.+Hetzelauthor=K.+Mainoauthor=N.+Kleindienstauthor=H.+J.+Mollerauthor=V.+Aroltauthor=M.+Riedel&title=The+cyclooxygenase-2+inhibitor+celecoxib+has+therapeutic+effects+in+major+depression%3A+results+of+a+double-blind%2C+randomized%2C+placebo+controlled%2C+add-on+pilot+study+to+reboxetine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DN.%26aulast%3DSchwarz%26aufirst%3DM.%2BJ.%26aulast%3DDehning%26aufirst%3DS.%26aulast%3DDouhe%26aufirst%3DA.%26aulast%3DCerovecki%26aufirst%3DA.%26aulast%3DGoldstein-Muller%26aufirst%3DB.%26aulast%3DSpellmann%26aufirst%3DI.%26aulast%3DHetzel%26aufirst%3DG.%26aulast%3DMaino%26aufirst%3DK.%26aulast%3DKleindienst%26aufirst%3DN.%26aulast%3DMoller%26aufirst%3DH.%2BJ.%26aulast%3DArolt%26aufirst%3DV.%26aulast%3DRiedel%26aufirst%3DM.%26atitle%3DThe%2520cyclooxygenase-2%2520inhibitor%2520celecoxib%2520has%2520therapeutic%2520effects%2520in%2520major%2520depression%253A%2520results%2520of%2520a%2520double-blind%252C%2520randomized%252C%2520placebo%2520controlled%252C%2520add-on%2520pilot%2520study%2520to%2520reboxetine%26jtitle%3DMol.%2520Psychiatry%26date%3D2006%26volume%3D11%26spage%3D680%26epage%3D684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Brumbaugh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H.</span><span> </span><span class="NLM_article-title">Psychotic mania associated with mefloquine in a bipolar patient</span> <span class="citation_source-journal">South. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">550</span><span class="NLM_x">–</span> <span class="NLM_lpage">551</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1097%2FSMJ.0b013e318167a9e2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=18414180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD1c3pslKluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2008&pages=550-551&author=M.+Brumbaughauthor=P.+Priceauthor=N.+Faganauthor=H.+Hsieh&title=Psychotic+mania+associated+with+mefloquine+in+a+bipolar+patient"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Psychotic mania associated with mefloquine in a bipolar patient</span></div><div class="casAuthors">Brumbaugh Meredith; Price Paul; Fagan Nancy; Hsieh Hudson</div><div class="citationInfo"><span class="NLM_cas:title">Southern medical journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">550-1</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A 63-year-old male patient with a history of bipolar I disorder presented to the emergency department in an acutely psychotic state.  The patient had just returned from vacation in a malarial high-risk area and, as a result, had taken five weekly doses of mefloquine for prophylaxis.  The patient's bipolar disorder was being treated with lithium, and he had been stable for about 8 years.  All organic causes of psychosis were ruled out.  The patient was admitted to the inpatient psychiatric unit and was treated with quetiapine until he was stable enough to return home.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRQ8iPuynTdBFw2ofyr07jXfW6udTcc2eZp8_UGxc31_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3pslKluw%253D%253D&md5=3c6f376d3c5baffbb6a8fd0c16bec9bc</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1097%2FSMJ.0b013e318167a9e2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FSMJ.0b013e318167a9e2%26sid%3Dliteratum%253Aachs%26aulast%3DBrumbaugh%26aufirst%3DM.%26aulast%3DPrice%26aufirst%3DP.%26aulast%3DFagan%26aufirst%3DN.%26aulast%3DHsieh%26aufirst%3DH.%26atitle%3DPsychotic%2520mania%2520associated%2520with%2520mefloquine%2520in%2520a%2520bipolar%2520patient%26jtitle%3DSouth.%2520Med.%2520J.%26date%3D2008%26volume%3D101%26spage%3D550%26epage%3D551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Tran, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browning, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dell, M. L.</span><span> </span><span class="NLM_article-title">Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report</span> <span class="citation_source-journal">Malar. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">74</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1186%2F1475-2875-5-74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=16925829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD28rktFyltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=74&author=T.+M.+Tranauthor=J.+Browningauthor=M.+L.+Dell&title=Psychosis+with+paranoid+delusions+after+a+therapeutic+dose+of+mefloquine%3A+a+case+report"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report</span></div><div class="casAuthors">Tran Tuan M; Browning Joseph; Dell Mary L</div><div class="citationInfo"><span class="NLM_cas:title">Malaria journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Convenient once-a-week dosing has made mefloquine a popular choice as malaria prophylaxis for travel to countries with chloroquine-resistant malaria.  However, the increased use of mefloquine over the past decade has resulted in reports of rare, but severe, neuropsychiatric adverse reactions, such as anxiety, depression, hallucinations and psychosis.  A direct causality between mefloquine and severe reactions among travelers has been partly confounded by factors associated with foreign travel and, in the case of therapeutic doses of mefloquine, the central nervous system manifestations of Plasmodium infection itself.  The present case provides a unique natural history of mefloquine-induced neuropsychiatric toxicity and revisits its dose-dependent nature.  CASE PRESENTATION:  This report describes an acute exacerbation of neuropsychiatric symptoms after an unwarranted therapeutic dose (1250 mg) of mefloquine in a 37-year-old male previously on a once-a-week prophylactic regimen.  Neuropsychiatric symptoms began as dizziness and insomnia of several days duration, which was followed by one week of escalating anxiety and subtle alterations in behaviour.  The patient's anxiety culminated into a panic episode with profound sympathetic activation.  One week later, he was hospitalized after developing frank psychosis with psychomotor agitation and paranoid delusions.  His psychosis remitted with low-dose quetiapine.  CONCLUSION:  This report suggests that an overt mefloquine-induced psychosis can be preceded by a prodromal phase of moderate symptoms such as dizziness, insomnia, and generalized anxiety.  It is important that physicians advise patients taking mefloquine prophylaxis and their relatives to recognize such symptoms, especially when they are accompanied by abrupt, but subtle, changes in behaviour.  Patients with a history of psychiatric illness, however minor, may be at increased risk for a mefloquine-induced neuropsychiatric toxicity.  Physicians must explicitly caution patients not to self-medicate with a therapeutic course of mefloquine when a malaria diagnosis has not been confirmed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGs4-TUZBEC0EgZCMqtRBifW6udTcc2eZp8_UGxc31_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rktFyltQ%253D%253D&md5=d63606804c411c52d7cde027065e28a7</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1186%2F1475-2875-5-74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2875-5-74%26sid%3Dliteratum%253Aachs%26aulast%3DTran%26aufirst%3DT.%2BM.%26aulast%3DBrowning%26aufirst%3DJ.%26aulast%3DDell%26aufirst%3DM.%2BL.%26atitle%3DPsychosis%2520with%2520paranoid%2520delusions%2520after%2520a%2520therapeutic%2520dose%2520of%2520mefloquine%253A%2520a%2520case%2520report%26jtitle%3DMalar.%2520J.%26date%3D2006%26volume%3D5%26spage%3D74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Alisky, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chertkova, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iczkowski, K. A.</span><span> </span><span class="NLM_article-title">Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis</span> <span class="citation_source-journal">Med. Hypotheses</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">1090</span><span class="NLM_x">–</span> <span class="NLM_lpage">1094</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.mehy.2006.01.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=16843615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVKlt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2006&pages=1090-1094&author=J.+M.+Aliskyauthor=E.+L.+Chertkovaauthor=K.+A.+Iczkowski&title=Drug+interactions+and+pharmacogenetic+reactions+are+the+basis+for+chloroquine+and+mefloquine-induced+psychosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis</span></div><div class="casAuthors">Alisky, Joseph M.; Chertkova, Elena L.; Iczkowski, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Medical Hypotheses</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1090-1094</span>CODEN:
                <span class="NLM_cas:coden">MEHYDY</span>;
        ISSN:<span class="NLM_cas:issn">0306-9877</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Chloroquine and mefloquine used for prophylaxis and treatment of malaria sometimes causes severe mental status changes, through mechanisms that are poorly understood.  Psychosis is caused by interactions with other drugs or by pharmacogenetic vulnerabilities that cause heightened responses to chloroquine or mefloquine alone, mediated through dopamine, acetylcholine, serotonin, P-glycoprotein, inhibited cortical activity, deranged calcium homeostasis, and impaired synaptogenesis.  Retrospective studies can identify all other drugs taken coincident with chloroquine or mefloquine psychosis.  Various genes from patients could be cloned and compared to those from individuals who tolerated chloroquine and mefloquine, culminating with transgenic animal studies.  Identification of candidate genes may be aided by pharmacogenomic anal. of single nucleotide polymorphism maps.  Finally, prospective studies with cerebrospinal fluid anal. and PET scanning could help verify the hypothesis.  If this hypothesis is correct, the incidence of chloroquine and mefloquine psychosis can be greatly reduced by avoiding interacting medications and by conducting genetic screening prior to initiating chloroquine and mefloquine.  Validation of the hypothesis would also provide a paradigm to follow for avoiding neuropsychiatric side effects if antidepressants and neuroleptics are used to overcome chloroquine resistance, if new antimalarial drugs chem. related to chloroquine and mefloquine are developed and if chloroquine and mefloquine are used for non-malarial applications such as HIV and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoud_A6w4q-6rVg90H21EOLACvtfcHk0lhntV4Cwdae-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVKlt7g%253D&md5=abf984795f847d453bf14ffa71dcd9ac</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.mehy.2006.01.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mehy.2006.01.059%26sid%3Dliteratum%253Aachs%26aulast%3DAlisky%26aufirst%3DJ.%2BM.%26aulast%3DChertkova%26aufirst%3DE.%2BL.%26aulast%3DIczkowski%26aufirst%3DK.%2BA.%26atitle%3DDrug%2520interactions%2520and%2520pharmacogenetic%2520reactions%2520are%2520the%2520basis%2520for%2520chloroquine%2520and%2520mefloquine-induced%2520psychosis%26jtitle%3DMed.%2520Hypotheses%26date%3D2006%26volume%3D67%26spage%3D1090%26epage%3D1094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Akhondzadeh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nejatisafa, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amini, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammadi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larijani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raisi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamalipour, A.</span><span> </span><span class="NLM_article-title">Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial</span> <span class="citation_source-journal">Prog. Neuro-Psychopharmacol. Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1007</span><span class="NLM_x">–</span> <span class="NLM_lpage">1012</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2FS0278-5846%2803%2900161-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=14499318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1Grsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2003&pages=1007-1012&author=S.+Akhondzadehauthor=A.+A.+Nejatisafaauthor=H.+Aminiauthor=M.+R.+Mohammadiauthor=B.+Larijaniauthor=L.+Kashaniauthor=F.+Raisiauthor=A.+Kamalipour&title=Adjunctive+estrogen+treatment+in+women+with+chronic+schizophrenia%3A+a+double-blind%2C+randomized%2C+and+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial</span></div><div class="casAuthors">Akhondzadeh, Shahin; Nejatisafa, Ali Akbar; Amini, Homayoun; Mohammadi, Mohammad Reza; Larijani, Bagher; Kashani, Ladan; Raisi, Firoozeh; Kamalipour, Abbas</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1007-1012</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The estrogen hypothesis of schizophrenia postulates that estrogen exerts a protective effect against schizophrenia and that this partly explains the obsd. sex differences in premorbid adjustment, onset age, treatment response, and illness course.  It has been suggested that estrogen supplementation can augment the treatment effects of antipsychotics.  The purpose of the present investigation was to access the efficacy of ethinyl estradiol as an adjuvant agent in the treatment of premenopausal women with chronic schizophrenia in an 8-wk, double-blind, and placebo-controlled trial.  Eligible participants in the study were 32 women of childbearing age with schizophrenia.  All patients were inpatients, in the active phase of illness, and met DSM-IV criteria for chronic schizophrenia.  Patients were allocated in a random fashion, 16 to haloperidol 15 mg/day plus ethinyl estradiol 0.05 mg/day and 16 to haloperidol 15 mg/day plus placebo for an 8-wk, double-blind, placebo-controlled study.  Although both protocols significantly decreased the score of the pos., neg., and general psychopathol. symptoms over the trial period, the combination of haloperidol and ethinyl estradiol showed a significant superiority over haloperidol alone in the treatment of pos. and general psychopathol. symptoms as well as Pos. and Neg. Syndrome Scale (PANSS) total scores.  Although the means Extrapyramidal Symptoms Rating Scale (ESRS) for the placebo group were higher than ethinyl estradiol group, the differences were not significant over the trial.  A significant difference was obsd. between the overall mean biperiden dosages in the two groups.  The results of this study suggest that estrogen may be an effective adjuvant agent in the management of women of childbearing age with chronic schizophrenia.  Nevertheless, results of larger controlled trials are needed before recommendation for a broad clin. application can be made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKxRwAe3ciYLVg90H21EOLACvtfcHk0lhntV4Cwdae-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1Grsbo%253D&md5=4f45255c2695d4693e13eea5fecfcac8</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2FS0278-5846%2803%2900161-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0278-5846%252803%252900161-1%26sid%3Dliteratum%253Aachs%26aulast%3DAkhondzadeh%26aufirst%3DS.%26aulast%3DNejatisafa%26aufirst%3DA.%2BA.%26aulast%3DAmini%26aufirst%3DH.%26aulast%3DMohammadi%26aufirst%3DM.%2BR.%26aulast%3DLarijani%26aufirst%3DB.%26aulast%3DKashani%26aufirst%3DL.%26aulast%3DRaisi%26aufirst%3DF.%26aulast%3DKamalipour%26aufirst%3DA.%26atitle%3DAdjunctive%2520estrogen%2520treatment%2520in%2520women%2520with%2520chronic%2520schizophrenia%253A%2520a%2520double-blind%252C%2520randomized%252C%2520and%2520placebo-controlled%2520trial%26jtitle%3DProg.%2520Neuro-Psychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2003%26volume%3D27%26spage%3D1007%26epage%3D1012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Kulkarni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Castella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzgerald, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurvich, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartholomeusz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span> </span><span class="NLM_article-title">Estrogen in severe mental illness: a potential new treatment approach</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">955</span><span class="NLM_x">–</span> <span class="NLM_lpage">960</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1001%2Farchpsyc.65.8.955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=18678800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD1cvpvFegtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=955-960&author=J.+Kulkarniauthor=A.+de+Castellaauthor=P.+B.+Fitzgeraldauthor=C.+T.+Gurvichauthor=M.+Baileyauthor=C.+Bartholomeuszauthor=H.+Burger&title=Estrogen+in+severe+mental+illness%3A+a+potential+new+treatment+approach"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen in severe mental illness: a potential new treatment approach</span></div><div class="casAuthors">Kulkarni Jayashri; de Castella Anthony; Fitzgerald Paul B; Gurvich Caroline T; Bailey Michael; Bartholomeusz Cali; Burger Henry</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">955-60</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CONTEXT:  Accumulating evidence suggests that estrogens may have therapeutic effects in severe mental illnesses, including schizophrenia, via neuromodulatory and neuroprotective activity.  OBJECTIVE:  To compare the efficacy of adjunctive transdermal estradiol with that of adjunctive placebo in the treatment of acute psychotic symptoms.  DESIGN:  Randomized, double-blind study.  SETTING:  Patients were recruited from inpatient acute hospital wards and outpatient clinics of 2 metropolitan Melbourne general hospitals.  PARTICIPANTS:  One hundred two women of childbearing age with schizophrenia.  All participants were in an acute or chronic phase of their illness; 73 participants were outpatients and the rest were inpatients.  Intervention Patients were randomized to receive 100 microg of transdermal estradiol (n = 56) or transdermal placebo (n = 46) for 28 days.  MAIN OUTCOME MEASURES:  Psychopathological symptoms were assessed weekly with the Positive and Negative Syndrome Scale.  RESULTS:  The addition of 100 microg of transdermal estradiol significantly reduced positive (P < .05) and general psychopathological (P < .05) symptoms during the 28-day trial period compared with women receiving antipsychotic medication alone.  CONCLUSION:  Estradiol appears to be a useful treatment for women with schizophrenia and may provide a new adjunctive therapeutic option for severe mental illness.  TRIAL REGISTRATION:  clinicaltrials.gov Identifier: NCT00206570.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ66w6qDcPMQZagfuraLLzSfW6udTcc2eaU4UsFbDqJn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvpvFegtQ%253D%253D&md5=5b3ddcbe3b6133a1067217946976c4c8</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.65.8.955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.65.8.955%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DJ.%26aulast%3Dde%2BCastella%26aufirst%3DA.%26aulast%3DFitzgerald%26aufirst%3DP.%2BB.%26aulast%3DGurvich%26aufirst%3DC.%2BT.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DBartholomeusz%26aufirst%3DC.%26aulast%3DBurger%26aufirst%3DH.%26atitle%3DEstrogen%2520in%2520severe%2520mental%2520illness%253A%2520a%2520potential%2520new%2520treatment%2520approach%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2008%26volume%3D65%26spage%3D955%26epage%3D960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Kulkarni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Castella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headey, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marston, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinclair, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurvich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzgerald, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span> </span><span class="NLM_article-title">Estrogens and men with schizophrenia: Is there a case for adjunctive therapy?</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.schres.2010.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=21062669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BC3M7ltF2gug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2011&pages=278-283&author=J.+Kulkarniauthor=A.+de+Castellaauthor=B.+Headeyauthor=N.+Marstonauthor=K.+Sinclairauthor=S.+Leeauthor=C.+Gurvichauthor=P.+B.+Fitzgeraldauthor=H.+Burger&title=Estrogens+and+men+with+schizophrenia%3A+Is+there+a+case+for+adjunctive+therapy%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogens and men with schizophrenia: is there a case for adjunctive therapy?</span></div><div class="casAuthors">Kulkarni Jayashri; de Castella Anthony; Headey Barbara; Marston Natasha; Sinclair Kelly; Lee Stuart; Gurvich Caroline; Fitzgerald Paul B; Burger Henry</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">278-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Adjunctive use of estrogen therapy has been shown to be effective in enhancing the treatment of schizophrenia in women.  In men, consideration of estrogen therapy has been impacted by concerns of feminising side effects, however, clinical trials of the use of estrogen in treating prostate cancer, bone density loss and even aggression and psychosis in dementia or traumatic brain injury, show this to be a safe and effective therapy.  The current 14-day randomised placebo-controlled trial in 53 men with schizophrenia was conducted to evaluate the efficacy of 2 mg oral estradiol valerate as an adjunct to atypical antipsychotic treatment.  Results demonstrated for estradiol participants a more rapid reduction in general psychopathology that occurred in the context of greater increases in serum estrogen levels and reductions in FSH and testosterone levels.  Approximately 28% of estradiol participants did not achieve an increase (at least a 50% from baseline) in serum estrogen suggesting that further research is needed to refine the type, dose and administration route for estrogen therapy in men.  Findings do, however, suggest further exploration of a therapeutic role for adjunctive estradiol treatment in men with schizophrenia is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKFUGAu5OVVEEksK8CslK8fW6udTcc2eY1EE25t12B67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7ltF2gug%253D%253D&md5=0de3a6f5363cad4f066b5710a2808b8e</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2010.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2010.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DJ.%26aulast%3Dde%2BCastella%26aufirst%3DA.%26aulast%3DHeadey%26aufirst%3DB.%26aulast%3DMarston%26aufirst%3DN.%26aulast%3DSinclair%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DGurvich%26aufirst%3DC.%26aulast%3DFitzgerald%26aufirst%3DP.%2BB.%26aulast%3DBurger%26aufirst%3DH.%26atitle%3DEstrogens%2520and%2520men%2520with%2520schizophrenia%253A%2520Is%2520there%2520a%2520case%2520for%2520adjunctive%2520therapy%253F%26jtitle%3DSchizophr.%2520Res.%26date%3D2011%26volume%3D125%26spage%3D278%26epage%3D283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Kulkarni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deCastella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taffe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keks, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copolov, D.</span><span> </span><span class="NLM_article-title">A clinical trial of the effects of estrogen in acutely psychotic women</span> <span class="citation_source-journal">Schizophr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2F0920-9964%2896%2982949-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=8827850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADyaK28visFCjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1996&pages=247&author=J.+Kulkarniauthor=A.+deCastellaauthor=D.+Smithauthor=J.+Taffeauthor=N.+Keksauthor=D.+Copolov&title=A+clinical+trial+of+the+effects+of+estrogen+in+acutely+psychotic+women"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">A clinical trial of the effects of estrogen in acutely psychotic women</span></div><div class="casAuthors">Kulkarni J; de Castella A; Smith D; Taffe J; Keks N; Copolov D</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">247-52</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">This study was a preliminary open clinical trial aimed at exploring the hypothesis that estrogen may provide protection against schizophrenia in women.  Eleven women with acute psychotic symptoms, as scored on the BPRS, SAPS and SANS, had 0.02 mg estradiol added to neuroleptic treatment for eight weeks.  Their response was compared to seven women with similar symptom severity receiving neuroleptic treatment alone.  Both groups had baseline hormonal assays of estrogen, progesterone, LH and FSH and underwent regular psychopathology ratings during the eight weeks.  The group receiving the estradiol adjunct showed more rapid improvement in psychotic symptoms compared with the group receiving neuroleptics only.  This difference was not sustained for the entirety of the trial.  Both groups reached similar levels of recovery by the eighth week.  These results suggest that estradiol may have antipsychotic properties and/or act as a catalyst for neuroleptic responsiveness in women with schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQJshNUbW-IRBrI9DTGjC0fW6udTcc2eY1EE25t12B67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28visFCjug%253D%253D&md5=bc77a43edf1df8c1996e6953c1f18372</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2F0920-9964%2896%2982949-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0920-9964%252896%252982949-5%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DJ.%26aulast%3DdeCastella%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DTaffe%26aufirst%3DJ.%26aulast%3DKeks%26aufirst%3DN.%26aulast%3DCopolov%26aufirst%3DD.%26atitle%3DA%2520clinical%2520trial%2520of%2520the%2520effects%2520of%2520estrogen%2520in%2520acutely%2520psychotic%2520women%26jtitle%3DSchizophr.%2520Res.%26date%3D1996%26volume%3D20%26spage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Kulkarni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurvich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavrilidis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzgerald, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S. R.</span><span> </span><span class="NLM_article-title">Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia</span> <span class="citation_source-journal">Psychoneuroendocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1142</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=1142&author=J.+Kulkarniauthor=C.+Gurvichauthor=S.+J.+Leeauthor=H.+Gilbertauthor=E.+Gavrilidisauthor=C.+A.+deauthor=M.+Berkauthor=S.+Doddauthor=P.+B.+Fitzgeraldauthor=S.+R.+Davis&title=Piloting+the+effective+therapeutic+dose+of+adjunctive+selective+estrogen+receptor+modulator+treatment+in+postmenopausal+women+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DJ.%26aulast%3DGurvich%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DGilbert%26aufirst%3DH.%26aulast%3DGavrilidis%26aufirst%3DE.%26aulast%3Dde%26aufirst%3DC.%2BA.%26aulast%3DBerk%26aufirst%3DM.%26aulast%3DDodd%26aufirst%3DS.%26aulast%3DFitzgerald%26aufirst%3DP.%2BB.%26aulast%3DDavis%26aufirst%3DS.%2BR.%26atitle%3DPiloting%2520the%2520effective%2520therapeutic%2520dose%2520of%2520adjunctive%2520selective%2520estrogen%2520receptor%2520modulator%2520treatment%2520in%2520postmenopausal%2520women%2520with%2520schizophrenia%26jtitle%3DPsychoneuroendocrinology%26date%3D2010%26volume%3D35%26spage%3D1142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Usall, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huerta-Ramos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iniesta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roca, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Blanco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teba, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochoa, S.</span><span> </span><span class="NLM_article-title">Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial</span> <span class="citation_source-journal">J. Clin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1552</span><span class="NLM_x">–</span> <span class="NLM_lpage">1557</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.4088%2FJCP.10m06610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=21903021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BC38XktV2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2011&pages=1552-1557&author=J.+Usallauthor=E.+Huerta-Ramosauthor=R.+Iniestaauthor=J.+Coboauthor=S.+Arayaauthor=M.+Rocaauthor=A.+Serrano-Blancoauthor=F.+Tebaauthor=S.+Ochoa&title=Raloxifene+as+an+adjunctive+treatment+for+postmenopausal+women+with+schizophrenia%3A+a+double-blind%2C+randomized%2C+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial</span></div><div class="casAuthors">Usall, Judith; Huerta-Ramos, Elena; Iniesta, Raquel; Cobo, Jesus; Araya, Susana; Roca, Mercedes; Serrano-Blanco, Antoni; Teba, Fernando; Ochoa, Susana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychiatry (Memphis, TN, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1552-1557</span>CODEN:
                <span class="NLM_cas:coden">JCLPDE</span>;
        ISSN:<span class="NLM_cas:issn">0160-6689</span>.
    
            (<span class="NLM_cas:orgname">Physicians Postgraduate Press, Inc.</span>)
        </div><div class="casAbstract">Objective: The potential therapeutic utility of estrogens in schizophrenia is increasingly being recognized.  Raloxifene, a selective estrogen receptor modulator, appears to act similarly to conjugated estrogens on dopamine and serotonin brain systems and may be a better option since it lacks the possible neg. effects of estrogen on breast and uterine tissue.  In this study, we assess the utility of raloxifene as an adjunctive treatment for neg. symptoms and other psychotic symptoms in postmenopausal women with schizophrenia.  Method: This was a 12-wk, double-blind, randomized, placebo-controlled study.  Patients were recruited from both the inpatient and outpatient departments of Parc Sanitari Sant Joan de Deu, Barcelona, Spain, and Corporacio Sanitaria Parc Tauli, Sabadell, Spain.  Thirty-three postmenopausal women with schizophrenia (DSM-IV criteria) who exhibited prominent neg. symptoms were randomized to either adjunctive raloxifene (16 women; mean age = 60.14 years, SD = 6.41 years) or adjunctive placebo (17 women; mean age = 62.66 years, SD = 4.54 years) for 12 wk.  The period of recruitment lasted from Jan. 2005 through June 2009.  Psychopathol. symptoms were assessed at baseline and weeks 4, 8, and 12 by means of the Pos. and Neg. Syndrome Scale.  Results: The addn. of raloxifene (60 mg/d) to regular antipsychotic treatment significantly reduced neg. (P=.044), pos. (P=.031), and general psychopathol. (P=.045) symptoms during the 12-wk trial as compared with women receiving placebo.  Conclusions: Raloxifene as an adjuvant treatment in postmenopausal women with schizophrenia who exhibit prominent neg. symptoms appears to be useful in improving neg., pos., and general psychopathol. symptoms.  If more extensive and longer-term studies confirm and expand upon these pos. results, the use of raloxifene could be recommended in postmenopausal patients with schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-3JjKvkzZwrVg90H21EOLACvtfcHk0liw6iKCAiwUZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktV2ktg%253D%253D&md5=3231444780d748a615c042b6c9f3ebca</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.4088%2FJCP.10m06610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FJCP.10m06610%26sid%3Dliteratum%253Aachs%26aulast%3DUsall%26aufirst%3DJ.%26aulast%3DHuerta-Ramos%26aufirst%3DE.%26aulast%3DIniesta%26aufirst%3DR.%26aulast%3DCobo%26aufirst%3DJ.%26aulast%3DAraya%26aufirst%3DS.%26aulast%3DRoca%26aufirst%3DM.%26aulast%3DSerrano-Blanco%26aufirst%3DA.%26aulast%3DTeba%26aufirst%3DF.%26aulast%3DOchoa%26aufirst%3DS.%26atitle%3DRaloxifene%2520as%2520an%2520adjunctive%2520treatment%2520for%2520postmenopausal%2520women%2520with%2520schizophrenia%253A%2520a%2520double-blind%252C%2520randomized%252C%2520placebo-controlled%2520trial%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D2011%26volume%3D72%26spage%3D1552%26epage%3D1557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Muramatsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawanishi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwasaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakiuchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, Y.</span><span> </span><span class="NLM_article-title">Study on zwitter-ionization of drugs. II. Synthesis and pharmacological activity of some <i>N</i>-[3-(5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>]cyclohepten-5-ylidene)propyl]-<i>N</i>-methylamino- and <i>N</i>-[3-(6<i>H</i>-dibenz[<i>b</i>,<i>e</i>]oxepin-11-ylidene)propyl]-<i>N</i>-methylamino-alkanoic acid derivatives and related compounds</span> <span class="citation_source-journal">Chem. Pharm. Bull. (Tokyo)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1987</span><span class="NLM_x">–</span> <span class="NLM_lpage">1993</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1993&pages=1987-1993&author=H.+Muramatsuauthor=H.+Sawanishiauthor=N.+Iwasakiauthor=M.+Kakiuchiauthor=T.+Ohashiauthor=H.+Katoauthor=Y.+Ito&title=Study+on+zwitter-ionization+of+drugs.+II.+Synthesis+and+pharmacological+activity+of+some+N-%5B3-%285H-dibenzo%5Ba%2Cd%5Dcyclohepten-5-ylidene%29propyl%5D-N-methylamino-+and+N-%5B3-%286H-dibenz%5Bb%2Ce%5Doxepin-11-ylidene%29propyl%5D-N-methylamino-alkanoic+acid+derivatives+and+related+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuramatsu%26aufirst%3DH.%26aulast%3DSawanishi%26aufirst%3DH.%26aulast%3DIwasaki%26aufirst%3DN.%26aulast%3DKakiuchi%26aufirst%3DM.%26aulast%3DOhashi%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DY.%26atitle%3DStudy%2520on%2520zwitter-ionization%2520of%2520drugs.%2520II.%2520Synthesis%2520and%2520pharmacological%2520activity%2520of%2520some%2520N-%255B3-%25285H-dibenzo%255Ba%252Cd%255Dcyclohepten-5-ylidene%2529propyl%255D-N-methylamino-%2520and%2520N-%255B3-%25286H-dibenz%255Bb%252Ce%255Doxepin-11-ylidene%2529propyl%255D-N-methylamino-alkanoic%2520acid%2520derivatives%2520and%2520related%2520compounds%26jtitle%3DChem.%2520Pharm.%2520Bull.%2520%2528Tokyo%2529%26date%3D1993%26volume%3D41%26spage%3D1987%26epage%3D1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Stevenson, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyakonova, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rillich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schildberger, K.</span><span> </span><span class="NLM_article-title">Octopamine and experience-dependent modulation of aggression in crickets</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1431</span><span class="NLM_x">–</span> <span class="NLM_lpage">1441</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1523%2FJNEUROSCI.4258-04.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=15703397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhs1Kmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=1431-1441&author=P.+A.+Stevensonauthor=V.+Dyakonovaauthor=J.+Rillichauthor=K.+Schildberger&title=Octopamine+and+experience-dependent+modulation+of+aggression+in+crickets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Octopamine and experience-dependent modulation of aggression in crickets</span></div><div class="casAuthors">Stevenson, Paul A.; Dyakonova, Varya; Rillich, Jan; Schildberger, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1431-1441</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Intraspecific aggression is influenced in numerous animal groups by the previous behavioral experiences of the competitors.  The underlying mechanisms are, however, mostly obscure.  The authors present evidence that a form of experience-dependent plasticity of aggression in crickets (Gryllus bimaculatus) is mediated by octopamine, the invertebrate counterpart of noradrenaline.  In a forced-fight paradigm, the experience of flying maximized the aggressiveness of crickets at their first encounter and accelerated the subsequent recovery of aggressiveness of the normally submissive losers, without enhancing general excitability as evaluated from the animals' startle responses to wind stimulation.  This effect is transitory and concurrent with the activation of the octopaminergic system that accompanies flight.  Hemocoel injections of the octopamine agonist chlordimeform (CDM) had similar effects on aggression but also enhanced startle responses.  Serotonin depletion, achieved using α-methyl-tryptophan, enhanced startle responses without influencing aggression, indicating that the effect of CDM on aggression is not attributable to increased general excitation.  Contrasting this, aggressiveness was depressed, and the effect of flying was essentially abolished, in crickets depleted of octopamine and dopamine using α-methyl-p-tyrosine (AMT).  CDM restored aggressiveness in AMT-treated crickets, indicating that their depressed aggressiveness is attributable to octopamine depletion rather than to dopamine depletion or nonspecific defects.  Finally, the flight effect was blocked in crickets treated with the octopamine receptor antagonist epinastine, or with the α-adrenoceptor and octopamine receptor antagonist phentolamine, but not with the β-adrenoceptor antagonist propranolol.  The idea that activity-specific induction of the octopaminergic system underlies other forms of experience-dependent plasticity of aggressive motivation in insects is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3hDy37wu1mbVg90H21EOLACvtfcHk0liFjFm1DSujDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhs1Kmu78%253D&md5=f4283fb22b8cbbf9a00042ecb51bc746</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4258-04.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4258-04.2005%26sid%3Dliteratum%253Aachs%26aulast%3DStevenson%26aufirst%3DP.%2BA.%26aulast%3DDyakonova%26aufirst%3DV.%26aulast%3DRillich%26aufirst%3DJ.%26aulast%3DSchildberger%26aufirst%3DK.%26atitle%3DOctopamine%2520and%2520experience-dependent%2520modulation%2520of%2520aggression%2520in%2520crickets%26jtitle%3DJ.%2520Neurosci.%26date%3D2005%26volume%3D25%26spage%3D1431%26epage%3D1441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Roeder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gewecke, M.</span><span> </span><span class="NLM_article-title">Epinastine, a highly specific antagonist of insect neuronal octopamine receptors</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">349</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2FS0014-2999%2898%2900192-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=9671095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADyaK1cXjvVSlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=1998&pages=171-177&author=T.+Roederauthor=J.+Degenauthor=M.+Gewecke&title=Epinastine%2C+a+highly+specific+antagonist+of+insect+neuronal+octopamine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Epinastine, a highly specific antagonist of insect neuronal octopamine receptors</span></div><div class="casAuthors">Roeder, Thomas; Degen, Jorn; Gewecke, Michael</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">2/3</span>),
    <span class="NLM_cas:pages">171-177</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The tetracyclic compd. epinastine, recently introduced as a vertebrate histamine H1 receptor antagonist, has also high affinity for insect neuronal octopamine receptors.  This was true for the neuronal octopamine receptor from the locust (Ki = 2 nM) as well as the honey bee (Ki = 1.1 nM).  In addn. to its high affinity, it had a high degree of specificity.  Its affinity for other insect receptors for biogenic amines, such as 5-hydroxytryptamine, dopamine, histamine, and tyramine, was ≥4 orders of magnitude lower.  Therefore, epinastine could serve as a highly specific antagonist of octopamine receptors to enable physiol. dissection of octopaminergic neurotransmission within the nervous system of insects.  To demonstrate these abilities, epinastine was used to inhibit the visually evoked activity of an identified interneuron in the locust visual pathway which is known to be modulated by octopamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbYSlMiNCQfbVg90H21EOLACvtfcHk0ljPIk1ZdjEoJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjvVSlsrw%253D&md5=6036ebcb2108489b894588983ff76395</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2898%2900192-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252898%252900192-7%26sid%3Dliteratum%253Aachs%26aulast%3DRoeder%26aufirst%3DT.%26aulast%3DDegen%26aufirst%3DJ.%26aulast%3DGewecke%26aufirst%3DM.%26atitle%3DEpinastine%252C%2520a%2520highly%2520specific%2520antagonist%2520of%2520insect%2520neuronal%2520octopamine%2520receptors%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1998%26volume%3D349%26spage%3D171%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Unoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizunami, M.</span><span> </span><span class="NLM_article-title">Participation of octopaminergic reward system and dopaminergic punishment system in insect olfactory learning revealed by pharmacological study</span> <span class="citation_source-journal">Eur. J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1409</span><span class="NLM_x">–</span> <span class="NLM_lpage">1416</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1111%2Fj.1460-9568.2005.04318.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=16190895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD2MrhvVGnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2005&pages=1409-1416&author=S.+Unokiauthor=Y.+Matsumotoauthor=M.+Mizunami&title=Participation+of+octopaminergic+reward+system+and+dopaminergic+punishment+system+in+insect+olfactory+learning+revealed+by+pharmacological+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Participation of octopaminergic reward system and dopaminergic punishment system in insect olfactory learning revealed by pharmacological study</span></div><div class="casAuthors">Unoki Sae; Matsumoto Yukihisa; Mizunami Makoto</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1409-16</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Biogenic amines play major roles in the regulation of behavior in vertebrates and invertebrates.  Previous studies in honey bees and fruit-flies Drosophila suggested that octopamine (OA, invertebrate counterpart of noradrenaline) and dopamine (DA) participate in appetitive olfactory conditioning with sucrose reward and aversive olfactory conditioning with electric shock punishment, respectively.  In order to determine whether the effects of the two chatecholamines on electric shock and sugar learning can be generalized to other kinds of appetitive and aversive reinforcers, we studied the effects of OA and DA receptor antagonists on appetitive olfactory learning with water reward, and aversive olfactory learning with saline punishment in the cricket Gryllus bimaculatus.  Crickets injected with epinastine or mianserin, OA receptor antagonists, into the hemolymph exhibited an impairment of appetitive learning with water reward, while aversive learning with saline punishment remained intact.  In contrast, fluphenazine, chlorpromazine or spiperone, DA receptor antagonists, impaired aversive learning without affecting appetitive learning.  This finding, combined with findings in previous studies, suggests that the octopaminergic reward system and dopaminergic punishment system participate in insect olfactory learning with various appetitive and aversive reinforcements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTt_VtG4hwKOTAyhZbj3lKdfW6udTcc2eaIqilh6pcOirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MrhvVGnug%253D%253D&md5=df9029bb283543a65d08e35ce833b80f</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.2005.04318.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.2005.04318.x%26sid%3Dliteratum%253Aachs%26aulast%3DUnoki%26aufirst%3DS.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DMizunami%26aufirst%3DM.%26atitle%3DParticipation%2520of%2520octopaminergic%2520reward%2520system%2520and%2520dopaminergic%2520punishment%2520system%2520in%2520insect%2520olfactory%2520learning%2520revealed%2520by%2520pharmacological%2520study%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2005%26volume%3D22%26spage%3D1409%26epage%3D1416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Unoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizunami, M.</span><span> </span><span class="NLM_article-title">Roles of octopaminergic and dopaminergic neurons in mediating reward and punishment signals in insect visual learning</span> <span class="citation_source-journal">Eur. J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2031</span><span class="NLM_x">–</span> <span class="NLM_lpage">2038</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1111%2Fj.1460-9568.2006.05099.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=17067299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD28nktFemtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=2031-2038&author=S.+Unokiauthor=Y.+Matsumotoauthor=M.+Mizunami&title=Roles+of+octopaminergic+and+dopaminergic+neurons+in+mediating+reward+and+punishment+signals+in+insect+visual+learning"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of octopaminergic and dopaminergic neurons in mediating reward and punishment signals in insect visual learning</span></div><div class="casAuthors">Unoki Sae; Matsumoto Yukihisa; Mizunami Makoto</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2031-8</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Insects, like vertebrates, have considerable ability to associate visual, olfactory or other sensory signals with reward or punishment.  Previous studies in crickets, honey bees and fruit-flies have suggested that octopamine (OA, invertebrate counterpart of noradrenaline) and dopamine (DA) mediate various kinds of reward and punishment signals in olfactory learning.  However, whether the roles of OA and DA in mediating positive and negative reinforcing signals can be generalized to learning of sensory signals other than odors remained unknown.  Here we first established a visual learning paradigm in which to associate a visual pattern with water reward or saline punishment for crickets and found that memory after aversive conditioning decayed much faster than that after appetitive conditioning.  Then, we pharmacologically studied the roles of OA and DA in appetitive and aversive forms of visual learning.  Crickets injected with epinastine or mianserin, OA receptor antagonists, into the hemolymph exhibited a complete impairment of appetitive learning to associate a visual pattern with water reward, but aversive learning with saline punishment was unaffected.  By contrast, fluphenazine, chlorpromazine or spiperone, DA receptor antagonists, completely impaired aversive learning without affecting appetitive learning.  The results demonstrate that OA and DA participate in reward and punishment conditioning in visual learning.  This finding, together with results of previous studies on the roles of OA and DA in olfactory learning, suggests ubiquitous roles of the octopaminergic reward system and dopaminergic punishment system in insect learning.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSCFx9m_qixeWLFM_lbR1VmfW6udTcc2eav25HF3GsZ-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nktFemtw%253D%253D&md5=44c446db4a267ad6355842273de476b8</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.2006.05099.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.2006.05099.x%26sid%3Dliteratum%253Aachs%26aulast%3DUnoki%26aufirst%3DS.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DMizunami%26aufirst%3DM.%26atitle%3DRoles%2520of%2520octopaminergic%2520and%2520dopaminergic%2520neurons%2520in%2520mediating%2520reward%2520and%2520punishment%2520signals%2520in%2520insect%2520visual%2520learning%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2006%26volume%3D24%26spage%3D2031%26epage%3D2038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Yokoyama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, T.</span><span> </span><span class="NLM_article-title">Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice</span> <span class="citation_source-journal">Metab. Brain Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1007%2Fs11011-008-9096-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=18648914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVSrsr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2008&pages=335-349&author=H.+Yokoyamaauthor=R.+Yanoauthor=E.+Aokiauthor=H.+Katoauthor=T.+Araki&title=Comparative+pharmacological+study+of+free+radical+scavenger%2C+nitric+oxide+synthase+inhibitor%2C+nitric+oxide+synthase+activator+and+cyclooxygenase+inhibitor+against+MPTP+neurotoxicity+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice</span></div><div class="casAuthors">Yokoyama, Hironori; Yano, Ryohei; Aoki, Eriko; Kato, Hiroyuki; Araki, Tsutomu</div><div class="citationInfo"><span class="NLM_cas:title">Metabolic Brain Disease</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-349</span>CODEN:
                <span class="NLM_cas:coden">MBDIEE</span>;
        ISSN:<span class="NLM_cas:issn">0885-7490</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The biochem. and cellular changes that occur following the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are remarkably similar to that seen in idiopathic Parkinson's disease(PD).  There is growing evidence indicating that reactive oxygen species (ROS), reactive nitrogen species (RNS) and inflammation are a major contributor to the pathogenesis and progression of PD.  Hence, we investigated whether 7-nitroindazole [neuronal nitric oxide synthase (nNOS) inhibitor], edaravone (free radical scavenger), minocycline [inducible NOS (iNOS) inhibitor], fluvastatin [endothelial NOS (eNOS) activator], pitavastatin (eNOS activator), etodolac [cyclooxygenase-2 (COX-2) inhibitor] and indomethacin (COX inhibitor) can protect against MPTP neurotoxicity in mice under the same conditions.  For the evaluation of each drug, the levels of dopamine, DOPAC and HVA were quantified using HPLC with an electrochem. detector.  Four administrations of MPTP at 1-h intervals to mice produced marked depletion of dopamine, DOPAC (3,4-dihydroxyphenylacetic acid) and HVA (homovanilic acid) in the striatum after 5 days. 7-Nitroindazole prevented dose-dependently a significant redn. in dopamine contents of the striatum 5 days after MPTP treatment.  In contrast, edaravone, minocycline, fluvastatin, pitavastatin, etodolac and indomethacin did not show the neuroprotective effect on MPTP-induced striatal dopamine, DOPAC and HVA depletions after 5 days.  The present study demonstrates that the overexpression of nNOS may play a major role in the neurotoxic processes of MPTP, as compared with the prodn. of ROS, the overexpression of iNOS, the modulation of eNOS and the involvement of inflammatory response.  Thus our pharmacol. findings provide further information for progressive neurodegeneration of the nigrostriatal dopaminergic neuronal pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3vDF5kMIOhLVg90H21EOLACvtfcHk0liunJi8HBTAKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVSrsr3L&md5=9de71b1163e80b50c18c22a031b77894</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1007%2Fs11011-008-9096-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11011-008-9096-3%26sid%3Dliteratum%253Aachs%26aulast%3DYokoyama%26aufirst%3DH.%26aulast%3DYano%26aufirst%3DR.%26aulast%3DAoki%26aufirst%3DE.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DAraki%26aufirst%3DT.%26atitle%3DComparative%2520pharmacological%2520study%2520of%2520free%2520radical%2520scavenger%252C%2520nitric%2520oxide%2520synthase%2520inhibitor%252C%2520nitric%2520oxide%2520synthase%2520activator%2520and%2520cyclooxygenase%2520inhibitor%2520against%2520MPTP%2520neurotoxicity%2520in%2520mice%26jtitle%3DMetab.%2520Brain%2520Dis.%26date%3D2008%26volume%3D23%26spage%3D335%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Brown, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomikos, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fibiger, H. C.</span><span> </span><span class="NLM_article-title">Chronic desipramine enhances the effect of locally applied amphetamine on interstitial concentrations of dopamine in the nucleus accumbens</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">202</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2F0014-2999%2891%2990266-S" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=1786799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADyaK3MXlvFynsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=1991&pages=125-127&author=E.+E.+Brownauthor=G.+G.+Nomikosauthor=C.+Wilsonauthor=H.+C.+Fibiger&title=Chronic+desipramine+enhances+the+effect+of+locally+applied+amphetamine+on+interstitial+concentrations+of+dopamine+in+the+nucleus+accumbens"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic desipramine enhances the effect of locally applied amphetamine on interstitial concentrations of dopamine in the nucleus accumbens</span></div><div class="casAuthors">Brown, Erin E.; Nomikos, George G.; Wilson, Catriona; Fibiger, Hans C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-7</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">In vivo microdialysis was used to study the effect of chronic desipramine (DMI, 5 mg/kg, twice daily for 21 days) on increases in interstitial dopamine (DA) produced by local administration of d-amphetamine (1.0, 3.3 and 10.0 μM) in the nucleus accumbens.  Locally applied amphetamine increased interstitial DA in a dose-dependent manner.  The amphetamine-induced increase was significantly greater in the DMI treated animals.  These data suggest that chronic DMI may directly influence the functional status of the DA terminals in the nucleus accumbens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoROhhIu9SkA7Vg90H21EOLACvtfcHk0lioT3XTNsUj7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlvFynsbk%253D&md5=5ac8ab022e9f76b3a5cfdfae48a57fe1</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2891%2990266-S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252891%252990266-S%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DE.%2BE.%26aulast%3DNomikos%26aufirst%3DG.%2BG.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DFibiger%26aufirst%3DH.%2BC.%26atitle%3DChronic%2520desipramine%2520enhances%2520the%2520effect%2520of%2520locally%2520applied%2520amphetamine%2520on%2520interstitial%2520concentrations%2520of%2520dopamine%2520in%2520the%2520nucleus%2520accumbens%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1991%26volume%3D202%26spage%3D125%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Nomikos, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damsma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenkstern, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fibiger, H. C.</span><span> </span><span class="NLM_article-title">Chronic desipramine enhances amphetamine-induced increases in interstitial concentrations of dopamine in the nucleus accumbens</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">195</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2F0014-2999%2891%2990382-Z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=2065713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADyaK3MXhvF2murs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=1991&pages=63-73&author=G.+G.+Nomikosauthor=G.+Damsmaauthor=D.+Wenksternauthor=H.+C.+Fibiger&title=Chronic+desipramine+enhances+amphetamine-induced+increases+in+interstitial+concentrations+of+dopamine+in+the+nucleus+accumbens"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic desipramine enhances amphetamine-induced increases in interstitial concentrations of dopamine in the nucleus accumbens</span></div><div class="casAuthors">Nomikos, George G.; Damsma, Geert; Wenkstern, Danielle; Fibiger, Hans C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-73</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">There is accumulating evidence that some antidepressant treatments can increase the functional output of the mesoaccumbens dopaminergic system.  For example, chronic administration of tricyclic antidepressant drugs such as imipramine and desipramine (DMI) enhances the locomotor stimulant effects of d-amphetamine.  Subsensitivity of inhibitory dopamine (DA) autoreceptors and supersensitivity of postsynaptic DA receptor mechanisms are among the mechanisms that have been suggested to underlie these observations.  The present expts. investigated the effects of acute and chronic DMI treatment on interstitial DA concns. in the nucleus accumbens and striatum using in vivo microdialysis in awake freely moving rats (48 h following implantation of a microdialysis probe).  Neither acute (5 mg/kg b.i.d. for 2 days followed by 72 h withdrawal) nor chronic (5 mg/kg b.i.d. for 21 days followed by 72 h withdrawal) DMI influenced the ability of apomorphine (25 μg/kg s.c.) to decrease extracellular concns. of DA or its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the nucleus accumbens.  In contrast, d-amphetamine (1.5 mg/kg s.c.)-induced increases in extracellular DA were significantly enhanced in the nucleus accumbens of the chronic but not the acute DMI group.  This effect was at least partially regionally selective, as significant effects were not obsd. in the striatum.  In accordance with previous reports, the locomotor stimulant effects of d-amphetamine were also enhanced in the chronic DMI groups.  DMI itself failed to alter the interstitial concns. of DA and its metabolites in the nucleus accumbens of the control and chronic DMI groups.  These results provide in vivo neurochem. confirmation that chronically administered DMI does not produce DA autoreceptor subsensitivity.  They also demonstrate that chronic DMI-induced increases in the locomotor stimulant effects of d-amphetamine are accompanied by a selective potentiation of the effects of this stimulant on interstitial DA concns. in the nucleus accumbens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa1qF02tJxrLVg90H21EOLACvtfcHk0lgYPfskBreF0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhvF2murs%253D&md5=5384f058135299064c3cee4391246b26</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2891%2990382-Z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252891%252990382-Z%26sid%3Dliteratum%253Aachs%26aulast%3DNomikos%26aufirst%3DG.%2BG.%26aulast%3DDamsma%26aufirst%3DG.%26aulast%3DWenkstern%26aufirst%3DD.%26aulast%3DFibiger%26aufirst%3DH.%2BC.%26atitle%3DChronic%2520desipramine%2520enhances%2520amphetamine-induced%2520increases%2520in%2520interstitial%2520concentrations%2520of%2520dopamine%2520in%2520the%2520nucleus%2520accumbens%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1991%26volume%3D195%26spage%3D63%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Smialowski, A.</span><span> </span><span class="NLM_article-title">Dopamine D2 receptor blocking effect of imipramine in the rat hippocampus</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1991&pages=105-108&author=A.+Smialowski&title=Dopamine+D2+receptor+blocking+effect+of+imipramine+in+the+rat+hippocampus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmialowski%26aufirst%3DA.%26atitle%3DDopamine%2520D2%2520receptor%2520blocking%2520effect%2520of%2520imipramine%2520in%2520the%2520rat%2520hippocampus%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D1991%26volume%3D39%26spage%3D105%26epage%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Tadokoro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekine, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanahara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyo, M.</span><span> </span><span class="NLM_article-title">Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis</span> <span class="citation_source-journal">Schizophr Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1012</span><span class="NLM_x">–</span> <span class="NLM_lpage">1020</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1093%2Fschbul%2Fsbr006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=21402722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BC38zjvVCgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2012&pages=1012-1020&author=S.+Tadokoroauthor=N.+Okamuraauthor=Y.+Sekineauthor=N.+Kanaharaauthor=K.+Hashimotoauthor=M.+Iyo&title=Chronic+treatment+with+aripiprazole+prevents+development+of+dopamine+supersensitivity+and+potentially+supersensitivity+psychosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis</span></div><div class="casAuthors">Tadokoro Shigenori; Okamura Naoe; Sekine Yoshimoto; Kanahara Nobuhisa; Hashimoto Kenji; Iyo Masaomi</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia bulletin</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1012-20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Long-term treatment of schizophrenia with antipsychotics is crucial for relapse prevention, but a prolonged blockade of D(2) dopamine receptors may lead to the development of supersensitivity psychosis.  We investigated the chronic effects of aripiprazole (ARI) on dopamine sensitivity.  METHODS:  We administered ARI (1.5 mg/kg/d), haloperidol (HAL; 0.75 mg/kg/d), or vehicle (VEH) via minipump for 14 days to drug-naive rats or to rats pretreated with HAL (0.75 mg/kg/d) or VEH via minipump for 14 days.  On the seventh day following treatment cessation, we examined the effects of the treatment conditions on the locomotor response to methamphetamine and on striatal D(2) receptor density (N = 4-10/condition/experiment).  RESULTS:  Chronic treatment with HAL led to significant increases in locomotor response and D(2) receptor density, compared with the effects of chronic treatment with either VEH or ARI; there were no significant differences in either locomotor response or D(2) density between the VEH- and ARI-treated groups.  We also investigated the effects of chronic treatment with HAL, ARI, or VEH preceded by HAL or VEH treatment on locomotor response and D(2) density.  ANOVA analysis indicated that the rank ordering of groups for both locomotor response and D(2) density was HAL-HAL > HAL-VEH > HAL-ARI > VEH-VEH.  CONCLUSIONS:  Chronic treatment with ARI prevents development of dopamine supersensitivity and potentially supersensitivity psychosis, suggesting that by reducing excessive sensitivity to dopamine and by stabilizing sensitivity for an extended period of time, ARI may be helpful for some patients with treatment-resistant schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9CqGZtdt2nzUE-swuRqsHfW6udTcc2ebJWpxmXNVukrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zjvVCgtA%253D%253D&md5=e2902305fec7a55ca511d41b880ede5b</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1093%2Fschbul%2Fsbr006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fschbul%252Fsbr006%26sid%3Dliteratum%253Aachs%26aulast%3DTadokoro%26aufirst%3DS.%26aulast%3DOkamura%26aufirst%3DN.%26aulast%3DSekine%26aufirst%3DY.%26aulast%3DKanahara%26aufirst%3DN.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DIyo%26aufirst%3DM.%26atitle%3DChronic%2520treatment%2520with%2520aripiprazole%2520prevents%2520development%2520of%2520dopamine%2520supersensitivity%2520and%2520potentially%2520supersensitivity%2520psychosis%26jtitle%3DSchizophr%2520Bull.%26date%3D2012%26volume%3D38%26spage%3D1012%26epage%3D1020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Golembiewski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, D.</span><span> </span><span class="NLM_article-title">A systematic approach to the management of postoperative nausea and vomiting</span> <span class="citation_source-journal">J. Perianesth. Nurs.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">364</span><span class="NLM_x">–</span> <span class="NLM_lpage">376</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1053%2Fjpan.2002.36596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=12476402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252FivFahsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2002&pages=364-376&author=J.+A.+Golembiewskiauthor=D.+O%E2%80%99Brien&title=A+systematic+approach+to+the+management+of+postoperative+nausea+and+vomiting"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">A systematic approach to the management of postoperative nausea and vomiting</span></div><div class="casAuthors">Golembiewski Julie A; O'Brien Denise</div><div class="citationInfo"><span class="NLM_cas:title">Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses / American Society of PeriAnesthesia Nurses</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">364-76</span>
        ISSN:<span class="NLM_cas:issn">1089-9472</span>.
    </div><div class="casAbstract">Postoperative nausea and vomiting (PONV), a common complication after anesthesia and surgery, often results in delayed discharge with the patient's unpleasant symptoms continuing at home.  To effectively prevent and treat PONV, it is important to understand the factors implicated in PONV, the mechanisms of PONV, the pharmacology of the antiemetic agents, and the nonpharmacologic measures that have been shown to be effective.  The cause of PONV is likely to be multifactorial, with important predictors being female gender, history of PONV, and history of motion sickness.  The vomiting center can be triggered by activation of dopamine, serotonin (type 3), histamine (type 1), and muscarinic cholingergic receptors in the chemoreceptor trigger zone and the nucleus tractus solitarus, as well as acetylcholine receptors in the vestibular apparatus, vagal afferents from the periphery, and the endocrine environment.  Antiemetic agents such as the serotonin antagonists (eg, ondansetron, dolasetron), droperidol, antihistamines (eg, diphenhydramine, dimenhydrinate), and promethazine can prevent and treat PONV effectively.  Transdermal scopolamine and dexamethasone have a role in the prevention of PONV, particularly for certain high-risk patients.  Nonpharmacologic measures and alternative treatments such as hydration, maintaining blood pressure, acupressure techniques, trancutaneous acupoint stimulation, and isopropyl alcohol must not be overlooked.  Finally, an evidence-based algorithm for the prevention and treatment of PONV in adults is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlMu-FS70fHLGbPKh4T9eAfW6udTcc2eafLYz0QhdQWrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252FivFahsg%253D%253D&md5=d8ebb0e90ed273bbccae4240531f1889</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1053%2Fjpan.2002.36596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fjpan.2002.36596%26sid%3Dliteratum%253Aachs%26aulast%3DGolembiewski%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DD.%26atitle%3DA%2520systematic%2520approach%2520to%2520the%2520management%2520of%2520postoperative%2520nausea%2520and%2520vomiting%26jtitle%3DJ.%2520Perianesth.%2520Nurs.%26date%3D2002%26volume%3D17%26spage%3D364%26epage%3D376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Oka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ukai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshikuni, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, K.</span><span> </span><span class="NLM_article-title">Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">727</span><span class="NLM_x">, </span> <span class="NLM_fpage">91</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2F0006-8993%2896%2900355-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=8842386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADyaK28Xkt12lurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=727&publication_year=1996&pages=91-98&author=M.+Okaauthor=Y.+Kimuraauthor=Y.+Itohauthor=Y.+Sasakiauthor=N.+Taniguchiauthor=Y.+Ukaiauthor=Y.+Yoshikuniauthor=K.+Kimura&title=Brain+pertussis+toxin-sensitive+G+proteins+are+involved+in+the+flavoxate+hydrochloride-induced+suppression+of+the+micturition+reflex+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats</span></div><div class="casAuthors">Oka, Michiko; Kimura, Yutaka; Itoh, Yoshinori; Sasaki, Yasuo; Taniguchi, Norihisa; Ukai, Yojiro; Yoshikuni, Yoshiaki; Kimura, Kiyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">727</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">91-98</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The effect of flavoxate hydrochloride (flavoxate), an anti-pollakiurea agent, on cAMP formation was investigated in the rat brain and a possible involvement of brain G proteins in the action of flavoxate on the bladder function was subsequently examd.  Flavoxate (10-8-10-5 M) inhibited cAMP formation in a concn.-dependent manner, an action which was completely abolished by pretreating the membranes with pertussis toxin (PTX).  The inhibitory effect of flavoxate was also completely antagonized by combined treatment with any two antagonists for adenosine A1 (8-cyclopentyl-1,3-dipropylxanthine), dopamine D2 (sulpiride) or adrenergic α2 (yohimbine) receptors, although each antagonist alone did not significantly block the flavoxate-induced inhibition of cAMP formation.  Radioligand binding studies indicated that flavoxate at micro- or submicromolar concns. has affinity for Gi-coupled receptors such as A1, D2 and α2 receptors.  Therefore, flavoxate may inhibit cAMP formation by the stimulation of A1, D2 and α2 receptors.  To clarify the involvement of brain Gi proteins in the flavoxate-induced inhibition of the micturition reflex, the effect of pretreatment with PTX (i.c.v.) on the flavoxate-induced inhibition of isovolumetric rhythmic bladder contractions was examd. in rats.  Flavoxate (3 mg/kg, i.v.) completely abolished rhythmic bladder contractions in vehicle-pretreated rats, but not in PTX-pretreated rats.  These findings suggest that signal transduction via Gi-coupled receptors is involved, at least in part, in the inhibition of the micturition reflex by flavoxate in rats.  These results also provide the first evidence suggesting a neg. role of brain PTX-sensitive G proteins in the micturition reflex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsT0ClRUprjbVg90H21EOLACvtfcHk0ljocREA76FXmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt12lurg%253D&md5=d6d7990db5c3199076631b65b5352d7c</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2896%2900355-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252896%252900355-1%26sid%3Dliteratum%253Aachs%26aulast%3DOka%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DTaniguchi%26aufirst%3DN.%26aulast%3DUkai%26aufirst%3DY.%26aulast%3DYoshikuni%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DK.%26atitle%3DBrain%2520pertussis%2520toxin-sensitive%2520G%2520proteins%2520are%2520involved%2520in%2520the%2520flavoxate%2520hydrochloride-induced%2520suppression%2520of%2520the%2520micturition%2520reflex%2520in%2520rats%26jtitle%3DBrain%2520Res.%26date%3D1996%26volume%3D727%26spage%3D91%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Simon, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigh-Smeller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peragovics, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csukly, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahoranszky-Kohalmi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauscher, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jelinek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hari, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitter, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malnasi-Csizmadia, A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czobor, P.</span><span> </span><span class="NLM_article-title">Relating the shape of protein binding sites to binding affinity profiles: Is there an association?</span> <span class="citation_source-journal">BMC Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1186%2F1472-6807-10-32" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=20923553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BC3cbntFSjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=32&author=Z.+Simonauthor=M.+Vigh-Smellerauthor=A.+Peragovicsauthor=G.+Csuklyauthor=G.+Zahoranszky-Kohalmiauthor=A.+A.+Rauscherauthor=B.+Jelinekauthor=P.+Hariauthor=I.+Bitterauthor=A+Malnasi-Csizmadiaauthor=P.+Czobor&title=Relating+the+shape+of+protein+binding+sites+to+binding+affinity+profiles%3A+Is+there+an+association%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Relating the shape of protein binding sites to binding affinity profiles: is there an association?</span></div><div class="casAuthors">Simon Zoltan; Vigh-Smeller Margit; Peragovics Agnes; Csukly Gabor; Zahoranszky-Kohalmi Gergely; Rauscher Anna A; Jelinek Balazs; Hari Peter; Bitter Istvan; Malnasi-Csizmadia Andras; Czobor Pal</div><div class="citationInfo"><span class="NLM_cas:title">BMC structural biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Various pattern-based methods exist that use in vitro or in silico affinity profiles for classification and functional examination of proteins.  Nevertheless, the connection between the protein affinity profiles and the structural characteristics of the binding sites is still unclear.  Our aim was to investigate the association between virtual drug screening results (calculated binding free energy values) and the geometry of protein binding sites.  Molecular Affinity Fingerprints (MAFs) were determined for 154 proteins based on their molecular docking energy results for 1,255 FDA-approved drugs.  Protein binding site geometries were characterized by 420 PocketPicker descriptors.  The basic underlying component structure of MAFs and binding site geometries, respectively, were examined by principal component analysis; association between principal components extracted from these two sets of variables was then investigated by canonical correlation and redundancy analyses.  RESULTS:  PCA analysis of the MAF variables provided 30 factors which explained 71.4% of the total variance of the energy values while 13 factors were obtained from the PocketPicker descriptors which cumulatively explained 94.1% of the total variance.  Canonical correlation analysis resulted in 3 statistically significant canonical factor pairs with correlation values of 0.87, 0.84 and 0.77, respectively.  Redundancy analysis indicated that PocketPicker descriptor factors explain 6.9% of the variance of the MAF factor set while MAF factors explain 15.9% of the total variance of PocketPicker descriptor factors.  Based on the salient structures of the factor pairs, we identified a clear-cut association between the shape and bulkiness of the drug molecules and the protein binding site descriptors.  CONCLUSIONS:  This is the first study to investigate complex multivariate associations between affinity profiles and the geometric properties of protein binding sites.  We found that, except for few specific cases, the shapes of the binding pockets have relatively low weights in the determination of the affinity profiles of proteins.  Since the MAF profile is closely related to the target specificity of ligand binding sites we can conclude that the shape of the binding site is not a pivotal factor in selecting drug targets.  Nonetheless, based on strong specific associations between certain MAF profiles and specific geometric descriptors we identified, the shapes of the binding sites do have a crucial role in virtual drug design for certain drug categories, including morphine derivatives, benzodiazepines, barbiturates and antihistamines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThdv0NUE0QxLZpSb_XWfMrfW6udTcc2eafLYz0QhdQWrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbntFSjsA%253D%253D&md5=afefcdafa264681ccfb4dc08157862ca</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1186%2F1472-6807-10-32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6807-10-32%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DZ.%26aulast%3DVigh-Smeller%26aufirst%3DM.%26aulast%3DPeragovics%26aufirst%3DA.%26aulast%3DCsukly%26aufirst%3DG.%26aulast%3DZahoranszky-Kohalmi%26aufirst%3DG.%26aulast%3DRauscher%26aufirst%3DA.%2BA.%26aulast%3DJelinek%26aufirst%3DB.%26aulast%3DHari%26aufirst%3DP.%26aulast%3DBitter%26aufirst%3DI.%26aulast%3DMalnasi-Csizmadia%26aufirst%3DA%26aulast%3DCzobor%26aufirst%3DP.%26atitle%3DRelating%2520the%2520shape%2520of%2520protein%2520binding%2520sites%2520to%2520binding%2520affinity%2520profiles%253A%2520Is%2520there%2520an%2520association%253F%26jtitle%3DBMC%2520Struct.%2520Biol.%26date%3D2010%26volume%3D10%26spage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Wishart, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrivastava, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tzur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gautam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassanali, M.</span><span> </span><span class="NLM_article-title">DrugBank: a knowledgebase for drugs, drug actions and drug targets</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">D901</span><span class="NLM_x">–</span> <span class="NLM_lpage">D906</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1093%2Fnar%2Fgkm958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=18048412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVSrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=D901-D906&author=D.+S.+Wishartauthor=C.+Knoxauthor=A.+C.+Guoauthor=D.+Chengauthor=S.+Shrivastavaauthor=D.+Tzurauthor=B.+Gautamauthor=M.+Hassanali&title=DrugBank%3A+a+knowledgebase+for+drugs%2C+drug+actions+and+drug+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">DrugBank: a knowledgebase for drugs, drug actions and drug targets</span></div><div class="casAuthors">Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">Database Iss</span>),
    <span class="NLM_cas:pages">D901-D906</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">DrugBank is a richly annotated resource that combines detailed drug data with comprehensive drug target and drug action information.  Since its first release in 2006, DrugBank has been widely used to facilitate in silico drug target discovery, drug design, drug docking or screening, drug metab. prediction, drug interaction prediction and general pharmaceutical education.  The latest version of DrugBank (release 2.0) has been expanded significantly over the previous release.  With ∼4900 drug entries, it now contains 60% more FDA-approved small mol. and biotech drugs including 10% more exptl.' drugs.  Significantly, more protein target data has also been added to the database, with the latest version of DrugBank contg. three times as many non-redundant protein or drug target sequences as before (1565 vs. 524).  Each DrugCard entry now contains more than 100 data fields with half of the information being devoted to drug/chem. data and the other half devoted to pharmacol., pharmacogenomic and mol. biol. data.  A no. of new data fields, including food-drug interactions, drug-drug interactions and exptl. ADME data have been added in response to numerous user requests.  DrugBank has also significantly improved the power and simplicity of its structure query and text query searches.  DrugBank is available at http://www.drugbank.ca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonqKjSWZe1ULVg90H21EOLACvtfcHk0liN7WVJTrmKBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVSrs7Y%253D&md5=f8f8ca15f248b8c8b9c6d3bd0e85eec8</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkm958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkm958%26sid%3Dliteratum%253Aachs%26aulast%3DWishart%26aufirst%3DD.%2BS.%26aulast%3DKnox%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DA.%2BC.%26aulast%3DCheng%26aufirst%3DD.%26aulast%3DShrivastava%26aufirst%3DS.%26aulast%3DTzur%26aufirst%3DD.%26aulast%3DGautam%26aufirst%3DB.%26aulast%3DHassanali%26aufirst%3DM.%26atitle%3DDrugBank%253A%2520a%2520knowledgebase%2520for%2520drugs%252C%2520drug%2520actions%2520and%2520drug%2520targets%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2008%26volume%3D36%26spage%3DD901%26epage%3DD906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallqvist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reifman, J.</span><span> </span><span class="NLM_article-title">DOVIS 2.0: an efficient and easy to use parallel virtual screening tool based on AutoDock 4.0</span> <span class="citation_source-journal">Chem. Cent. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1186%2F1752-153X-2-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=18778471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A280%3ADC%252BD1cnht1Wkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2008&pages=18&author=X.+Jiangauthor=K.+Kumarauthor=X.+Huauthor=A.+Wallqvistauthor=J.+Reifman&title=DOVIS+2.0%3A+an+efficient+and+easy+to+use+parallel+virtual+screening+tool+based+on+AutoDock+4.0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">DOVIS 2.0: an efficient and easy to use parallel virtual screening tool based on AutoDock 4.0</span></div><div class="casAuthors">Jiang Xiaohui; Kumar Kamal; Hu Xin; Wallqvist Anders; Reifman Jaques</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry Central journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Small-molecule docking is an important tool in studying receptor-ligand interactions and in identifying potential drug candidates.  Previously, we developed a software tool (DOVIS) to perform large-scale virtual screening of small molecules in parallel on Linux clusters, using AutoDock 3.05 as the docking engine.  DOVIS enables the seamless screening of millions of compounds on high-performance computing platforms.  In this paper, we report significant advances in the software implementation of DOVIS 2.0, including enhanced screening capability, improved file system efficiency, and extended usability.  IMPLEMENTATION:  To keep DOVIS up-to-date, we upgraded the software's docking engine to the more accurate AutoDock 4.0 code.  We developed a new parallelization scheme to improve runtime efficiency and modified the AutoDock code to reduce excessive file operations during large-scale virtual screening jobs.  We also implemented an algorithm to output docked ligands in an industry standard format, sd-file format, which can be easily interfaced with other modeling programs.  Finally, we constructed a wrapper-script interface to enable automatic rescoring of docked ligands by arbitrarily selected third-party scoring programs.  CONCLUSION:  The significance of the new DOVIS 2.0 software compared with the previous version lies in its improved performance and usability.  The new version makes the computation highly efficient by automating load balancing, significantly reducing excessive file operations by more than 95%, providing outputs that conform to industry standard sd-file format, and providing a general wrapper-script interface for rescoring of docked ligands.  The new DOVIS 2.0 package is freely available to the public under the GNU General Public License.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrUMPR06SazzDnmmyUf5qOfW6udTcc2eaZctw4NugDkrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnht1Wkuw%253D%253D&md5=a803731aaab1b2d6ecc47b5f24315c83</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1186%2F1752-153X-2-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1752-153X-2-18%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DWallqvist%26aufirst%3DA.%26aulast%3DReifman%26aufirst%3DJ.%26atitle%3DDOVIS%25202.0%253A%2520an%2520efficient%2520and%2520easy%2520to%2520use%2520parallel%2520virtual%2520screening%2520tool%2520based%2520on%2520AutoDock%25204.0%26jtitle%3DChem.%2520Cent.%2520J.%26date%3D2008%26volume%3D2%26spage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Huey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodsell, D. S.</span><span> </span><span class="NLM_article-title">A semiempirical free energy force field with charge-based desolvation</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1145</span><span class="NLM_x">–</span> <span class="NLM_lpage">1152</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1002%2Fjcc.20634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=17274016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVSms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=1145-1152&author=R.+Hueyauthor=G.+M.+Morrisauthor=A.+J.+Olsonauthor=D.+S.+Goodsell&title=A+semiempirical+free+energy+force+field+with+charge-based+desolvation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">A semiempirical free energy force field with charge-based desolvation</span></div><div class="casAuthors">Huey, Ruth; Morris, Garrett M.; Olson, Arthur J.; Goodsell, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1145-1152</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The authors describe the development and testing of a semiempirical free energy force field for use in AutoDock4 and similar grid-based docking methods.  The force field is based on a comprehensive thermodn. model that allows incorporation of intramol. energies into the predicted free energy of binding.  It also incorporates a charge-based method for evaluation of desolvation designed to use a typical set of atom types.  The method has been calibrated on a set of 188 diverse protein-ligand complexes of known structure and binding energy, and tested on a set of 100 complexes of ligands with retroviral proteases.  The force field shows improvement in redocking simulations over the previous AutoDock3 force field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonvP0et7yst7Vg90H21EOLACvtfcHk0lgo0e1JQET9pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVSms78%253D&md5=6fe6ef9bc0bd8149203a2b7351a2f15c</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1002%2Fjcc.20634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.20634%26sid%3Dliteratum%253Aachs%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26atitle%3DA%2520semiempirical%2520free%2520energy%2520force%2520field%2520with%2520charge-based%2520desolvation%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2007%26volume%3D28%26spage%3D1145%26epage%3D1152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Further development and validation of empirical scoring functions for structure-based binding affinity prediction</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1023%2FA%3A1016357811882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=12197663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlSqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=11-26&author=R.+Wangauthor=L.+Laiauthor=S.+Wang&title=Further+development+and+validation+of+empirical+scoring+functions+for+structure-based+binding+affinity+prediction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Further development and validation of empirical scoring functions for structure-based binding affinity prediction</span></div><div class="casAuthors">Wang, Renxiao; Lai, Luhua; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-26</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">New empirical scoring functions have been developed to est. the binding affinity of a given protein-ligand complex with known three-dimensional structure.  These scoring functions include terms accounting for van der Waals interaction, hydrogen bonding, deformation penalty, and hydrophobic effect.  A special feature is that three different algorithms have been implemented to calc. the hydrophobic effect term, which results in three parallel scoring functions.  All three scoring functions are calibrated through multivariate regression anal. of a set of 200 protein-ligand complexes and they reproduce the binding free energies of the entire training set with std. deviations of 2.2 kcal/mol, 2.1 kcal/mol, and 2.0 kcal/mol, resp.  These three scoring functions are further combined into a consensus scoring function, X-CSCORE.  When tested on an independent set of 30 protein-ligand complexes, X-CSCORE is able to predict their binding free energies with a std. deviation of 2.2 kcal/mol.  The potential application of X-CSCORE to mol. docking is also investigated.  Our results show that this consensus scoring function improves the docking accuracy considerably when compared to the conventional force field computation used for mol. docking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqULje6PqR73rVg90H21EOLACvtfcHk0lgo0e1JQET9pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlSqs7k%253D&md5=f77fd72d168df67d7fb66a88bc3b6cd9</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1023%2FA%3A1016357811882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1016357811882%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLai%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DFurther%2520development%2520and%2520validation%2520of%2520empirical%2520scoring%2520functions%2520for%2520structure-based%2520binding%2520affinity%2520prediction%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2002%26volume%3D16%26spage%3D11%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Lam le, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ukeda, H.</span><span> </span><span class="NLM_article-title">Assay of angiotensin I-converting enzyme-inhibiting activity based on the detection of 3-hydroxybutyrate with water-soluble tetrazolium salt</span> <span class="citation_source-journal">Anal. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1057</span><span class="NLM_x">–</span> <span class="NLM_lpage">1060</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.2116%2Fanalsci.24.1057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=18689950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvFKrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2008&pages=1057-1060&author=H.+Lam+leauthor=T.+Shimamuraauthor=S.+Manabeauthor=M.+Ishiyamaauthor=H.+Ukeda&title=Assay+of+angiotensin+I-converting+enzyme-inhibiting+activity+based+on+the+detection+of+3-hydroxybutyrate+with+water-soluble+tetrazolium+salt"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Assay of angiotensin I-converting enzyme-inhibiting activity based on the detection of 3-hydroxybutyrate with water-soluble tetrazolium salt</span></div><div class="casAuthors">Lam, Le Hoang; Shimamura, Tomoko; Manabe, Sachiyo; Ishiyama, Munetaka; Ukeda, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1057-1060</span>CODEN:
                <span class="NLM_cas:coden">ANSCEN</span>;
        ISSN:<span class="NLM_cas:issn">0910-6340</span>.
    
            (<span class="NLM_cas:orgname">Japan Society for Analytical Chemistry</span>)
        </div><div class="casAbstract">A newly synthesized substrate, 3-hydroxybutyrylglycyl-glycyl-glycine (3HB-GGG), was applied to the assay of ACE-inhibiting activity to overcome the smaller selectivity and sensitivity of the conventional method.  In this study, an ACE-inhibiting assay was improved by the use of a water-sol. tetrazolium salt, 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate sodium salt (WST-1), for the detection of 3-hydroxybutyrate, derived from 3HB-GGG.  The optimized conditions were as follows: 0.333 mM NAD+, 0.333 mM WST-1, 0.1 mM EDTA, 0.633 U ml-1 diaphorase, and 0.700 U ml-1 3-hydroxybutyrate dehydrogenase.  The developed assay was efficiently applicable to evaluate the ACE-inhibiting activity of practical ACE inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV7ibH0DLU5rVg90H21EOLACvtfcHk0lgo0e1JQET9pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvFKrt7Y%253D&md5=d54647c972709d8cd87c40c195cff351</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.2116%2Fanalsci.24.1057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2116%252Fanalsci.24.1057%26sid%3Dliteratum%253Aachs%26aulast%3DLam%2Ble%26aufirst%3DH.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DManabe%26aufirst%3DS.%26aulast%3DIshiyama%26aufirst%3DM.%26aulast%3DUkeda%26aufirst%3DH.%26atitle%3DAssay%2520of%2520angiotensin%2520I-converting%2520enzyme-inhibiting%2520activity%2520based%2520on%2520the%2520detection%2520of%25203-hydroxybutyrate%2520with%2520water-soluble%2520tetrazolium%2520salt%26jtitle%3DAnal.%2520Sci.%26date%3D2008%26volume%3D24%26spage%3D1057%26epage%3D1060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Lam le, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ukeda, H.</span><span> </span><span class="NLM_article-title">Assay of angiotensin I-converting enzyme-inhibiting activity based on the detection of 3-hydroxybutyric acid</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2007&pages=104-111&author=H.+Lam+leauthor=T.+Shimamuraauthor=K.+Sakaguchiauthor=K.+Noguchiauthor=M.+Ishiyamaauthor=Y.+Fujimuraauthor=H.+Ukeda&title=Assay+of+angiotensin+I-converting+enzyme-inhibiting+activity+based+on+the+detection+of+3-hydroxybutyric+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLam%2Ble%26aufirst%3DH.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DSakaguchi%26aufirst%3DK.%26aulast%3DNoguchi%26aufirst%3DK.%26aulast%3DIshiyama%26aufirst%3DM.%26aulast%3DFujimura%26aufirst%3DY.%26aulast%3DUkeda%26aufirst%3DH.%26atitle%3DAssay%2520of%2520angiotensin%2520I-converting%2520enzyme-inhibiting%2520activity%2520based%2520on%2520the%2520detection%2520of%25203-hydroxybutyric%2520acid%26jtitle%3DAnal.%2520Biochem.%26date%3D2007%26volume%3D364%26spage%3D104%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Nurtjahja-Tjendraputra, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ammit, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roufogalis, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, V. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duke, C. C.</span><span> </span><span class="NLM_article-title">Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger</span> <span class="citation_source-journal">Thromb. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">265</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1016%2Fj.thromres.2003.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=14693173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2003&pages=259-265&author=E.+Nurtjahja-Tjendraputraauthor=A.+J.+Ammitauthor=B.+D.+Roufogalisauthor=V.+H.+Tranauthor=C.+C.+Duke&title=Effective+anti-platelet+and+COX-1+enzyme+inhibitors+from+pungent+constituents+of+ginger"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger</span></div><div class="casAuthors">Nurtjahja-Tjendraputra, Effie; Ammit, Alaina J.; Roufogalis, Basil D.; Tran, Van H.; Duke, Colin C.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">4-5</span>),
    <span class="NLM_cas:pages">259-265</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Background: Based on recent studies, pungent constituents of ginger (Zingiber officinale) and related substances represent a potential new class of anti-platelet agents.  The ability of 20 pungent constituents of ginger and related substances to inhibit arachidonic acid (AA) induced platelet activation in human whole blood was studied.  Methods: Anti-platelet activity of the compds. was measured in vitro by the Chrono Log whole blood platelet aggregometer.  Mol. hydrophobicity (log P) was measured by reversed-phase high-performance liq. chromatog.  COX-1 (ovine) inhibitory effect of [8]-paradol and analogs was carried out using a COX-1 inhibitor assay kit.  Results: [8]-Gingerol, [8]-shogaol, [8]-paradol and gingerol analogs exhibited anti-platelet activities with IC50 values ranging from 3 to 7 μM, while under similar conditions the IC50 value for aspirin was 20±11 μM.  The COX-1 inhibitory activity of [8]-paradol (IC50=4±1 μM) was more potent than the gingerol analogs (IC50 approx. 20 μM).  Conclusion: The above findings show that gingerol compds. and their derivs. are more potent anti-platelet agents than aspirin under the conditions described in this study.  [8]-Paradol, a natural constituent of ginger, was found to be the most potent COX-1 inhibitor and anti platelet aggregation agent.  The mechanism underlying AA-induced platelet aggregation inhibition may be related to attenuation of COX-1/Tx synthase enzymic activity.  Lastly, important features of phenolic compds. for inhibition of AA-induced platelet aggregation and COX-1 activity were revealed in this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9nd4ba0jGL7Vg90H21EOLACvtfcHk0lgiHf4A-tZNcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtbfM&md5=bf6f24890257fe1898a00883f5f640fa</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2003.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2003.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DNurtjahja-Tjendraputra%26aufirst%3DE.%26aulast%3DAmmit%26aufirst%3DA.%2BJ.%26aulast%3DRoufogalis%26aufirst%3DB.%2BD.%26aulast%3DTran%26aufirst%3DV.%2BH.%26aulast%3DDuke%26aufirst%3DC.%2BC.%26atitle%3DEffective%2520anti-platelet%2520and%2520COX-1%2520enzyme%2520inhibitors%2520from%2520pungent%2520constituents%2520of%2520ginger%26jtitle%3DThromb.%2520Res.%26date%3D2003%26volume%3D111%26spage%3D259%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Zykova, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ermakova, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Z.</span><span> </span><span class="NLM_article-title">Resveratrol directly targets COX-2 to inhibit carcinogenesis</span> <span class="citation_source-journal">Mol. Carcinog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">–</span> <span class="NLM_lpage">805</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Fjm400813y&amp;key=10.1002%2Fmc.20437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Fjm400813y&amp;key=18381589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Fjm400813y&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1agurjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=797-805&author=T.+A.+Zykovaauthor=F.+Zhuauthor=X.+Zhaiauthor=W.+Y.+Maauthor=S.+P.+Ermakovaauthor=K.+W.+Leeauthor=A.+M.+Bodeauthor=Z.+Dong&title=Resveratrol+directly+targets+COX-2+to+inhibit+carcinogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol directly targets COX-2 to inhibit carcinogenesis</span></div><div class="casAuthors">Zykova, Tatyana A.; Zhu, Feng; Zhai, Xiuhong; Ma, Wei-Ya; Ermakova, Svetlana P.; Lee, Ki Won; Bode, Ann M.; Dong, Zigang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">797-805</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Targeted mol. cancer therapies can potentially deliver treatment directly to a specific protein or gene to optimize efficacy and reduce adverse side effects often assocd. with traditional chemotherapy.  Key oncoprotein and oncogene targets are rapidly being identified based on their expression, pathogenesis and clin. outcome.  One such protein target is cyclooxygenase-2 (COX-2), which is highly expressed in various cancers.  Research findings suggest that resveratrol (RSVL; 3,5,4'-trihydroxy-trans-stilbene) demonstrates nonselective COX-2 inhibition.  We report herein that RSVL directly binds with COX-2 and this binding is absolutely required for RSVL's inhibition of the ability of human colon adenocarcinoma HT-29 cells to form colonies in soft agar.  Binding of COX-2 with RSVL was compared with two RSVL analogs, 3,3',4',5',5-pentahydroxy-trans-stilbene (RSVL-2) or 3,4',5-trimethoxy-trans-stilbene (RSVL-3).  The results indicated that COX-2 binds with RSVL-2 more strongly than with RSVL, but does not bind with RSVL-3.  RSVL or RSVL-2, but not RSVL-3, inhibited COX-2-mediated PGE2 prodn. in vitro and ex vivo.  HT-29 human colon adenocarcinoma cells express high levels of COX-2 and either RSVL or RSVL-2, but not RSVL-3, suppressed anchorage independent growth of these cells in soft agar.  RSVL or RSVL-2 (not RSVL-3) suppressed growth of COX-2+/+ cells by 60% or 80%, resp.  Notably, cells deficient in COX-2 were unresponsive to RSVL or RSVL-2.  These data suggest that the anticancer effects of RSVL or RSLV-2 might be mediated directly through COX-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBfmZcwFvhNLVg90H21EOLACvtfcHk0lgiHf4A-tZNcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1agurjN&md5=12260cd20de1f1fffa6f79855065761b</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1002%2Fmc.20437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.20437%26sid%3Dliteratum%253Aachs%26aulast%3DZykova%26aufirst%3DT.%2BA.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DZhai%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DW.%2BY.%26aulast%3DErmakova%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DK.%2BW.%26aulast%3DBode%26aufirst%3DA.%2BM.%26aulast%3DDong%26aufirst%3DZ.%26atitle%3DResveratrol%2520directly%2520targets%2520COX-2%2520to%2520inhibit%2520carcinogenesis%26jtitle%3DMol.%2520Carcinog.%26date%3D2008%26volume%3D47%26spage%3D797%26epage%3D805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i16"><a href="/doi/suppl/10.1021/jm400813y">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_43105"></div></div></div></div></div><hr /></hr><p class="last">Chemical structures and plasma concentrations of the studied drugs and activity and inhibition data for compounds predicted with low DPM probability. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm400813y/suppl_file/jm400813y_si_001.pdf">jm400813y_si_001.pdf (453.57 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm400813y&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm400813y%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-21%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm400813y" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679982043fcb195b","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
